Clinical trial NCT02497287
Conditions: Treatment-resistant Depression
Keywords: Treatment-resistant Depression Esketamine Oral Antidepressant
Sponsor: Janssen Research & Development, LLC
Start date: 2015-09-30; Completion date: 2017-10-28
Enrollment: 802 participants; Allocation: NA; Intervention model: SINGLE_GROUP

Brief summary:
The purpose of this open-label, multicenter study is to assess the long term safety and efficacy of intranasal esketamine plus an oral antidepressant in participants with treatment-resistant depression (TRD).

Detailed description:
This is an open-label (the researchers and participants know the treatment the participant is receiving), multicenter (more than 1 study site), long-term safety and efficacy study of intranasal esketamine plus an oral antidepressant in participants with treatment-resistant depression (TRD). Participants will enter the study either directly (direct-entry participants) or after completing the Double-Blind Induction Phase of ESKETINTRD3005 (transferred-entry participants). The study consists of 4 phases: Screening Phase (4 weeks), Open-Label Induction Phase (4 weeks), Open-Label Optimization/Maintenance phase (48 weeks), and Follow up Phase (4 weeks). Transferred entry non-responders in the ESKETINTRD3005 may enter study at the Open-Label Induction Phase and responders in the ESKETINTRD3005 may enter Optimization/Maintenance phase. In the Open-Label Induction Phase, participants will self-administer flexibly-dosed intranasal esketamine (participants who are less than (\<) 65 years old self-administer 56 mg or 84 mg dose, participants who are greater than or equal to (\>=) 65 years old self-administer 28 mg, 56 mg or 84 mg dose) twice weekly for 4 weeks. The starting dose for all participants \>= 65 years old will be 28 mg. In addition, each direct-entry participants will be assigned to receive 1 of 4 selected oral antidepressant medications (escitalopram or sertraline or duloxetine or venlafaxine extended release \[XR\]), initiated on Day 1 of the open-label induction phase and continued through the duration of the study. Transferred-entry participants will continue their same antidepressant from ESKETINTRD3005 through the duration of this study. Participants who are responders at the end of the Open-Label Induction phase and transferred-entry responder participants (from study ESKETINTRD3005) will enter the Optimization/Maintenance Phase where intranasal esketamine treatment sessions will be reduced from that in the induction phase (twice weekly) to weekly for the first 4 weeks of this phase, and then individualized to either once weekly or once every other week based on the severity of depressive symptoms. Participants' safety and depressive symptoms will be assessed and monitored throughout the study.

Arms: arm 1: Open-Label Induction Phase: Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 mg or 84 mg). Participants greater than or equal to (\>=) 65 will start at a dose of 28 mg on Day 1. Direct-entry participants will initiate a new, open-label oral antidepressant (duloxetine, escitalopram, sertraline, or venlafaxine extended release \[XR\]) on Day 1; transferred-entry participants will continue the same oral antidepressant from ESKETINTRD3005. Optimization/Maintenance Phase: Participants will self-administer esketamine (56mg or 84mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years) intranasally once per week for 4 weeks; transferred entry responder subjects from ESKETINTRD3005 will start at a dose of 28 mg in the first week. All participants will continue their same oral antidepressant during this phase.
Interventions: intervention 1: Esketamine (Intranasal Spray) intervention 2: Duloxetine (Oral Antidepressant) intervention 3: Escitalopram (Oral Antidepressant) intervention 4: Sertraline (Oral Antidepressant) intervention 5: Venlafaxine Extended Release (XR) (Oral Antidepressant)
Intervention descriptions: intervention 1: Open-Label Induction Phase: Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 mg or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years). Participants \>= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants will self-administer esketamine intranasally (56 mg or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years) once weekly then individualized to either once weekly or once every other week based on the severity of depressive symptoms. Transferred-entry responder participants from ESKETINTRD3005 \>= 65 years old will start at a dose of 28 mg in Week 5. intervention 2: Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day). intervention 3: Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. The minimum therapeutic dose is 10 mg/day. Participants \>= 65 years of age will be titrated up to 20 mg/day, but can lower the dose to 10 mg/day for tolerability. intervention 4: Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day. intervention 5: Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated for participants \< 65 years of age up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day. For participants \>= 65, it can be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.

Protocol documents:
Prot_000.pdf: 
1
Status: Approved, Date: 6 July 2016
Janssen Research & Development *
Clinical Protocol
An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in 
Treatment-resistant Depression
Safety and Sustenance of Esketamine Treatment Response With Repeated Doses at Intervals 
Determined by Symptom Severity (SUSTAIN-2)
Protocol ESKETINTRD3004; Phase 3
AMENDMENT 4
JNJ-54135419 (esketamine)
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development 
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen 
Biologics, BV; Janssen-Cilag International NV; Janssen, Inc; Janssen Sciences Ireland UC; or Janssen 
Research & Development, LLC. The term “sponsor” is used throughout the protocol to represent these 
various legal entities; the sponsor is identified on the Contact Information page that accompanies the 
protocol.  
This compound is being investigated in Phase 3 clinical studies.
This study will be conducted under US Food & Drug Administration IND regulations (21 CFR 
Part 312).
EudraCT NUMBER: 2014-004587-38
Status:
Approved
Date:
6 July 2016
Prepared by:
Janssen Research & Development, LLC
EDMS number: EDMS-ERI-93094730, 6.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements. 
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and may 
not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by 
them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as privileged or 
confidential.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
2
Status: Approved, Date: 6 July 2016
TABLE OF CONTENTS
TABLE OF CONTENTS ............................................................................................................................... 2
LIST OF ATTACHMENTS............................................................................................................................ 5
LIST OF IN-TEXT TABLES AND FIGURES................................................................................................ 5
PROTOCOL AMENDMENTS....................................................................................................................... 6
SYNOPSIS.................................................................................................................................................. 31
TIME AND EVENTS SCHEDULE (Screening [Direct-entry Subjects Only] and Open-label 
Induction Phase [Direct-entry and Transferred-entry Non-responder Subjects from 
ESKETINTRD3005 Study Only])...................................................................................................... 45
TIME AND EVENTS SCHEDULE (Optimization/Maintenance Phase [Responder Subjects 
from the Open-label Induction Phase and Transferred-entry Responder Subjects from 
ESKETINTRD3005 Study])............................................................................................................... 49
TIME AND EVENTS SCHEDULE (Follow-up Phase) .............................................................................. 53
ABBREVIATIONS ...................................................................................................................................... 55
1.
INTRODUCTION................................................................................................................................ 57
1.1.
Background .................................................................................................................................... 58
1.1.1.
Summary of Nonclinical Findings ............................................................................................... 58
1.1.2.
Clinical Studies ........................................................................................................................... 61
1.1.2.1.
Pharmacokinetics and Product Metabolism ............................................................................ 61
1.1.2.2.
Pharmacodynamics and Efficacy ............................................................................................ 63
1.1.2.3.
Safety and Tolerability............................................................................................................. 65
1.1.3.
Marketing Experience................................................................................................................. 70
1.2.
Oral Antidepressants: Study Medication........................................................................................ 70
1.2.1.
Selective Serotonin Reuptake Inhibitors..................................................................................... 71
1.2.1.1.
Escitalopram............................................................................................................................ 71
1.2.1.2.
Sertraline ................................................................................................................................. 71
1.2.2.
Serotonin and Norepinephrine Reuptake Inhibitors ................................................................... 72
1.2.2.1.
Duloxetine................................................................................................................................ 72
1.2.2.2.
Venlafaxine Extended-release................................................................................................. 73
1.3.
Overall Rationale for the Study...................................................................................................... 74
2.
OBJECTIVES AND HYPOTHESIS ................................................................................................... 75
2.1.
Objectives ...................................................................................................................................... 75
2.2.
Hypothesis ..................................................................................................................................... 76
3.
STUDY DESIGN AND RATIONALE ................................................................................................. 76
3.1.
Overview of Study Design.............................................................................................................. 76
3.1.1.
Study Phases.............................................................................................................................. 77
3.2.
Study Design Rationale.................................................................................................................. 81
3.2.1.
Study Population......................................................................................................................... 81
3.2.2.
Study Phases.............................................................................................................................. 83
3.2.3.
Blinding and Controls.................................................................................................................. 84
3.2.4.
Treatment Groups and Dose Selection ...................................................................................... 84
3.2.5.
Safety Evaluations...................................................................................................................... 87
3.2.6.
Efficacy Measures ...................................................................................................................... 88
3.2.7.
Medical Resource Utilization ...................................................................................................... 89
3.2.8.
Patient Stated-choice Preference Survey................................................................................... 89
3.2.9.
Biomarker and DNA Collection................................................................................................... 90
4.
SUBJECT POPULATION.................................................................................................................. 90
4.1.
Inclusion Criteria ............................................................................................................................ 91
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
3
Status: Approved, Date: 6 July 2016
4.1.1.
Direct-Entry Subjects.................................................................................................................. 91
4.1.2.
Transferred-Entry Subjects (From Study ESKETINTRD3005)................................................... 93
4.1.3.
Both Types of Subjects (Direct-entry and Transferred-entry Subjects)...................................... 94
4.2.
Exclusion Criteria ........................................................................................................................... 94
4.2.1.
Direct-Entry Subjects.................................................................................................................. 94
4.2.2.
Transferred-Entry Subjects......................................................................................................... 99
4.3.
Prohibitions and Restrictions ......................................................................................................... 99
5.
TREATMENT ALLOCATION AND BLINDING............................................................................... 100
6.
DOSAGE AND ADMINISTRATION ................................................................................................ 101
6.1.
Intranasal Study Drug .................................................................................................................. 101
6.1.1.
Open-label Induction Phase ..................................................................................................... 103
6.1.2.
Optimization/Maintenance Phase............................................................................................. 105
6.1.3.
Follow-up Phase....................................................................................................................... 109
6.2.
Oral Antidepressants.................................................................................................................... 109
6.2.1.
Screening Phase for Direct-entry Subjects............................................................................... 109
6.2.2.
Open-label Induction and Optimization/Maintenance Phases.................................................. 109
6.2.3.
Follow-up Phase....................................................................................................................... 110
7.
TREATMENT COMPLIANCE.......................................................................................................... 110
8.
PRESTUDY AND CONCOMITANT THERAPY .............................................................................. 110
9.
STUDY EVALUATIONS .................................................................................................................. 112
9.1.
Study Procedures......................................................................................................................... 112
9.1.1.
Overview................................................................................................................................... 112
9.1.2.
Screening Phase ...................................................................................................................... 113
9.1.3.
Open-label Induction Phase ..................................................................................................... 114
9.1.4.
Optimization/Maintenance Phase............................................................................................. 115
9.1.5.
Follow-up Phase....................................................................................................................... 116
9.1.6.
Early Withdrawal or End of Optimization/Maintenance Phase Visit ......................................... 116
9.2.
Safety ........................................................................................................................................... 117
9.2.1.
Safety Evaluations.................................................................................................................... 117
9.2.2.
Safety Endpoints....................................................................................................................... 124
9.3.
Efficacy......................................................................................................................................... 125
9.3.1.
Efficacy Evaluations.................................................................................................................. 125
9.3.1.1.
Montgomery-Asberg Depression Rating Scale (MADRS)..................................................... 125
9.3.1.2.
Clinical Global Impression - Severity (CGI-S) ....................................................................... 126
9.3.1.3.
Patient Health Questionnaire, 9-Item (PHQ-9)...................................................................... 126
9.3.1.4.
Generalized Anxiety Disorder, 7-item (GAD-7) ..................................................................... 126
9.3.1.5.
European Quality of Life (EuroQol) Group, 5-Dimension, 5-Level (EQ 5D-5L) .................... 126
9.3.1.6.
Sheehan Disability Scale (SDS)............................................................................................ 127
9.3.2.
Efficacy Endpoints .................................................................................................................... 127
9.4.
Biomarker and Pharmacogenomic Evaluations........................................................................... 127
9.5.
Medical Resource Utilization........................................................................................................ 128
9.6.
Other Evaluations......................................................................................................................... 128
9.7.
Sample Collection and Handling.................................................................................................. 130
10.
SUBJECT COMPLETION/WITHDRAWAL..................................................................................... 131
10.1.
Criteria for Completion ................................................................................................................. 131
10.2.
Criteria for Withdrawal from the Study......................................................................................... 131
10.3.
Withdrawal from the Use of Samples in Future Research........................................................... 133
11.
STATISTICAL METHODS............................................................................................................... 133
11.1.
Subject Information ...................................................................................................................... 133
11.2.
Sample Size Determination ......................................................................................................... 133
11.3.
Safety Analyses ........................................................................................................................... 133
11.4.
Efficacy Analyses ......................................................................................................................... 136
11.5.
Biomarker and Pharmacogenomic Analysis ................................................................................ 136
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
4
Status: Approved, Date: 6 July 2016
11.6.
Medical Resource Utilization Analysis ......................................................................................... 136
11.7.
Patient Stated-choice Preference Survey.................................................................................... 136
11.8.
Independent Data Monitoring Committee .................................................................................... 137
12.
ADVERSE EVENT REPORTING .................................................................................................... 137
12.1.
Definitions .................................................................................................................................... 137
12.1.1.
Adverse Event Definitions and Classifications ......................................................................... 137
12.1.2.
Attribution Definitions................................................................................................................ 139
12.1.3.
Severity Criteria ........................................................................................................................ 139
12.2.
Special Reporting Situations........................................................................................................ 139
12.3.
Procedures................................................................................................................................... 140
12.3.1.
All Adverse Events.................................................................................................................... 140
12.3.2.
Serious Adverse Events ........................................................................................................... 141
12.3.3.
Pregnancy................................................................................................................................. 142
12.4.
Contacting Sponsor Regarding Safety......................................................................................... 142
13.
PRODUCT QUALITY COMPLAINT HANDLING............................................................................ 142
13.1.
Procedures................................................................................................................................... 142
13.2.
Contacting Sponsor Regarding Product Quality .......................................................................... 143
14.
STUDY DRUG INFORMATION....................................................................................................... 143
14.1.
Physical Description of Study Drugs............................................................................................ 143
14.1.1.
Intranasal Study Drug............................................................................................................... 143
14.1.2.
Oral Antidepressant Medications.............................................................................................. 143
14.2.
Packaging .................................................................................................................................... 144
14.3.
Labeling........................................................................................................................................ 144
14.4.
Preparation, Handling, and Storage............................................................................................. 144
14.5.
Drug Accountability ...................................................................................................................... 144
15.
STUDY-SPECIFIC MATERIALS..................................................................................................... 145
16.
ETHICAL ASPECTS ....................................................................................................................... 146
16.1.
Study-Specific Design Considerations......................................................................................... 146
16.2.
Regulatory Ethics Compliance..................................................................................................... 148
16.2.1.
Investigator Responsibilities ..................................................................................................... 148
16.2.2.
Independent Ethics Committee or Institutional Review Board ................................................. 148
16.2.3.
Informed Consent ..................................................................................................................... 149
16.2.4.
Privacy of Personal Data .......................................................................................................... 150
16.2.5.
Long-Term Retention of Samples for Additional Future Research .......................................... 151
16.2.6.
Country Selection ..................................................................................................................... 151
17.
ADMINISTRATIVE REQUIREMENTS ............................................................................................ 151
17.1.
Protocol Amendments.................................................................................................................. 151
17.2.
Regulatory Documentation .......................................................................................................... 152
17.2.1.
Regulatory Approval/Notification .............................................................................................. 152
17.2.2.
Required Prestudy Documentation........................................................................................... 152
17.3.
Subject Identification, Enrollment, and Screening Logs .............................................................. 153
17.4.
Source Documentation................................................................................................................. 153
17.5.
Case Report Form Completion .................................................................................................... 154
17.6.
Data Quality Assurance/Quality Control ...................................................................................... 154
17.7.
Record Retention ......................................................................................................................... 155
17.8.
Monitoring .................................................................................................................................... 155
17.9.
Study Completion/Termination..................................................................................................... 156
17.9.1.
Study Completion ..................................................................................................................... 156
17.9.2.
Study Termination..................................................................................................................... 156
17.10.
On-Site Audits .............................................................................................................................. 157
17.11.
Use of Information and Publication.............................................................................................. 157
REFERENCES.......................................................................................................................................... 159
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
5
Status: Approved, Date: 6 July 2016
ATTACHMENTS....................................................................................................................................... 164
INVESTIGATOR AGREEMENT ............................................................................................................... 171
LIST OF ATTACHMENTS
Attachment 1:
Prohibited Concomitant Medications with Intranasal Study Medication 
(Esketamine) ............................................................................................................ 164
Attachment 2:
New York Heart Association Classification of Cardiac Disease............................... 167
Attachment 3:
Oral Antidepressant Titration Schedules for Open-label Induction Phase............... 168
Attachment 4:
Anticipated Events.................................................................................................... 169
LIST OF IN-TEXT TABLES AND FIGURES 
TABLES
Table 1:
Adverse Reactions Listed as Very Common, Common, or Frequent Occurrences in 
the Product Information of Anesthetic Ketamine and Esketamine ........................................... 66
Table 2:
Mean Supine Blood Pressure and Heart Rate - Cohort 1 (ESKETINTRD1012)..................... 67
Table 3:
Open-label Induction Phase Dose Titration of Intranasal Esketamine for Direct-entry 
Subjects <65 Years................................................................................................................. 104
Table 4:
Open-Label Induction Phase Intranasal Treatment Sessions for Subjects <65 Years .......... 104
Table 5:
Open-Label Induction Phase Dose Titration of Intranasal Esketamine for Direct-entry 
and Transferred-entry Non-responder Subjects ≥65 Years.................................................... 105
Table 6:
Open-Label Induction Phase Intranasal Treatment Sessions for Subjects ≥65 Years .......... 105
Table 7:
Optimization/Maintenance Phase Dose Titration of Intranasal Esketamine for 
Transferred-entry Responder Subjects................................................................................... 106
Table 8:
Intranasal Esketamine Treatment Sessions: Optimization/Maintenance Phase.................... 108
Table 9:
Volume of Blood to be Collected From Each Subject............................................................. 113
FIGURES
Figure 1:
Schematic Overview of the Study............................................................................................. 81
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
6
Status: Approved, Date: 6 July 2016
PROTOCOL AMENDMENTS
Protocol Version 
Issue Date
Original Protocol
21 April 2015
Amendment 1
11 June 2015
Amendment 2
17 February 2016
Amendment 3
6 June 2016
Amendment 4
6 July 2016
Amendments below are listed beginning with the most recent amendment.
Amendment 4 (6 July 2016)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.
The overall reason for the amendment: To remove the exclusion criteria for subjects aged ≥ 65 years with first 
degree AV block.  Data from Phase 1 studies (ESKETINTRD1003 and 1012) and preliminary data from the current 
study showed no effect on the PR interval in subjects aged ≥ 65 years.
Applicable Section(s)
Description of Change(s)
Rationale: Based on analyses of available data that showed no impact of intranasal esketamine on PR interval, 
evidence of 1st degree AV block was removed as an exclusion criterion for subjects aged ≥ 65 years. 
4.2.1. Direct-Entry 
Subjects
The following text was deleted from Exclusion Criterion 11.2: 
-
Evidence of 1st degree AV block (in subjects ≥65 years only):
-
During Screening: If the PR interval on the initial ECG is > 200 msec but < 240 
msec, the average PR interval of 2 ECGs recorded 4 minutes apart on the same day 
must not be > 200 msec.
-
On Day 1 (predose): If the PR interval is > 200 msec but < 240 msec based on the 
site-evaluated ECG; the average PR interval of 2 ECGs, recorded 4 minutes apart on 
the same day, must not be > 200 msec.
Amendment 3 (6 June 2016)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union. 
The overall reason for the amendment: To modify entry criteria with respect to PR interval based on Phase 1 and 
Phase 2 data, to add the information about the long-term safety study 54135419TRD3008; to implement changes 
and align language being applied across all Phase 3 studies in the esketamine development program; to correct 
errors and make minor clarifications in the text of the inclusion and exclusion criteria.
Applicable Section(s)
Description of Change(s)
Rationale: Based on analyses from phase 1 and 2 studies that showed no impact of esketamine on PR interval, 1st
degree AV block (PR interval > 200 msec) was removed as an exclusion criterion for subjects <65 years; however, 
it is maintained as an exclusion criterion for subjects ≥ 65 years old, as the number of elderly subjects exposed to 
intranasal esketamine was limited so far.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
7
Status: Approved, Date: 6 July 2016
Applicable Section(s)
Description of Change(s)
4.2.1 Direct Entry 
Subjects
Revised Exclusion Criterion 11.1 so that 1st degree AV block only applies for subjects ≥65 
years. Qualified the conditions for retesting during screening (for the initial ECG) and on 
Day 1 (predose ECG) such that if the PR interval is > 200 msec but < 240 msec, the 
average PR interval of 2 ECGs, recorded 4 minutes apart on the same day, must not be > 
200 msec. Clarified that if QTcF is prolonged on the initial ECG, the average QTcF was to 
be calculated from the total of three ECGs. 
Rationale: To add information about the open-label safety extension study 54135419TRD3008 that may be 
available for eligible subjects participating in this study. 
Synopsis, Overview 
of Study Design, 
Follow-up Phase; 
3.1.1. Study Phases; 
9.1.5. Follow-up 
Phase
10.1. Criteria for 
Completion
Added the following statement:
An open label safety extension study, 54135419TRD3008, may be available (pending 
country and site approval) for  eligible subjects  participating in the ESKETINTRD3004 
study. Please refer to the 54135419TRD3008 protocol for full details, when available.
Rationale: Corrections to two of the inclusion criteria for direct entry subjects that were inadvertently combined.
4.1.1. Direct Entry 
Subjects 
The sentence below was moved from Inclusion Criterion 4 to Inclusion Criterion 3.2 (it 
was inadvertently included in Inclusion Criterion 4 in Amendment 2): 
“For specific tricyclic antidepressants which are ongoing and being taken at a dose below 
the MGH ATRQ minimum therapeutic dose, a blood level that is within the therapeutic 
(antidepressant) range, is acceptable to establish the adequacy of the antidepressant 
treatment.”
Rationale: In Amendment 2, inclusion of subjects who have thyroid-stimulating hormone (TSH) outside the normal 
ranges was permitted; however, the text indicating that a subject must have a normal TSH at screening was not 
removed from Amendment 2. This has been corrected in Amendment 3.
4.1.1. Direct Entry 
Subjects
The following sentence was removed from Inclusion Criteria 6.2: 
“For subjects without a pre-existing history of hypothyroidism, a normal thyroid-
stimulating hormone [TSH] is required at screening.”
The second bullet of this criterion was revised to read as follows (new text in bold font; 
strikethrough text deleted):  “For any subject (regardless of thyroid history), if the thyroid 
stimulating hormone (TSH) value is out of range, a free thyroxine (FT4) will be 
conducted. If the FT4 value is within the normal range, such cases should be abnormal 
and considered to be clinically significant (after discussion ed directly with the medical 
monitor) before the subject is enrolled. If the FT4 value is out of range, the subject is not 
eligible.”
In the last bullet of this criterion the phrase “and have thyroid stimulating hormone [TSH] 
within normal range at screening” was deleted.  
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
8
Status: Approved, Date: 6 July 2016
Applicable Section(s)
Description of Change(s)
Rationale: Inclusion criterion no. 14 was revised to specify the same requirements for contraception for female 
partners of male study subjects as specified for female subjects, and to add additional text regarding highly effective 
methods of birth control for female partners of male study subjects (this text was implemented in prior amendments 
for the other Phase 3 protocols in the esketamine development program; however it was not included in Amendment 
2 of the ESKETINRD3004 protocol).
4.1.3. Both Types of 
Subjects (Direct-entry 
and Transferred-entry 
Subjects)
The text of inclusion criterion no. 14 has been changed as follows (bold text added; 
strikethrough text deleted):
During the study (ie, from Day 1 of the open-label induction phase), and for a minimum of 
1 spermatogenesis cycle (defined as approximately 90 days) after receiving the last dose of  
study drug, in addition to the user independent highly effective method of contraception, a 
man who is sexually active with a woman of childbearing potential
-
must be practicing a highly effective method of contraception with his 
female partner from those listed above (see examples of highly effective 
methods of contraception provided for female subjects). who is sexually active 
with a woman of childbearing potential must agree to use a double-barrier method 
of contraception (eg, diaphragm or cervical/vault caps plus condom with 
spermicidal foam/gel/film/cream/suppository).
-
who is sexually active with a woman who is pregnant must use a condom if his 
partner is pregnant.
-
must agree not to donate sperm.
Note: If the childbearing potential changes after start of the study, a female partner 
of a male study subject, must begin a highly effective method of birth control, as 
described above. 
Rationale: Clarification of exclusion criterion for direct entry subjects with non-response to previous treatment, for 
consistency with other esketamine Phase 3 protocols. 
Synopsis, Subject 
Population, Direct-
entry subjects; 
4.2.1. Direct Entry 
Subjects 
Exclusion Criterion 1 for direct-entry subjects was revised to indicate that a subject could 
be excluded if their depressive symptoms have previously not responded to either of the 
following (the word “or” was added):
esketamine or ketamine in the current major depressive episode per clinical judgment, 
or 
All of the 4 oral antidepressant treatment options available in the respective country for 
the open-label induction phase (ie, duloxetine, escitalopram, sertraline, and 
venlafaxine XR) in the current major depressive episode (based on MGH-ATRQ). 
Rationale: Revision to exclusion criterion for direct entry subjects due to errors in the text of the criterion.
4.2.1 Direct Entry 
Subjects
Deleted the following note from Exclusion Criterion 8.1, which is a duplication in the text 
of the criterion: 
“Note: subjects who had unstable angina or myocardial infarction with revascularization 
done ˃12 months prior to screening and are symptom-free, can be included.”
Deleted the word “regimen” from the second paragraph of Exclusion Criteria 9.1. Sentence 
now reads “A potential subject may have his/her current antihypertensive medication(s) 
adjusted during the screening phase and be re-evaluated to assess their blood pressure 
control.”
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
9
Status: Approved, Date: 6 July 2016
Applicable Section(s)
Description of Change(s)
Rationale: Clarification to inclusion criterion for direct entry subjects for consistency with updated protocol 
template text. 
4.1.1 Direct Entry 
Subjects
Revised Inclusion Criterion 8.1 to add the leading statement “Contraceptive use by men or 
women should be consistent with local regulations regarding the use of contraceptive 
methods for subjects participating in clinical studies.” 
Rationale: To clarify that subjects taking prescribed psychostimulants at the start of the screening phase may 
continue to take this medication during the study, except on intranasal treatment session days, to allow subjects to 
safely use these medications at other permitted times during study participation. 
4.2.1. Direct-entry 
Subjects
Modified Exclusion Criterion 14.1 to add that subjects who have a positive test result at 
screening due to prescribed psychostimulants taken for an indication other than MDD (e.g. 
amphetamine, methylphenidate etc.) are permitted to take this medication during the study 
(in accordance with Attachment 1). Deleted amphetamines from the text of the second 
bullet so that this bullet only applies to opiates or barbiturates. 
Rationale: Clarification made regarding the usage of antidepressant treatments for indications other than depression 
during the screening phase and for the use of corticosteroids, psychostimulants, and ADHD medications.
Attachment 1
The phrase “or placebo” was deleted from the title of Attachment 1, as there is no placebo 
in this study. 
Added the following statement to the text preceding the table (to align the text in 
Attachment 1 with the protocol section 9.1.2).: 
“Of note, other than for MAOIs (see table below), for all antidepressants being taken at the 
start of or during the screening phase, no washout or drug-free period is required after 
discontinuing the antidepressant treatment; however, if clinically indicated, the 
antidepressant treatment can be tapered and discontinued during the screening phase.”
For corticosteroids, changed “oral” to “systemic”; allowed episodic use (previously 
prohibited); added that intermittent IM/IV corticosteroids are permitted (chronic use 
prohibited). 
For pseudoephedrine, clarified that is an orally administered agent (not intranasal).
For psychostimulants and ADHD medications, continuous use is allowed (previously 
prohibited); added that these prescribed medications can be continued but must not be 
taken within 12 hours prior to the intranasal treatment session or for 2 hours after the 
intranasal treatment session. Qualified that this applies to prescribed psychostimulants 
taken for indications other than MDD.
Rationale: To revise a visit window during the open label induction phase to allow more flexibility for conducting 
the visit. 
Time and Events 
Schedule, Screening 
and Open-label 
Induction Phase
For Visit 2.9 during the induction phase, the visit window was revised to ±1 day (rather 
than -1 day).
Rationale: Clarification to text regarding measurement of pulse oximetry, to align with other Phase 3 protocols. 
9.2.1. Safety 
Evaluations, Pulse 
Oximetry
The following statement was added: 
Any arterial oxygen saturation (SpO2) <93% should be confirmed by an additional 
measurement on another part of the body. 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
10
Status: Approved, Date: 6 July 2016
Applicable Section(s)
Description of Change(s)
Rationale: Removal of requirement for reporting treatment emergent changes in (or worsening from baseline) nasal 
examinations as adverse events, as reporting for such instances should be at the discretion of the Investigator. 
9.2.1. Safety 
Evaluations, Nasal 
Examinations
Deleted the following text: 
Any treatment emergent change or worsening from the baseline examination will be 
recorded as an adverse event. 
Rationale: Clarification of adverse event reporting procedures in the instance of pregnancy. In addition, 
clarification that all SAEs must be reported using the SAE Form.
12.3.1. Adverse 
Events
Text revised as follows (bold text added; strikeout text removed):
All adverse events and special reporting situations, whether serious or non-serious, will be 
reported from the time a signed and dated ICF is obtained until completion of the subject's 
last study-related procedure (which may include contact for follow-up of safety), with the 
exception of pregnancy which will be reported up to 6 weeks after the last dose of 
study medication (females) or 90 days after the last dose of study medication 
(partners of male participants).  Serious adverse events, including those spontaneously 
reported to the investigator, within 30 days after the last dose of study drug, must be 
reported using the Serious Adverse Event Form. The sponsor will evaluate any safety 
information that is spontaneously reported by an investigator beyond the time frame 
specified in the protocol.
Rationale: Removal of MDMA from urine drug screen results that will lead to discontinuation as prescribed 
psychostimulants are now permitted.
4.3. Prohibitions and 
Restrictions
MDMA was deleted from the list of drugs that will lead to discontinuation if detected in 
the urine drug screen during the study. 
Rationale: Minor changes were made throughout the protocol for compliance with updated protocol template text, 
and to correct for an omission in the previous amendment, regarding the template convention for indicating 
modified exclusion criterion.
Cover page
Updated Sponsor Statement to remove Janssen Infectious Diseases BVBA. 
4.2.1. Direct-Entry 
Subjects
Corrected Exclusion Criterion 2 to show that it was first modified in amendment 1 (not 
amendment 2), and inserted a line (numbered as 2.1) to show that it was modified again in 
amendment 2, in order to agree with the template numbering convention (this line was 
inadvertently left out of Amendment 2). The content of this criterion was not modified in 
this amendment, thus this exclusion criterion remains numbered as 2.2 (as it was in 
Amendment 2). 
17.5 Case Report 
Form Completion
Deleted text stating “All data relating to the study must be recorded in CRF.”
References 
Removed edition number and date from reference 41.
Investigator 
Agreement Page
Removed the “LAST PAGE” designation.
Amendment 2 (17 February 2016)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.
The overall reason for the amendment: The overall reason for this amendment is to update and/or clarify protocol 
content based on ongoing feedback received during the study initiation activities. In addition, key protocol entry 
criteria for direct entry subjects have been added for transferred entry subjects, in order to confirm that subject’s,
who completed ESKETINTRD3005, continue to meet the criteria at entry to the ESKETINTRD3004 study.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
11
Status: Approved, Date: 6 July 2016
Applicable Section(s)
Description of Change(s)
Rationale: A stated-choice preference survey was added as an exploratory measure to analyze subject’s willingness 
to accept tradeoffs between treatment-related benefits and harm.
Synopsis, Objectives and
Hypothesis;
Synopsis, Medical Resource 
Utilization;
Synopsis, Statistical Methods;
Time & Events Schedule;
2.1. Objectives;
3.2.8. Patient Stated-choice 
Preference Survey;
9.6. Other Evaluations;
11.7 Patient Stated-choice 
Preference Survey
Addition of Sections 3.2.8., and 11.7.for Patient Stated-choice Preference Survey, 
and inclusion of additional text to section 9.6. Other Evaluations.
‘The Patient Stated-choice Preference Survey (stated-choice conjoint analysis) will 
be used as an exploratory tool to assess the manner and degree to which the study 
subjects value or weigh the clinical outcome associated with esketamine treatment, 
thus allowing assessment of the maximum acceptable treatment-related risk 
subjects would accept for various degrees of benefit.’
Exploratory Objectives: the following text was added:

“To assess subject tradeoff preferences for key benefit and harm outcomes 
associated with TRD treatment, using a stated-choice conjoint analysis survey. 
Reporting of these survey results may be conducted separately from this 
study”.
Medical Resource Utilization, Other Evaluations: the following text was added;

“Patient stated-choice preference survey to assess subject tradeoff preferences 
for key benefit and harm outcomes associated with TRD treatment, using a 
stated-choice conjoint analysis survey”.
Statistical Methods: the following text added;
“Patient stated-choice preference Summary statistics and a regression model will 
be used to estimate a distribution of preferences weights for each level of each 
benefit and harm in the preference survey (described in a SAP). Maximum 
acceptable risk for harms will be calculated for varying degrees of benefit. 
Analyses and reporting of these survey results may be conducted separately from 
this study”.
Time and Events Schedule: Open-label Induction Phase
(Direct-entry Subjects and Transferred-entry Non-responder Subjects Only)
Patient Stated-choice Preference Survey to be completed during visit 2.9.
Addition of following legends:
o) Patient Stated-choice Preference Survey to be completed only by English-
speaking subjects at United States, United Kingdom and Australia sites. The 
survey will not be conducted in any other countries, regardless of whether the 
subjects in those other countries speak English. The survey is conducted only once 
per subject.
p) The survey should be completed during or shortly after Visit 2.9, or if the 
subject has completed this visit prior to when the survey becomes available, trial 
sites should have the subject complete the survey at the earliest possible 
opportunity or at early withdrawal. The survey should be administered predose 
(if/when performed on intranasal dosing days).
Time & Events Schedule: Optimization/Maintenance Phase 
(Responder Subjects from the Open-label Induction Phase and Transferred-entry 
Responder Subjects from ESKETINTRD3005)
Patient Stated-choice Preference Survey’ to be completed during visit 3.5. or 
during Early Withdrawal/End of Optimization/Maintenance Phase
Addition of following legends:
o) Patient Stated-choice Preference Survey to be completed only by English-
speaking subjects in United States, United Kingdom and Australia sites. The 
survey will not be conducted in any other countries, regardless of whether the 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
12
Status: Approved, Date: 6 July 2016
Applicable Section(s)
Description of Change(s)
subjects in those other countries speak English. The survey is conducted only once 
per subject.
p) NOTE for transferred-entry responder subjects from ESKETINTRD3005 study 
who enter directly to the optimization/maintenance phase, the survey should be 
completed during or shortly after Visit 3.5, or if the subject completed this visit 
prior to when the survey becomes available, the subject should complete the 
survey at the earliest possible opportunity or at early withdrawal. The survey 
should be administered predose (if/when performed on intranasal dosing days).
Subjects who completed the Patient Stated-choice Preference survey while 
enrolled in ESKETINTRD3005 should not be issued the survey.
Rationale: Clarification of the definition of MDD and obsessive compulsive disorder, under criteria for subject 
exclusion. 
Synopsis, Study Population;
4.2. Exclusion Criteria,
4.2.1. Direct-entry Subjects
The text of the current exclusion criteria no.2. was modified: 
- Subjects with MDD with “psychotic features” will be excluded
- “Only” subjects with “current” obsessive compulsive disorder will be excluded.
Rationale: Subjects with previously diagnosed cognitive impairment may be more vulnerable to any potential 
effects of esketamine on the cognitive function. Generally diseases pre-specified in this exclusion criterion are 
typically observed in the elderly population, however one cannot exclude the possibility that they will occur in a 
subject < 65 years old.
4.2. Exclusion Criteria,
4.2.1. Direct-entry Subjects;
Synopsis, Subject population, 
Direct-entry subjects;
9.6. Other Evaluations, 
MMSE
4.2. Exclusion Criteria,
4.2.1. Direct-entry Subjects
The text of the current exclusion no. 7 was modified. 
The initial sentence: “Subject aged ≥65 years” will be deleted and replaced by
“Subject who:”
- Has a Mini Mental State Examination (MMSE) <25
- Has neurodegenerative disorder (eg, Alzheimer’s disease, vascular dementia, 
Parkinson’s disease), or evidence of mild cognitive impairment (MCI).
Deletion of the following text: “≥65 years” as this criteria no longer applies to the 
following statement ‘In addition, subjects will be excluded if they have a 
neurodegenerative disorder’
Deletion of the following sentence: “This assessment is only completed at 
screening in subject’s ≥65 years”.
The text of exclusion criteria no.8. was modified, such that the following 
cardiovascular conditions will now be excluded:

Coronary artery disease with myocardial infarction, unstable angina, “or” 
revascularization procedure (eg, coronary angioplasty or bypass graft surgery) 
within 12 months before the start of the screening phase. ‘Subjects who have 
had a revascularization performed > 12 months prior to screening and are 
clinically stable and symptom-free, “per investigator’s clinical judgment”, can 
be included’.
- “Note: subjects who had unstable angina or myocardial infarction with 
revascularization done ˃12 months prior to screening and are symptom-free, 
can be included.”
4.2. Exclusion Criteria,
4.2.1. Direct-entry Subjects
The text of the current exclusion criteria no. 9 was modified as follows:
On Day 1 of the open-label induction phase;
For subjects <65 years: a supine systolic blood pressure (SBP) >140 mmHg or a 
diastolic blood pressure (DBP) >90 mmHg is exclusionary.
For subjects ≥65 years: a SBP >150 mmHg or a DBP >90 mmHg is exclusionary.
Correction: “<” 65 years, and not ‘≤’ 65 years.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
13
Status: Approved, Date: 6 July 2016
Applicable Section(s)
Description of Change(s)
The text will now state: antihypertensive “medication(s)” rather than “therapy”.
Rationale: Clarification of definition of clinically significant ECG abnormalities as defined by QT interval 
corrected according to Fridericia’s formula (QTcF).
4.2. Exclusion Criteria,
4.2.1. Direct-entry Subjects
The text of the current exclusion criteria no.11 was modified as follows:

The first subbullet, was separated into 2 separate bullets, and the following 
bold text was added: 
- During screening, a QT interval corrected according to Fridericia’s 
formula (QTcF): ≥450 msec; if the QTcF is prolonged on the initial 
ECG, the average QTcF of three ECG’s, recorded 4 minutes apart, 
must not be ≥450 msec.
- On Day 1 (predose), a QT interval corrected according to Fridericia’s 
formula (QTcF): ≥450 msec based on the site-evaluated ECG; if the QTcF 
is prolonged on the initial ECG, the average QTcF of three ECG’s, 
recorded 4 minutes apart, must not be ≥450 msec.

In the second subbullet, the following bold text was added:
- Evidence of 2nd or 3rd degree AV block, or 1st degree AV block with PR 
interval ˃200 msec “[may repeat the ECG once, and use average of 
both readings, if the initial PR interval is <240 msec]”.
- The word “complete” was added to LBBB and RBBB.
Rationale: The use of concomitant medications that prolong the QT interval/corrected QT (QTc) interval is 
permitted.
4.2. Exclusion criteria 
The current exclusion criteria no. 12 has been modified:
The following text has been deleted, as:
The ”use of concomitant medications that prolong the QT interval/corrected 
QT (QTc) interval” no longer excludes a subject from study enrollment.
Rationale: Inclusion of a repeat screening test for abnormal ALT and AST values during the screening phase.
4.2. Exclusion criteria
The current exclusion criteria no. 13 has been modified:
Where the subject has a history of, or symptoms and signs suggestive of liver 
cirrhosis OR alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 
values ≥2x the upper limit (of normal), the following is applicable:
“Repeat of screening test for abnormal ALT and AST is permitted once during 
the screening period, provided per investigator discretion and provided that there is 
an alternative explanation for the out of range value.”
Rationale: Clarification that a positive test for cannabinoids on Day 1 (predose) of the open-label induction phase is 
exclusionary, but not at screening. 
4.2. Exclusion Criteria,
4.2.1.Direct-entry Subjects
The text of the current exclusion criteria no. 14 was modified:
Clarification that “a positive test for cannabinoids at the start of the screening 
phase is not exclusionary, however, a positive test result for cannabinoids on Day 1 
(predose) of the open label induction phase is exclusionary”.
Rationale: The term “secondary diabetes” was removed from the exclusion criterion because, as stated in the 
criterion, any uncontrolled diabetes mellitus is exclusionary.
4.2. Exclusion Criteria,
4.2.1. Direct-entry Subjects
The text of the current exclusion criteria no. 16 was modified to delete the terms 
“secondary diabetes”.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
14
Status: Approved, Date: 6 July 2016
Applicable Section(s)
Description of Change(s)
Rationale: Provide clarification that investigator’s clinical judgment based on the assessment will be used to 
exclude subjects on the basis of any anatomical or medical condition that may impede delivery or absorption of 
intranasal study drug.
4.2. Exclusion Criteria,
4.2.1. Direct-entry Subjects
The text of exclusion criteria no. 18 was modified to indicate that the 
‘investigator’s clinically judgment based on the assessment’ will be used to 
determine eligibility.
Text that is redundant (ie, examples of structural or functional abnormalities) has 
been deleted.
Rationale: Exclusion criteria no. 19 is no longer relevant.
4.2. Exclusion Criteria,
4.2.1. Direct-entry Subjects
The text of exclusion criteria no. 19 has been deleted.
Rationale: Clarification that a subject is excluded if currently enrolled in an investigational study, which is 
interventional, and clarification that the limit for participation in 2 or more MDD or other psychiatric condition 
clinical interventional studies in the previous 1 year is based on studies with different investigational medications..
4.2. Exclusion Criteria,
4.2.1. Direct-entry Subjects
The text of exclusion criteria no. 24 has been modified to include:
- Subject who has participated in 2 or more MDD or other psychiatric 
condition clinical interventional studies “(with different investigational 
medication)” in the previous 1 year)
- Subject is currently enrolled in an investigational “interventional” study.
Rationale: Correction to exclusion criteria, which now specifies a time interval of 6 weeks after last dose of 
intranasal study drug
4.2. Exclusion Criteria,
4.2.1. Direct-entry Subjects
The text of exclusion criteria no. 25 was modified:
Subject is a woman who is pregnant, breast-feeding, or planning to become 
pregnant while enrolled in this study or within “6 weeks” after the last dose of 
intranasal study drug.
Rationale: Subjects with severe renal impairment (creatinine clearance < 30 ml/min) are being excluded (exclusion 
criteria no. 32), as a safety precaution, since the effect of impaired renal clearance on the PK of intranasal 
esketamine is not fully known and subjects may be more vulnerable to blood pressure increases.
4.2. Exclusion Criteria,
4.2.1. Direct-entry Subjects;
4.2.2. Transferred-entry 
Subjects
Added exclusion criteria no. 32 for all direct-entry subjects: Severe renal 
impairment (creatinine clearance < 30 ml/min).
In order to distinguish between direct-entry and transferred entry subjects, the 
exclusion criteria have not been numbered sequentially; 
- Direct-entry subjects (section 4.2.1.): criterion no. 32 follows criterion no. 29. 
- Transferred entry subjects (section 4.2.2.): criteria no.’s 30 and 31 remain 
the same. 
- Transferred entry subjects (section 4.2.2.): criteria no. 32 added
A NOTE has been added clarifying that:
- The following criterion (ie, no. 32) is intentionally not numbered 
sequentially.
Rationale: Clarification to inclusion criterion regarding nonresponse to oral antidepressant treatments in current 
episode of depression was added. 
Synopsis, Subject Population;
4.1. Inclusion Criteria;
3.1.1. Study Phases;
9.1.2. Screening Phase
The text of the current inclusion criteria no. 3 was modified:

Nonresponse to ≥2 oral antidepressant treatments in the current episode of 
depression as assessed using the MGH-ATRQ.

Non-response is confirmed by documented records (eg,
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
15
Status: Approved, Date: 6 July 2016
Applicable Section(s)
Description of Change(s)
medical/pharmacy/prescription records or a letter from a treating physician). 
- For specific tricyclic antidepressants which are being taken at a dose below 
the MGH-ATRQ minimum therapeutic dose, a blood level that is within 
the therapeutic (antidepressant) range, is acceptable to establish the 
adequacy of the antidepressant treatment. 
Rationale: Inclusion of an additional lab test which measures levels of free thyroxine, in the event that TSH values 
are out of range.
4.1. Inclusion Criteria,
4.1.1. Direct-entry Subjects
The text of the inclusion criteria no. 6 was modified to include an additional lab 
test for assessing levels of free thyroxine:
- For any subject (regardless of thyroid history), if the TSH value is out of 
range, a free thyroxine (FT4) will be conducted. If the FT4 value is within 
the normal range, such cases should be discussed directly with the medical 
monitor before the subject is enrolled. If the FT4 value is out of range, the 
subject is not eligible.
Rationale: Clarification of the criteria for assessing pregnancy in women of childbearing potential.
4.1. Inclusion Criteria,
4.1.1. Direct-entry Subjects
The text of the current inclusion criteria no.9 now states that:

A woman of childbearing potential must have a “highly sensitive” negative 
serum (β-human chorionic gonadotropin [β-hCG]) at the start of the screening 
phase.

A negative urine pregnancy test “must be obtained before the first dose of 
study drug” on Day 1 of the open-label induction phase prior to the first 
intranasal treatment session.
Rationale: Inclusion criteria for methods of birth control were updated per new Sponsor protected template.
4.1. Inclusion Criteria, 4.1.1. 
Direct-entry Subjects;
4.1.3. Both Types of Subjects 
(Direct-entry and Transferred-
entry Subjects)
4.1.1. Inclusion Criteria Direct Entry Subjects no. 10 has been moved from section 
4.1.1. Direct-entry subjects to section 4.1.3. Both types of subjects (Direct-entry 
and Transferred-entry subjects) and modified per 3001 protocol amendment.
This is now Inclusion Criteria no. 14
The text of the current inclusion criteria no. 10 was modified and moved to no.14:
During the study (ie, from Day 1 of the open-label induction phase) and for a 
minimum of 1 spermatogenesis cycle (defined as approximately 90 days) after 
receiving the last dose of intranasal study medication, in addition to the user 
independent highly effective method of contraception, a man 

who is sexually active with a woman of childbearing potential must agree to 
use a double-barrier method of contraception (eg, diaphragm or cervical/vault 
caps plus condom with spermicidal foam/gel/film/cream/suppository).

who is sexually active with a woman who is pregnant must use a condom 

must agree not to donate sperm.
4.1. Inclusion Criteria,
4.1.1. Direct-entry Subjects
The text of the current inclusion criteria no. 8 was also modified:
A woman must be either:
a.
Not of childbearing potential defined as:
o
postmenopausal
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. A high follicle stimulating hormone (FSH) 
level (˃40 IU/L or mIU/ml in the postmenopausal range) may be used to 
confirm a postmenopausal state in women not using hormonal 
contraception or hormonal replacement therapy, however in the absence 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
16
Status: Approved, Date: 6 July 2016
Applicable Section(s)
Description of Change(s)
of 12 months of amenorrhea, a single FSH measurement is insufficient.
o
permanently sterile 
Permanent sterilization methods include hysterectomy, bilateral 
salpingectomy, bilateral tubal occlusion/ligation procedures, and bilateral 
oophorectomy.
b.
Of childbearing potential and
o
practicing a highly effective method of contraception (failure rate of <1% 
per year when used consistently and correctly).
Examples of highly effective contraceptives include 
-user-independent methods:
implantable progestogen-only hormone contraception associated with 
inhibition of ovulation; intrauterine device (IUD); intrauterine 
hormone-releasing system (IUS); vasectomized partner; sexual 
abstinence (sexual abstinence is considered a highly effective method 
only if defined as refraining from heterosexual intercourse during the 
entire period of risk associated with the study drug. The reliability of 
sexual abstinence needs to be evaluated in relation to the duration of 
the study and the preferred and usual lifestyle of the subject.)
-user-dependent methods:
combined (estrogen- and progestogen-containing ) hormonal 
contraception associated with inhibition of ovulation: oral, 
intravaginal, and transdermal; progestogen-only hormone 
contraception associated with inhibition of ovulation: oral and 
injectable
Typical use failure rates may differ from those when used consistently 
and correctly. Use should be consistent with local regulations 
regarding the use of contraceptive methods for subjects participating 
in clinical studies.
Hormonal contraception may be susceptible to interaction with the 
study drug, which may reduce the efficacy of the contraceptive 
method.
o
agrees to use a highly effective method throughout the study and for at 
least 6 weeks after the last dose of study drug.
Note: If the childbearing potential changes after start of the study or the risk of 
pregnancy changes (eg, a woman who is not heterosexually active becomes active) 
a woman must begin a highly effective method of contraception, as described 
throughout the inclusion criteria.
Rationale: Confirmation that the subject remains in a stable medical condition while being transferred from the 
ESKETINTRD3005 to the ESKETINTRD3004 study.
4.1. Inclusion Criteria, 
4.1.2. Transferred-entry 
Subjects (From Study 
ESKETINTRD3005)
The text of inclusion criteria no. 11 was modified to include additional 
information: 
The study specific eligibility criteria referred to are now in Sections “4.1.2”, 4.1.3 
and 4.2.2. Additional text:
“Subject must be medically stable on the basis of physical examination, medical 
history, vital signs (including blood pressure), pulse oximetry, and 12-lead ECG 
performed at entry into the study. If there are any abnormalities that are not 
specified in the inclusion and exclusion criteria, their clinical significance must be 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
17
Status: Approved, Date: 6 July 2016
Applicable Section(s)
Description of Change(s)
determined by the investigator and recorded in the subject's source documents and 
initialed by the investigator.
Subject must be medically stable on the basis of clinical laboratory tests performed 
at screening. If the results of the serum chemistry panel, hematology, or urinalysis 
are outside the normal reference ranges, the subject may be included only if the 
investigator judges the abnormalities or deviations from normal to be not clinically 
significant or to be appropriate and reasonable for the population under study. This 
determination must be recorded in the subject's source documents and initialed by 
the investigator.”
Rationale: Clarification of guidelines for intranasal esketamine dose titration during the open-label induction and 
optimization/maintenance phase
Synopsis, Dosage and 
Administration;
6.1.1. Open-label Induction 
phase;
6.1.2. 
Optimization/Maintenance 
phase (Table 7)
Open-label induction phase (all subjects): 
The following text has been deleted: “No up titration in dose is permitted during 
the open-label induction phase if there was a prior down titration due to elevated 
blood pressure”.
Optimization/Maintenance phase (transferred-entry responder subjects only):
The following text has been deleted: “An up titration is not allowed if a subject has 
had a prior down titration from a higher dose due to elevated blood pressure” 
Rationale: Allow option for subjects to start at a 30 mg dose of duloxetine in the oral antidepressant titration schedule.
1.2.2.1. Duloxetine; 
Attachment 3
Deletion of text in Section 1.2.2.1. stating: ‘although not in the US prescribing 
information, an initial starting dose of 30 mg/day has also been evaluated’.
The following text has been added, as the US prescribing information does 
indicated that:
”For some patients, it may be desirable to start at 30 mg once daily for 1 week, to 
allow patients to adjust to the medication before increasing to 60 mg once daily”. 
“In the current study, subjects should be initiated with 60 mg/day. Subjects who have 
in the past shown increased sensitivity towards SSRI/SNRI’s, can at the discretion 
of the treating physician, be started on a 30 mg dose and up-titrated into the 
therapeutic range of 60 mg by the start of Week 2 of the open-label induction phase.
“In Taiwan and South Korea (only), all subjects (ie, including those <65 years of 
age) should receive an initial dose of 30 mg during Week 1 of the screening phase 
(see Attachment 3)”.
Attachment 3, Legend (a) added:
aDuloxetine: Subjects should be initiated with 60 mg/day. Subjects that have in the 
past shown increased sensitivity towards serotonin reuptake inhibitors (SSRI) and 
norepinephrine reuptake inhibitors (SNRI), can, at the discretion of the treating 
physician, be started on a 30 mg dose and up-titrated into the therapeutic range of 
60 mg by the start of Week 2.
Rationale: Update to align with new protocol template text regarding data being collected for medical resource 
utilization
9.5. Medical Resource 
Utilization

Deleted text that specified “including surgeries and other selected procedures; 
“number and character of diagnostic and therapeutic tests and procedures”, 
and “outpatient medical encounters and treatments (including physician or 
emergency room visits, tests and procedures, and medications)”.
Rationale: A predose ECG at visit 3.2 was necessary as it represents a baseline for the optimization/maintenance 
phase; a post dose ECG is a safety evaluation
Time & Events Schedule,
Time & Events Schedule for the optimization/maintenance phase; 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
18
Status: Approved, Date: 6 July 2016
Applicable Section(s)
Description of Change(s)
Optimization/Maintenance 
Phase
A 12-lead ECG reading has been added to visit 3.2 in Time & Events Schedule.
Rationale: Addition of an extra PWC-20 assessment for potential withdrawal symptoms following cessation of 
intranasal esketamine treatment, during Week 1 of the Follow-up Phase.
Time & Events Schedule,
Follow-up Phase
Time & Events Schedule for the Follow-up phase; 
Addition of PWC-20 assessment in Week 1 of the Follow-up Phase.
Rationale: Clarify that in the event that an intranasal treatment session is postponed/delayed (within a visit window) 
due to a predose vital sign assessment (eg, blood pressure), on the actual day of intranasal treatment session, specific
assessments (including predose) must be performed/repeated, as specified in the T&E Schedule.
9.2.1. Safety Evaluations;
Time & Events Schedule 
Where a decision has been made to postpone/delay the intranasal treatment session 
within the visit window, all time points (including predose) of the following 
assessments listed in Time & Events Schedule (open-label induction phase 
footnote ‘m’, optimization/maintenance phase footnote ‘n’) must be repeated on 
the actual intranasal treatment session day: vital signs (ie, blood pressure, pulse, 
respiratory rate and temperature), 12-lead ECG, C-SSRS (since last visit), 
MOAA/S, pulse oximetry, BPRS+, and CADSS, and CGADR.
Footnote ‘m’ of the open-label induction phase, and footnote ‘n’ of the 
optimization/maintenance phase, indicate what needs to be performed/repeated for 
a postponed (within the visit window) intranasal dosing visit.
Rationale: Footnote corrected to specify at which clinic visit a predose and/or postdose 12-lead ECG will be 
performed. 
Time & Events Schedule,
Open-label Induction Phase 
only 
The footnote ‘f’ was corrected to indicate that:
Twelve-lead ECG will be performed at t = 1 h postdose “only (ie, no predose ECG 
required)” at Visits 2.3, 2.5, and 2.8.
Rationale: Clarify arterial oxygen saturation level that requires further monitoring.
9.2.1. Safety Evaluations
The symbol “<” was added to this sentence to clarify that additional assessments 
are required when oxygen saturation levels are < 93%: 
The text now states that:
“If oxygen saturation levels are < 93% at any time during the 1.5 hour postdose 
interval, pulse oximetry will be recorded every 5 minutes until levels return to 
≥93%, or until the subject is referred for appropriate medical care, if clinically 
indicated.”
The following text on adverse event reporting was deleted:
“Any arterial oxygen saturation (SpO2) <93% and lasting for more than 2 minutes, 
and confirmed by an additional manual measurement on another part of the body, 
will be reported as an adverse event”
Rationale: Clarification of the description for the HVLT-R recall test.
9.2.1.. Safety Evaluations
Changes added to the description of the HVLT-R recall test:

Administration includes a delayed recall (20 minute) trial and a 24-word 
recognition list.

The test administrator reads instructions and word lists aloud, and records 
words recalled/recognized by the subjects.

Scores include learning, delayed recall, and recognition.

Additional text added stating that “All subjects will complete a practice 
session for the computerized cognitive battery during the screening phase. 
There is no practice session for the HVLT-R.”
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
19
Status: Approved, Date: 6 July 2016
Applicable Section(s)
Description of Change(s)
Rationale: Clarification of guidance on blood pressure monitoring on intranasal treatment session days.
6.1. Intranasal Study Drug, 
Guidance on Blood Pressure 
Monitoring on Intranasal 
Treatment Session Days
(Subjects < 65 years of age)
Clarification that guidance on blood pressure monitoring;
Subjects <65 years:
Predose blood pressure monitoring:

If subsequent to fulfilling the inclusion and exclusion criteria on Day 1 “(ie, 
applicable for all other treatment session days after Day 1)”, a subject’s
“predose systolic blood pressure (SBP) ˃140 mmHg and/or diastolic blood 
pressure (DBP) ˃90 mmHg”, it is recommended to repeat the blood pressure 
measurement after subject rests in sitting or recumbent position.

If “after rest and repeated measurements”, predose SBP is ˃140 mmHg and/or 
DBP is ˃90 mmHg, then dosing should be postponed.

-If the blood pressure elevation still persists on the next visit, the subject will 
be scheduled for a consultation by cardiologist “other specialist,” or primary 
care physician, prior to further dosing.
Postdose blood pressure monitoring:

If at any postdose time point on the dosing day, the SBP is ≥180 mmHg but 
<200 mmHg and/or the DBP is ≥110 mmHg but <120 mmHg, further 
intranasal dosing should be interrupted and cardiologist, “other specialist” or 
primary care physician, for a follow-up assessment.
- After the assessment by a cardiologist, “other specialist or primary care 
physician, if recommended by the referring doctor and considered  
appropriate according to the clinical judgment” for the subject to continue 
in the study, the subject may continue with intranasal dosing, if the predose 
blood pressure, at the next scheduled visit is within the acceptable range 
(see bullet point above).

If at any postdose time point on the dosing day the SBP is ≥200 mmHg and/or 
the DBP is ≥120 mmHg, the subject “must” discontinue from further dosing 
and be referred “to a” cardiologist, “other specialist or primary care physician 
for a” follow-up assessment.
Addition of the following criteria for discharge based on  post-dose blood pressure 
assessments:
During the open-label induction phase, at 1.5 hours postdose, if the SBP is 
≥160 mmHg and/or the DBP ≥100 mmHg, assessments should continue every 
30 minutes until:

the blood pressure is <160 mmHg SBP and <100 mmHg DBP, or 

“in the investigator’s clinical judgment, the subject is clinically stable  and can 
be discharged from the study site”, or

the subject is referred for appropriate medical care, if clinically indicated.

“If the blood pressure remains ≥ 180 mmHg SBP and/or ≥110 mmHg DBP, 
2 hours after dosing, the subject should be referred for immediate medical 
treatment”.
6.1. Intranasal Study Drug, 
Guidance on Blood Pressure 
Monitoring on Intranasal 
Treatment Session Days
(Subjects ≥65 years of age)
Clarification that guidance on blood pressure monitoring;
Subjects ≥65 years:
Predose blood pressure monitoring:

If subsequent to fulfilling the inclusion and exclusion criteria on Day 1 “(ie, 
applicable for all other treatment session days after Day 1)”, a subjects 
“predose systolic blood pressure (SBP) ˃150 mmHg and/or diastolic blood 
pressure (DBP) ˃90 mmHg”, it is recommended to repeat the blood pressure 
measurement after subject rests in sitting or recumbent position.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
20
Status: Approved, Date: 6 July 2016
Applicable Section(s)
Description of Change(s)

If “after rest and repeated measurements”, predose SBP is ˃150 mmHg and/or 
DBP is ˃90 mmHg, then dosing should be postponed.

-If the blood pressure elevation still persists on the next visit, the subject will 
be scheduled for a consultation by cardiologist “other specialist,” or primary 
care physician, prior to further dosing.
Postdose blood pressure monitoring:

If at any postdose time point on the dosing day, the SBP is ≥180 mmHg but 
<190 mmHg and/or the DBP is ≥100 mmHg but <110 mmHg, further 
intranasal dosing should be interrupted and cardiologist, “other specialist” or 
primary care physician for a follow-up assessment.
- After the assessment by a cardiologist, “other specialist or primary care 
physician, if recommended by the referring doctor and considered  
appropriate according to the clinical judgment” for the subject to continue 
in the study, the subject may continue with intranasal dosing, if the predose 
blood pressure, at the next scheduled visit is within the acceptable range 
(see bullet point above).

If at any postdose time point on the dosing day the SBP is ≥190 mmHg and/or 
the DBP is ≥110 mmHg, the subject “must” discontinue from further dosing 
and be referred “to a” cardiologist, “other specialist or primary care physician 
for a” follow-up assessment.
Addition of the following criteria for discharge based on  post-dose blood pressure 
assessments: 
During the open-label induction phase, at 1.5 hours postdose, if the SBP is 
≥160 mmHg and/or the DBP ≥100 mmHg, assessments should continue every 
30 minutes until:

the blood pressure is <160 mmHg SBP and <100 mmHg DBP, or 

“in the investigator’s clinical judgment, the subject is clinically stable  and can 
be discharged from the study site”, or

the subject is referred for appropriate medical care, if clinically indicated.

“If the blood pressure remains ≥ 180 mmHg SBP and/or / ≥110 mmHg DBP, 
2 hours after dosing, the subject should be referred for immediate medical 
treatment”.
Rationale: Provide further clarification on how the current oral antidepressant treatment regimen should remain 
unchanged for the duration of the screening phase.
Synopsis, Overview of Study 
Design;
3.1.1. Study Phases;
Eligible subjects who are entering the open-label induction phase will discontinue 
all of their current oral antidepressant medication(s), being used for depression 
treatment, including adjunctive/augmentation therapies, prior to the start of the 
induction phase. 
- Subjects taking benzodiazepines (at dosages equal to or less than the 
equivalent of 6 mg/day of lorazepam) and/or permitted non-
benzodiazepine sleep medications (e.g., zolpidem, zaleplon) during the 
screening phase can continue these medications.
- No dose increases beyond the equivalent of 6 mg/day of lorazepam, or new 
benzodiazepine or non-benzodiazepine sleep medications are permitted, 
with the exception of the use of permitted benzodiazepine as rescue 
medication (where required).
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
21
Status: Approved, Date: 6 July 2016
Applicable Section(s)
Description of Change(s)
Rationale: Clarification that both direct entry and transferred entry subjects will receive the same dose of oral 
antidepressant on proceeding to the optimization/maintenance phase. 
3.1.1. Study Phases, 
Optimization/Maintenance 
Phase
New text added to section: Responder subjects who are eligible to proceed to the 
optimization/maintenance phase, will continue receiving the same oral 
antidepressant medication(s) as taken in the last week of the induction phase of 
ESKETINTRD3004 study. “Both for direct entry and transferred entry subjects, 
the dose of the oral antidepressant the subject is on at the end of the induction 
phase is continued into the subsequent study phase.”
Rationale: Update list of substances that can be ingested or that are restricted prior to intranasal study medication 
based on the recent drug-interaction study results.
4.3. Prohibitions and 
Restrictions
Removal of the following restriction: ‘Subjects should not ingest grapefruit juice, 
Seville oranges, or quinine for 24 hours before an intranasal dose of study 
medication is to be administered. 
Subjects who were taking benzodiazepines (at dosages equal to or less than the 
equivalent of 6 mg/day of lorazepam) and/or permitted non-benzodiazepine sleep 
medications (eg, zolpidem, zaleplon) during the screening phase can continue 
these medications during the study. No dose increases beyond the equivalent of 
6 mg/day of lorazepam, or new benzodiazepine medications are permitted during 
the study, with the exception of the use of permitted benzodiazepine rescue 
medication. Benzodiazepines and non-benzodiazepine sleeping medication 
(eg, zolpidem, zaleplon, eszopiclone, and ramelteon) are prohibited within 
12 hours prior to the start of each intranasal treatment session or cognition testing.
Rationale: Clarifications for the use of prestudy and concomitant therapies.
8. Prestudy and Concomitant 
Therapy;
4.3. Prohibitions and 
Restrictions
Clarification of the following:
Concomitant Therapy
Antidepressant treatments which are not listed on the MGH-ATRQ, but were used, 
or are currently being used, as antidepressant treatments in the current depressive 
episode must be recorded under ‘Concomitant Therapy’ eCRF.
Concomitant therapies must be recorded from signing of the informed consent and 
continuing up the last visit.
If a subject routinely takes his/her oral antihypertensive medications in the 
morning on dosing days, the morning dose should be taken prior to intranasal 
dosing. 
Prohibitions and Restrictions
Subjects receiving psychotherapy (including cognitive behavioral therapy; CBT) 
can continue receiving psychotherapy. New psychotherapy is allowed during this 
study. Any change in existing therapy or new therapy must be documented on the 
concomitant therapies form.
Rationale: Changes to Attachment 1, including the table listing of Prohibited Concomitant Medications:
Attachment 1
- Deletion of row referring to CYP3A4 inhibitors as prohibited concomitant 
medication.
- Additional example of anorexiants (eg, phendimetrazine) that are 
prohibited as concomitant medication for reasons of safety.
- An additional example of anticonvulsants (eg, pregabalin) that are 
permitted as concomitant medication when used for indications other that 
seizures was added.
- Methylphenidate, modafinil, and armodafinil, were added as additional 
examples of prohibited psychostimulants. 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
22
Status: Approved, Date: 6 July 2016
Applicable Section(s)
Description of Change(s)
- A new row was added for prohibited non-stimulant ADHD medications 
(eg, .atomoxetine, guanfacine).
- Addition of new text to comments on the use of antidepressants in this 
study, stating that ”Even if used primarily for sleep, trazodone use is not 
permitted during the treatment phase”.
- Deletion of text in comments on the use of Non-benzodiazepine sleeping 
medication.
- Clarification that benzodiazepine medication should be taken at dosages 
equal to or less than the equivalent of 6 mg/day of lorazepam.
- Addition of new text to comments on the use of cough/cold 
preparations/nasal solutions containing vasoconstrictors, decongestants 
“pseudoephedrine – containing products should not be used within 
12 hours prior to an intranasal treatment session”. This is for reasons of 
safety and due to potential PD interactions.
- Added row for non-vitamin K antagonist oral anticoagulant agents (eg, 
dabigatran, rivaroxaban, apixaban).
- Deletion of text in comments on the use of thyroid hormone supplements.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
23
Status: Approved, Date: 6 July 2016
Applicable Section(s)
Description of Change(s)
Rationale: Clarification of criteria for withdrawal of consent
10.2. Withdrawal from the 
Study
For clarification the following additions to the text were made:
Withdrawal of consent:
Should only be selected as a reason for withdrawal if the subject does not agree to 
any further study assessments or procedures. If the subject is agreeable to 
participating in the Early Withdrawal visit and the follow-up phase, another reason 
for withdrawal should be selected.
If the subject withdraws from the study before the end of the open-label induction 
phase or optimization/maintenance phase, an Early Withdrawal visit is to be 
performed. 
If the subject is lost to follow-up, every reasonable effort must be made by the 
study site personnel to contact the subject and determine the reason for 
discontinuation/withdrawal. This should include at least 3 telephone calls, certified 
letters, email requests, etc,. To ensure access to follow-up subjects, the study site 
personnel should attempt to obtain both primary and secondary telephone contact 
numbers (eg, home, work, and mobile numbers), as well as other contact 
information (eg, email addresses) from subjects. In addition the study site should 
emphasize the importance of follow-up information to the subject before initiation 
of the open-label induction phase. The measures taken to follow-up must be 
documented.
Subjects who withdraw will not be replaced.
Addition of the following text:
Withdrawal of Consent
Every effort will be made in the study to ensure withdrawal of consent is not 
selected as a reason for discontinuation when in fact the subject withdrew for an 
identifiable reason (e.g. due to an adverse event or lack of efficacy).
Subjects who wish to withdraw from the study should be asked if they are 
agreeable to be contacted to collect follow-up information. Subjects who are not 
agreeable to follow-up contact will be withdrawn from the study as “withdrawal of 
consent.” Subjects who no longer wish to take study drug but agree to provide 
follow-up information will be withdrawn from the study, with the reason noted as 
“Other” and will specify the reason why.
For a subject who “withdraws consent”, it is recommended that the subject 
withdraw consent in writing; if the subject refuses or is physically unavailable, the 
study site should document and sign the reason for the subject’s failure to 
withdraw consent in writing and maintain it with the subjects source records.
- The investigator will be responsible for making all required notifications to 
the Institutional Review Board (IRB) or Independent Ethics Committee 
(IEC).
Rationale: Clarification of procedures that need to be followed with respect sample collection and handling, on 
withdrawal of a subject from the study.
10.2. Withdrawal from the 
Study 
Addition of new text specifying that:

When a subject withdraws before completing the study, the reason for 
withdrawal must be documented in the CRF and in the source document.

Study drug assigned to the withdrawn subject may not be assigned to another 
subject.

Subjects who withdraw will not be replaced.

If a subject withdraws before the end of the open-label induction phase, 
assessments must be obtained.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
24
Status: Approved, Date: 6 July 2016
Applicable Section(s)
Description of Change(s)
Rationale: Clarification on administration of oral antidepressant 
Synopsis, Overview of Study 
Design;
1.2. Oral Antidepressants: 
Study Medication;
3.1.1. Study Phases;
3.2.4. Treatment Groups and 
Dose Selection;
9.1.4. 
Optimization/Maintenance 
phase
Addition of the following criteria, applicable to both direct-entry and transferred-
entry non-responder subjects:
Induction phase: Subjects “should” continue to take the same oral antidepressant 
throughout the course of the study.
Maintenance/Optimization phase: Subjects “should” continue to take the same oral 
antidepressant during the study, “unless poorly tolerated, in which case the oral 
antidepressant may be discontinued after review with sponsor”.
Rationale: Inclusion of tests for measuring free thyroxine (FT4) and for determining rates of creatinine clearance
9.2.1.. Safety Evaluations
Inclusion of the following tests at time points specified in the Time & Events 
Schedule:

Free thyroxine (FT4), if applicable

Calculation of creatinine clearance
Rationale: Clarification on the use of oral antidepressant in the morning on the intranasal esketamine dosing days.
6.2 Oral Antidepressants
The following  sentence has been added: 
“If the oral antidepressant is taken in the morning on a dosing day, intranasal 
dosing may proceed provided acceptable blood pressure based on the pre-dose 
blood pressure guidance.
Rationale: Provide further clarification to site staff requirements for intranasal treatment sessions. 
Synopsis, Dosage and 
administration;
6.1. Intranasal Study Drug
On all intranasal treatment session days, a site staff member with training in 
cardiopulmonary resuscitation (eg, Basic Life Support course or equivalent courses) 
that is up to date per local regulations must be present with the subject during the 
intranasal treatment sessions and the postdose observational period. Subjects must 
remain at the site until study procedures have been completed and the subject is 
ready for discharge. At the time of discharge, subjects should be accompanied by a 
responsible adult when released from the clinical site. Subjects must not drive a car 
or work with machines for 24 hours after receiving study drug.
Rationale: Clarification on the oral antidepressant used by the transferred- entry subjects
3.1.1. Study Phases,
Figure 1
A legend was added to the study diagram in Figure 1 (study diagram),:
Footnote “a” was added to replace the asterisk denoting the footnote.
Footnote “b” was added, which contains the following text: “At entry to the 
ESKETINTRD3004, transferred-entry subjects will continue to receive the same 
oral AD initiated in the ESKETINTRD3005 study. The new oral AD is for direct 
entry subjects only.”
Rationale: Alert site staff to ECG readings that would raise safety concerns and necessitate subject withdrawal and 
study discontinuation
9.2.1. Safety Evaluations;
10.2. Withdrawal from the 
Study
The following text was added:
-The subject must be discontinued at any time point after baseline (Day 1, 
predose), if:

QTcF change from baseline is ≥ 60 msec and QTcF > 480 msec, or 

QTCF > 500 msec.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
25
Status: Approved, Date: 6 July 2016
Applicable Section(s)
Description of Change(s)
Rationale: Correction to the Volume of Blood collected from each Subject for Study Evaluations.
9.1.1. Overview,
Table 9
Total Volume of Blood to be collected is now 139 mL.
This reflects the following changes:
- Volume of Blood sample for Biomarker: Protein is now 10 mL
- Volume of Blood sample for Biomarker: DNA is now 6 mL
- Screening Phase: Row added to blood volume table to include:
A single 3.5 mL sample per subject for analysis of blood levels of free 
thyroxine (FT4), if required.
Addition of footnote ‘e’ “for any subject (regardless of thyroid history), if 
the TSH value is out of range, a free thyroxine (FT4) will be conducted.”
- Open-label Induction Phase: The two rows for ‘Biomarker: protein visits’ 
have been merged to a single row, that will now state: “Biomarker: protein 
(at Visits 2.1, 2.3, and 2.9). The volume of sample collected at each visit is 
10 mL, and the number of samples per subject is now 3.
- Optimization/Maintenance Phase (only): Hematology. The number of 
blood samples per subject has been changed to 7 samples. The total volume 
of blood taken for hematology is now 14 mL.
- Optimization/Maintenance Phase (only): Serum Chemistry. The number 
of blood samples per subject has been changed to 7 samples. The total 
volume of blood taken for serum chemistry is now 17.5 mL.
- Delete footnote ‘c’ Blood volume listed under protein biomarkers 
represents the combined volume of several different collection tubes.
- The Note in the legend now states: ’Note: “10 mL” of blood for protein 
biomarkers represents the volume of several tubes combined’
Rationale: Clarification of the language regarding subjects who develop treatment emergent ulcerative cystitis to 
indicate the discontinuation of such subjects is mandatory.
3.2.5. Safety Evaluations;
9.2.1. Safety Evaluations
Updated/added the text in these sections describing the BPIC-SS and instructions 
for discontinuing due to ulcerative cystitis, to read as follows; “If a subject is 
diagnosed with ulcerative cystitis, the subjects must be discontinued from the 
study and followed up with appropriate medical care.”
Rationale: Update Source Documentation in line with changes to the Template
17.4. Source Documentation
The following text (bold) was added:
At a minimum, source documentation “consistent in the type and level of detail 
with that commonly recorded at the study site as a basis for standard medical 
care” must be available for the following to confirm data collected in the eCRF.
Deletion of following: 
Data recorded directly into the eCRF as source data:
- Race 
- Blood pressure and pulse/heart rate
- Height and weight
- Details of physical examination
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
26
Status: Approved, Date: 6 July 2016
Applicable Section(s)
Description of Change(s)
Rationale: Update the process for completion of the Case Report Form (CRF) in line with new changes to template
17.5. Case Report Form 
Completion
The following updates were included:
- All data relating to the study must be recorded in CRF.
- All CRF entries, correction, and alterations must be made by the 
investigator or authorized study-site personnel. The investigator must 
verify that all data entries in the CRF are accurate and correct.
- All subject measurements (eg, clinician reported questionnaires) will be 
completed by the same individual who made the initial baseline 
determination whenever possible.
- If correction to an eCRF are needed after the initial entry into the eCRF, 
this can be done in either of the following ways:
- (i) Investigator and Study site personnel can make correction in the eDC 
tool at their own initiative or in response to an auto query (generated by the 
eDC tool)
- (ii) Sponsor or sponsor delegate can generate a query for resolution by the 
study-site personnel.
Rationale: Update list of study-specific materials and removal of sentence referring to an additional document 
outlining required equipment for supportive ventilation. This sentence was added to this protocol in error, and is 
now being removed in order to be consistent with the other phase 3 protocols, as no additional document was 
provided.
15. Study-Specific Materials
- ‘Guidance document for the use of the MGH-ATRQ’ has been added.
- Removal of the statement: ‘Guidance on required equipment for supportive 
ventilation and resuscitation will be provided in a separate document.’
- ‘Web-based Patient Stated-choice Preference Survey’ has been added
Rationale: Minor errors and clarification were noted.
Throughout the protocol
Grammatical, formatting, or spelling changes were made.
12.3.1. All Adverse Events
Removal of the statement: ‘Any other information that is required to do an 
emergency breaking of the blind’
Time & Events Schedule,
Open-label Induction Phase
Dispensing of oral antidepressant for a subject who has discontinued treatment, has 
been added to visit 2.9.  
4.3 Prohibitions and 
Restrictions
Clarification of the abbreviations used:
Electroconvulsive therapy (ECT), deep brain stimulation (DBS), transcranial 
magnetic stimulation (TMS) and vagal nerve stimulation (VNS) are prohibited 
from study entry though the end of the last treatment phase.
10.3 Withdrawal from the Use 
of Samples in Future Research
This paragraph has been designated as a distinct section 10.3. Withdrawal from the 
use of Samples in Future Research
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
27
Status: Approved, Date: 6 July 2016
Amendment 1 (11 June 2015)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.  
The overall reason for the amendment: The overall reason for the amendment is to allow for the use of a 28 mg 
dose throughout the study, based on pharmacokinetic data from study ESKETINTRD1012 in elderly subjects.
Applicable Section(s)
Description of Change(s)
Rationale: Based on pharmacokinetic data from study ESKETINTRD1012 a change was made to allow for the use 
of a 28 mg dose of esketamine throughout the study which could potentially improve safety and tolerability
1.1.2.1. Pharmacokinetics 
and Product Metabolism; 
1.1.2.3. Safety and 
Tolerability
Description of preliminary pharmacokinetic results for study ESKETINTRD1012 was 
added in addition to a safety overview from the study.
1.1.2.2. 
Pharmacodynamics and 
Efficacy; 3.2.4 Treatment 
Groups and Dose 
Selection
Justification statement for including the 28 mg dose beyond Day 1, based on PK data 
from ESKETINTRD1012, was added.
Synopsis Dosage and 
Administration;
6.1.1. Open-label 
Induction Phase;
6.1.2. Optimization/
Maintenance Phase
For direct-entry and transferred-entry non-responder subjects 65 years, the dose 
titration of intranasal esketamine was revised to allow for use of a 28 mg dose 
throughout the induction phase and optimization/maintenance phase. For transferred 
entry responder subjects, the dose titration of intranasal esketamine was revised to 
allow for the use of a 28 mg dose throughout the optimization/maintenance phase.
Added guidance that dose changes are determined by the investigator based on 
efficacy and tolerability and in accordance with blood pressure guidelines.
Synopsis Overview of 
Study Design; 
1.2. Oral Antidepressants: 
Study Medication’
3.1. Overview of Study 
Design; 
3.1.1. Study Phases; 
3.2.4 Treatment Groups 
and Dose Selection
Addition of 28 mg dose which can be continued throughout the study for subjects ≥65 
years of age.
Rationale: More conservative blood pressure parameters related to patient dosing were incorporated to improve 
subject safety
Synopsis Dosage and 
Administration; 
6.1 Intranasal Study Drug;
6.1.1 Open-label 
Induction Phase
Added that prior to intranasal dosing, subjects ≥65 years of age must have a pre-dose 
blood pressure ≤150/90 mm Hg and prior to dose escalation, subjects ≥65 years of age 
must have had a post-dose blood pressure, on the prior intranasal dosing day, of 
<180 mmHg systolic and <100 mm Hg diastolic.
6.1 Intranasal Study Drug
A separate guidance for monitoring blood pressure on intranasal treatment session 
days was created for subjects ≥65 years of age: if on the dosing day, the post-dose SBP 
is 180 mm Hg but ≤190 mm Hg and/or the DBP is 100 mm Hg but <110 mm Hg, 
further intranasal dosing should be interrupted.  If post dose the SBP is 190 mm Hg 
and/or the DBP is 110 mm Hg, the subject should discontinue from further dosing.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
28
Status: Approved, Date: 6 July 2016
Applicable Section(s)
Description of Change(s)
T&E Schedule Screening 
and Open-label Induction 
Phase; T&E Schedule 
Optimization/Maintenance 
Phase
Added guidance in footnote that if dosing is postponed (but occurs within visit 
window) due to blood pressure elevation, predose procedures and all procedures at 
postdose time points (if applicable) must be repeated on the actual dosing day (a 
footnote was added for each assessment that is to be repeated).   
Synopsis Dosage and 
Administration; 
6.1.1 Open-label 
Induction Phase;
6.1.2. Optimization/ 
Maintenance Phase
Added that no up-titration is permitted during the open-label induction phase if there 
was a prior down titration due to elevated blood pressure.
Rationale: Correction/clarification made to the planned number of enrolled subjects
Synopsis, Overview of 
Study Design; Synopsis, 
Statistical Methods;
3.1. Overview of Study 
Design;
11.2 Sample Size 
Determination
Text previously stated that 750 subjects would be enrolled into the study. Correction 
was made to state that 750 direct-entry subjects would be enrolled, plus transferred 
entry subjects from study ESKETINTRD3005. Clarification added to meet the 
regulatory requirement of having 100 subjects 65 years or older, the number will be 
made up of direct entry subjects plus transferred entry subjects from study 
ESKETINTRD3005.
Rationale: Exclusion criteria expanded to include additional DSM-5 diagnostic codes for intellectual disability and 
autism spectrum disorder
Synopsis Subject 
Population;
4.2.1. Exclusion Criteria 
Direct-entry Subjects
Exclusion criteria #2 for direct-entry subjects was expanded to include additional 
DSM-5 diagnostic codes for intellectual disability as well as autism spectrum disorder.
Rationale: Updated to clarify that those without a history of thyroid disease are required to have a normal Thyroid 
Stimulating Hormone (TSH) level at Screening.
4.1.1 Inclusion Criteria 
Direct-entry Subjects
Added to inclusion criteria #6 for Direct-entry subjects the requirement for a normal 
TSH at screening, even for subjects without an existing history of hyperthyroidism. 
Also added that if the TSH is below the normal range, free thyroxine (fT4) levels will 
be measured and if fT4 is within the normal range the subject can be enrolled.
Rationale: Correction to the number of missing consecutive MADRS assessments that will lead to a subject being 
discontinued from the study
Synopsis Dosage and 
Administration;
6.1.2. Optimization/ 
Maintenance Phase;
10.2 Criteria for 
Withdrawal from the 
Study
Subjects who miss 4 or more consecutive MADRS assessments (changed from >4) in 
the optimization/maintenance phase will be discontinued from the study. 
Rationale: Correction to dispensing of oral antidepressants during the open-label induction phase
T&E Schedule Open-label 
Induction Phase
Removed dispensing of oral antidepressants on study Day 28.
Rationale: Correction to SDS assessments during the open-label induction phase
T&E Schedule Open-label 
Induction Phase
Added SDS assessment on study Day 15.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
29
Status: Approved, Date: 6 July 2016
Applicable Section(s)
Description of Change(s)
Rationale: Clarification on recommendation for continuation of oral antidepressants during the follow-up phase
Synopsis Overview of 
Study Design; Synopsis 
Dosage and 
Administration;
3.1.1. Study Phases;
6.1.3 Follow-up Phase;
6.2.3. Follow-up Phase;
9.1.5. Follow-up Phase
The decision to continue the oral antidepressant in the follow-up phase remains at the 
discretion of the investigator. Language was added that continuation of oral 
antidepressant is strongly recommended to “facilitate maintenance of clinical benefit”. 
Guidance now states that it is “strongly” recommended to continue the oral 
antidepressant for “the duration” of the follow-up phase (changed from “at least the 
first 2 weeks”).
Rationale: Correction to exclusion criteria for subjects with pulmonary insufficiency
4.2.1. Direct-entry 
Subjects
Exclusion criterion #6 was deleted as this criterion statement “current or past history of 
significant pulmonary insufficiency/condition” was duplicated in Exclusion criteria 
#10. 
Rationale: Correction to exclusion criteria for subjects who had major surgery
4.2.1 Direct-entry subjects
The following statement was removed from Exclusion criterion #27 “Note: Subjects 
with planned surgical procedures to be conducted under local anesthesia may 
participate”.
Rationale: Clarification on use of intranasal decongestants
6.1 Intranasal Study Drug
Clarification added that subjects should wait for at least 1 hour after using an 
intranasal decongestant or corticosteroid before administering esketamine.
Rationale: Correction to description of MMSE
9.6. Other Evaluations
The description of the MMSE was incorrect. The statement “attention (total score, 5), 
calculation (total score, 5)” was changed to “attention and calculation (total score, 5)”.
Rationale: Correction made to description of oral antidepressant packaging
14.2. Packaging
Reference to blister packaging was removed. 
Rationale: Clarification that SIGMA is the structured interview guide of the MADRS
9.3.1.1 Montgomery-
Asberg Depression Rating 
Scale (MADRS)
The following sentence was added to describe the MADRS “The structured interview 
guide for the MADRS (SIGMA) will be used for each administration”.
Rationale: Clarify that menstrual cycle tracking is only applicable to women with a menstrual cycle
T&E Schedule Open-label 
Induction Phase, 
Optimization/Maintenance 
Phase, Follow-up Phase;
9.6 Other Evaluations
Added statement “with a menstrual cycle” to definition of applicable women.
Rationale: Blood volume table updated to include tricyclic antidepressant blood level testing
9.1.1. Overview
Row added to blood volume table for tricyclic antidepressant blood level. Applicable 
to subjects taking specific tricyclic antidepressants at a dose below the MGH-ATRQ 
minimum therapeutic dose – a blood level that is within the therapeutic range is 
acceptable to establish the adequacy of antidepressant treatment.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
30
Status: Approved, Date: 6 July 2016
Applicable Section(s)
Description of Change(s)
Rationale: Correction for use of new form for documenting return to the sponsor of unused study drug, or used 
returned study drug for destruction. 
Section 14.5. Drug 
Accountability
Drug return form replaced with Investigational product destruction form.
Rationale: Minor errors were noted
Throughout the protocol
Minor grammatical, formatting, or spelling changes were made.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
31
Status: Approved, Date: 6 July 2016
SYNOPSIS
An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-
resistant Depression
Study Acronym: SUSTAIN-2
Major depressive disorder (MDD), a serious, recurrent, and disabling psychiatric illness, is the second 
leading cause of years lost to disability worldwide. MDD is associated with excess mortality, and with 
years of potential life lost. About 30% of patients fail to achieve remission despite treatment with multiple 
antidepressant medications, and are considered to have treatment-resistant depression (TRD). There is a 
significant need to develop novel treatments based upon relevant pathophysiologic pathways underlying 
MDD for the rapid relief of symptoms of depression, especially in patients with TRD.
Ketamine and esketamine (S-ketamine, the S enantiomer of ketamine) are approved and widely used for 
the induction and maintenance of anesthesia via intramuscular (IM) or intravenous (IV) administration. 
The desired analgesic-anesthetic effects of ketamine and esketamine are attributed to the blockade of 
ionotropic N-methyl-D-aspartate (NMDA) glutamate receptors. The mechanism of action of ketamine and 
esketamine is distinct from conventional monoaminergic antidepressant treatments and ketamine 
profoundly affects fast excitatory glutamate transmission, increases brain-derived neurotrophic factor 
(BDNF) release, and stimulates synaptogenesis.
Janssen Research & Development (JRD) is developing intranasal esketamine as an antidepressant 
therapy. A higher NMDA receptor affinity of esketamine allows a lower volume of medication to be 
administered via the non-invasive, rapidly absorbed intranasal route.
The current study will investigate the long-term (up to 52 weeks) safety and efficacy of intranasal 
esketamine plus an oral antidepressant in subjects with TRD.
OBJECTIVES AND HYPOTHESIS
Primary Objective
The primary objective of this study is to assess the long-term safety and tolerability of intranasal 
esketamine plus a newly initiated oral antidepressant in subjects with TRD, with special attention to the 
following:

Potential effects on cognitive function

Potential treatment-emergent symptoms of cystitis and/or lower urinary tract symptoms

Potential withdrawal and/or rebound symptoms following cessation of intranasal esketamine 
treatment 
Secondary Objectives
To assess the effect of intranasal esketamine plus a newly initiated oral antidepressant in subjects with 
TRD on

Safety and tolerability with special attention to the following:

Treatment-emergent adverse events (TEAEs), including TEAEs of special interest

Local nasal tolerability 

Effects on heart rate, blood pressure, respiratory rate and blood oxygen saturation
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
32
Status: Approved, Date: 6 July 2016

Effects on alertness and sedation 

Potential psychosis-like effects

Dissociative symptoms 

Potential effects on suicidal ideation/behavior.

Long-term efficacy, including effects on:

Depressive symptoms (clinician and self-reported), overall severity of depressive illness, 
functional impairment and associated disability, anxiety symptoms, and health-related quality of 
life and health status

Response rate over time, defined as:
o
percentage of subjects with 50% reduction from baseline (induction phase) in the 
Montgomery-Asberg Depression Rating Scale (MADRS) total score, 
o
percentage of subjects with 50% reduction from baseline (induction phase) in the Patient 
Health Questionnaire, 9-item (PHQ-9) total score 

Remission rate over time, defined as:
o
percentage of subjects with MADRS total score 12, 
o
percentage of subjects with PHQ-9 total score 5
Exploratory Objectives

To assess the potential relationship of biomarkers with response/non-response to intranasal 
esketamine plus an oral antidepressant in subjects with TRD

To assess medical resource utilization

To assess subject tradeoff preferences for key benefit and harm outcomes associated with TRD 
treatment, using a stated-choice conjoint analysis survey. Reporting of these survey results may be 
conducted separately from this study.  
Hypothesis
There is no formal hypothesis for this safety study.
OVERVIEW OF STUDY DESIGN
This is an open-label, multicenter, long-term study to evaluate the safety and efficacy of intranasal 
esketamine plus a newly initiated oral antidepressant in subjects with TRD. Subjects will enter the study 
either directly (referred to as ‘direct-entry subjects’) or after completing the double-blind induction phase 
of ESKETINTRD3005, a short-term efficacy study in elderly subjects with TRD (referred to as 
‘transferred-entry subjects’). Approximately 750 direct entry subjects will be enrolled in this study, plus 
transferred-entry subjects from study ESKETINTRD3005. At total of at least 100 subjects 65 years or 
older (who are either direct entry subjects or transferred entry subjects from the ESKETINTRD3005 
study) will be enrolled.
ESKETINTRD3005 is a randomized, double-blind, active-controlled, 4-week study in male and female 
elderly subjects (65 years) with TRD to assess the efficacy, safety, and tolerability of flexibly dosed 
intranasal esketamine (28 mg, 56 mg or 84 mg) plus a newly initiated oral antidepressant, compared with 
a newly initiated oral antidepressant (active comparator) plus intranasal placebo.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
33
Status: Approved, Date: 6 July 2016
Transferred-entry subjects who are non-responders (defined as <50% reduction in the MADRS total score 
from baseline [Day 1] at the end of the 4-week double-blind induction phase of ESKETINTRD3005
study) will be referred to as ‘transferred-entry non-responder subjects’ in the subsequent sections of the 
protocol. Transferred-entry subjects who are responders (defined as ≥50% reduction in the MADRS total 
score from baseline [Day 1])
at
the
end of the 4-week double-blind
induction phase of 
ESKETINTRD3005 study) will be referred to as ‘transferred-entry responder subjects’ in the subsequent 
sections of the protocol. 
An Independent Data Monitoring Committee (IDMC) will be commissioned for this study to review 
safety data periodically.
This study (ESKETINTRD3004) has 4 phases:

Up to 4-week screening phase (direct-entry subjects only)

A 4-week open-label induction phase (direct-entry subjects and transferred-entry non-responder
subjects)

A 48-week open-label optimization/maintenance phase (all responder subjects from the 
open-label induction phase of the current study, and transferred-entry responder subjects).  

A 4-week follow-up phase (for all subjects treated with intranasal esketamine)
The maximum duration of the subject’s participation in ESKETINTRD3004 study will be 60 weeks for 
direct-entry subjects; 56 weeks for transferred-entry non-responder subjects, and 52 weeks for 
transferred-entry responder subjects. The end of the study will occur when at least 300 subjects have 
received treatment with intranasal esketamine for 6 months and at least 100 subjects for 12 months
(Note: the total number of subjects will be based on subjects from this study and subjects from other 
intranasal esketamine Phase 3 studies). 
A description of the study phases is provided below.
Screening Phase
After giving informed consent, direct-entry subjects with TRD who are 18 years of age (or older if the 
minimum legal age of consent in the country in which the study is taking place is >18 years), will be 
screened to 
determine 
eligibility 
for study 
participation. Transferred-entry 
subjects from 
ESKETINTRD3005 study will not participate in this 4-week screening phase. 
Direct-entry subjects will be eligible for screening regardless of whether or not they are currently taking 
oral antidepressant treatments. At screening, subjects must have had a nonresponse to 2 different oral 
antidepressant treatments in the current episode of depression, as assessed by the Massachusetts General 
Hospital-Antidepressant Treatment Response Questionnaire (MGH-ATRQ), and confirmed by 
documented records (eg, medical/pharmacy/prescription records or a letter from treating physician etc,), 
in their current episode of depression. 
Eligible subjects taking antidepressant medication(s) at the start of the screening phase must discontinue 
all of their current oral antidepressant medication(s), being used for depression treatment, including 
adjunctive/augmentation therapies, prior to the start of the induction phase. Of note, subjects taking 
benzodiazepines (at dosages equal to or less than the equivalent of 6 mg/day of lorazepam) and/or 
permitted non-benzodiazepine sleep medications (eg, zolpidem, zaleplon) during the screening phase can 
continue these medications. No dose increases beyond the equivalent of 6 mg/day of lorazepam, or new 
benzodiazepine medications are permitted. If clinically indicated, the antidepressant treatments) may 
either be tapered and discontinued during the screening phase, or, discontinued and switched directly to 1 
of the 4 new oral antidepressant medication(s) on Day 1 of the open-label induction phase, per clinical 
judgment.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
34
Status: Approved, Date: 6 July 2016
Subjects not currently taking oral antidepressant medication(s) at screening will start 1 of the 4 new oral 
antidepressant medication (duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on 
Day 1 of the open-label induction phase. 
Subjects meeting the inclusion/exclusion criteria are eligible to proceed to the open-label induction phase.
Open-label Induction Phase (4 weeks)
Direct-entry subjects and transferred-entry non-responder subjects will participate in this phase.
Direct-entry subjects: Intranasal esketamine treatment will be self-administered at scheduled treatment 
sessions in the clinic/study site, twice weekly for 4 weeks. Subjects who are <65 years old will start 
intranasal esketamine with an initial dose of 56 mg on Day 1, with the dose adjusted based on efficacy 
and tolerability in the subsequent visits of the induction phase (flexible dose: 56 mg or 84 mg). Subjects 
who are 65 years old will start intranasal esketamine with an initial dose of 28 mg on Day 1, with the
dose adjusted based on efficacy and tolerability (28, 56 or 84 mg) in the subsequent visits of the induction 
phase. In addition, all direct-entry subjects will initiate a new, open-label oral antidepressant on Day 1, 
which should be taken daily during the study. 
The assigned oral antidepressant will be 1 of 4 oral antidepressant medications (duloxetine, escitalopram, 
sertraline, or venlafaxine extended release [XR]), that the subject has not previously had a nonresponse to 
in the current depressive episode, has not been previously intolerant to (lifetime), and is available in the 
participating country.
Transferred-entry non-responder subjects from ESKETINTRD3005 study (all will be ≥65 years old) will 
join this study at the start of the open-label induction phase. These subjects will start intranasal 
esketamine with an initial dose of 28 mg on Day 1, with the dose adjusted based on efficacy and 
tolerability (28, 56 or 84 mg) in the subsequent visits of the induction phase. These subjects should
continue taking the same oral antidepressant (at the same dose) during the study, as taken in the last week 
of the double-blind induction phase of ESKETINTRD3005 study.
Transferred-entry subjects’ may participate in this study only if it is clinically appropriate in the opinion
of the investigator.
For transferred-entry non-responder subjects, results of all assessments performed on Day 28 of the 
induction phase of that study (Visit 2.9 of ESKETINTRD3005 study) will not be repeated as part of 
Visit 2.1 of the current study. For these subjects, the Day 28 visit of the ESKETINTRD3005 study will 
coincide with Day 1 (Visit 2.1) for the current study. There is no gap allowed between studies.
Optimization/Maintenance Phase: 
Responder subjects at the end of the induction phase (≥50% reduction in MADRS from baseline [Day 1] 
to end of induction phase) of the ESKETINTRD3004 study, will be eligible to proceed to the 
optimization/maintenance phase; and continue receiving open-label intranasal esketamine treatment (at 
the same dose; 28 mg, 56 mg, or 84 mg) and should continue to take the same oral antidepressant (at the 
same dose) as taken in the last week of the induction phase of ESKETINTRD3004 study, unless poorly 
tolerated, in which case the oral antidepressant may be discontinued after review with sponsor.
Non-responders at the end of the induction phase of the current study will complete an early withdrawal 
visit and proceed to the follow-up phase.
Eligible transferred-entry responder subjects from the ESKETINTRD3005 study (all will be ≥65 years 
old) will join the current study starting from the optimization/maintenance phase. Transferred-entry 
subjects may participate in this study only if, it is clinically appropriate in the opinion of the investigator. 
These subjects will start intranasal esketamine with an initial dose of 28 mg (Week 5; Study Day 32) and 
have their dose adjusted over the following 3 weeks of the optimization/maintenance phase as described 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
35
Status: Approved, Date: 6 July 2016
below under the section Dosage and Administration. Subjects should continue to take the same oral 
antidepressant (at the same dose) during the study, as taken in the last week of the double-blind induction 
phase of ESKETINTRD3005 study, unless poorly tolerated, in which case the oral antidepressant may be 
discontinued after review with sponsor.
For transferred-entry responder subjects’, results of all assessments performed on Day 28 of the induction
phase (Visit 2.9 of ESKETINTRD3005 study) will not be repeated as part of Visit 3.1 of the current 
study. The Day 28 visit of the ESKETINTRD3005 study will coincide with Day 28 (Visit 3.1) for the 
current study. There is no gap allowed between studies.
For all subjects, the intranasal treatment session frequency will be reduced from that in the induction 
phase (twice weekly) to weekly for the first 4 weeks of optimization/maintenance phase (ie, Week 5 to 
Week 8). After the first 4 weeks, the frequency of intranasal treatment sessions will be adjusted to either 
once weekly or once every other week based on the severity of depressive symptoms, as assessed by the 
MADRS total score. A maximum of 3 changes in intranasal treatment session frequency from weekly to 
every other week is permitted during the optimization/maintenance phase. 
Follow-up Phase: 
This phase will include all subjects who have received at least 1 dose of intranasal study medication in 
this study. Follow-up visits will be performed at 1, 2 and 4 weeks after the last dose of intranasal study 
drug.
At the start of the follow-up phase, further clinical/standard of care for the treatment of depression will be 
arranged by the study investigator and/or the subject’s treating physician. There will be no intranasal 
esketamine administered during this phase. Subject will be provided with an additional 4 week supply of 
the oral antidepressant medication, to ensure that there is no interruption of oral antidepressant therapy 
during the transition to further clinical/standard of care.
The decision to continue the oral antidepressant in this phase will be at the discretion of the investigator.
However, in order to better assess potential withdrawal symptoms from intranasal study drug and 
facilitate maintenance of clinical benefit,  the oral antidepressant medication should be continued for the 
duration of the follow-up phase unless determined as not clinically appropriate.
An open label safety extension study, 54135419TRD3008, may be available (pending country and site 
approval) for eligible subjects participating in the ESKETINTRD3004 study. Please refer to the 
54135419TRD3008 protocol for full details, when available.
SUBJECT POPULATION
Direct-entry subjects
The study population will include men and women, 18 years of age (or older if the minimum legal age 
of consent in the country in which the study is taking place is >18 years), who meet the Diagnostic and 
Statistical Manual of Mental Disorders (5th Edition; DSM-5) diagnostic criteria for single-episode MDD 
(if a single episode MDD, the duration of episode must be 2 years), or recurrent MDD without psychotic 
features, based upon clinical assessment, and confirmed by the Mini-International Neuropsychiatric 
Interview (MINI). At screening, the subject must have a MADRS total score of ≥22, which corresponds 
to at least moderate depression.
Direct-entry subjects will be eligible for screening regardless of whether or not they are currently taking 
oral antidepressant medications. At screening, direct-entry subjects must have had non-response to 
2 oral antidepressant treatments in the current episode of depression, as assessed using 
the 
Massachusetts General Hospital – Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and
documented records (eg, medical/pharmacy/prescription records or a letter from treating physician, etc,). 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
36
Status: Approved, Date: 6 July 2016
Potential subjects will be excluded from participating in the study if they have previously demonstrated 
non-response of depressive symptoms to esketamine or ketamine in the current major depressive episode 
or all of the oral antidepressant treatment options available in the respective country for the open-label 
induction phase (ie, duloxetine, escitalopram, sertraline, and venlafaxine XR) in the current major 
depressive episode (based on MGH-ATRQ). Subjects will also be excluded if they have a current or prior 
DSM-5 diagnosis of a psychotic disorder or MDD with psychosis, bipolar or related disorders (confirmed 
by the MINI), obsessive compulsive disorder (current only), intellectual disability (DSM-5 diagnostic 
codes 317, 318.0, 318.1, 318.2, 315.8, and 319), autism spectrum disorder, borderline personality 
disorder, antisocial personality disorder, histrionic personality disorder, or narcissistic personality 
disorder; if they have homicidal ideation/intent or suicidal ideation with some intent to act within 
6 months prior to the start of the screening phase per the investigator’s clinical judgment and/or based on 
the Columbia Suicide Severity Rating Scale (C-SSRS); or if they have a history of moderate or severe 
substance or alcohol use disorder according to DSM-5 criteria. In addition, subjects will be excluded if 
they have neurodegenerative disorder (eg, Alzheimer’s Disease, vascular dementia, Parkinson’s disease) 
or evidence of mild cognitive impairment (MCI), or a Mini Mental State Examination (MMSE) 
score <25.
Transferred-entry Subjects
All transferred-entry subjects (elderly subjects ≥65 years old) who have completed the double-blind 
induction phase of the ESKETINTRD3005 study will be eligible for this study. 

Non-responder subjects will join the study at the start of the open-label induction phase

Responder subjects will join the study from the start of the optimization/maintenance phase.
DOSAGE AND ADMINISTRATION
Intranasal Study Medication
Open-label Induction Phase:
This phase is only for direct-entry subjects and transferred-entry non-responder subjects. All subjects will 
self-administer intranasal esketamine twice a week for 4 weeks at the study site.
For direct-entry subjects <65 years, the dose titration of intranasal esketamine will be done as follows:
Open-Label Induction Phase Dose Titration of Intranasal Esketamine for Direct-entry Subjects <65 Years
Day 
Dose
Dose Titration Guidance
Day 1
56 mg
Day 4
56 or 84 mg
The dose may be increased to 84 mg or remain at 56 mg, as determined 
by the investigator based on efficacy and tolerability.
Day 8
56 or 84 mg
The dose may be increased to 84 mg (if Day 4 dose was 56 mg), remain 
the same as Day 4, or be reduced to 56 mg (if Day 4 dose was 84 mg), 
as determined by the investigator based on efficacy and tolerability.
Day 11
56 or 84 mg
The dose may be increased to 84 mg (if Day 8 dose was 56 mg), remain 
the same as on Day 8, or be reduced to 56 mg (if Day 8 dose was 84 
mg), as determined by the investigator based on efficacy and 
tolerability.
Day 15
56 or 84 mg
A dose reduction from 84 mg to 56 mg is permitted, if required for 
tolerability. If the dose is 56 mg on Day 11, no dose increase is 
permitted on Day 15.  
Day 18, 22, 25
56 mg or 84 mg 
No dose increase from 56 mg is permitted beyond Day 15. If needed for 
tolerability, one additional dose down-titration from 84 mg to 56 mg is 
permitted from Day 15 until Day 25.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
37
Status: Approved, Date: 6 July 2016
For direct-entry and transferred-entry non-responder subjects 65 years, titration of intranasal 
esketamine will be done as follows:
Open-Label Induction Phase Dose Titration of Intranasal Esketamine for Direct-entry and Transferred-
entry Non-responder Subjects 65 Years
Day
Dose
Dose Titration Guidance*
Day 1
28 mg
Day 4
28 or 56 mg
The dose may remain at 28 mg or be increased to 56 mg , as 
determined by the investigator based on efficacy and tolerability
Day 8, 11, 15
28, 56 or 84 mg
The dose may be maintained, or increased or reduced by 28 mg from 
the previous dosing session, as determined by the investigator based on 
efficacy and tolerability. No dose increase is permitted beyond Day 15.
Days 18, 22 and 25
28, 56 or 84 mg 
No dose increase is permitted beyond Day 15. If needed for 
tolerability, a dose reduction by 28 mg from the previous dose is 
permitted on Days 18, 22, and 25.
*Dose changes are determined by the investigator based on efficacy and tolerability and in accordance with blood 
pressure guidelines.
From Day 8 to Day 15, inclusive, for those who have had a prior down titration from a higher dose, a
dose increase by 28 mg is allowed based on clinical judgment. 
On all intranasal treatment session days, a site staff member with 
training in cardiopulmonary 
resuscitation (eg, Basic Life Support course or equivalent course) that is up to date per local regulations
must be present with the subject during the intranasal treatment sessions and the postdose observation 
period. Subjects must remain at the site until study procedures have been completed and the subject is 
ready for discharge. At the time of discharge, subjects should be accompanied by a responsible adult 
when released from the clinical site. Subjects must not drive a car or work with machines for 24 hours 
after receiving study drug.

Prior to the first intranasal dose on Day 1 of the open-label induction phase, direct-entry subjects will 
practice spraying (into the air, not intranasal) a demonstration intranasal device that is filled with a 
placebo solution.

All subjects will self-administer the intranasal study drug at treatment sessions at the study site. 
Intranasal treatment sessions should not take place on consecutive days.

After Day 1 all dosing decisions are to be determined by the investigator based on efficacy and 
tolerability.

Instructions for intranasal dosing for subjects ≥65 years of age (only):

Prior to intranasal dosing, subjects must have a blood pressure ≤150/90 mm Hg

Prior to any dose escalation, subjects ≥65 years of age must have had a post-dose blood pressure, 
on the prior intranasal dosing day, of <180 mmHg systolic and <100 mm Hg diastolic blood 
pressure.
On all intranasal dosing days, subjects must remain at the site until study procedures have been completed 
and the subject is ready for discharge, and should be accompanied by a responsible adult when released 
from the clinical site. Subjects must not drive a car or work with machines for 24 hours after receiving 
intranasal study drug.
Optimization/maintenance Phase
Subjects who meet the response criteria at the end of the 4-week induction phase will participate in the 
optimization/maintenance phase. Subjects will receive weekly treatment sessions of intranasal esketamine 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
38
Status: Approved, Date: 6 July 2016
for the first 4 weeks of optimization/maintenance phase at the same dose from the open-label induction 
phase.
Those entering the optimization/maintenance phase following the open-label induction phase may have 
the dose adjusted during this phase for tolerability.
Eligible transferred-entry responder subjects from ESKETINTRD3005 will join the study at this phase. 
The first intranasal treatment session for these subjects will begin on Study Day 32 of the 
optimization/maintenance phase. For the first 4 weeks of optimization/maintenance phase, these subjects 
will receive weekly treatment sessions with open-label intranasal esketamine as described in the table 
below.
Optimization/Maintenance Phase Dose Titration of Intranasal Esketamine for Transferred-entry Responder
Subjects
Week
Dose
Dose Titration Guidance
Week 5 
28 mg
Week 6 
28 or 56 mg
The dose may remain at 28mg or be increased 
to 56mg as determined by the investigator 
based on efficacy and tolerability
Week 7, 8 
28, 56 or 84 mg
The dose maybe maintained, increased or 
reduced by 28mg from the previous dosing 
session No dose increase is permitted after
Week 8
For those who have had a prior down titration 
from a higher dose, a dose increase by 28 mg 
is allowed based on clinical judgment.
Week 9 through end of phase
28, 56 or 84 mg
No dose increase is permitted after Week 8. If 
needed for tolerability, a dose reduction by 
28mg from the previous dose is permitted 
from week 9 through the end of the phase.
Instructions for intranasal dosing for subjects ≥65 years:

After week 5 all dosing decisions are to be determined by the investigator based on efficacy and 
tolerability.

Prior to intranasal dosing, subjects must have a blood pressure ≤150/90 mm Hg

Prior to any dose escalation, subjects ≥65 years must have had a post-dose blood pressure, on the 
prior intranasal dosing day, of <180 mmHg systolic and <100 mmHg diastolic. 
Intranasal Treatment Session Frequency
As described above, for all subjects, the frequency of intranasal treatment sessions will be reduced from 
the twice-weekly frequency used in the induction phase to weekly for the first 4 weeks of the 
optimization/maintenance phase (Week 5 to Week 8). 
During the optimization/maintenance phase, the MADRS will be performed weekly for all subjects either 
at the clinic visit (prior to intranasal treatment session) or remotely during a telephone contact visit (if no 
intranasal treatment session planned that week). 
After the first 4 weeks of this phase (ie, starting from Week 8), the intranasal treatment session frequency 
will be adjusted (if applicable) at fixed, 4-week intervals (starting at Week 8, and subsequently at 
Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48), based on the guidance below. 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
39
Status: Approved, Date: 6 July 2016
Week 8:

If the MADRS total score is 12:

The esketamine treatment session frequency will be changed to every other week (ie, the next 
intranasal treatment session after Week 8 will be at Week 10)

If the MADRS total score is >12:

There will be no change in esketamine treatment session frequency

If the MADRS assessment at Week 8 is missed, the last MADRS total score available prior to 
Week 8 will be used to determine if a change in treatment session frequency is indicated at Week 8.
In this case:

If the MADRS total score is ≤12, the subject will reduce the frequency to receive intranasal 
treatment sessions every other week for the next 4 weeks (ie, next treatment sessions will be at 
Weeks 10 and 12)

If the MADRS total score is >12, the subject will continue to receive weekly intranasal treatment 
sessions and no further change to the treatment session frequency is permitted for the next 4 
weeks
From Week 12 onwards and at subsequent visits every 4 weeks:

If the MADRS total score is 12:

If esketamine treatment session frequency is weekly, the frequency will be changed to every 
other week. (eg, If this is Week 12, the next intranasal treatment session after Week 12 will be at 
Week 14)

If esketamine treatment session frequency is every other week, there will be no change in 
frequency

If the MADRS total score is >12:

If esketamine treatment session frequency is weekly, there will be no change in frequency

If esketamine treatment session frequency is every other week, the frequency will be changed to 
weekly

If the MADRS is missed at that week, the last MADRS total score available prior to that week will 
be used to determine if a change in treatment session frequency is indicated at that week. 

If the MADRS total score is 12:
o
If esketamine treatment session frequency is weekly, the frequency will be changed to 
every other week. (eg, If this is Week 12, the next intranasal treatment session after 
Week 12 will be at Week 14)
o
If esketamine treatment session frequency is every other week, there will be no change in 
frequency

If the MADRS total score is >12:
o
If esketamine treatment session frequency is weekly, there will be no change in frequency
o
If esketamine treatment session frequency is every other week, the frequency will be 
changed to weekly
A maximum of 3 changes in intranasal treatment session frequency from weekly to every other week is 
permitted during the optimization/maintenance phase. After this time, if a given subject is unable to 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
40
Status: Approved, Date: 6 July 2016
sustain improvement on every other week treatment sessions, they will remain on a weekly frequency for 
the remainder of the study.
If a subject misses >4 consecutive intranasal treatment sessions and/or ≥4 consecutive MADRS 
assessments in the optimization/maintenance phase, the subject will be discontinued from the study, 
complete an early withdrawal visit, and will proceed to the follow-up phase.
Oral Antidepressants
Study-site personnel will instruct subjects on how to store and take the oral antidepressant treatment
supplied during this study for at-home use.
On intranasal treatment sessions days, it is recommended that oral antidepressant treatment not be taken 
until at least 3 hours after the intranasal treatment session.
Screening Phase for direct-entry subjects
Subjects will be eligible for screening regardless of whether or not they are currently taking oral 
antidepressant medication(s). 
Subjects taking oral antidepressant medication(s) at screening phase will discontinue their current 
antidepressant medications(s) prior to the start of the induction phase. If clinically indicated, the 
antidepressant medication(s) can be either tapered and discontinued during the screening period, or 
discontinued and switched directly to the new oral antidepressant on Day 1 of the open-label induction 
phase, per clinical judgment.
Subjects currently not taking any oral antidepressant medication(s) at screening will start 1 of 4 oral 
antidepressant medications on Day 1 of the induction phase.
Open-label induction and optimization/maintenance phases 
Direct-entry subjects: Starting on Study Day 1of the open-label induction phase, a new, open-label oral 
antidepressant will be initiated, and will be continued during the induction and optimization/maintenance 
phases of this study. The oral antidepressant will be 1 of 4 oral antidepressant medications (duloxetine, 
escitalopram, sertraline, or venlafaxine XR).The antidepressant medication will be assigned by the 
investigator, and will be 1 that the subject has not previously had a nonresponse to in the current episode 
(based on MGH-ATRQ), has not been previously intolerant to (lifetime), and that is available in the 
participating country.
Dosing of the new antidepressant will begin on Day 1 and will follow the local prescribing information 
for the respective product, with a forced titration to the maximally tolerated dose. A protocol-specified 
titration schedule is provided. As subjects may not be able to tolerate the higher doses of the oral 
antidepressant during the induction phase, a down titration of the dose is permitted based on clinician’s 
judgment.
Transferred-entry subjects (responder and non-responder subjects): These subjects will continue taking
the same oral antidepressant medication(s) (duloxetine, escitalopram, sertraline, or venlafaxine XR),
which they started on Day 1 of the double-blind induction phase of ESKETINTRD3005 study, at the 
same dose, during their participation in the optimization/maintenance phase of this ESKETINTRD3004
study.
Study-site personnel will instruct subjects on how to store and take the oral antidepressant treatment 
supplied during this study for at home use. A subject diary will be provided to capture oral antidepressant 
study medication use.
On intranasal dosing days, it is recommended the oral antidepressant medication not be taken until at least 
3 hours after the intranasal treatment session.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
41
Status: Approved, Date: 6 July 2016
Follow-up Phase
At the start of the follow-up phase, further clinical/standard of care for the treatment of depression will be 
arranged by the study investigator and/or the subject’s treating physician. 
No intranasal esketamine will be administered during this phase. 
All subjects will be provided with an additional 4-week supply of the oral antidepressant medication, at 
the last clinic visit prior to entering the follow-up phase, to ensure there is no interruption of 
antidepressant therapy during the transition to further clinical/standard of care. 
The decision to continue the oral antidepressant in this phase will be at the discretion of the investigator, 
however, in order to better assess potential withdrawal symptoms from intranasal study drug and facilitate 
maintenance of clinical benefit, it is strongly recommended that the oral antidepressant be continued for 
of the duration of the follow-up phase unless determined as not clinically appropriate.
SAFETY AND TOLERABILITY EVALUATIONS
Safety evaluations will include:

Monitoring of TEAEs, including TEAEs of special interest

Clinical laboratory tests, including hematology, serum chemistry, and urinalysis

Physical examination and body weight measurements

Serum and urine pregnancy testing (for women of childbearing potential)

Urine drug screen

Alcohol breath test
Safety evaluations to assess short-term effects following intranasal esketamine dosing will include:

12-lead electrocardiogram

Vital signs

Pulse oximetry

Clinician Administered Dissociative States Scale (CADSS), to assess treatment-emergent 
dissociative symptoms

Four-item positive symptom subscale of the Brief Psychiatric Rating Scale (BPRS+), to assess 
treatment-emergent psychotic symptoms

Modified Observer’s Assessment of Alertness/Sedation (MOAA/S), to measure treatment-emergent 
sedation

Clinical Global Assessment of Discharge Readiness (CGADR), to document the subject’s current 
clinical status based on the clinician's assessment of the readiness to be discharged from the study 
site
Safety evaluations will also include assessment of any long-term adverse events, with special attention to:

Nasal examination and nasal symptom questionnaire to assess local nasal tolerability

Columbia Suicide Severity Rating Scale (C-SSRS), to assess suicidal ideation and behavior

Bladder Pain/ Interstitial Cystitis Symptom Score (BPIC-SS), to monitor for symptoms of cystitis, 
bladder pain, and interstitial cystitis
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
42
Status: Approved, Date: 6 July 2016

Physician Withdrawal Checklist (PWC-20) to assess potential withdrawal symptoms following 
cessation of intranasal esketamine treatment

Computerized cognitive battery and Hopkins Verbal Learning Test-Revised (HVLT-R), to assess the 
effect of intranasal esketamine on cognition
EFFICACY EVALUATIONS/ENDPOINTS
Efficacy endpoints include the following: mean total score over time, individual scores over time, as well 
as change from baseline in the total score and individual scores for the following rating scales:

Depressive symptoms, using the MADRS and self-reported PHQ-9 

Overall severity of illness, using the Clinical Global Impression Severity (CGI-S)

Symptoms of anxiety, using the Generalized Anxiety Disorder, 7-items (GAD-7) scale

Health-related quality of life and health status, using the European Quality of Life (EuroQol) Group, 
5 Dimension, 5-Level (EQ-5D-5L) questionnaire 

Functioning and associated disability, using the Sheehan Disability Scale (SDS)
Long-term efficacy will also be assessed by:

Response rate over time, defined as:
o
percentage of subjects with 50% reduction from baseline (induction phase) in the 
MADRS total score
o
percentage of subjects with 50% reduction from baseline (induction phase) in the PHQ-9 
total score 

Remission rate over time, defined as: 
o
percentage of subjects with MADRS total score 12
o
percentage of subjects with PHQ-9 total score 5
BIOMARKER AND PHARMACOGENOMIC (DNA) EVALUATIONS
Assessment of biomarkers and their potential relationship to maintenance/stabilization of response and
non-response will be explored. Blood samples will be collected to measure genetic and epigenetic 
markers (including but not limited to BDNF allelic variants) and protein markers (including but not 
limited to growth factors, inflammation, endocrine, or metabolic markers). Samples of DNA and 
biomarkers (protein) may be used to help address emerging issues and to enable the development of safer, 
more effective, and ultimately individualized therapies.
MEDICAL RESOURCE UTILIZATION
Medical resource utilization data, associated with medical encounters, will be collected using the 
Healthcare Resource Use Questionnaire (HRUQ) during the optimization/maintenance phase and 
follow-up phase. The HRUQ includes information regarding utilization of healthcare services (including 
the timing and type of services), enabling changes in level and quantity of services to be considered as a 
variable in economic models.
Other Evaluations
Patient stated-choice preference survey to assess subject tradeoff preferences for key benefit and harm 
outcomes associated with TRD treatment, using a stated-choice conjoint analysis survey.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
43
Status: Approved, Date: 6 July 2016
STATISTICAL METHODS
Analysis Sets
The following analysis sets will be used to summarize efficacy and safety data:
Full Analysis Set for open-label induction phase: will be defined as all subjects who receive at least one 
dose of intranasal esketamine or 1 dose of oral antidepressant during this phase.
Full Analysis Set for optimization/maintenance phase: will be defined as all subjects who receive at least 
one dose of intranasal esketamine or 1 dose of oral antidepressant during this phase.
Sample Size Determination
No formal sample size calculation was performed for the study. The projected sample size of 750 direct 
entry subjects plus transferred entry subjects is considered adequate to obtain at least 300 subjects who
have received treatment with esketamine for 6 months and at least 100 subjects for 12 months (Note: the 
total number of subjects will be based on subjects from this study and subjects from other intranasal 
esketamine Phase 3 studies). The number of transferred entry subjects is based on predictions related to 
discontinuation rate and efficacy, and therefore may vary.
The sample size will include at least 100 older subjects (who are either direct entry subjects or transferred 
entry subjects from the ESKETINTRD3005 study) aged 65 years.
Safety Analysis 
Safety data for the open label induction phase, the optimization/maintenance phase and follow-up phase 
will be analyzed separately for each phase as well as for the entire treatment period (induction and 
optimization/maintenance phase). 
Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). For 
each adverse event, the percentage of subjects who experience at least 1 occurrence of the given event 
will be summarized. Subjects who die, who discontinue treatment due to an adverse event, or who 
experience a severe or a serious adverse event will be summarized separately. 
TEAEs of special interest will be examined separately grouped in the following categories: drug abuse, 
dependence and withdrawal (standardized MedDRA queries [SMQ]), increased blood pressure, increased 
heart rate, dizziness/vertigo; impaired cognition; anxiety and lower urinary tract symptoms SMQ 
including cystitis.
Body weight, systolic and diastolic blood pressure, pulse/heart rate, respiratory rate, 12-lead 
electrocardiogram (ECG), pulse oximetry, and clinical laboratory test results, and changes from baseline 
will be tabulated over time, using descriptive statistics. Any treatment-emergent abnormalities will be 
listed. 
Changes in findings from the baseline nasal examination (including the upper respiratory tract/throat) will 
be listed. A shift table for changes in rating for each examination (visual inspection of the nostrils, nasal 
mucosa, and throat for nasal erythema, rhinorrhea, rhinitis, capillary/blood vessel disruption, crust 
formation on the nose, and epistaxis) will be presented. Scoring from the nasal symptom questionnaire 
will be summarized descriptively.
Cognitive status from the computerized test battery and HVLT-R, bladder symptom/cystitis data from the 
BPIC-SS, and withdrawal symptoms from the PWC-20 will be provided as descriptive statistics of scores 
and their changes (and/or percent changes) from predose or baseline, as appropriate per assessment. 
Dissociative data from the CADSS, psychosis-like effect data from the BPRS+, sedation data from the 
MOAA/S, and data from the CGADR including changes from baseline, will be summarized at each 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
44
Status: Approved, Date: 6 July 2016
scheduled time point. Suicidal ideation and behaviors based on the C-SSRS will be summarized in 
incidence and shift tables.
Efficacy Analysis
Depression symptoms assessed by MADRS as well as PHQ-9, global change in severity (CGI-S), social, 
occupational and family functioning related disability (SDS), anxiety (GAD-7), and health status 
(EQ-5D-5L), will be summarized descriptively at each scheduled visit for each phase, using both last 
observation carried forward and observed case data. The proportions of subjects who responded and 
remitted based on the MADRS total score as well as PHQ-9 total score will be provided over time for 
each phase. 
Biomarker and Pharmacogenomic Analysis
Baseline biomarker values and changes from baseline biomarker values to the time points specified in the 
Time and Events Schedule will be summarized. Exploratory analyses may include correlation of
biomarker values at baseline and change from baseline in biomarker values with the efficacy parameters 
and other measures. Additional exploratory analyses may also include relationship of baseline and change 
from baseline in biomarker measures to clinical response, maintenance/stabilization of response and 
non-response. 
Pharmacogenomic analyses may include candidate gene analyses or genome-wide association analyses in 
relation to treatment response, maintenance/stabilization of response, non-response and MDD/TRD.
Details of the analysis plan and summary of results from both biomarker and pharmacogenomics analyses 
will be reported separately.
Medical Resource Utilization Analysis
Medical resource utilization data (including HRUQ results) will be analyzed descriptively.
Patient stated-choice preference
Summary statistics and a regression model will be used to estimate a distribution of preferences weights 
for each level of each benefit and harm in the preference survey (described in a SAP). Maximum 
acceptable risk for harms will be calculated for varying degrees of benefit. Analyses and reporting of 
these survey results may be conducted separately from this study.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
45
Status: Approved, Date: 6 July 2016
TIME AND EVENTS SCHEDULE (Screening [Direct-entry Subjects Only] and Open-label Induction Phase [Direct-entry 
and Transferred-entry Non-responder Subjects from ESKETINTRD3005 Study Only])
Phase
Screening
(Direct-entry Subjects Only)
Open-label Induction Phase
(Direct-entry Subjects and Transferred-entry Non-responder Subjects Only)
Visit number
1
2.1b
2.2
2.3
2.4
2.5
2.6
2.7
2.8 
2.9a
Week
Within 4 weeks of 
Day 1
1
2
3
4
Study day
1
(baseline)
4
8
11
15
18
22
25
28
Clinic visit window (in days)
-
-
±1
±1
±1
±1
±1
±1
±1
±1
Study Procedures
Screening/Administrative
Informed consent (ICF)- direct entry 
subjects
X
ICF- transferred-entry non-responder 
subjects
Xc
Medical history, psychiatric history, 
demographics , and employment status
X
MINI
X
MMSE 
X
MGH-ATRQ n
X
Height 
X
Inclusion/exclusion criteria-direct-entry 
subjects
X
Xc
Inclusion/exclusion criteria-
transferred-entry subjects
Xc
Patient Stated-choice Preference Surveyo
Xp
Prestudy therapy
X
Preplanned surgery/procedures- direct 
entry subjects
X
Preplanned surgery/procedures-
transferred-entry non-responder subjects
Xc
STOP-Bang Questionnaire (including 
assessment of BMI and neck 
circumference)
X
Study Drug 
Dispensing of oral antidepressant   
X
X
Practice session for use of intranasal 
device (Direct entry subjects only)
Xc
Intranasal esketaminem
X
X
X
X
X
X
X
X
Drug accountability 
(intranasal study medication)
X
X
X
X
X
X
X
X
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
46
Status: Approved, Date: 6 July 2016
Phase
Screening
(Direct-entry Subjects Only)
Open-label Induction Phase
(Direct-entry Subjects and Transferred-entry Non-responder Subjects Only)
Visit number
1
2.1b
2.2
2.3
2.4
2.5
2.6
2.7
2.8 
2.9a
Week
Within 4 weeks of 
Day 1
1
2
3
4
Study day
1
(baseline)
4
8
11
15
18
22
25
28
Clinic visit window (in days)
-
-
±1
±1
±1
±1
±1
±1
±1
±1
Drug accountability (oral antidepressant 
study medication)
X
Dispense subject diary for oral 
antidepressant
X
Review subject diary and update 
(if applicable)
X
X
X
X
X
X
X
X
Oral antidepressant compliance check
X
X
X
X
Collect/return of subject diary
X
Safety Assessments (Site-completed)
Physical examination
X
Xb, c
X
Nasal examinationc
X
Xb
X
Vital signsc: blood pressure, pulse, 
respiratory rate, temperaturem
X
X
X
X
X
X
X
X
X
Vital signse (postdose): blood pressure, 
pulse, respiratory ratem
.
X
X
X
X
X
X
X
X
Weight
X
Xb
X
12-lead ECGf, m
X
X
X
X
X
C-SSRS: Baseline/Screening version
X
C-SSRS: Since last visit versionc, m
Xb
X
X
X
X
X
X
X
X
MOAA/S and pulse oximetryg, m
X
X
X
X
X
X
X
X
X
BPRS+h, m
X
X
X
X
X
X
X
X
CADSSh, m
X
X
X
X
X
X
X
X
CGADRi, m
X
X
X
X
X
X
X
X
PWC-20j 
X
Safety Assessments (Subject-completed)
Nasal symptom questionnaire k
X
X
X
X
X
BPIC-SSc
Xb
X
X
Efficacy Assessments (Clinician)
MADRS (7-day recall)
X
Xb
X
X
X
X
CGI-Sc
X
Xb
X
X
X
X
X
X
Subject-completed Assessments
PHQ-9d
X
Xb
X
X
SDSd
X
Xb
X
X
GAD-7d
X
Xb
X
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
47
Status: Approved, Date: 6 July 2016
Phase
Screening
(Direct-entry Subjects Only)
Open-label Induction Phase
(Direct-entry Subjects and Transferred-entry Non-responder Subjects Only)
Visit number
1
2.1b
2.2
2.3
2.4
2.5
2.6
2.7
2.8 
2.9a
Week
Within 4 weeks of 
Day 1
1
2
3
4
Study day
1
(baseline)
4
8
11
15
18
22
25
28
Clinic visit window (in days)
-
-
±1
±1
±1
±1
±1
±1
±1
±1
EQ-5D-5Ld
X
Xb
X
X
Cognition Testing
Practice sessions (only for direct-entry 
subjects)
X
Computerized test battery and HVLT-R
Xb
X
Clinical Laboratory Assessments
TSH, HbA1c
X
Lipid panel (fasting)
X
Hematology, chemistryc
X
Xb
X
Urine drug screenc
X
X
X
X 
Alcohol breath test
X
X
Urinalysisc
X
Xb
X
X
Serum pregnancy test (only for females 
of child bearing potential)
X
Urine pregnancy testc(only for females 
of child bearing potential)
Xb
X
X
Biomarkers
Blood sample collection (protein)c,l
X
Xb
X
X
Blood sample collection (DNA)l
X
X
Ongoing Subject Review
Menstrual cycle tracking (Start date of 
last menstrual period prior to study visit; 
only for female subjects <65 years with 
menstrual cycle)
X
Xb
X
Concomitant Therapy
Ongoing
Adverse Events
Ongoing
Footnotes:
Abbreviations: BMI=Body mass index; BPIC-SS=Bladder Pain/Interstitial Cystitis Symptom Score; BPRS+=Four-item Positive Symptom Subscale of the Brief Psychiatric Rating Scale; 
C= clinic visit; CADSS=Clinician Administered Dissociative States Scale; CGADR=Clinical Global Assessment of Discharge Readiness; CGI-S =Clinical Global Impression – Severity; 
C-SSRS=Columbia Suicide Severity Rating Scale; ECG=electrocardiogram;.EQ-5D-5L=EuroQol-5D, 5-level; GAD-7=7-item Generalized Anxiety Disorder scale; HbA1C=glycosylated 
hemoglobin; HVLT-R=Hopkins Verbal Learning Test-Revised; ICF=informed consent form; MADRS=Montgomery-Asberg Depression Rating Scale; MGH-ATRQ=Massachusetts 
General Hospital Antidepressant Treatment History Questionnaire; MINI=Mini International Neuropsychiatric Interview; MMSE= Mini Mental State Examination; MOAA/S=Modified 
Observer's Assessment of Alertness/Sedation; PHQ-9=Patient Health Questionnaire – 9; PWC-20= 20-item Physician Withdrawal Checklist; SDS=Sheehan Disability Scale; STOP-
Bang=Snoring, Tired, Observed Apnea, High Blood Pressure, Body mass index, Age, Neck Size, Gender (a questionnaire); TSH= thyroid-stimulating hormone
Note: On intranasal dosing days, time 0 is defined as the time of the first intranasal spray. Therefore, postdose time points are referenced from this.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
48
Status: Approved, Date: 6 July 2016
a)
If a subject withdraws before the end of the open-label induction phase (ie, Visit 2.9, Day 28) for reasons other than withdrawal of consent, an early withdrawal visit (refer to Time and 
Events Schedule: Optimization/Maintenance Phase) should be conducted, followed by the follow-up phase. If the early withdrawal visit is conducted on the same day as a scheduled 
visit, duplicate assessments are not required. 
b) For transferred-entry non-responder subjects. Visit 2.9 (Day 28) of 3005 study coincides with Visit 2.1 (Day 1) of 3004 study, and assessments of Visit 2.9 (Day 28) of 3005 study do 
not need to be repeated on Visit 2.1 (Day 1) of 3004 study.
c)
Predose (if/when performed on intranasal dosing days).  
d) Subject-reported outcome assessments should be administered before all other study related procedures during a clinic visit.
e)
Postdose vital signs will be performed at 40 minutes, 1 hour, and 1.5 hours postdose. Please refer to Section 6.1 for guidance on blood pressure monitoring on intranasal dosing days.
f)
Twelve-lead ECG will be performed predose and t = 1 hour postdose at Visit 2.1. Twelve-lead ECG will be performed at t=1 hour postdose only (ie, no predose ECG required),  at 
Visits 2.3, 2.5 and 2.8. A time window of ±15 minutes will be permitted.
g)
The MOAA/S will not be performed at Visit 1 (pulse oximetry only). The MOAA/S will be performed every 15 minutes from predose to t=+1.5 hours postdose (please refer to 
Section 9.2.1 for further guidance on MOAA/S assessments). Pulse oximetry will be performed every 15 minutes from predose to t=1.5 hours postdose (please refer to Section 9.2.1
for further guidance on timing of pulse oximetry assessments).
h) The BPRS+ and CADSS to be performed predose and at 40 minutes and 1.5 hours postdose. 
i)
CGADR to be performed at 1 hour and 1.5 hours postdose; if the response is not “Yes” at 1.5 hours postdose, the assessment will be repeated every 15 minutes until a “Yes” response 
is achieved or until the subject is referred for appropriate medical care if clinically indicated. A subject should not be discharged before study visit procedures are complete.
j)
PWC-20 to be performed pre-dose in all subjects.
k) Nasal symptom questionnaire will be performed predose and at 1 hour postdose. 
l)
It is preferred that subjects adhere to a low fat diet on the day of sample collection
m) If intranasal dosing is postponed (but occurs within the visit window) due to blood pressure elevation, predose procedures and procedures at all postdose time points (if applicable)
must be repeated on the actual intranasal dosing day.
n) For specific tricyclic antidepressants which are being taken at a dose below the MGH-ATRQ minimum therapeutic dose, a blood level that is within the therapeutic (antidepressant) 
range, is acceptable to establish the adequacy of the antidepressant treatment.
o) Patient Stated-choice Preference Survey to be completed only by English-speaking subjects at United States, United Kingdom and Australia sites. The survey will not be conducted in 
any other countries, regardless of whether the subjects in those other countries speak English. The survey is conducted only once per subject.
p) The survey should be completed during or shortly after Visit 2.9, or if the subject has completed this visit prior to when the survey becomes available, trial sites should have the subject
complete the survey at the earliest possible opportunity or at early withdrawal. The survey should be administered predose (if/when performed on intranasal dosing days). 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
49
Status: Approved, Date: 6 July 2016
TIME AND EVENTS SCHEDULE (Optimization/Maintenance Phase [Responder Subjects from the Open-label Induction 
Phase and Transferred-entry Responder Subjects from ESKETINTRD3005 Study])
Phase
Optimization/Maintenance Phasec
(Responder Subjects from the Open-label Induction Phase and Transferred-entry Responder Subjects from ESKETINTRD3005)
Visit Numbera
3.1b
3.2
3.3
3.4
3.5
3.6 to 3.X
EW or End of 
O/M Phase c
Study procedure frequency from Week 9 through end of phase
Week
4
5
6
7
8
Every
week
Every
2 Weeks
Every
4 Weeks
Every
8 Weeks
Every
12 Weeks
Study Day
28
32
39
46
53
Every
7 days
Every
14 days
Every
28 days 
Every
56 days
Every
84 days
Clinic (C) or Telephone Contact (T)
C
C
C
C
C
C/T
C
C
C
C
C
Study Procedures
Screening/Administrative
Informed consent (for transferred-entry 
responder subjects only) 
X
Inclusion/exclusion criteria 
(transferred-entry responder subjects 
only)
X
Preplanned surgery/procedures-
transferred-entry responder subjects
Xe
Study Drug
Intranasal esketamine treatmentn
X
X
X
X
Xd
Xd
Adjustment of intranasal treatment 
session frequency (if applicable)
X
X
Dispensing oral antidepressant 
(open-label)e
X
X
Xd
X
Dispense subject diary for oral 
antidepressant
X
Oral antidepressant compliance checke, 
including review of subject diary 
X
X
Xd
X
Collect/return of subject diary
X
Drug accountability for intranasal study 
medication 
X
X
X
X
Xd
Drug accountability for oral 
antidepressante
X
Xd, e
X
Efficacy Assessments (Clinician)
MADRS (7-day recall)e
X
X
X
X
X
X
CGI-S e
X
X
X
X
Xd
X
Subject-Completed Assessments
PHQ-9f
X
X
X
X
SDSf
X
X
X
GAD-7f
X
X
X
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
50
Status: Approved, Date: 6 July 2016
Phase
Optimization/Maintenance Phasec
(Responder Subjects from the Open-label Induction Phase and Transferred-entry Responder Subjects from ESKETINTRD3005)
Visit Numbera
3.1b
3.2
3.3
3.4
3.5
3.6 to 3.X
EW or End of 
O/M Phase c
Study procedure frequency from Week 9 through end of phase
Week
4
5
6
7
8
Every
week
Every
2 Weeks
Every
4 Weeks
Every
8 Weeks
Every
12 Weeks
Study Day
28
32
39
46
53
Every
7 days
Every
14 days
Every
28 days 
Every
56 days
Every
84 days
Clinic (C) or Telephone Contact (T)
C
C
C
C
C
C/T
C
C
C
C
C
Study Procedures
EQ-5D-5Lf
X
X
X
X
Patient Stated-choice
Preference Surveyo
Xp
Xp
Safety Assessments (Clinician)
Physical examination, nasal 
examination, weight
X
Xd, e
X
Vital signs (predose): blood pressure, 
pulse, respiratory rate, and temperaturen
X
X
X
X
Xd
X
Vital signs (postdose)g: blood pressure, 
pulse, and respiratory rate onlyn
X
X
X
X
Xd
12-lead electrocardiogramh, n
X
X
X
Xd,
X
C-SSRS (since last visit version)e, n
X
X
X
X
Xd
X
MOAA/Si, n
X
X
X
X
Xd
Pulse oximetryi, n
X
X
X
X
Xd
BPRS+ and CADSSj, n
X
X
X
X
Xd
CGADRk, n
X
X
X
X
Xd
PWC-20
(performed [pre-dose if applicable] at 
last clinic visit of this phase)
X
Safety Assessments (Subject)
Nasal symptom questionnairel
X
X
Xd
BPIC-SSe
X
Xd
X
Cognitive Testing
Computerized cognitive battery and 
HVLT-Re
Xd
X
Clinical Laboratory Tests
Hematology and chemistrye
X
Xd
X
Urinalysise
X
X d
X
Urine drug screene
X
Xd
Alcohol breath teste
X
Xd
Urine pregnancy teste (only for females 
of child bearing potential)
X
Xd
Serum pregnancy test(only for females 
of child bearing potential)
X
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
51
Status: Approved, Date: 6 July 2016
Phase
Optimization/Maintenance Phasec
(Responder Subjects from the Open-label Induction Phase and Transferred-entry Responder Subjects from ESKETINTRD3005)
Visit Numbera
3.1b
3.2
3.3
3.4
3.5
3.6 to 3.X
EW or End of 
O/M Phase c
Study procedure frequency from Week 9 through end of phase
Week
4
5
6
7
8
Every
week
Every
2 Weeks
Every
4 Weeks
Every
8 Weeks
Every
12 Weeks
Study Day
28
32
39
46
53
Every
7 days
Every
14 days
Every
28 days 
Every
56 days
Every
84 days
Clinic (C) or Telephone Contact (T)
C
C
C
C
C
C/T
C
C
C
C
C
Study Procedures
Medical Resource Utilization
HRUQe
X
X
Xd
X
Biomarker
Blood sample collection (protein)e,m
X
X
Ongoing Subject Review
Menstrual cycle tracking (start date of 
last menstrual period prior to study 
visit; only for females of child bearing 
potential with a menstrual cycle)
X
Xd
Concomitant therapy
Ongoing
Adverse events
Ongoing
Footnotes:
Abbreviations: BPIC-SS = Bladder Pain/Interstitial Cystitis Symptom Score; BPRS+ = Four-item Positive Symptom Subscale of the Brief Psychiatric Rating Scale; CADSS = Clinician-
Administered Dissociative States Scale; CGADR = Clinical Global Assessment of Discharge Readiness; CGI-S = Clinical Global Impression - Severity; C-SSRS = Columbia Suicide 
Severity Rating Scale; ECG = electrocardiogram; EQ-5D-5L = European Quality of Life (EuroQol) Group, 5-Dimension, 5-Level; EW = Early Withdrawal; GAD-7 = Generalized 
Anxiety Disorder, 7-item; HbA1C= Glycated hemoglobin; HRUQ=Healthcare Resource Use Questionnaire; HVLT-R = Hopkins Verbal Learning Test - Revised; MADRS = 
Montgomery-Asberg Depression Rating Scale; MOAA/S = Modified Observer's Assessment of Alertness/Sedation; PHQ-9 = Patient Health Questionnaire, 9-item; PWC-20 = Physician 
Withdrawal Checklist, 20-item; SDS = Sheehan Disability Scale; TSH= thyroid-stimulating hormone.
Note: On intranasal dosing days, time = 0 is defined as the time of the first intranasal spray. Therefore, “postdose” time points are referenced from this.
a)
Visits (clinic or telephone contacts) will be conducted weekly during the optimization/maintenance phase. Clinic visits (visit window: ±3 days) will be conducted for all intranasal 
treatment sessions (weekly from week 5 to 8; weekly or every other week from week 9 to the end of phase); Telephone contact visits (visit window +/- 3 days) for MADRS assessment 
will occur on the weeks without a clinic visit. Due to the variable clinic visit frequency, following Visit 3.5, visit numbers will continue sequentially (eg, 3.6, 3.7, etc) until the subject 
completes the phase. The frequency of study procedures from Week 9 to the end of the phase is provided within the respective column (ie, every week, 2 weeks, 4 weeks, 8 weeks, and 
12 weeks).
b) Results for all assessments performed on Day 28 of the open-label induction phase of ESKETINTRD3004 (direct and transferred-entry non-responder subjects) or Day 28 of the 
ESKETINTRD3005 (transferred-entry responder subjects) will not be repeated as part of Visit 3.1. For transferred-entry responder subjects, the Day 28 visit of the double-blind 
induction phase in ESKETINTRD3005 must coincide exactly with Day 28 (Visit 3.1) for this study. There is no gap allowed between studies. All transferred-entry responder subjects 
must meet all of the transferred-entry subject-specific inclusion criteria and none of the exclusion criteria in order to be enrolled.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
52
Status: Approved, Date: 6 July 2016
c)
If a subject withdraws before the end of the induction or optimization/maintenance phase for reasons other than withdrawal of consent, or has completed the induction phase but is not 
eligible to continue to the optimization/maintenance phase, an early withdrawal visit should be conducted followed by the follow-up phase (Refer to Time and Events Schedule:  
Follow-up Phase). If the early withdrawal visit is conducted on the same day as a scheduled visit, duplicate assessments are not required. Subjects who are currently in the 
optimization/maintenance phase at the time the study is completed, as well as subjects who completed this phase, will conduct an End of Optimization/Maintenance phase visit 
followed by the follow-up phase.
d) Performed only at clinic visits for intranasal treatment sessions (omit if telephone contact visit). If necessary, the study procedure can be performed ±1 week to the subject’s clinic visit 
schedule (based on the frequency of intranasal treatment sessions).
e)
Predose (if/when performed on intranasal dosing days).   
f)
Subject-reported outcome assessments should be administered before all other study-related procedures during a clinic visit.
g) Postdose vital signs will be performed at t = +40 minutes, 1 hour, and 1.5 hours postdose. Please refer to Section 6.1 for guidance for blood pressure monitoring on intranasal dosing 
days.
h) At clinic visit 3.2 the 12-lead electrocardiogram will be performed predose and at 1 hour postdose. At the remaining clinic visits for intranasal treatment sessions with 12-lead 
electrocardiogram scheduled, it will be performed at 1 hour postdose. A time window of ±15 minutes is permitted.
i)
The MOAA/S will be performed every 15 minutes from predose to t = 1.5 hours postdose (please refer to Section 9.2.1 for further guidance on MOAA/S assessments). Pulse oximetry 
will be performed every 15 minutes from predose to t=1.5 hours postdose (please refer to Section 9.2.1for further guidance on timing of pulse oximetry assessments).
j)
The BPRS+ and CADSS to be performed predose and at 40 minutes and 1.5 hours postdose.
k) CGADR to be performed at 1 hour and 1.5 hour postdose; if the response is not “Yes” at 1.5 hour postdose, the assessment will be repeated every 15 minutes until a “Yes” response is 
achieved or until the subject is referred for appropriate medical care if clinically indicated. A subject should not be discharged before study visit procedures are complete.
l)
Nasal symptom questionnaire will be performed predose and at 1 hour postdose.
m) It is preferred that subjects adhere to a low fat diet on the day of sample collection.
n) If intranasal dosing is postponed (but occurs within visit window) due to blood pressure elevation, predose procedures and procedures at all postdose time points (if applicable) must be 
repeated on the actual intranasal dosing day.
o) Patient Stated-choice Preference Survey to be completed only by English-speaking subjects in United States, United Kingdom and Australia sites. The survey will not be conducted in 
any other countries, regardless of whether the subjects in those other countries speak English. The survey is conducted only once per subject.  
p) NOTE for transferred-entry responder subjects from ESKETINTRD3005 study who enter directly to the optimization/maintenance phase, the survey should be completed during or 
shortly after Visit 3.5, or if the subject completed this visit prior to when the survey becomes available, the subject should complete the survey at the earliest possible opportunity or at 
early withdrawal. The survey should be administered predose (if/when performed on intranasal dosing days). Subjects who completed the Patient Stated-choice Preference Survey 
while enrolled in ESKETINTRD3005 should not be issued the survey.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
53
Status: Approved, Date: 6 July 2016
TIME AND EVENTS SCHEDULE (Follow-up Phase)
Phase
Follow-up Phasea
Visit Number
4.1
4.2
4.3
Weeks After Last Intranasal Dose
1
2
4
Clinic (C) Visit or Telephone Contact (T)
T
C
C
Study Procedures
Study Drug
Drug accountability (oral antidepressant study medication)
X
Oral Antidepressant Compliance
Oral antidepressant compliance check
X
X
Safety Assessments (Clinician-Completed)
Physical examination
X
Nasal examination
X
Vital signs: blood pressure, pulse, respiratory rate, temperature
X
X
12-lead electrocardiogram
X
C-SSRS: Since last visit version
X
X
PWC-20
X
X
X
Safety Assessments (Subject-Completed)
BPIC-SSb
X
X
Efficacy Assessments (Clinician-Completed)
MADRS
X
X
X
CGI-S 
X
X
Efficacy Assessments (Subject-Completed)
PHQ-9b
X
X
SDSb
X
GAD-7b
X
EQ-5D-5Lb
X
X
Cognition testing
Computerized test battery and HVLT-R
X
Medical Resource Utilization
HRUQ
X
X
Clinical Laboratory Assessments
Hematology and chemistry
X
Urinalysis
X
X
Serum pregnancy test(only for females of child bearing potential)
X
Biomarker
Blood sample collection (protein)b
X
Ongoing Assessments
Menstrual cycle tracking (start date of last menstrual period prior to study visit; only for female subjects <65 years
with a menstrual cycle)
X
Concomitant therapy
Ongoing
Adverse events
Ongoing
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
54
Status: Approved, Date: 6 July 2016
Footnotes:
Key: BPIC-SS = Bladder Pain/Interstitial Cystitis Symptom Score; CGI-S = Clinical Global Impression - Severity; C-SSRS = Columbia Suicide Severity Rating Scale; 
EQ-5D-5L = European Quality of Life (EuroQol) Group, 5-Dimension, 5-Level; GAD-7 = Generalized Anxiety Disorder, 7-item; HRUQ = Healthcare Resource Utilization Questionnaire; 
HVLT-R = Hopkins Verbal Learning Test - Revised; MADRS = Montgomery-Asberg Depression Rating Scale; PHQ9= Patient Health Questionnaire9, SDS = Sheehan Disability Scale; 
PWC-20 = Physician Withdrawal Checklist, 20-item.
a)
Visit window will be ±3 days.
b) Subject-reported outcome assessments should be administered before all other study-related procedures during a clinic visit.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
55
Status: Approved, Date: 6 July 2016
ABBREVIATIONS
AHI
apnea-hypopnea index
AIDS
acquired immunodeficiency syndrome
ALT
alanine aminotransferase
ASA
American Society of Anesthesiologists
AST
aspartate aminotransferase
AUC
area under the plasma concentration-time curve
BDNF
brain-derived neurotrophic factor
BMI
body mass index
BPIC-SS
Bladder Pain/Interstitial Cystitis Symptom Score 
BPRS
(the full 18-item) Brief Psychiatric Rating Scale
BPRS+
(the 4-item) Brief Psychiatric Rating Scale, positive-symptom subscale
-hCG
-human chorionic gonadotropin
CADSS
Clinician-Administered Dissociative States Scale
CGADR
Clinical Global Assessment of Discharge Readiness
CGI-S
Clinical Global Impression - Severity
Cmax
maximum plasma concentration
CPR
cardiopulmonary resuscitation 
CRF
case report form
C-SSRS
Columbia Suicide Severity Rating Scale
CYP
DBS
cytochrome P450, with any appended letters (2B6, 3A4, etc) indicating subtypes
Deep brain stimulation
DSM-5
Diagnostic and Statistical Manual of Mental Disorders, fifth edition
ECG
electrocardiogram
eCRF
ECT
electronic case report form
electroconvulsive therapy
eDC
electronic data capture
EQ-5D-5L
European Quality of Life (EuroQol) Group, 5-Dimension, 5-Level (questionnaire)
EQ-VAS
EuroQol group: Visual Analogue Scale
EU
European Union
FSH
FT4
follicle stimulating hormone 
Free thyroxine
GAD-7
Generalized Anxiety Disorder, 7-item (scale)
GCP
Good Clinical Practice
HCL
hydrochloride
HDL
high-density lipoprotein
HDRS
Hamilton Depression Rating Scale
HIV
human immunodeficiency virus
HPA
hypothalamic pituitary adrenal
HRUQ
Healthcare Resource Use Questionnaire 
HVLT-R
Hopkins Verbal Learning Test - Revised
ICF
informed consent form
ICH
International Conference on Harmonisation 
IDMC
Independent Data Monitoring Committee
IDS-C30
Inventory of Depressive Symptomatology - Clinician-rated, 30 item 
IEC
Independent Ethics Committee
IM
intramuscular
IRB
Institutional Review Board
ITT
intent-to-treat
IUD
intrauterine device
IUS
intrauterine system
IV
intravenous
IWRS
interactive web response system
JRD
Janssen Research & Development
LDL
low-density lipoprotein
LSD
lysergic acid diethylamide
LBBB
left bundle branch block
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
56
Status: Approved, Date: 6 July 2016
MADRS
Montgomery-Asberg Depression Rating Scale
MAOI
monoamine oxidase inhibitor
MCI
mild cognitive impairment
MDMA
3, 4-methylenedioxy-methamphetamine
MedDRA
Medical Dictionary for Regulatory Activities
MINI
Mini International Neuropsychiatric Interview
MMRM
mixed-effects model for repeated measures
MMSE
Mini Mental State Examination
MOAI
monoamine oxidase inhibitor
MOAA/S
Modified Observer's Assessment of Alertness/Sedation
MDD
major depressive disorder
MGH-ATRQ
Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire
MGH-FRLHQ
Massachusetts General Hospital - Female Reproductive Lifecycle and Hormones Questionnaire
NMDA
N-methyl-D-aspartate
NYHA
New York Heart Association 
OSA
obstructive sleep apnea
PACs
premature atrial contractions
PCP
PCP
primary care physician
phencyclidine
PHQ-9
Patient Health Questionnaire, 9-item
PK
pharmacokinetics
PQC
product quality complaint
PTSD
posttraumatic stress disorder 
PWC-20
Physician Withdrawal Checklist, 20-item
QTc
QT interval corrected
QTcB
QT interval corrected according to Bazett's formula
QTcF
QT interval corrected according to Fridericia's formula
RBBB
right bundle branch block
SAP
statistical analysis plan
SD
standard deviation
SDS
Sheehan Disability Scale
SE
standard error
SmPC
Summary of Product Characteristics
SMQ
standardized MedDRA queries
SNRI
serotonin-norepinephrine reuptake inhibitor
SpO2
saturation of peripheral blood oxygen
SSRI
selective serotonin reuptake inhibitors
STOP-Bang
Snoring, Tiredness, Observed Apnea, High Blood Pressure, Body Mass Index, Age, Neck Size, 
Gender (questionnaire)
SUSAR
suspected unexpected serious adverse reaction
TEAEs
treatment-emergent adverse events
TMS
transcranial magnetic stimulation
Tmax
time to reach the maximum plasma concentration
TRD
treatment-resistant depression
TSH
thyroid stimulating hormone
USPI
United States Prescribing Information
US
VNS
United States
Vagal nerve stimulation
XR
extended-release
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
57
Status: Approved, Date: 6 July 2016
1.
INTRODUCTION
Major depressive disorder (MDD) is a serious, recurrent, and disabling psychiatric illness91. It is 
the second leading cause of years lost to disability worldwide and is associated with excess 
mortality, and the estimated median years of potential life lost is 10 years.92,97 About 30% of 
patients fail to achieve remission despite treatment with multiple antidepressant medications, and 
are considered to have treatment-resistant depression (TRD).31,74 In patients who respond to 
antidepressants, the time to onset of effect is typically 4 to 7 weeks, during which time patients 
continue to suffer from their symptoms and continue to be at risk of self-harm, as well as being 
impacted by the associated harm to their personal and professional lives.74,79 Therefore, there is a 
significant need to develop novel treatments based upon relevant pathophysiologic pathways 
underlying MDD for the rapid relief of symptoms of depression, especially in patients with 
TRD.21,24
Ketamine and esketamine (S-ketamine, the S enantiomer of ketamine) are approved and widely 
used for the induction and maintenance of anesthesia via intramuscular (IM) or intravenous (IV) 
administration.44 The desired analgesic-anesthetic effects of ketamine and esketamine are 
attributed to the blockade of ionotropic N-methyl-D-aspartate (NMDA) glutamate 
receptors.52,67,99
Monoamines (serotonin, norepinephrine, and/or dopamine) are only modulatory transmitters; 
therefore, conventional monoaminergic antidepressants would not be expected to robustly affect 
synaptic transmission, activity-dependent release of brain-derived neurotrophic factor (BDNF), 
or synaptogenesis.24 In contrast, the mechanism of action of ketamine and esketamine is distinct 
from conventional antidepressants and both ketamine and esketamine profoundly affects fast 
excitatory glutamate transmission, increases BDNF release, and stimulates synaptogenesis.24
Most literature reports of the antidepressant effects of ketamine describe studies using IV 
administration of the racemate, with a few exceptions.47 Janssen Research & Development (JRD) 
is developing intranasal esketamine as an antidepressant therapy as, in contrast to the racemate, it 
has higher NMDA receptor affinity over arketamine (R-ketamine), thereby requiring a lower 
volume which can be administered via the intranasal route.51,63,68
For the most comprehensive nonclinical and clinical information regarding esketamine 
(JNJ-54135419), please refer to the latest edition of the Investigator’s Brochure.41
The term “sponsor” used throughout this document refers to the entities listed in the Contact 
Information page(s), which will be provided as a separate document.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
58
Status: Approved, Date: 6 July 2016
1.1.
Background
1.1.1.
Summary of Nonclinical Findings
Safety Pharmacology
The following text is quoted from the United States (US) prescribing information for anesthetic 
Ketalar® (ketamine hydrochloride injection)44 is provided below: Intravenous Ketalar produces a 
fall in arterial blood pressure in the Rhesus monkey and a rise in arterial blood pressure in the 
dog. In this respect the dog mimics the cardiovascular effect observed in man. The pressor 
response to Ketalar injected into intact, unanesthetized dogs is accompanied by a tachycardia, 
rise in cardiac output and a fall in total peripheral resistance. The pressor response to Ketalar is 
reduced or blocked by chlorpromazine (central depressant and peripheral α-adrenergic blockade), 
by β-adrenergic blockade, and by ganglionic blockade. 
Findings from animal studies suggest that the increase in blood pressure produced by 
ketamine/esketamine is due to selective activation of central cardiac stimulating mechanisms 
leading to an increase in cardiac output.
In a 3-month repeat-dose toxicity study with intranasally administered esketamine in dogs, no 
relevant electrocardiogram (ECG) changes were noted up to the highest dose tested, 
ie, 72 mg/day. Heart rate was slightly increased. The cardiovascular safety of racemic ketamine 
and esketamine in humans and animals is summarized in the Investigator’s Brochure.41
Toxicology
Repeat-dose Toxicity Studies
In repeat-dose toxicity studies with intranasally administered esketamine in rats up to 9 mg/day 
for 6 months, and dogs up to 72 mg/day for 3 months of duration, the clinical observations 
mainly related to the central nervous system (eg, changes in activity and gait). No adverse effects 
were noted up to the highest dose tested, ie, 9 mg/day in rats and 72 mg/day in dogs. These 
observations reflected the (exaggerated) pharmacology of the test compound. Minor histologic 
findings were noted in the nasal cavity. These tissue changes were not considered adverse.
In 3- and 9-month repeat-dose toxicity studies with intranasally administered esketamine in dogs, 
no relevant electrocardiogram (ECG) changes were noted up 72 mg/day. Heart rate was slightly 
increased. 
Further details can be found in the Investigator’s Brochure.41
Genetic Toxicity
A series of in vitro and in vivo genotoxicity studies was conducted with ketamine and 
esketamine. The weight of evidence indicates that esketamine poses no genotoxic risk to 
humans.41
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
59
Status: Approved, Date: 6 July 2016
Neurotoxicity
Racemic ketamine has been reported to induce neurotoxicity in animal fetuses, and in juvenile, 
adolescent, and adult animals, as evidenced by histopathologic brain lesions and functional 
sequelae. The precise thresholds for dose and duration of exposure causing neurotoxicity in 
animals remain to be established. The relevance to humans of ketamine’s neurotoxic action in 
animals is unknown.
In studies exploring neurotoxic effects of ketamine on juvenile and prenatal monkeys, 
neuroapoptosis was observed to be more widespread in fetal brains than in neonatal brains, after 
administration of ketamine anesthesia IV for 5 hours. In fetal brains, the cerebellum, caudate 
nucleus, putamen, and nucleus accumbens were most severely affected. In neonatal brains, the 
cerebellum was not affected; the strongest neuroapoptotic response was noted in the basal 
ganglia and several thalamic areas.
In juvenile rodents, ketamine induced apoptotic neurodegeneration was observed that was more 
widespread than in adult rodents, with the developing brain affected in several major regions. 
Neuronal cell death was induced in the dorsolateral thalamus at blood levels of ketamine of 
14 µg/mL (7 times the human anesthetic blood level of approximately 2 µg/mL).
No significant neurotoxic effects occurred in juvenile Rhesus monkeys if the anesthesia was 
administered as IM induction followed by IV maintenance duration was 3 hours. Ketamine 
infusion for 9 or 24 hours increased neuronal cell death in the frontal cortex, but no significant 
changes were noted in the hippocampus, thalamus, striatum, or amygdala. Cognitive 
impairments were observed beginning around 10 months of age, and persisted at 3.5 years of 
age.
The clinical studies will exclude neonates, infants, children, pregnant women, and breastfeeding 
women. Therefore, ketamine’s neurotoxicity in juvenile animals does not represent a safety risk 
to eligible adult subjects. Moreover, the large dosages and prolonged treatment durations 
associated with neurotoxicity in juvenile animals do not suggest a concern.
Chronic treatment with ketamine at high dose levels affected the brain of adolescent monkeys, as 
evidenced by histopathologic lesions and functional impairment. 
The neurotoxicity of ketamine in adult animals is also associated with high dose levels, in 
contrast to the relatively low dose levels of esketamine associated with antidepressant efficacy in 
humans. In single-dose and 14-day repeated-neurotoxicity studies with intranasally administered 
esketamine in rats, no histopathologic brain lesions were noted even upon high exposures, as 
achieved at 54 mg/day in the 14-day study. In the 6-month rat and 9-month dog repeat-dose 
toxicology studies with intranasally administered esketamine, where the animals were of 
adolescent age at initiation of treatment, and in the pre- and post-natal developmental toxicity 
study in rats, no evidence of neurotoxicity was found. Consequently, the risk of neurotoxicity 
associated with intranasal administration of esketamine to adult and adolescent patients is 
considered low.41
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
60
Status: Approved, Date: 6 July 2016
Abuse Potential
Animal studies with ketamine suggest that it would have abuse potential in humans. These 
studies included self-administration and withdrawal experiments in several species.41
Reproductive Toxicity
In a rat fertility and early embryonic developmental toxicity study with intranasally administered 
esketamine, no adverse effects on fertility or reproductive capacity or performance were found.
Rat and rabbit embryo-fetal developmental toxicity studies with intranasally administered 
racemic ketamine did not reveal evidence of reproductive toxicity. However, when monkey 
fetuses were exposed in utero to high dose levels of racemic ketamine, neurotoxicity was 
observed. 
Intranasally administered esketamine did not affect pre- and postnatal development in rats. 
However, high dose levels of racemic ketamine induced neurotoxicity in early postnatal rat 
pups.41
Considering the neurotoxic potential of ketamine and esketamine, and the fact that no threshold 
for these effects has been demonstrated, female subjects of childbearing potential should be 
adequately protected from becoming pregnant and pregnant women should not be enrolled.
Cardiovascular toxicity
In guinea pig tissues, ketamine-induced negative inotropic effects and shortening of action 
potential duration at the 0-mV level was observed, likely as a result of the suppression of inward 
calcium current, whereas in rat left atria and ketamine-induced positive inotropic effects and 
prolongation of action potential duration at the 0-mV level was observed, likely as a result of a 
decrease in calcium-insensitive transient outward current.26 The inhibitory action on membrane 
currents may partly explain the species and tissue differences in inotropic responses to ketamine.
Blood pressure responses to ketamine also vary with the laboratory species and with 
experimental conditions. Blood pressure is increased in normotensive and renal hypertensive rats 
with and without adrenalectomy and under pentobarbital anesthesia. The US prescribing 
information for the anesthetic Ketalar (ketamine hydrochloride [HCl] for injection) provides the 
following guidance:44
Intravenous Ketalar produces a fall in arterial blood pressure in the Rhesus monkey and a rise in 
arterial blood pressure in the dog. In this respect the dog mimics the cardiovascular effect 
observed in man. The pressor response to Ketalar injected into intact, unanesthetized dogs is 
accompanied by a tachycardia, rise in cardiac output and a fall in total peripheral resistance. It 
causes a fall in perfusion pressure following a large dose. The tachycardia and increase in 
myocardial contractile force seen in intact animals does not appear in isolated hearts. These 
observations support the hypothesis that the hypertension produced by Ketalar is due to selective 
activation of central cardiac stimulating mechanisms leading to an increase in cardiac output. 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
61
Status: Approved, Date: 6 July 2016
The dog would be considered the most predictive species in terms of ketamine’s cardiovascular 
effects in humans, but the antidepressant effects of ketamine were studied only in rodent models. 
The myocardial contractility effects and blood pressure responses to ketamine vary between 
species.41 Consequently, a margin of safety could not be reliably derived from the available 
animal data.
Overall Conclusion
The currently available nonclinical safety studies support chronic intranasal administration of 
esketamine in human subjects up to a dosage of 84 mg/day.
Further details can be found in the Investigator’s Brochure.41
1.1.2.
Clinical Studies
1.1.2.1.
Pharmacokinetics and Product Metabolism
Metabolism
Ketamine (and esketamine) undergoes extensive metabolism by hepatic cytochrome P450 
(CYP). In humans, N-demethylation to norketamine is the major route of metabolism, which can 
undergo further metabolism to form hydroxynorketamine. Ketamine and norketamine are 
extensively 
hydroxylated 
to 
a 
series 
of 
6 
hydroxynorketamine 
metabolites 
and 
2 hydroxyketamine metabolites.96 Like ketamine, norketamine is a noncompetitive antagonist at 
the NMDA receptor.25,38 Norketamine has a half-life in plasma of approximately 5 hours.36 The 
major human hepatic CYPs that catalyze ketamine N-demethylation in vitro are CYP2B6 and 
CYP3A4.37,69,98 The CYP enzymes responsible for the formation of norketamine metabolites 
include CYP2A6 and CYP2B6.69 Published results of a clinical PK study indicate that 
esketamine does not invert to the R-enantiomer.33
Excretion
Racemic ketamine and its metabolites have been previously shown to be predominantly excreted 
in the urine. An average of 91% and 3% of a tritium-labeled dose (1 mg/kg) administered to 
6 healthy subjects was recovered in urine and feces, respectively.6 Less than 3% of an 
administered dose was excreted in urine as parent drug.94
A summary of the pharmacokinetics (PK) of esketamine administered by the IV and intranasal 
routes is provided below.
Intravenous Esketamine 
Subjects with TRD received 0.2 mg/kg or 0.4 mg/kg esketamine as a 40-minute IV infusion 
during Study ESKTIVTRD2001.14 Maximum concentrations of esketamine were observed at the 
end of the infusion. Mean values for maximum plasma concentration (Cmax) and area under the 
concentration-time curve (AUC) increased with an increase in the esketamine dose administered 
(80.9 and 135 ng/mL, respectively, and 150 and 218 ng*h/mL, respectively, for 0.2 mg/kg and 
0.4 mg/kg esketamine). The mean plasma clearance of esketamine was high (109 L/h and 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
62
Status: Approved, Date: 6 July 2016
141 L/h for the 0.2 mg/kg and 0.4 mg/kg doses, respectively), as it was similar to or exceeded 
hepatic blood flow in humans.14 The large volume of distribution suggests that esketamine 
distributes widely into tissues (236 L and 303 L, respectively). The half-life of esketamine in 
plasma was 2.14 and 2.65 hours, respectively, for the 2 doses. 
Intranasal Esketamine
Plasma esketamine PK results from Studies ESKETINTRD1001, ESKTINTRD1002,
ESKETINTRD1003, ESKETINTRD1012, and the double-blind phase of Panel A of the 
ESKETIVTRD2003 that inform dose selection for the Phase 3 program are described below. The 
results demonstrate that plasma esketamine concentrations produced by effective IV regimens 
(0.2 mg/kg and 0.4 mg/kg as 40-minute infusions) may be achieved by the intranasal route. 
Study ESKETINTRD1001 included 3 cohorts of subjects who were healthy male and female 
subjects.11 The intranasal esketamine treatments were self-administered under the direct 
supervision of the investigator or designee. Subjects in Cohorts 1 and 3 received esketamine 
doses that ranged from 28 to 112 mg. The regimens were self-administered in the upright 
position. No instructions were given with regards to sniffing after administration. The reported 
median time of Cmax (Tmax) of esketamine ranged from 0.37 to 0.83 hours from the time the first 
spray was administered (ie, 0.33 to 0.5 hours after the last spray was administered). The doses of 
28 to 112 mg produced mean Cmax values ranging from 63.3 to 151 ng/mL, whereas mean AUC∞
values ranged from 164 to 565 ng*h/mL. Mean Cmax and AUC values of esketamine increased in 
a less than dose-proportional manner across the dose regimens. Furthermore, there was 
substantial overlap in the range of individual Cmax and AUC values among the 3 doses. The mean 
terminal half-life of esketamine ranged from 5.86 to 9.83 hours across all treatments. Subjects in 
Cohort 2 received 84 mg in a semi-reclined position and were instructed to sniff after each spray. 
Higher mean Cmax and AUC∞values were observed in this cohort (174 ng/mL and 437 ng*h/mL, 
respectively) compared with the same esketamine dose self-administered by subjects in Cohort 1 
(107 ng/mL and 363 ng*h/mL, respectively). The semi-reclined position of the head and the 
instruction to subjects to sniff following intranasal dosing are believed to be the cause for the 
increase in exposure observed in Cohort 2 compared with Cohort 1. As a result, the instructions 
for self-administration of intranasal esketamine were adapted to include the semi-reclined 
position of the head and sniffing following dosing for all future studies.
During the Phase 1 study ESKETINTRD1002, healthy Japanese and Caucasian subjects received 
single intranasal doses of esketamine 28 mg, 56 mg, and 84 mg in a crossover manner.12 On 
average, plasma esketamine Cmax and AUC values were up to 48% higher in Japanese subjects 
compared with Caucasian subjects.
Study ESKETINTRD1003 compared the PK, safety, and tolerability of intranasally administered 
esketamine in healthy elderly (65 years of age) and younger adult subjects (18 to 55 years of 
age, inclusive).13 Subjects received a single intranasal treatment of esketamine 28 mg. Median 
time to reach the maximum plasma concentration (Tmax) of esketamine was approximately 
30 minutes for both age groups. The geometric means of Cmax and AUC from time 0 to infinite 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
63
Status: Approved, Date: 6 July 2016
time, AUC∞, for esketamine were approximately 21% and 17% higher, respectively, in the 
elderly compared with younger adult subjects.
Study ESKETINTRD1012 evaluated the pharmacokinetics and safety of a single intranasal 
84-mg dose, which was self-administered by 8 healthy subjects who were ≥75 years of age and 
8 healthy younger adults (18 to 55 years of age).10 Preliminary data showed the median time to 
reach the maximum plasma concentration (Tmax) of esketamine was 0.53 hours and 0.83 hours, in 
healthy elderly subjects ≥75 years of age and younger adults, respectively. The means of the Cmax
and area under the plasma concentration-time curve from time 0 to infinite time (AUC∞), for 
esketamine were approximately 48% and 31% higher, respectively, in the elderly compared with 
younger adult subjects. Differences were greater based on median Cmax and AUC∞values (97% 
and 63% higher in the elderly, respectively).
Study ESKETINTRD2003 is an ongoing 2-panel, doubly randomized, double-blind, placebo-
controlled, multicenter study.8 Panel A was conducted in the United States and Belgium and 
Panel B in Japan. Panel A assessed the efficacy and safety of 3 dose strengths of intranasal 
esketamine (28, 56, and 84 mg) administered twice a week in subjects with TRD. Panel B 
(ongoing) is designed to assess the efficacy and safety of 14 mg and 56 mg dose strengths. 
Results of a preliminary analysis of data from the double-blind phase of Panel A indicate mean 
(standard deviation) esketamine concentrations at 40 minutes postdose were 36.4 ng/mL (16.4), 
58.1 ng/mL (24.5), and 72.5 ng/mL (34.2), respectively, for the 3 doses (data on file). The mean 
esketamine concentrations in plasma samples collected on Days 1 and 11 were similar, 
suggesting that the PK are consistent after repeated administration.
1.1.2.2.
Pharmacodynamics and Efficacy
The efficacy of subanesthetic doses (0.5 mg/kg IV administered over 40 minutes) of IV ketamine 
has been evaluated in approximately 192 subjects with MDD (cases and controls), and 2 studies 
in bipolar depressed subjects (meta-analyses).32 This recent meta-analysis of studies suggests that 
ketamine has a rapid onset (within 1 day) of antidepressant efficacy, including in those who have 
not benefitted from other antidepressants used as monotherapy or in combination with oral 
antidepressants.
Esketamine (0.2 and 0.4 mg/kg administered over 40 minutes) has similar, rapid, and robust 
antidepressant effect as that seen with IV ketamine. A double-blind, double-randomization, 
placebo-controlled study (ESKETIVTRD2001) enrolled 30 adult subjects with TRD: 10 in the 
IV placebo group, 9 in the IV esketamine 0.20-mg/kg group, and 11 in the IV esketamine 
0.40-mg/kg group (based on Day 1 randomization).14 The intent-to-treat (ITT) analysis of the 
primary efficacy variable (change in Montgomery-Asberg Depression Rating Scale [MADRS]
total score from baseline Day 1 to Day 2) indicated that the improvement in both esketamine 
dose groups was statistically significant (1-sided p =0.001 in both dose groups) compared with 
the placebo group. The mean (standard deviation) change from baseline Day 1 to Day 2 in 
MADRS total score was -4.9 (4.72) in the placebo group, -16.8 (10.12) in the esketamine 
0.20 mg/kg group, and -17.8 (9.45) in the esketamine 0.40 mg/kg group. 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
64
Status: Approved, Date: 6 July 2016
The studies listed above assessed the efficacy of ketamine or esketamine after a single dose as 
the primary endpoint. The average duration of response to a single dose of ketamine (0.5 mg/kg) 
was approximately 5 days. An open-label study demonstrated that the response to the first dose 
could be maintained by multiple infusions 3 times a week over 2 weeks. The duration of 
response lasted for approximately 19 days.1
The KETIVTRD2002 study assessed whether multiple doses of ketamine given twice a week 
would also maintain the antidepressant response; the data from this study suggest that ketamine 
(0.50 mg/kg IV over 40 minutes) administered twice a week was sufficient for maintaining the 
initial effect over a 4 week treatment period.15
As noted above, Study ESKETINTRD2003 is a 2-panel, doubly randomized, double-blind, 
placebo-controlled, multicenter study.8 Panel A was conducted in the United States and Belgium 
and Panel B in Japan. Panel A assessed the efficacy and safety of 3 dose strengths of intranasal 
esketamine (28, 56, and 84 mg) administered twice a week in subjects with TRD. Panel B 
(ongoing) is designed to assess the efficacy and safety of 14 mg and 56 mg dose strengths. In 
Panel A, subjects in period 1 (1 week duration) were randomly assigned in a 3:1:1:1 ratio to 
placebo (33 subjects), esketamine 28 mg (11 subjects), esketamine 56 mg (11 subjects), or 
esketamine 84 mg (12 subjects). An initial analysis of the data from the double-blind phase of 
Panel A indicates that of the 67 subjects randomized in Period 1, 63 entered Period 2 (1 week 
duration), in which 28 placebo subjects who were eligible for re-randomization at the end of 
Period 1, were randomly assigned in a 1:1:1:1 ratio to placebo (n=6), esketamine 28 mg (n=8), 
esketamine 56 mg (n=9), or esketamine 84 mg (N=5) (data on file). Subjects eligible for re-
randomization had to have a Quick Inventory of Depressive Symptomatology – Self Report 
(QIDS-SR16) total score >11 at the end of Period 1. 
The improvement (with respect to change in MADRS total score from baseline Day 1 to Day 8) 
in all 3 esketamine dose groups reached statistical significance (p=0.021, p=0.001, and p<0.001 
for esketamine 28 mg, 56 mg, and 84 mg, respectively) compared with placebo. The results of 
the 2 periods were consistent. The mean differences from placebo on Day 8 (after 1 week of 
treatment), estimated using data from the combined periods, were: 

Esketamine 28 mg:
-4.2 (SE 2.09) 

Esketamine 56 mg: 
-6.3 (SE 2.07) 

Esketamine 84 mg:
-9.0 (SE 2.13)
The effect sizes in Period 1 for esketamine compared with placebo were:

Esketamine 28 mg:
0.43 (CI -0.259-1.118)

Esketamine 56 mg:
0.92 (CI 0.201-1.621)

Esketamine 84 mg:
1.19 (CI 0.473-1.883)
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
65
Status: Approved, Date: 6 July 2016
The duration of effect with the 28 mg dose appears to be shorter, with the MADRS total score 
higher on Day 8 than on Day 2. The duration of effect for the 56 mg and 84 mg doses appears to 
support twice-a-week dosing.
These data with intranasal esketamine support the hypotheses that intranasal esketamine is 
effective as a treatment for depression, that it has rapid onset of effect within 2 hours, and that 
multiple repeated sessions dose-dependently show sustained response throughout the study 
duration. A clear dose response was seen in the double-blind data in Panel A, and the point 
estimates and confidence intervals suggest a high effect size (Cohen’s D) with the 56 mg and 
84 mg dose groups, supporting further development. Based on PK data from ESKETINTRD1012 
it is also possible that the 28 mg dose in the elderly may overlap with the 56 mg dose in younger 
patients, so addition of the 28 mg dose in the elderly may provide an efficacious dose while 
improving safety.
1.1.2.3.
Safety and Tolerability
Ketamine is a rapidly acting general anesthetic that is approved and widely used intravenously or 
intramuscularly for the induction and maintenance of anesthesia in children and adults at a dose 
of 1 to 3 mg/kg given as a bolus. Ketamine is marketed as a racemic mixture and in Europe also 
as the S-enantiomer, esketamine. Ketamine was first introduced as an anesthetic in 1963 and is 
considered to have an excellent medical safety profile (Ketalar® United States Prescribing 
Information 
[USPI]
2011; 
Ketanest®S 
Summary 
of 
Product 
Characteristics 
[SmPC] 2011).35,44,45,71,86
In the US prescribing information for ketamine HCl for injection and the SmPC for esketamine 
HCl for injection, the following adverse reactions were listed as very common, common, or 
frequent occurrences: emergence or recovery reactions, elevated blood pressure and pulse rate, 
stimulation of respiration, nausea, and vomiting. See Table 1 for details.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
66
Status: Approved, Date: 6 July 2016
Table 1:
Adverse Reactions Listed as Very Common, Common, or Frequent Occurrences in the Product 
Information of Anesthetic Ketamine and Esketamine
System 
Organ Class
"Frequent" Adverse Reactions
Per Anesthetic Ketamine USPI44,a
"Very Common" or "Common" Reactions
Per Anesthetic Esketamine SmPC90,b
Psychiatric 
disorders
Frequency: Emergence reactions occurred in 
approximately 12% of patients.
Characteristics: Severity varied from pleasant 
dreamlike states, vivid imagery, hallucinations, 
and emergence delirium. Some states were 
accompanied by confusion, excitement, and 
irrational behavior, which some patients 
recalled as an unpleasant experience.
Frequency: Recovery reactions were common. 
When esketamine was the sole anesthetic, up to 
30% of patients displayed dose-dependent 
recovery reactions.
Characteristics: Reactions included vivid dreams 
(including nightmares), nausea and vomiting, 
increased salivation, blurred vision, dizziness, 
and motor restlessnessc
Cardiac 
disorders
Blood pressure and pulse rate were frequently 
elevated after administration. However, 
hypotension and bradycardia have been 
observed. Arrhythmia has also occurred.
Common occurrences were temporary 
tachycardia and increase in blood pressure and 
heart rate (approximately 20% of the initial value 
was typical).
Respiratory, 
thoracic, and 
mediastinal 
disorders
Although stimulation of respiration was a 
frequently observed effect, severe depression 
of respiration or apnea also could occur after 
rapid intravenous administration of high doses.
Common effects were increase in vascular 
resistance in pulmonary circulation and increase 
in mucus secretion. Increased oxygen 
consumption, laryngospasms, and temporary 
respiratory depression were common; the risk of 
respiratory depression was noted to depend on 
dose and injection speed.
Gastro-
intestinal 
disorders
No gastrointestinal effects were listed as 
frequent, but the USPI stated that anorexia, 
nausea, and vomiting have been observed.
Common effects included nausea and vomiting.
Abbreviations: SmPC, Summary of Product Characteristics; USPI, United States Prescribing Information
a
"Frequent" was not defined numerically, except in the case of emergence reactions (12%). The terms "very 
common" and "common" did not appear in the adverse effects section of the USPI.
b
"Very common" was defined in the SmPC as 1/10 and "common" was defined as 1/100 to <1/10.
c
The incidence of these events can be greatly reduced by the administration of a benzodiazepine.
Adverse Events Associated with Short-term Use of Intranasal Esketamine in Patients with 
MDD
According to the SmPC for esketamine,45 the following are reported as common adverse effects: 
transient tachycardia, vivid dreams (including nightmares), nausea and vomiting, increased blood 
pressure, increased salivation, blurred vision, dizziness, motor unrest, increase in vascular 
resistance in pulmonary circulation and increase in mucus secretion, increased oxygen 
consumption, laryngospasms, and temporary respiratory depression. It is reported that the risk of 
respiratory depression typically depends on the dosage and injection speed.53
Administration of esketamine is associated with a number of adverse events, which are transient 
in nature and typically resolve in 2 hours or less from the start of drug administration. The 
Phase 1 study ESKETINTRD1003 evaluated the pharmacokinetics and safety of a single 
intranasal esketamine 28 mg in 14 healthy elderly subjects (65 years of age, with 3 subjects 
75 years of age) and 20 healthy younger adult subjects (18 to 55 years of age, inclusive).13 The 
incidences of the treatment emergent adverse events (TEAEs) were slightly higher in young 
subjects (100% [20 subjects]) as compared with elderly subjects (85.7% [12 subjects]). The most 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
67
Status: Approved, Date: 6 July 2016
commonly reported TEAEs by preferred term (>20%) in elderly subjects were dysgeusia and 
vertigo (9 [64%], of 14 subjects each).
Additionally, another recently completed Phase 1 study, ESKETINTRD1012, evaluated the 
pharmacokinetics and safety of a single intranasal 84 mg dose, which was self-administered by 
8 healthy elderly subjects who were ≥75 years of age (Cohort 1) and 8 healthy younger adults 
(18 to 55 years of age – Cohort 2). An initial review noted TEAEs occurred in all subjects in 
both cohorts (100% [16 subjects – 8 in each cohort]). The TEAE of illusions was reported in 
5 younger subjects (62.5%) and in none of the elderly subjects. In elderly subjects, the incidence 
of TEAEs of vascular disorders (6 subjects [75%] including hot flush [2 subjects, 25%] and 
hypertension [3 subjects, 37.5%]) was higher than in younger adults (hypertension in 1 subject, 
12.5%). Vertigo and vertigo positional were more common in elderly subjects (5 subjects, 62.8% 
and 1 subject, 12.5%, respectively) than in younger adults (vertigo – 3 subjects, 37. 5%).
In both cohorts, the maximal mean increase in systolic and diastolic blood pressure as well as 
heart rate was observed at 32 minutes post dose measurement time point. The mean increase in 
supine systolic blood pressure and pulse rate was slightly greater in Cohort 1 (elderly) than in 
Cohort 2 (young adult), while the mean increase in the supine diastolic blood pressure was 
greater in Cohort 2. In both Cohort 1 and Cohort 2, the mean systolic and diastolic blood 
pressure returned to baseline within 4 hours post dose. Mean blood pressure and heart rate for 
Cohort 1 is provided in Table 2
Table 2:
Mean Supine Blood Pressure and Heart Rate - Cohort 1 (ESKETINTRD1012)
Mean
Range
Mean Change from Baseline
Range
Supine SBP (mm Hg)
Day 1, predose
133.5
104; 164
Day 1, 32 min
165.3
141; 194
31.8
16; 44
Day 1, 50 min
154.1
127; 177
20.6
- 5; 38
Day 1, 1.5 h
145.6
123; 177
12.1
-11; 32
Day 1, 4 h
130.4
130; 170
-3.1
-36; 31
Supine DBP (mm Hg)
Day 1, predose
  68.0
54; 79
Day 1, 32 min
  81.5
64; 93
13.5
3; 20
Day 1, 50 min
  77.1
65; 87
  9.1
-3; 17
Day 1, 1.5 h
  76.5
63; 81
  8.5
-6; 14
Day 1, 4 h
  68.5
57; 81
  0.6
-16; 17
Supine Heart Rate (beats/min)
Day 1, predose
  60.0
48; 79
Day 1, 32 min
  74.8
53; 102
14.8
3; 38
Day 1, 50 min
  70.9
53; 96
10.9
1; 32
Day 1, 1.5 h
  62.9
46; 81
  2.9
-7; 17
Day 1, 4 h
  78.0
55; 97
18.0
-6; 39
DBP = diastolic blood pressure; h = hours; min = minutes; SBP = systolic blood pressure
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
68
Status: Approved, Date: 6 July 2016
In Panel A of the Phase 2 study with intranasal esketamine (ESKETINTRD2003), the most 
common TEAEs (>10% of subjects in the pooled esketamine treatment groups) during the 
double-blind phase were: dizziness, headache, dissociation, dysgeusia (metallic taste), nausea, 
dissociative disorder, and oral hypoesthesia.77 Dissociative symptoms were the most typical of 
these adverse events observed post dose and were characterized by perceptual changes. Transient 
perceptual changes (dissociation), dizziness, and nausea were typically seen immediately after 
drug administration, resolving by 2 hours. 
No deaths were reported in ESKETINTRD2003 study during the double-blind and open-label 
study phase. One subject experienced a serious adverse event of esophagitis in Panel A (double-
blind phase, placebo/placebo treatment group). A total of 3 subjects withdrew during the 
double-blind phase because of adverse events. One subject in esketamine 28 mg group 
experienced a TEAE of syncope of severe intensity on Day 2 of Period 1, 1 day after receiving 
the first dose of study medication. The subject discontinued from the study and the study agent 
was permanently withdrawn due to this event, which resolved on the same day. The investigator 
considered the event to be possibly related to the study agent. Another subject in the 
placebo/esketamine 56 mg group experienced a TEAE of headache of moderate intensity on 
Day 11 of Period 2 and the study agent was permanently withdrawn due to this event, which 
resolved on the same day. The investigator considered the event to be very likely related to the 
study agent. A third subject in the esketamine group (esketamine 84 mg) experienced a TEAE of 
dissociative disorder (verbatim term: Dissociative syndrome) of moderate intensity on Day 8 of 
Period 2 (day of the third esketamine 84 mg dose in the study). The subject discontinued from 
the study and the study agent was permanently withdrawn due to the event of dissociative 
disorder, which resolved on the same day. The investigator considered the event to be very likely 
related to the study agent.77
Dissociative symptoms measured on the Clinician Administered Dissociative States Scale 
(CADSS) were dose-dependent and were observed to reduce significantly with multiple doses 
over 2 weeks. No psychotic symptoms were seen. Transient increases in mean blood pressure 
(systolic and diastolic) were observed post dose following the intranasal esketamine 
administration.
The mean (standard deviation [SD]) peak systolic blood pressure after the first administration in 
each dose group was:

Placebo: 124.2 (11.51) mmHg (mean [SD] increase of 5.4 [7.84] mmHg)

28 mg:
131.8 (15.49) mmHg (mean [SD] increase of 10.4 [10.44] mmHg)

56 mg:
130.4 (18.64 mmHg
(mean [SD] increase of 11.2 [15.01] mmHg)

84 mg:
146.1 (19.9) mmHg
(mean [SD] increase of 17.1 [15.5] mmHg)
Mean (SD) peak diastolic blood pressure after the first administration in each dose group was: 

Placebo: 81.2 (8.36) mmHg
(mean [SD] increase of 3.8 [7.99] mmHg)

28 mg:
85.7 (9.16) mmHg
(mean [SD] increase of 6.5 [7.00] mmHg)
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
69
Status: Approved, Date: 6 July 2016

56 mg:
86.5 (11.34) mmHg
(mean [SD] increase of 7.2 [9.67] mmHg)

84 mg:
87.8 (10.62) mmHg
(mean [SD] increase of 8.1 [9.12] mmHg)
The blood pressure increase typically resolved within 2 hours. Unlike dissociative symptoms, the 
blood pressure changes observed do not appear to attenuate over time with multiple doses. 
Transient increases in heart rate were also observed in parallel with blood pressure change. There 
was no clinically meaningful change in blood oxygen level.
Adverse Events Associated with Chronic Use of Ketamine
There are no controlled studies of long-term use with esketamine/ketamine in patients with 
MDD. Much of the literature on chronic use of ketamine comes from data gathered from 
street/illegal use of the drug, rather than systematically conducted clinical studies. Data therefore 
should be interpreted with caution, as in many cases, no baseline pre-drug data are available and 
drug exposure is poorly documented. 
In a 1-year longitudinal study, 150 subjects were divided into 5 groups of 30 subjects each: 
frequent ketamine users (more than 4 times per week), infrequent ketamine users (at least once a 
month), abstinent users (abstinent for at least 1 month), polydrug controls, and non-users of illicit 
drugs.59 Eighty percent of the participants were retested at the end of 1 year. Cognitive deficits 
were mainly observed in frequent users and not with the infrequent users. Short-lasting, 
dose-dependent effects of psychosis were associated with ketamine users. There was no increase 
in symptoms over time, and symptoms were completely reversible upon stopping use of 
ketamine. As noted, these data should be interpreted with caution, as baseline data predating 
drug use were not available. Furthermore, in their recent review, Morgan and Curran report that 
there is little evidence of any link between chronic, heavy use of ketamine and diagnosis of a 
psychotic disorder.58
The principal action of ketamine is at the NMDA receptor, and the consequences of ketamine use 
on cognition have been fairly widely investigated. Several studies have examined cognitive 
function in infrequent and frequent ketamine users.19,56,57,62 Overall, infrequent or recreational 
ketamine use does not appear to be associated with long-term cognitive impairment.59 The most 
robust findings are that frequent ketamine users (more than 5 times a week) exhibit impairments in 
both short- and long-term memory.56 Although dosages have varied, dosages reported by ketamine 
users in this study were much higher than the dosages of ketamine or equivalent doses of 
esketamine intended for use in treating TRD. Memory impairments may be reversible when 
individuals stop using the drug, as they were not found in a group of 30 ex-ketamine users who had 
been abstinent for at least a year.59
Ketamine-induced ulcerative cystitis is a recently identified complication.58 The most common 
symptoms are frequency and urgency of urination, dysuria, urge incontinence, and occasionally 
painful hematuria (blood in urine). In the series of 9 patients with ketamine-associated ulcerative 
cystitis, computerized tomography scans revealed a marked thickening of the bladder wall, a small 
bladder capacity, and perivesicular stranding consistent with severe inflammation82. At cystoscopy, 
all patients had severe ulcerative cystitis. Biopsies in 4 of these cases found denuded urothelial 
mucosa with thin layers of reactive and regenerating epithelial cells, and ulcerations with vascular 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
70
Status: Approved, Date: 6 July 2016
granulation tissue and scattered inflammatory cells. Cessation of ketamine use provided some 
relief of symptoms. Most of the described cases are in near-daily users of ketamine for recreational 
purposes. The prevalence is difficult to determine, as it is seen in recreational users who often do 
not seek help.
The majority of cases resolved after stopping ketamine use, one-third remaining static84.
Abuse Liability, Dependence, and Withdrawal
There are a number of reports of ketamine dependence in the literature40,42,55,66 but no large-scale 
studies, and so the incidence of ketamine dependence is largely unknown.58 An interview study 
of 90 ketamine users found that 57% of frequent users, 43% of infrequent users, and 60% of ex-
users expressed concerns about ketamine addiction.60 The majority of frequent users in that study 
reported using the drug without stopping until supplies ran out, so compulsive patterns of 
behavior are also a concern. Oral ketamine has also been evaluated as a positive control in 
human abuse potential studies, with dosages of 65 mg and 110 mg reported as appropriate for 
use as positive controls for future abuse potential studies of compounds with a similar 
mechanism of action or with possible perception-altering effects.85 There is conflicting evidence 
of the existence of a "withdrawal syndrome" after cessation of ketamine use.58 Cravings seem to 
be a key problem in frequent users: 28 of the 30 daily users in 1 study reported having tried to 
stop taking the drug but failed; all reported ketamine cravings as the reason for failure.58 The 
same study found that 12 of the 30 daily users reported withdrawal symptoms characterized by 
anxiety, shaking, sweating, and palpitations when they stopped using. A few published case 
studies also show craving and somatic and psychological aspects of anxiety as withdrawal 
symptoms.18,50 However, a specific ketamine withdrawal syndrome has not yet been described.58
Please refer to the Investigator's Brochure for a summary of the adverse events reported in 
ketamine and esketamine studies.41
1.1.3.
Marketing Experience
No intranasal formulation of esketamine is currently marketed.
1.2.
Oral Antidepressants: Study Medication
This study will evaluate 3 doses of intranasal esketamine (28 mg, 56 mg, or 84 mg) plus a newly 
initiated oral antidepressant. In the open-label induction phase, direct-entry subjects will be 
assigned to receive 1 of the 4 commercially available oral antidepressant medications from 
2 different classes of antidepressant medications, selective serotonin reuptake inhibitors (SSRIs: 
escitalopram or sertraline), or serotonin and norepinephrine reuptake inhibitors (SNRIs: 
duloxetine or venlafaxine extended release [XR]). For direct-entry subjects, the oral 
antidepressant medication will be started on Day 1 of the induction phase and continued in the 
optimization, maintenance, and follow-up (if clinically indicated) phases. The transferred-entry 
subjects (both responder and non-responder subjects) should continue oral antidepressant 
medication previously assigned to them in the ESKETINTRD3005 study during their entire 
participation in the ESKETINTRD3004 study.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
71
Status: Approved, Date: 6 July 2016
The indications and safety information provided below for each oral antidepressant are from the 
USPI.22,27,80,89 For further information, please refer to the appropriate package insert or SmPC 
applicable to the local country in which the study is being conducted.
In the US, all of the oral antidepressant options include a black box warning in the prescribing 
information regarding suicidality and antidepressant drugs. The black box warning informs the 
prescriber that antidepressant treatments increased the risk compared with placebo of suicidal 
thinking and behavior (suicidality) in children, adolescents, and young adults in short-term 
studies of MDD and other psychiatric disorders. It states that anyone considering using the 
antidepressant in this population must balance the risk with the clinical need. Refer to the US 
prescribing information for the entire content of the black box warning.22,27,80,89
1.2.1.
Selective Serotonin Reuptake Inhibitors
1.2.1.1.
Escitalopram
Escitalopram is indicated in adults for acute and maintenance treatment of MDD and acute 
treatment of generalized anxiety disorder.27
The adult starting dosage for MDD in the USPI is 10 mg once daily, with a maximum of 20 mg 
once daily. If the dosage is increased to 20 mg, this should occur after a minimum of 1 week. No 
additional benefits have been seen at the 20 mg/day dose. In the current study, for subjects 
<65 years old, maximum daily dose is 20 mg/day. The 10 mg/day dose is recommended for most 
elderly subjects, and, for subjects aged 65 years 10 mg/day will be the maximum dose used in 
the current study. 
In adult MDD subjects treated with escitalopram, the most commonly observed adverse reactions 
with escitalopram (incidence of approximately 5% or greater and approximately twice the 
incidence in placebo subjects) were insomnia, ejaculation disorder (primarily ejaculatory delay), 
nausea, sweating increased, fatigue, and somnolence.
Contraindications to the use of escitalopram include serotonin syndrome and monoamine oxidase 
inhibitor (MAOI) use (concomitant use with MAOIs intended to treat psychiatric disorders, 
linezolid, or IV methylene blue; use within 14 days of stopping treatment with an MAOI 
intended to treat psychiatric disorders; in addition, an MAOI should not be used within 14 days 
of stopping escitalopram) concomitant use with pimozide; and known hypersensitivity to 
escitalopram or citalopram or any of the inactive ingredients.
As with most SSRIs, a gradual reduction in the dosage rather than abrupt cessation of 
escitalopram treatment is recommended whenever possible.
1.2.1.2.
Sertraline
Sertraline hydrochloride is indicated in adults for the treatment of MDD, obsessions and 
compulsions in patients with obsessive compulsive disorder, panic disorder (with or without 
agoraphobia), post-traumatic stress disorder, premenstrual dysphoric disorder, and social anxiety 
disorder.80
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
72
Status: Approved, Date: 6 July 2016
According to the USPI, sertraline should be administered at a dose of 50 mg once daily for the 
treatment of MDD. While a relationship between dose and effect has not been established for 
MDD, obsessive compulsive disorder, panic disorder, posttraumatic stress disorder (PTSD), or 
social anxiety disorder, subjects were dosed in a range of 50 to 200 mg/day in the clinical trials 
demonstrating the effectiveness of sertraline for the treatment of these indications. Given the 
24 hour elimination half-life of sertraline, dose changes should occur in at least weekly intervals. 
In the current study, patients not tolerating higher doses of sertraline may have the dose reduced 
to a minimum of 50 mg/day.
In the current study the dosing is as follows:

For subjects <65 years, the starting dose is 50 mg, administered once daily and the 
maximum dose in the current study is 150 mg/day. 

For subjects aged 65 years, the starting dose will be 25 mg and the maximum dose will be 
150 mg/day.
Contraindications to the use of sertraline include serotonin syndrome and MAOI use
(concomitant use with MAOIs intended to treat psychiatric disorders, linezolid, or IV methylene 
blue; use within 14 days of stopping treatment with an MAOI intended to treat psychiatric 
disorders); concomitant use with pimozide; and known hypersensitivity to sertraline or any of the 
inactive ingredients.
In adult subjects, the most common TEAEs associated with the use of sertraline (incidence of at 
least 5% for sertraline or at least twice that for placebo within at least one of the indications) 
were ejaculation failure, dry mouth, increased sweating, somnolence, tremor, dizziness, fatigue, 
pain, malaise, abdominal pain, anorexia, constipation, diarrhea/loose stools, dyspepsia, nausea, 
agitation, insomnia, and decreased libido.
As with most SSRIs, a gradual reduction in the dosage rather than abrupt cessation treatment is 
recommended whenever possible.
1.2.2.
Serotonin and Norepinephrine Reuptake Inhibitors
1.2.2.1.
Duloxetine
Duloxetine is indicated in adults for MDD, generalized anxiety disorder, diabetic peripheral 
neuropathic pain, fibromyalgia, and chronic musculoskeletal pain.22
The starting dosage for MDD in the United States Prescribing Information (USPI) is 40 to
60 mg/day. The dosage for acute treatment is 40 to 60 mg/day, with maintenance treatment at 
60 mg/day. An initial starting dose of 30 mg/day has also been evaluated.93.For some subjects, it 
may be desirable to start at 30 mg once daily for 1 week, to allow patients to adjust to the 
medication before increasing to 60 mg once daily.
In the current study, subjects should be initiated with 60 mg/day. Subjects who have in the past 
shown increased sensitivity towards SSRI/SNRI’s, can, at the discretion of the treating 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
73
Status: Approved, Date: 6 July 2016
physician, be started on a 30 mg dose and up-titrated into the therapeutic range of 60 mg by the 
start of Week 2 of the open-label induction phase. 
In Taiwan and South Korea (only), all subjects (ie, including those <65 years of age) should 
receive an initial dose of 30 mg during Week 1 of the open-label induction phase (see 
Attachment 3)
Per, USPI no dose adjustment is recommended for elderly patients on the basis of age. As with 
any drug, caution should be exercised in treating the elderly. When individualizing the dosage in 
elderly patients, extra care should be taken when increasing the dose. The maximum dosage per 
USPI is 120 mg/day, although there is no evidence that dosages greater than 60 mg/day confer 
any additional benefits.
In the current study the dosing is as follows:

For subjects <65 years, the starting dose is 60 mg; and the maximum dose in this study.

For improved tolerability, the starting dose for those 65 years is 30 mg/day and the 
maximum dose is 60 mg. 
For pooled studies for all approved indications, the most commonly observed adverse reactions 
in duloxetine-treated subjects (incidence of at least 5% and at least twice the incidence in 
placebo subjects) were nausea, dry mouth, somnolence, fatigue, constipation, decreased appetite, 
and hyperhidrosis. As observed in diabetic peripheral neuropathy studies, duloxetine treatment 
worsens glycemic control in some subjects with diabetes.
Contraindications to the use of duloxetine include use of an MAOI concomitantly or within 
2 weeks of MAOI use; and use in patients with uncontrolled narrow-angle glaucoma.
A gradual reduction in the dosage rather than abrupt cessation is recommended whenever 
possible.
1.2.2.2.
Venlafaxine Extended-release
Venlafaxine XR is indicated in adults for MDD and social anxiety disorder.89
The starting dosage for MDD in the USPI is 75 mg/day (in elderly subjects and in some Asian 
countries e.g, Taiwan, South Korea, and Malaysia the starting dose is 37.5 mg/day for 4 to 
7 days), with a dosage increase by 75 mg/day at intervals of 4 days or longer, and a maximum 
dosage of 225 mg/day. Dosage reductions are recommended for hepatic impairment (including 
mild) and renal impairment. No dose adjustment is recommended for the elderly subjects on the 
basis of age alone, although other clinical circumstances, such as renal or hepatic impairment 
would require a dose adjustment.
Dosage reductions are recommended for hepatic impairment (including mild) and renal 
impairment. 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
74
Status: Approved, Date: 6 July 2016
In the current study the dosing is as follows:

For those <65 years the starting dose is 75 mg and the maximum dose is 225 mg/day. 

For subjects 65 years, the starting dose of venlafaxine is 37.5 mg and the maximum dose 
attained is 150 mg/day. 
Contraindications to the use of venlafaxine XR include serotonin syndrome and MAOI use 
(concomitant use with MAOIs intended to treat psychiatric disorders, linezolid, or IV methylene 
blue; use within 14 days of stopping treatment with an MAOI intended to treat psychiatric 
disorders); concomitant use with pimozide and known hypersensitivity to venlafaxine XR or any 
of the inactive ingredients.
In adult subjects with MDD, adverse events in short-term studies that occurred in at least 5% of 
the subjects receiving venlafaxine XR capsules and at a rate at least twice that of the placebo 
group were abnormal ejaculation, gastrointestinal complaints (nausea, dry mouth, and anorexia), 
central nervous system complaints (dizziness, somnolence, and abnormal dreams), and sweating.
Sustained hypertension is noted within the Warnings and Precautions section. Preexisting 
hypertension should be controlled before treatment with venlafaxine XR. It is recommended that 
patients receiving venlafaxine hydrochloride XR tablets have regular monitoring of blood 
pressure. For patients who experience a sustained increase in blood pressure while receiving 
venlafaxine XR, either dosage reduction or discontinuation should be considered.
Across most indications, a dose-related increase in supine systolic and diastolic blood pressure 
was evident in venlafaxine XR-treated patients. Across all clinical studies, 1.4% of subjects in 
the venlafaxine XR-treated groups experienced a 15 mmHg increase in supine diastolic blood 
pressure, with blood pressure 105 mmHg, compared with 0.9% of subjects in the placebo 
groups. Similarly, 1% of subjects in the venlafaxine XR-treated groups experienced a 
20 mmHg increase in supine systolic blood pressure, with blood pressure 180 mmHg, 
compared with 0.3% of subjects in the placebo groups.
A gradual dosage
reduction, individualized as necessary, is recommended to avoid 
discontinuation symptoms.
1.3.
Overall Rationale for the Study
In contrast to available data about short-term antidepressant effects of esketamine/ketamine, 
much less is known about safety of the long term administration of esketamine and how to 
sustain the antidepressant effect over the long term. No systematic studies have yet characterized 
long term safety and sustaining the response to esketamine administered at subanesthestic doses 
in patients with treatment-resistant depression. The long term safety reports summarizing data 
from recreational ketamine users may not be a reliable source as the dose used was either 
unknown or several times greater. The only available clinical data are case reports and anecdotal 
reports from clinicians who have been using ketamine over extended periods of time to sustain 
the initial response to ketamine.4 On average, the duration of response from a single IV dose of 
ketamine is approximately 5 to 7 days.100 The duration of response after the last IV session 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
75
Status: Approved, Date: 6 July 2016
following repeated administration studies (up to 6 sessions over 2 weeks) varies highly between 
subjects; the time to relapse has been reported as a median of 18 days (range, 2 to >83 days)61 or 
a mean of 16 days (range, 7 to 28 days).84
In the abovementioned Study KETIVTRD2002, in the group that received IV ketamine twice per 
week for 2 weeks, all subjects maintained the response for at least 15 days following the last IV 
ketamine dose. Similarly, in the abovementioned Study ESKETIVTRD2001, subjects maintained 
their response for approximately 2 weeks following the last IV esketamine dose.
Long term maintenance of efficacy could be achieved either through repeated intranasal dosing 
as is the case with most antidepressant medications or possibly by an oral antidepressant alone. 
Studies to assess whether venlafaxine or lithium may be able to maintain the antidepressant 
response induced by ketamine are underway by other sponsors.16,17
No systematic studies have yet described sustaining the response to ketamine. The safety of 
long-term use needs to be systematically assessed with repeated interval dosing. This study will 
address the long term safety and efficacy of repeated dose esketamine.
2.
OBJECTIVES AND HYPOTHESIS
2.1.
Objectives
The primary objective of this study is to assess the long-term safety and tolerability of intranasal 
esketamine plus a newly initiated oral antidepressant in subjects with TRD, with special attention 
to the following: 

Potential effects on cognitive function

Potential treatment-emergent symptoms of cystitis and/or lower urinary tract symptoms

Potential withdrawal and/or rebound symptoms following cessation of intranasal esketamine 
treatment 
Secondary Objective
To assess the effect of intranasal esketamine plus a newly initiated oral antidepressant in subjects 
with TRD on

Safety and tolerability with special attention to the following:
Treatment-emergent adverse events, including TEAEs of special interest
Local nasal tolerability 
Effects on heart rate, blood pressure, respiratory rate and blood oxygen saturation, 
Effects on alertness and sedation 
Potential psychosis-like effects
Dissociative symptoms 
Potential effects on suicidal ideation/behavior 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
76
Status: Approved, Date: 6 July 2016

Long-term efficacy, including effects on:
Depressive symptoms (clinician and self-reported), overall severity of depressive illness, 
functional impairment and associated disability, anxiety symptoms, and health-related quality of 
life and health status

Response rate over time, defined as:
o
percentage of subjects with 50% reduction from baseline (induction phase) in the 
MADRS total score,
o
percentage of subjects with 50% reduction from baseline (induction phase) in the 
Patient Health Questionnaire, 9-item (PHQ-9) total score 
Remission rate over time, defined as: 
o
percentage of subjects with MADRS total score 12, 
o
percentage of subjects with PHQ-9 total score 5
Exploratory Objectives

To assess the potential relationship of biomarkers with response/non-response to intranasal 
esketamine plus an oral antidepressant in subjects with TRD

To assess medical resource utilization.

To assess subject tradeoff preferences for key benefit and harm outcomes associated with 
TRD treatment, using a stated-choice conjoint analysis survey. Reporting of these survey 
results may be conducted separately from this study.
2.2.
Hypothesis
There is no formal hypothesis for this safety study.
3.
STUDY DESIGN AND RATIONALE
3.1.
Overview of Study Design
This is an open-label multicenter, long-term study to evaluate the safety and efficacy of 
intranasal esketamine plus a newly initiated oral antidepressant in subjects with TRD. Subjects 
will enter the study either directly (referred to as ‘direct-entry subjects’) or after completing the 
double-blind induction phase of ESKETINTRD3005, a short-term efficacy study, in elderly 
subjects with TRD (referred to as ‘transferred-entry subjects’). Approximately 750 direct entry 
subjects will be enrolled in this study, plus transferred-entry subjects from study 
ESKETINTRD3005. At total of at least 100 subjects 65 years or older (who are either direct 
entry subjects or transferred entry subjects from the ESKETINTRD3005 study) will be enrolled.
ESKETINTRD3005 is a randomized, double-blind, active-controlled, 4 week study in male and 
female elderly subjects (65 years) with TRD to assess the efficacy, safety, and tolerability of 
flexibly dosed intranasal esketamine (28 mg, 56 mg, or 84 mg) plus a newly initiated oral 
antidepressant, compared with a newly initiated oral antidepressant (active comparator) plus 
intranasal placebo.9
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
77
Status: Approved, Date: 6 July 2016
Transferred-entry subjects, who are non-responders (defined as <50% reduction in the MADRS 
total score from baseline [Day 1] at the end of the 4 week double-blind induction phase of 
ESKETINTRD3005 study), will be referred to as ‘transferred-entry non-responder subjects’ in 
the subsequent sections of the protocol. Transferred-entry subjects, who are responders (defined 
as ≥50% reduction in the MADRS total score from baseline [Day 1]) at the end of the 4 week 
double-blind induction phase of ESKETINTRD3005
study), will be referred to as 
‘transferred-entry responder subjects’ in the subsequent sections of the protocol. 
An Independent Data Monitoring Committee (IDMC) will be commissioned for this study to 
review safety data periodically (see Section 11.8, Independent Data Monitoring Committee, for 
details).
This study (ESKETINTRD3004) will have 4 phases:
Up to 4-week screening phase (direct-entry subjects only)
A 4-week open-label induction phase (direct-entry subjects and transferred-entry non-
responders)
A 48-week open-label optimization/maintenance phase (all responder subjects from the open 
label induction phase of the current study and transferred-entry responder subjects)
A 4-week follow-up phase (for all subjects treated with intranasal esketamine)
The maximum duration of the subject’s participation in ESKETINTRD3004 study will be 
60 weeks for direct-entry subjects, 56 weeks for transferred-entry non-responder subjects, and 
52 weeks for transferred-entry responder subjects. The end of the study will occur when at least 
300 subjects have received treatment with intranasal esketamine for 6 months and at least 
100 subjects for 12 months (Note: the total number of subjects will be based on subjects from 
this study and subjects from other intranasal esketamine Phase 3 studies).
Detailed description of the study phases are provided below.
3.1.1.
Study Phases
Subjects may participate in up to 4 phases. Study treatment phases are detailed below.
Screening Phase
After giving informed consent, direct-entry subjects with TRD who are 18 years of age (or 
older if the minimum legal age of consent in the country in which the study is taking place is 
>18 years), will be screened to determine eligibility for study participation. Transferred-entry 
subjects from ESKETINTRD3005 study will not participate in this 4-week screening phase.
Direct-entry subjects will be eligible for screening regardless of whether or not they are currently 
taking oral antidepressant treatments. At screening, subjects must have had a non-response to 
2 oral antidepressants treatments in the current episode of depression, as assessed by the 
Massachusetts 
General 
Hospital-Antidepressant 
Treatment 
Response 
Questionnaire 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
78
Status: Approved, Date: 6 July 2016
(MGH-ATRQ), and confirmed by documented records (eg, medical//pharmacy/prescription
records or a letter from a treating physician, etc,).
Eligible subjects who are entering the open-label induction phase will discontinue all of their 
current oral antidepressant medication(s), being used for depression treatment, including 
adjunctive/augmentation therapies, prior to the start of the induction phase. Of note, subjects 
taking benzodiazepines (at dosages equal to or less than the equivalent of 6 mg/day of 
lorazepam) and/or permitted non-benzodiazepine sleep medications (eg, zolpidem, zaleplon) 
during the screening phase can continue these medications. No dose increases beyond the 
equivalent of 6 mg/day of lorazepam, or new benzodiazepine or non-benzodiazepine sleep 
medications are permitted during the screening phase, with the exception of the use of permitted 
benzodiazepine as rescue medication (where required). If clinically indicated, the antidepressant 
medication(s) may either be tapered and discontinued during the screening phase, or 
discontinued and switched directly to 1 of the 4 new oral antidepressant medication(s) on Day 1 
of the open-label induction phase, per clinical judgment. 
Subjects not currently taking oral antidepressant medication(s) at screening will start 1 of the
4 selected new oral antidepressants medication (duloxetine, escitalopram, sertraline, or 
venlafaxine extended release [XR]) on Day 1 of the open-label induction phase. 
Subjects meeting the inclusion/exclusion criteria are eligible to proceed to the open-label 
induction phase. 
Open-label Induction Phase
Direct-entry subjects and transferred-entry non-responder subjects will participate in this phase.
Direct-entry subjects: Intranasal esketamine treatment will be self-administered at scheduled 
treatment sessions in the clinic/study site, twice weekly for 4 weeks. Subjects who are <65 years 
old will start intranasal esketamine with an initial dose of 56 mg on Day 1, with the dose 
adjusted based on efficacy and tolerability in the subsequent visits of the induction phase, 
(flexible dose: 56 mg or 84 mg). Subjects who are 65 years old will start intranasal esketamine 
with a dose of 28 mg on Day 1 with the dose adjusted based on efficacy and tolerability (28, 56,
or 84 mg) in the subsequent visits of the induction phase. In addition, all direct-entry subjects 
will initiate a new, open-label oral antidepressant on Day 1, which should be taken daily during 
the study.
The oral antidepressant will be 1 of 4 oral antidepressant medications (duloxetine, escitalopram, 
sertraline, or venlafaxine XR), that the subject has not previously had a non-response to in the 
current episode, has not been previously intolerant to (lifetime), and is available in the 
participating country.
Transferred-entry non-responder subjects from ESKETINTRD3005 study (all will be ≥65 years 
old), will join at the start of the open-label induction phase. These subjects will start intranasal 
esketamine with a dose of 28 mg on Day 1 with the dose adjusted based on efficacy and 
tolerability (28, 56, or 84 mg) in the subsequent visits of the induction phase. These subjects
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
79
Status: Approved, Date: 6 July 2016
should continue taking the same oral antidepressant during the study, at the same dose as taken 
in the last week of the double-blind induction phase of ESKETINTRD3005 study. 
Transferred-entry subjects may participate in this study only if this is clinically appropriate in the 
opinion of the investigator. 
For transferred-entry non-responder subjects, results of all assessments performed on Day 28 of 
the induction phase of that study (Visit 2.9 of ESKETINTRD3005 study) will not be repeated as 
part of Visit 2.1 of the current study. For these subjects, the Day 28 visit of the 
ESKETINTRD3005 study will coincide with Day 1 (Visit 2.1) for the current study. There is no 
gap allowed between studies.
If a subject withdraws from the study before the end of the open-label induction phase for 
reasons other than withdrawal of consent, an early withdrawal visit should be conducted 
followed by the follow-up phase.
Optimization/Maintenance Phase
Responder subjects at the end of the induction phase of the ESKETINTRD3004 study, will be 
eligible to proceed to the optimization/maintenance phase; and continue receiving open-label 
intranasal esketamine treatment (at the same dose; 28 mg, 56 mg, or 84 mg) and should continue 
to take the same oral antidepressant medication(s) (at the same dose) as taken in the last week of 
the induction phase of ESKETINTRD3004 study, unless poorly tolerated, in which case the oral 
antidepressant may be discontinued after review with sponsor.
Non-responders at the end of the induction phase of the current study will complete an early
withdrawal visit and proceed to the follow-up phase. 
Eligible transferred-entry responder subjects from the ESKETINTRD3005 study (all will be 
≥65 years old) will join the current study starting from the optimization/maintenance phase. 
These subjects will all start intranasal esketamine with a dose of 28 mg (Week 5; Study Day 32) 
and have their dose adjusted over the following 3 weeks of the optimization/maintenance phase 
as described under the section “Dosing and Administration” Subjects should continue to take the 
same oral antidepressant (at the same dose) during the study, that they received at the end of the 
induction phase of ESKETINTRD3005 study, unless poorly tolerated, in which case the oral 
antidepressant may be discontinued after review with sponsor.
For transferred-entry responder subjects, results of all assessments performed on Day 28 of the 
induction phase (Visit 2.9 of ESKETINTRD3005 study) will not be repeated as part of Visit 3.1
of the current study. The Day 28 visit of the ESKETINTRD3005 study will coincide with 
Day 28 (Visit 3.1) for the current study. There is no gap allowed between studies.
For all subjects, the intranasal treatment session frequency will be reduced from that in the 
induction phase (twice weekly) to weekly for the first 4 weeks of the optimization/maintenance 
phase (ie, Week 5 to Week 8). After the first 4 weeks, the frequency of intranasal treatment 
sessions will be adjusted to once weekly or once every other week based on the severity of 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
80
Status: Approved, Date: 6 July 2016
depressive symptoms, as assessed by the MADRS total score. A maximum of 3 changes in 
intranasal treatment session frequency from weekly to every other week is permitted during the 
optimization/maintenance phase. 
If a subject withdraws from the study before the end of the optimization/maintenance phase for 
reasons other than withdrawal of consent, an early withdrawal visit should be conducted, 
followed by the follow-up phase.
Follow-up Phase
This phase will include all subjects who have received at least 1 dose of intranasal study 
medication in this study. Follow-up visits will be performed at 1, 2 and 4 weeks after the last 
dose of intranasal study drug. At the start of the follow-up phase, further clinical/standard of care 
for the treatment of depression will be arranged by the study investigator and/or the subject’s 
treating physician. There will be no intranasal esketamine administered during this phase. 
Subjects will be provided with an additional 4-week supply of the oral antidepressant medication 
to ensure that there is no interruption of oral antidepressant therapy during the transition to 
further clinical/standard of care.
The decision to continue the oral antidepressant in this phase will be at the discretion of the
investigator, but in order to better assess potential withdrawal symptoms from intranasal study 
drug and facilitate maintenance of clinical benefit, it is strongly recommended that the oral 
antidepressant medication(s) be continued for the duration of the follow-up phase unless 
determined as not clinically appropriate.
An
open label safety extension study, 
54135419TRD3008, may be available (pending country and site approval) for eligible subjects 
participating in the ESKETINTRD3004 study. Please refer to the 54135419TRD3008 protocol 
for full details, when available.
A diagram of the study design is provided in Figure 1.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
81
Status: Approved, Date: 6 July 2016
Figure 1:
Schematic Overview of the Study
a Intranasal esketamine 28 mg dose is the only option for subjects ≥65 years.
bAt entry to the ESKETINTRD3004, transferred entry subjects will continue to receive the same oral antidepressant 
initiated in the ESKETINTRD3005 study. The new oral AD is for direct entry subjects only.   
3.2.
Study Design Rationale
3.2.1.
Study Population
The study population will include adult men and women who meet Diagnostic and Statistical 
Manual of Mental Disorders (5th edition) (DSM-5) diagnostic criteria for single episode MDD 
(duration of episode must be 2 years) or recurrent MDD. 
Subjects will enter the study either directly (referred to as direct-entry subjects) or after 
completing the double-blind induction phase of a short-term study in elderly subjects 
(ESKETINTRD3005) (referred to as “transferred-entry non-responder subjects”, or “transferred 
entry responder subjects”). The direct-entry subjects will include both younger (18 and 
<65 years) and elderly (65 years old) subjects while the transferred-entry subjects include only
elderly subjects (65 years old). Enrichment of study population with elderly subjects is 
important to evaluate the safety of intranasal esketamine in this long-term safety study as elderly 
subjects may be more vulnerable to any adverse drug effects than younger adults (elderly 
subjects are known to have more comorbidities and need to administer more concomitant 
medications than younger subjects). Also prevalence of depression in the over 65 years age 
group is higher than in the general adult population. 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
82
Status: Approved, Date: 6 July 2016
Direct-entry subjects
The direct-entry study population will include adult men and women, 18 years of age (or older 
if the minimum legal age of consent in the country in which the study is taking place is >18), 
who meet DSM-5 diagnostic criteria for recurrent MDD or single episode MDD (duration of 
episode must be 2 years), without psychotic features, based upon clinical assessment, and 
confirmed by the Mini International Neuropsychiatric Interview (MINI). 
Treatment-resistant depression is defined as a lack of clinically meaningful improvement after 
treatment with at least 2 different antidepressant agents prescribed in adequate dosages for 
adequate duration. At screening, subjects must have had nonresponse to 2 oral antidepressant 
treatments taken at adequate dosage and for adequate duration (including currently taken oral 
antidepressant, if applicable), as assessed on the MGH-ATRQ and documented by medical 
history and/or prescription/pharmacy records, in the current episode of depression. Subjects who 
have had some initial response, but then lost the response (eg, tolerance effects/bradyphylaxis), 
to an antidepressant treatment will not be considered to have failed that antidepressant treatment. 
The use of historical data to define non-response to antidepressant treatment prior to patient 
enrollment in an antidepressant treatment study is considered practical and valid. The 
MGH-ATRQ is a validated tool assessing treatment response. Direct-entry subjects will be 
eligible for screening regardless of whether or not they are currently taking oral antidepressant 
medications.
Transferred-entry responder subjects
The transferred-entry responder subjects are the elderly (65 years old) subjects who have 
completed the double-blind induction phase and demonstrated response at the end of the 
induction phase in the short-term study (ESKETINTRD3005). To maintain the blinding of 
intranasal treatment in the ongoing ESKETINTRD3005 study, this group will consist of 
responders to intranasal esketamine plus oral antidepressant (anticipated to be the majority), and 
responders to intranasal placebo plus oral antidepressant. Responders to intranasal esketamine 
plus oral antidepressant from ESKETINTRD3005 can continue to receive intranasal esketamine 
in ESKETINTRD3004 to maintain the treatment response.
For subjects who are responders to intranasal placebo and oral antidepressant there may be no 
additional benefit to such subjects in participating in ESKETINTRD3004. However, as these 
subjects were documented to be treatment-resistant prior to the study, the probability of 
responding to a new oral antidepressant is considered relatively low and so it is expected that
much less subjects would be responders to the oral antidepressant plus intranasal placebo in 
ESKETINTRD3005 compared to those receiving intranasal esketamine plus an oral 
antidepressant.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
83
Status: Approved, Date: 6 July 2016
Transferred-entry non-responder subjects
These are the elderly (65 years old) subjects who completed the double-blind induction phase 
without demonstrating a response at the end of induction phase in the short-term study 
(ESKETINTRD3005). This group will consist of non-responders to intranasal placebo and oral 
antidepressant (anticipated to be the majority), and non-responders to intranasal esketamine plus 
an oral antidepressant. 
The rationale for the participation of subjects who are non-responders to the intranasal placebo
plus oral antidepressant is that they may benefit from open-label esketamine therapy in the open 
label induction phase in the current study. 
Subjects who are non-responders to intranasal esketamine who decide to participate in the 
ESKETINTRD3004 study may not benefit from additional treatment with esketamine. However, 
time to response to oral antidepressants in elderly may take longer than 4 weeks and the potential 
benefit of additional treatment with esketamine in terms of efficacy remains unknown. 
As the blind of the ESKETINTRD3005 study will be maintained, further participation of 
non-responder transfer-entry subjects will be decided by the subject and the investigator, after 
individual evaluation of the risk-benefit, based on the experience from the ESETINTRD3005 
study. 
3.2.2.
Study Phases
Screening Phase
The 4-week screening phase for direct-entry subjects will provide adequate time to assess subject 
eligibility according to the study entry criteria.
If a subject is taking an oral antidepressant medication(s) at the start of screening, the 4-week 
duration of the screening phase will provide adequate time to taper and discontinue these 
medication(s). Otherwise, oral antidepressant medication(s) can be discontinued directly and 
subjects can be switched to a new oral antidepressant in the open-label induction phase, per 
clinical judgment.  
Open-label Induction Phase
As described in Section 1.1.2, the duration of the 4 week open-label induction phase for 
direct-entry subjects was selected based upon the onset of effect of typical antidepressants, with 
a 4 week duration required to consolidate the initial response beyond which a lower frequency 
can be attempted without losing the antidepressant effects of treatment. 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
84
Status: Approved, Date: 6 July 2016
Optimization/Maintenance Phase
The duration of 48 weeks for the optimization/maintenance phase for both direct-entry and 
transferred-entry subjects allows for a reduction in the frequency of intranasal treatment sessions 
and subsequent individualization and stabilization of the treatment session frequency (weekly or 
every other week) for a given subject (using the MADRS total score to assess depressive 
symptoms). In total, the maximal duration of exposure to intranasal esketamine and newly 
initiated oral antidepressant in completers of this study will be 1 year (52 weeks), which in line 
with the requirements for long-term safety assessments by Health Authorities. The required 
duration of exposures and number of subjects exposed to intranasal esketamine and oral 
antidepressant (i.e. 300 subjects with 6 months exposure and 100 subjects with 1 year exposure) 
will provide sufficient long term safety data to support regulatory approval of intranasal 
esketamine and will be used as a milestone determining the time point of completion the study.
Follow-up Phase
The 4 week duration of the follow-up phase will allow sufficient time to assess safety and 
tolerability after
cessation of intranasal dosing. Given the frequency of esketamine 
administration, the 4 week follow-up should be sufficient to assess potential withdrawal 
symptoms and reversibility of any drug related adverse events and/or laboratory abnormalities. 
During this phase, further clinical/standard of care for the treatment of depression will be 
arranged by the study investigator and/or the subject’s treating physician.
3.2.3.
Blinding and Controls
Blinding will not be used in the study. An open-label design has been selected for this study as 
this is preferred for a patient population with a large unmet medical need and severe condition 
(TRD) which makes it difficult to justify administration of placebo only for up to 52 weeks from 
ethical perspective. 
The blind of the ESKETINTRD3005 study will be maintained for transferred-entry subjects, and 
all eligible subjects can participate in the current study, thereby the decision to participate in the 
ESKETINTRD3004 will be independent from subject’s treatment response, to either intranasal 
esketamine plus an oral antidepressant, or intranasal placebo plus an oral antidepressant in 
ESKETINTRD3005 study.  
3.2.4.
Treatment Groups and Dose Selection 
Intranasal Study Drug
Open-label Induction Phase
All direct-entry subjects and transferred-entry non-responder subjects will receive intranasal 
esketamine during this phase. The dose selection (56 mg or 84 mg) and administration interval 
(2 treatment sessions per week for 4 weeks) for this phase were based on the sponsor’s previous 
clinical data; in particular the results from Studies ESKETIVTRD2001, KETIVTRD2002, 
ESKETINTRD1001, ESKETINTRD1012, and Panel A of the Study ESKETINTRD2003, 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
85
Status: Approved, Date: 6 July 2016
described above in Section 1.1.2. Of note, to improve tolerability, subjects 65 years who are 
assigned to esketamine will start with 28 mg of intranasal esketamine on Day 1.
The data from Study ESKETINTRD2003 Panel A support the hypotheses that both the 56 mg
and 84 mg doses are effective as a treatment for depression in subjects with TRD, that they have 
a rapid onset of effect, and that 2 treatment sessions per week can sustain the response 
throughout the 4 week duration of the open-label induction phase. In addition, the 56 mg and 
84 mg dosages were generally well tolerated by subjects. More recently,
Study 
ESKETINTRD1012 evaluated the pharmacokinetics and safety of a single intranasal 84 mg dose 
in elderly subjects ≥75 years of age. Preliminary data showed the means of the Cmax and AUC∞
were approximately 48% and 31% higher, respectively, in the elderly compared with younger 
adult subjects. Differences were greater based on median Cmax and AUC∞values (97% and 63% 
higher in the elderly, respectively).
Based on PK data from ESKETINTRD1012 it is also possible that the 28 mg dose in the elderly 
may overlap with the 56 mg dose in younger patients, so addition of the 28 mg dose in the 
elderly may provide an efficacious dose while improving safety.
The use of flexible dosing for intranasal esketamine may provide improved tolerability by 
gradually increasing to a higher dose and will also inform clinical practice, as many clinicians 
prefer to gradually increase, and then adjust as clinically required, the dose of antidepressant 
medication.
In the current study, all subjects 65 years of age will start intranasal esketamine at a dose of
28 mg on Day 1, thereafter adjusting the dose (28 mg, 56 mg, or 84 mg) in a flexible fashion 
based on efficacy and tolerability up to Day 15 (see Section 6 Dosage and Administration). 
Starting with a lower dose (28 mg) initially and then adjusting the dose in increments of 28 mg 
based on efficacy and tolerability may allow these elderly subjects to adjust to the effects of the 
lower dose before going to higher doses. Similarly for those <65 years the lower dose, 56 mg, 
will be the starting dose on Day 1, thereby providing the subjects time to tolerate the lower dose 
before the higher dose (84 mg). For example, internal data from the CADSS suggest a dose 
response, with the greatest effect seen initially on the 84 mg dose (ESKETINTRD2003). 
However, on subsequent repeated dosing, dissociative symptoms lessen. Starting with the lower 
dose may therefore limit the number of elderly subjects discontinuing the study because of 
intolerability. 
The dose will be flexible (28 mg, 56 mg, or 84 mg) in the first part of the induction phase. This 
approach is aimed to resemble clinical practice where the investigator can modify the dose of the 
medication depending on tolerability and efficacy for each subject individually.
The objective is that the dose remains stable from Day 18 onwards so that subjects are on a 
stable dose at the end of the open-label induction phase. However, if needed for tolerability, one 
additional dose down-titration of 28 mg is permitted from Day 15 until Day 25. 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
86
Status: Approved, Date: 6 July 2016
Optimization/maintenance Phase
All responder subjects from the open-label induction phase of ESKETINTRD3004 study and 
eligible transferred-entry responder subjects from ESKETINTRD3005 study will participate in 
this phase. 
Subjects entering the optimization/maintenance phase following the open-label induction phase 
may have the dose down titrated during this phase for tolerability. 
As the blind will be maintained to the intranasal treatment received in ESKETINTRD3005 study 
for transferred-entry responder subjects, within that group there may be responders to intranasal 
placebo and oral antidepressant who did not receive intranasal esketamine before. For this 
reason, all transferred-entry responder subjects will start at a dose of 28 mg of intranasal 
esketamine.
Eligible transferred-entry responder subjects from ESKETINTRD3005 will join the study at this 
phase. The first intranasal treatment session for these subjects will begin on Study Day 32 of the 
optimization/maintenance phase. Transferred-entry responder subjects who enter the 
ESKETINTRD3004 study from the optimization/maintenance phase will start intranasal dosing 
sessions starting at the 28 mg dose and will titrate the dose to 56 mg in the second week of the 
phase and then adjust the dose (28 mg, 56 mg, or to 84 mg) thereafter based on efficacy and 
tolerability (see Section 6 for dosing administration details). For the first 4 weeks of 
optimization/maintenance phase, these subjects will receive weekly treatment sessions with 
open-label intranasal esketamine as described Section 6.1.2, Table 7.
For all subjects, the intranasal treatment session frequency will be reduced from that in the 
induction phase (twice weekly) to weekly for the first 4 weeks of the optimization/maintenance 
phase. After the first 4 weeks, the frequency of intranasal treatment sessions will be 
individualized to once weekly or once every other week based on the severity of depression, as 
assessed by the MADRS total score. This reduction
in frequency and subsequent 
individualization is intended to allow subjects to sustain the antidepressant response while 
minimizing the frequency of intranasal treatment sessions required.
The selected dose frequencies were guided by clinical experience with the use of IV ketamine for 
the treatment of MDD/TRD in the community and the (albeit) limited Panel A data from the 
phase 2 study in treatment-resistant depression ESKETINTRD2003 study, where subjects after 
an initial induction phase, in a subsequent optional open label phase and, after an additional 
2 weeks of dosing twice weekly, had their dosing frequency reduced to weekly for 3 weeks and 
then every other week for 4 weeks. The ESKETINTRD2003 Panel A data suggests that even 
after reducing to weekly and every other week dosing, the majority of subjects were able to 
maintain their antidepressant response/remission.
Oral Antidepressant
On Day 1 of the open-label induction phase, a new, open-label oral antidepressant treatment will 
be initiated for all direct-entry subjects.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
87
Status: Approved, Date: 6 July 2016
Each subject will be either assigned (for direct-entry subject) or will continue (for transferred-
entry subjects) to receive 1 of the 4 oral antidepressant medications from 2 different classes of 
antidepressant treatments, an SSRI (escitalopram or sertraline) or an SNRI (duloxetine or 
venlafaxine XR). The assignment of the oral antidepressant treatment will be done by the 
investigator based on review of the MGH-ATRQ and relevant prior antidepressant medication 
information. 
These 2 antidepressant classes were selected because they are the most commonly prescribed 
antidepressant classes in this population and are generally well-tolerated. The oral antidepressant 
treatment assigned will be one that the subject has not previously had a nonresponse to in the 
current episode, has not been previously intolerant to (lifetime), and is available in the 
participating country. 
Dosing of the oral antidepressant will follow the country-specific prescribing information for the 
respective product, with a forced titration to the maximally tolerated dosage to ensure that the 
oral antidepressant is taken at an adequate dosage and duration for assessment of potential 
maintenance of effect. A protocol-specified titration schedule is provided in Attachment 3. If 
higher doses are not tolerated, a down-titration is permitted based on clinician’s judgment. 
For all subjects, the same oral antidepressant treatment initiated in the induction phase is 
continued throughout the optimization/maintenance, and follow-up (if clinically indicated) 
phases, unless poorly tolerated, in which case the oral antidepressant may be discontinued after 
review with sponsor.
Refer to Section 1.3 (Overall Rationale for study) the rationale of initiating and continuing an 
oral antidepressant along with intranasal esketamine treatment. 
3.2.5.
Safety Evaluations
Physical examination, body weight, vital signs (including blood pressure measurements), 12-lead 
ECG, pulse oximetry, clinical laboratory tests, nasal examinations, and evaluation of TEAEs and 
concomitant therapies will be performed throughout the study to monitor subject safety. 
TEAEs of special interest will be examined separately grouped in the following categories: drug 
abuse, dependence and withdrawal (standardized Medical Dictionary for Regulatory Activities 
[MedDRA]
queries [SMQ]), increased blood pressure, increased heart rate, transient 
dizziness/vertigo; impaired cognition; anxiety and cystitis.
A subject-completed nasal symptom questionnaire will also be to assess for any treatment-
emergent nasal tolerability symptoms.
The Columbia Suicide Severity Rating Scale (C-SSRS) will be performed to assess suicidal 
ideation and behavior, the CADSS will be administered to assess treatment-emergent 
dissociative symptoms, the Brief Psychiatric Rating Scale (BPRS+; four-item positive symptom 
subscale) will be administered to assess treatment-emergent psychotic symptoms, the MOAA/S 
will be used to measure treatment-emergent sedation, the CGADR will be used to measure the 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
88
Status: Approved, Date: 6 July 2016
subject’s readiness for discharge based on parameters including sedation, blood pressure, and 
adverse events, and the PWC-20 will be administered (as applicable) to assess potential 
withdrawal symptoms after cessation of esketamine treatment.
Given the potential for treatment emergent transient elevation in systolic and diastolic blood 
pressure, heart rate and blood pressure will be monitored throughout the study and at multiple 
time points on dosing days. Specific guidance to be followed on intranasal dosing days is 
provided in Section 6.1.
Even though it is anticipated that the potential risk for treatment-emergent cystitis is very low 
based upon the doses to be used in this study, subjects will be monitored for symptoms of 
cystitis, bladder pain, and interstitial cystitis using the subject-completed BPIC-SS at specific 
time points.39 A score >18 on the BPIC-SS scale is considered as probable cystitis, and any 
subjects meeting this cut-off will have a urinalysis and culture conducted at that visit to assess 
for potential urinary tract infection. Those without evidence of an ongoing urinary tract infection 
will be referred to a specialist for diagnostic workup. There are no definitive tests for diagnosing 
ulcerative cystitis. If a subject is diagnosed with ulcerative cystitis, the subject must be 
discontinued from the study and followed up with appropriate medical care.
The effect of intranasal esketamine on cognition will be assessed using the computerized 
cognitive battery and Hopkins Verbal Learning Test-Revised (HVLT-R). The cognitive battery 
will provide assessment of multiple cognitive domains, including attention, visual learning and 
memory, and executive function. The HVLT-R is a measure of verbal learning and memory.
On all intranasal dosing days, subjects must remain at the site until study procedures have been 
completed and the subject is ready for discharge and should be accompanied by a responsible 
adult when released from the clinical site. Subjects must not drive a car or work with machines 
for 24 hours after receiving intranasal study drug.
A list of prohibited medications is provided in Attachment 1 for general guidance for the 
investigator (not all-inclusive).
3.2.6.
Efficacy Measures
The efficacy measures were chosen for their reliability, validity, and ability to measure 
depression severity (including changes due to antidepressant treatment).
MADRS
The 10-item clinician-administered MADRS was designed to be used in subjects with MDD to 
measure the overall severity of depressive symptoms.53,54 The MADRS scale is a validated, 
reliable scale and acceptable to regulatory health authorities as a primary scale to determine 
efficacy in major depression. 
Efficacy endpoints include assessment of depression symptoms using the MADRS individual 
scores and total score, as well as response and remission rate over time. 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
89
Status: Approved, Date: 6 July 2016
Direct-entry subjects and transferred-entry non-responder subjects (from ESKETINTRD3005) 
with a 50% reduction from baseline (Day 1) at the end of the 4 week open-label induction 
phase in ESKETINTRD3004 will be considered responders and eligible to proceed into the 
optimization/maintenance phase.
PHQ-9
The PHQ-9 will be used as a patient-reported measure of depressive symptomatology.88 Refer to 
Section 9.3.1.3 for additional information regarding PHQ-9.
SDS
The Sheehan Disability Scale (SDS) is a patient reported measure included as an assessment of 
functional impairment and associated disability.48,83 Refer to Section 9.3.1.6 for additional 
information regarding SDS.
CGI-S 
The CGI-S is included to rate the severity of the subject’s illness at the time of assessment, 
relative to the clinician’s past experience with subjects who have the same diagnosis and 
improvement with treatment.34 Refer to Section 9.3.1.2 for additional information regarding 
CGI-S.
GAD-7
GAD-7 is included as a brief and validated measure of overall anxiety.87 Refer to Section 9.3.1.4
for additional information regarding GAD-7.
EQ 5D-5L
The EQ-5D-5L is included as a standardized patient self-completed instrument for use as a 
measure of health-related quality of life and health status.29,30 Refer to Section 9.3.1.5 for 
additional information regarding EQ-5D-5L.
3.2.7.
Medical Resource Utilization 
Superior and sustained response and remission rates to the current antidepressant medication(s) 
are expected to result in low utilization of services, whereas nonresponse is expected to result in 
higher utilization of healthcare services (such as outpatient visits, emergency room visits, or 
hospitalization), as assessed using the Healthcare Resource Use Questionnaire (HRUQ) during 
the follow-up phase. The HRUQ includes information regarding utilization of healthcare 
services, including the timing of services, enabling changes in level and quantity of services to 
be considered as a variable in economic models.
3.2.8.
Patient Stated-choice Preference Survey
Stated-choice conjoint analysis is a method specifically designed to provide information about an 
individual’s willingness to accept tradeoffs between treatments with multiple outcomes. It has 
been used in many therapeutic areas and with many types of patients, including patients with 
depression. The Patient Stated-choice Preference Survey will be used as an exploratory tool to 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
90
Status: Approved, Date: 6 July 2016
assess the manner and degree to which the study subjects value or weigh the clinical outcome 
associated with esketamine treatment, thus allowing assessment of the maximum acceptable 
treatment-related risk subjects would accept for various degrees of benefit.
3.2.9.
Biomarker and DNA Collection
Assessment of biomarkers and their potential relationship to maintenance/optimization of 
response and non-response will be explored. Blood samples will be collected to measure genetic 
and epigenetic markers (including but not limited to BDNF allelic variants), and protein markers 
(including but not limited to growth factors, inflammation, endocrine, or metabolic). Samples of 
DNA and biomarker may be used to help address emerging issues and to enable the development 
of safer, more effective, and ultimately individualized therapies.
Genetic variation can be an important contributory factor to inter-individual differences in drug 
distribution and response and can also serve as a marker for disease susceptibility and prognosis. 
Pharmacogenomic research may help to explain inter-individual variability in clinical outcomes 
and may help to identify population subgroups that respond differently to a drug or subgroups 
that are more susceptible to relapse. In addition, pharmacogenomics research may allow for the 
identification of genetic factors that influence the pharmacokinetics, pharmacodynamics, 
efficacy, safety, or tolerability of intranasal esketamine and oral antidepressant comedication and 
for the identification of genetic factors associated with TRD, or MDD. Specifically, genetic and 
epigenetic changes in genes known to be in pathways relevant to depression (HPA axis, 
inflammation, growth factors, monoamine transporters, ion channels, circadian rhythm) will be 
evaluated.
Protein, DNA and metabolic biomarkers may aid in the elucidation of the mechanism of action 
of intranasal esketamine and oral antidepressant co-medication or help to explain interindividual 
variability in clinical outcomes or may help to identify population subgroups that respond 
differently to a drug or may help to identify subgroups that are more susceptible to relapse. The 
goal of the biomarker analyses is to evaluate the pharmacodynamics of intranasal esketamine and 
oral antidepressant comedication, and aid in evaluating the drug-clinical response relationship.
On the day of biomarker sample collection, it is preferred that subjects adhere to a low fat diet 
(as an alternative to fasting) to reduce the level of postprandial lipemia, since moderately or 
grossly lipemic specimens may interfere with assay results.
4.
SUBJECT POPULATION
The inclusion and exclusion criteria for enrolling subjects in this study are described in the 
following subsections. If there is a question about the inclusion or exclusion criteria below, the 
investigator must consult with the appropriate sponsor representative and resolve any issues 
before enrolling a subject in the study. Waivers are not allowed.
Screening for eligible direct-entry subjects will be performed within 4 weeks (28 days) before 
the first administration of study drug.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
91
Status: Approved, Date: 6 July 2016
The sponsor will evaluate and approve/reject requests to rescreen an individual direct-entry 
subject on a case-by-case basis.
4.1.
Inclusion Criteria
4.1.1.
Direct-Entry Subjects
The following criteria apply only to those subjects entering directly into the study 
Each potential subject must satisfy all of the following criteria to be enrolled in the study.
1.
Subject must be a man or woman, 18 years of age.
2.
At the start of the screening phase, each subject must meet DSM-5 diagnostic criteria of
single-episode MDD (if single episode MDD, the duration must be 2 years) or recurrent 
MDD, without psychotic features, based on clinical assessment and confirmed by the MINI.
3.
Criterion modified per amendment 2
3.1 Criterion modified per amendment 3
3.2 At the start of the screening phase, each subject must have had non-response to 2 oral
antidepressant treatments in the current episode of depression, as assessed using the MGH-
ATRQ and confirmed by documented records (eg, medical/pharmacy/prescription records or 
a letter from treating a physician, etc,). 
Note: For specific tricyclic antidepressants which are ongoing and being taken at a dose 
below the MGH-ATRQ minimum therapeutic dose, a blood level that is within the 
therapeutic (antidepressant) range, is acceptable to establish the adequacy of the 
antidepressant treatment.
4.
Criterion modified per amendment 3. 
4.1 At screening, subject must have a MADRS total score of 22.
5.
Subject must be medically stable on the basis of physical examination, medical history, vital 
signs (including blood pressure), pulse oximetry, and 12-lead ECG performed at screening. 
If there are any abnormalities that are not specified in the inclusion and exclusion criteria, 
their clinical significance must be determined by the investigator and recorded in the 
subject's source documents and initialed by the investigator.
6.
Criterion modified per amendment 1 
6.1 Criterion modified per amendment 2
6.2 Criterion modified per amendment 3
6.3 Subject must be medically stable on the basis of clinical laboratory tests performed at 
screening. If the results of the serum chemistry panel, hematology, or urinalysis are outside 
the normal reference ranges, the subject may be included only if the investigator judges the 
abnormalities or deviations from normal to be not clinically significant or to be appropriate 
and reasonable for the population under study. This determination must be recorded in the 
subject's source documents and initialed by the investigator.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
92
Status: Approved, Date: 6 July 2016
For any subject (regardless of thyroid history), if the thyroid stimulating hormone (TSH)
value is out of range, a free thyroxine (FT4) will be conducted. If the FT4 value is 
abnormal and considered to be clinically significant (after discussion with the medical 
monitor) the subject is not eligible.
Subjects with a pre-existing history of thyroid disease/disorder who are treated with 
thyroid hormones must be on a stable dosage for 3 months prior to the start of the 
screening phase.
7.
Subject must be comfortable with self-administration of intranasal medication and be able to 
follow the intranasal administration instructions provided.
8.
Criterion modified per amendment 2
8.1. Criterion modified per amendment 3
8.2 Contraceptive use by men or women should be consistent with local regulations 
regarding the use of contraceptive methods for subjects participating in clinical studies.
Before the start of the screening phase, a woman must be either:
A woman must be either:
a.
Not of childbearing potential defined as:

postmenopausal
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. A high follicle stimulating hormone (FSH) level 
(>40 IU/L or mIU/mL in the postmenopausal range) may be used to confirm a 
postmenopausal state in women not using hormonal contraception or hormonal 
replacement therapy, however in the absence of 12 months of amenorrhea, a 
single FSH measurement is insufficient.

permanently sterile
Permanent sterilization methods include hysterectomy, bilateral salpingectomy, 
bilateral tubal occlusion/ligation procedures, and bilateral oophorectomy.
b.
Of childbearing potential and

practicing a highly effective method of contraception (failure rate of <1% per year 
when used consistently and correctly).
Examples of highly effective contraceptives include 
user-independent methods:
implantable progestogen-only hormone contraception associated with inhibition 
of ovulation; intrauterine device (IUD); intrauterine hormone-releasing system 
(IUS); vasectomized partner; sexual abstinence (sexual abstinence is considered a 
highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study drug. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of 
the study and the preferred and usual lifestyle of the subject.)
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
93
Status: Approved, Date: 6 July 2016
user-dependent methods:
combined (estrogen- and progestogen-containing) hormonal contraception 
associated with inhibition of ovulation: oral, intravaginal, and transdermal; 
progestogen-only hormone contraception associated with inhibition of ovulation: 
oral and injectable
Typical use failure rates may differ from those when used consistently and 
correctly. Use should be consistent with local regulations regarding the use of 
contraceptive methods for subjects participating in clinical studies.
Hormonal contraception may be susceptible to interaction with the study drug, 
which may reduce the efficacy of the contraceptive method.

agrees to use a highly effective method throughout the study and for at least 
6 weeks after the last dose of study drug
Note: If the childbearing potential changes after start of the study, or the risk of pregnancy 
changes (eg, woman who is not heterosexually active becomes active), a woman must begin 
a highly effective method of contraception, as described throughout the inclusion criteria.
Women must agree to continue using these methods of contraception throughout the study 
and for at least 6 weeks after the last dose of study drug. 
9.
Criterion modified per amendment 2
9.1. A woman of childbearing potential must have a highly sensitive negative serum 
(-human chorionic gonadotropin [-hCG]) at the start of the screening phase and a negative
urine pregnancy test must be obtained before the first dose of study drug on Day 1 of the 
open-label induction phase prior to the first intranasal treatment session.
10. Criterion deleted per amendment 2  
4.1.2.
Transferred-Entry Subjects (From Study ESKETINTRD3005)
11. Criterion modified per amendment 2
11.1. All subjects who completed the double-blind induction phase of ESKETINTRD3005
study, regardless of their response status, will be eligible to participate in this study, if they 
meet the study specific eligibility criteria in Sections 4.1.2, 4.1.3 and 4.2.2. 
Subject must be medically stable on the basis of physical examination, medical history, vital 
signs (including blood pressure), pulse oximetry, and 12-lead ECG performed at entry into 
the study. If there are any abnormalities that are not specified in the inclusion and exclusion 
criteria, their clinical significance must be determined by the investigator and recorded in 
the subject's source documents and initialed by the investigator.
Subject must be medically stable on the basis of clinical laboratory tests performed at 
screening. If the results of the serum chemistry panel, hematology, or urinalysis are outside 
the normal reference ranges, the subject may be included only if the investigator judges the 
abnormalities or deviations from normal to be not clinically significant or to be appropriate 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
94
Status: Approved, Date: 6 July 2016
and reasonable for the population under study. This determination must be recorded in the 
subject's source documents and initialed by the investigator.
4.1.3.
Both Types of Subjects (Direct-entry and Transferred-entry Subjects)
12. Each subject must be willing and able to adhere to the prohibitions and restrictions specified 
in this protocol.
13. Each subject must sign an informed consent form (ICF) indicating that he or she understands 
the purpose of and procedures required for the study and is willing to participate in the 
study.
14. Criterion modified per amendment 3
14.1 During the study (ie, from Day 1 of the open-label induction phase) and for a minimum 
of 1 spermatogenesis cycle (defined as approximately 90 days) after receiving the last dose 
of study drug, a man who is sexually active with a woman of childbearing potential

must be practicing a highly effective method of contraception with his female partner 
from those listed above (see examples of highly effective methods of contraception 
provided for female subjects).

must use a condom if his partner is pregnant. 

must agree not to donate sperm.
Note: If the childbearing potential changes after start of the study, a female partner of a male 
study subject must begin a highly effective method of birth control, as described above.
4.2.
Exclusion Criteria
Any potential subject who meets any of the following criteria will be excluded from participating 
in the study.
4.2.1.
Direct-Entry Subjects
The following exclusion criteria only apply to those subjects entering directly into the study:
1.
Criterion modified per amendment 3
1.1 Subject’s depressive symptoms have previously not responded to:
Esketamine or ketamine in the current major depressive episode per clinical judgment, or
All of the 4 oral antidepressant treatment options available in the respective country for the 
open-label induction phase (ie, duloxetine, escitalopram, sertraline, and venlafaxine XR) in 
the current major depressive episode (based on MGH-ATRQ).
2.
Criterion modified per amendment 1
2.1 Criterion modified per amendment 2
2.2. Subject has a current or prior DSM-5 diagnosis of a psychotic disorder or MDD with 
psychotic features, bipolar or related disorders (confirmed by the MINI), obsessive 
compulsive disorder (current only), intellectual disability (DSM-5 diagnostic codes 317, 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
95
Status: Approved, Date: 6 July 2016
318.0, 318.1, 318.2, 315.8, and 319), autism spectrum disorder, borderline personality 
disorder, antisocial personality disorder, histrionic personality disorder, or narcissistic 
personality disorder.
3.
Subject has homicidal ideation/intent, per the investigator’s clinical judgment, or has 
suicidal ideation with some intent to act within 6 months prior to the start of the screening 
phase, per the investigator’s clinical judgment or based on the C-SSRS, corresponding to 
response of “Yes” on Item 4 (active suicidal ideation with some intent to act, without 
specific plan) or Item 5 (active suicidal ideation with specific plan and intent) for suicidal 
ideation on the C-SSRS, or a history of suicidal behavior within the past year prior to the 
start of the screening phase. Subjects reporting suicidal ideation with intent to act or suicidal 
behavior prior to the start of the open-label induction phase should be excluded.
4.
Subject has a history of moderate or severe substance or alcohol use disorder according to 
DSM-5 criteria, except nicotine or caffeine, within 6 months before Screening. 
A history (lifetime) of ketamine, phencyclidine, lysergic acid diethylamide (LSD), or 3, 
4-methylenedioxy-methamphetamine (MDMA) hallucinogen-related use disorder is 
exclusionary.
5.
Subject has a current or past history of seizures (uncomplicated childhood febrile seizures 
with no sequelae are not exclusionary).
6.
Criterion deleted per amendment, duplicate to exclusion criterion #10.   
7.
Criterion modified per amendment 2
7.1. Subject who:

Has a Mini Mental State Examination (MMSE) <25

Has neurodegenerative disorder (eg, Alzheimer’s disease, vascular dementia, 
Parkinson’s disease), or evidence of mild cognitive impairment (MCI).
8.
Criterion modified per amendment 2.
8.1 Criterion modified per amendment 3
8.2 Subject has one of the following cardiovascular-related conditions 
Cerebrovascular disease with a history of stroke or transient ischemic attack
Aneurysmal vascular disease (including intracranial, thoracic or abdominal aorta, or 
peripheral arterial vessels)
Coronary artery disease with myocardial infarction, unstable angina or revascularization 
procedure (eg, coronary angioplasty or bypass graft surgery), within 12 months before 
the start of the screening phase. Subjects who have had a revascularization performed 
˃12 months prior to screening and are clinically stable and symptom free, per 
investigator’s clinical judgment, can be included.
Hemodynamically significant valvular heart disease such as mitral regurgitation, aortic 
stenosis, or aortic regurgitation
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
96
Status: Approved, Date: 6 July 2016
New York Heart Association (NYHA) Class III-IV heart failure of any etiology 
(see Attachment 2)
9.
Criterion modified per amendment 2.
9.1. Criterion modified per amendment 3
9.2 Subject has a history of uncontrolled hypertension despite diet, exercise, or 
antihypertensive medications at the start of the screening phase or any past history of 
hypertensive crisis or ongoing evidence of uncontrolled hypertension defined as a supine 
systolic blood pressure (SBP) >140 mmHg or diastolic blood pressure DBP >90 mmHg for 
those <65 years during screening phase which continues to be above this range with 
repeated testing during this phase. For those 65 years uncontrolled hypertension is defined 
as a supine systolic blood pressure (SBP) >150 mm Hg or diastolic blood pressure DBP 
>90 mmHg during screening phase which continues to be above this range with repeated 
testing during this phase. Note: On Day 1 of the open-label induction phase, a supine SBP 
>140 mmHg or DBP >90 mm Hg is exclusionary for those <65 years; and for those 
65 years a SBP >150 mm Hg or DBP >90 mmHg is exclusionary.
A potential subject may have his/her current antihypertensive medication(s)  adjusted during 
the screening phase and be re-evaluated to assess their blood pressure control. The subject 
must be on a stable regimen for at least 2 weeks before Day 1 of the open-label induction 
phase.
10. Subject has a current or past history of significant pulmonary insufficiency/condition or an 
arterial blood oxygen saturation (SpO2) of <93% at the start of the screening phase or Day 1 
of the open-label induction phase prior to the first intranasal treatment session. 
11. Criterion modified per amendment 2
11.1 Criterion modified per amendment 3
11.2 Criterion modified per amendment 4
11.3 Subject has clinically significant ECG abnormalities at the start of screening or on Day 
1 of the open-label induction phase prior to the first intranasal treatment session, defined as:
- During screening, a QT interval corrected according to Fridericia’s formula (QTcF): 
≥450 msec; if the QTcF is prolonged on the initial ECG, the average QTcF of three 
ECGs, recorded 4 minutes apart, must not be ≥450 msec.
- On Day 1 (predose), a QT interval corrected according to Fridericia’s formula (QTcF): 
≥450 msec based on the site-evaluated ECG; if the QTcF is prolonged on the initial ECG, 
the average QTcF of three ECGs, recorded 4 minutes apart, must not be ≥450 msec.
- Evidence of 2nd or 3rd degree AV block. 
- Features of new ischemia.
- Arrhythmia (except premature atrial contractions [PACs] and premature ventricular 
contractions [PVCs]).
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
97
Status: Approved, Date: 6 July 2016
12. Criterion modified per amendment 2
12.1. Subject has a history of additional risk factors for Torsades des Pointes (eg, heart 
failure, hypokalemia, family history of Long QT Syndrome).
13. Criterion modified per amendment 2
13.1. Subject has history of, or symptoms and signs suggestive of liver cirrhosis (eg, 
esophageal varices, ascites, and increased prothrombin time) OR alanine aminotransferase 
(ALT) or aspartate aminotransferase (AST) values 2x the upper limit of normal or total 
bilirubin >1.5 times the ULN in the during the screening phase. 
- Repeat of screening test for abnormal ALT and AST is permitted once during the 
screening period, provided per investigator discretion and provided that there is an 
alternative explanation for the out of range value.
For elevations in bilirubin if, in the opinion of the investigator and agreed upon by the 
sponsor’s medical officer, the elevation in bilirubin is consistent with Gilbert’s disease, the 
subject may participate in the study.
14. Criterion modified per amendment 2
14.1 Criterion modified per amendment 3
14.2 Subject has positive test result(s) for drugs of abuse (including barbiturates, methadone, 
opiates, cocaine, phencyclidine, and amphetamine/methamphetamine) at the start of the 
screening phase or Day 1 of the open-label induction phase prior to the first intranasal 
treatment session.
- Subjects who have a positive test result at screening due to prescribed psychostimulants 
taken for an indication other than MDD (e.g. amphetamine, methylphenidate etc.) are 
permitted to continue to take this medication during the study in accordance with 
Attachment 1.
- Otherwise, subjects who have a positive test result at screening due to prescribed/over-
the-counter opiates or barbiturates may be permitted to continue in the screening phase
if the medication is discontinued at least 1 week or 5 half-lives, whichever is longer, 
before Day 1 of the open-label induction phase prior to the first intranasal treatment 
session in accordance with Attachment 1 restrictions (for opiates). The result of the Day 
1 (prior to the first intranasal treatment session) test for drugs of abuse must be negative 
for the subject to have the first intranasal treatment session.
Retesting is not permitted for positive test result(s), except for reasons stated above.
-
Prior intermittent use of cannabinoids prior to the start of the screening phase is not 
exclusionary as long as the subject does not meet the criteria for substance use 
disorder. A positive test for cannabinoids at the start of the screening phase is not 
exclusionary however a positive test result for cannabinoids on Day 1 (predose) of the 
open-label induction phase is exclusionary.
15. Subjects who are taking a total daily dose of benzodiazepines greater than the equivalent of 
6 mg/day of lorazepam at the start of the screening phase.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
98
Status: Approved, Date: 6 July 2016
16. Criterion modified per amendment 2
16.1. Subject has uncontrolled diabetes mellitus, as evidenced by HbA1c >9% at screening 
or history in the prior 3 months prior to the start of the screening phase of diabetic 
ketoacidosis, hyperglycemic coma or severe hypoglycemia with loss of consciousness.
17. Subject has untreated glaucoma, current penetrating or perforating eye injury, brain injury, 
hypertensive encephalopathy, intrathecal therapy with ventricular shunts, or any other 
condition associated with increased intracranial pressure or increased intraocular pressure or 
planned eye surgery.
18. Criterion modified per amendment 2
18.1. Subject has any anatomical or medical condition that may, per the investigator’s 
clinical judgment based on assessment, impede delivery or absorption of intranasal study 
drug
19. Criterion deleted per amendment 2
20. Subject has a history of malignancy within 5 years before screening (exceptions are 
squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or 
malignancy that in the opinion of the investigator, with concurrence with the sponsor's 
medical monitor, is considered cured with minimal risk of recurrence).
21. Subject has known allergies, hypersensitivity, intolerance, or contraindications to 
esketamine/ketamine, and/or excipients or all of the available oral antidepressant treatment 
options for the open-label induction phase.
22. Subject has taken any prohibited therapies that would not permit dosing on Day 1, as noted 
in Section 8 (Pre study and Concomitant Therapy) and Attachment 1.
23. If a subject has a score of 5 on the STOP-Bang questionnaire, in which case, obstructive 
sleep apnea must be ruled out (eg, apnea-hypopnea index [AHI] <30. A subject with 
obstructive sleep apnea can be included if he or she is using a positive airway pressure 
device or other treatment/therapy that is effectively treating his or her sleep apnea.
24. Criterion modified per amendment 2. 
24.1. Subject has received an investigational drug (including investigational vaccines) or
used an invasive investigational medical device within 60 days before the start of the 
screening phase, or has participated in 2 or more MDD or other psychiatric condition 
interventional clinical studies (with different investigational medication) in the previous 1 
year before the start of the screening phase, or is currently enrolled in an investigational 
interventional study.
25. Criterion modified per amendment 2
25.1. Subject is a woman who is pregnant, breast-feeding, or planning to become pregnant 
while enrolled in this study or within 6 weeks after the last dose of intranasal study drug.
26. Subject has a diagnosis of acquired immunodeficiency syndrome (AIDS). No human 
immunodeficiency virus (HIV) testing is required for this study.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
99
Status: Approved, Date: 6 July 2016
27. Criterion modified per amendment 1
27.1 Subject has had major surgery (eg, requiring general anesthesia) within 12 weeks 
before the start of the screening phase, or will not have fully recovered from surgery. 
28. Subject has any condition or situation/circumstance for which, in the opinion of the 
investigator, participation would not be in the best interest of the subject (eg, compromise 
the well-being) or that could prevent, limit, or confound the protocol-specified assessments
29. Subject is an employee of the investigator or study site, with direct involvement in the 
proposed study or other studies under the direction of that investigator or study site, as well 
as family members of the employees or the investigator.
NOTE: the following criterion is intentionally not numbered sequentially.
32. Subject has severe renal impairment (creatinine clearance <30 ml/min).
4.2.2.
Transferred-Entry Subjects
30. Subject has taken any prohibited therapies that would not permit dosing on Day 1, as noted 
in Section 8 (Prestudy and Concomitant Therapy) and Attachment 1.
31. Subject has any condition or situation/circumstance for which, in the opinion of the 
investigator, participation would not be in the best interest of the subject (eg, compromise 
the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
32. Subject has severe renal impairment (creatinine clearance <30 ml/min).
NOTE: Investigators should ensure that, all study enrollment criteria have been met prior to 
Day 1 of the induction phase (for direct-entry and transferred-entry non-responder subjects) or 
the start of the optimization phase (for transferred-entry responder subjects). If a subject's status 
changes (eg, laboratory results or receipt of additional medical records) after the start of 
screening but before the first dose of intranasal study drug is given in this study, such that he or 
she no longer meets all eligibility criteria, then the subject should be excluded from participation 
in the study. Section 17.4, Source Documentation, describes the required documentation to 
support meeting the enrollment criteria.
The sponsor will evaluate and approve/reject requests to rescreen an individual subject on a case-
by-case basis.
4.3.
Prohibitions and Restrictions
Potential subjects must be willing and able to adhere to the following prohibitions and 
restrictions during the course of the study to be eligible for participation:

Refer to Section 4.1 (Inclusion Criteria) and Section 4.2 (Exclusion Criteria) for information 
regarding contraception requirements. 

Refer to Section 8 (Prestudy and Concomitant Therapy) and Attachment 1 (Prohibited 
Concomitant Medications for Intranasal Study Medication) for further information on 
prohibited therapies.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
100
Status: Approved, Date: 6 July 2016

A positive urine drug screen for use of phencyclidine, or cocaine from Day 1 of the 
induction phase through the final visit in the final treatment phase (open-label induction, 
optimization, or maintenance phase) will lead to discontinuation.

Subjects must abstain from using alcohol within 24 hours before and after each intranasal 
treatment session. If a subject appears intoxicated, dosing should not occur (delayed per the 
permitted visit window; see the Time and Events Schedule).

On all intranasal study drug dosing days, all subjects must remain at the clinical study site 
until study procedures have been completed and the subject is ready for discharge and 
should be accompanied by a responsible adult when released from the clinical study site. 
Subjects must not drive a car or work with machines for 24 hours after study drug dosing.

Electroconvulsive therapy (ECT), deep brain stimulation (DBS), transcranial magnetic 
stimulation (TMS), and vagal nerve stimulation (VNS) are prohibited from study entry 
through 
the 
end 
of 
the 
last 
treatment 
phase 
(open-label 
induction, 
or 
optimization/maintenance phase) 

Subjects receiving psychotherapy (including cognitive behavioral therapy; CBT) can 
continue receiving psychotherapy. New psychotherapy is allowed during this study. Any 
change in existing therapy or new therapy must be documented on the concomitant therapies 
form.

Subjects who were taking benzodiazepines (at dosages equal to or less than the equivalent of 
6 mg/day of lorazepam) and/or permitted non-benzodiazepine sleep medications (eg, 
zolpidem, zaleplon) during the screening phase can continue these medications during the 
study. No dose increases beyond the equivalent of 6 mg/day lorazepam or new 
benzodiazepine medications are permitted during the study, with the exception of the use of 
permitted benzodiazepine rescue medication. Benzodiazepines and non-benzodiazepine 
sleeping medication (e.g., zolpidem, zaleplon, eszopiclone, and ramelteon) are prohibited 
within 12 hours prior to the start of each intranasal treatment session or cognition testing.
5.
TREATMENT ALLOCATION AND BLINDING
Treatment Allocation
There will be no randomization for subjects enrolled in this study. All direct-entry subjects who 
meet the entry criteria will start intranasal esketamine treatment as well as newly assigned oral 
antidepressant medication on Day 1 of the open-label induction phase. Transferred-entry 
non-responder subjects will join this study from the induction phase and will receive intranasal 
esketamine in open-label manner, and continue the same oral antidepressant treatment that they 
started in the double-blind induction phase of ESKETINTRD3005 study. Transferred-entry 
responder subjects will join this study from the optimization/maintenance phase and will receive 
intranasal esketamine in open-label manner, and continue the same oral antidepressant treatment 
(at the same dose) that they were taking at end of the double-blind induction phase of 
ESKETINTRD3005 study. The details of treatment for direct-entry subjects and transferred-
entry non-responder subjects are included in Section 6.1.1.and treatment for transferred-entry
responder subjects are included in Section 6.1.2.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
101
Status: Approved, Date: 6 July 2016
Blinding
Blinding procedures will not be applicable for this study. All the subjects will self-administer 
intranasal esketamine and an oral antidepressant in an open label manner. 
The blind of intranasal treatment (from ESKETINTRD3005 study) will not be broken. 
6.
DOSAGE AND ADMINISTRATION
6.1.
Intranasal Study Drug
On all intranasal treatment days, a site staff member with recent training in cardiopulmonary 
resuscitation (eg, Basic Life Support course or equivalent course) that is up to date per local 
regulations must be present with the subject during the intranasal treatment session and the 
postdose observation period. Subjects must remain at the site until study procedures have been 
completed and the subject is ready for discharge. At the time of discharge, subjects should be 
accompanied by a responsible adult when released from the clinical site. Subjects must not drive 
a car or work with machines for 24 hours after receiving study drug.
Instructions for use documents (subject and healthcare provider versions) for intranasal study 
drug administration will be provided as separate documents. Details regarding study drug 
administration will be recorded in the source documents and the electronic case report form 
(eCRF).

Prior to the first intranasal dose on Day 1, direct-entry subjects will practice spraying (into 
the air, not intranasally) a demonstration intranasal device that is filled with a placebo 
solution.

All subjects will self-administer the intranasal study drug at treatment sessions at the study 
site. Intranasal treatment sessions cannot be given on consecutive days.

After Day 1, all dosing decisions are to be determined by the investigator based on efficacy 
and tolerability.
Food will be restricted for at least 2 hours before each administration of study drug. Drinking of 
any fluids will be restricted for at least 30 minutes before the first nasal spray.
If the subject has nasal congestion on the dosing day an intranasal decongestant may be used to 
reduce congestion, but it cannot be used within 1 hour prior to intranasal study drug dosing.
On all intranasal dosing days, subjects must remain at the site until study procedures have been 
completed and the subject is ready for discharge and should be accompanied by a responsible 
adult when released from the clinical site. Subjects must not drive a car or work with machines 
for 24 hours after receiving intranasal study drug.
Guidance for Blood Pressure Monitoring on Intranasal Treatment Session Days (Subjects 
<65 years of age)
Given the potential for treatment emergent transient elevation in systolic and diastolic blood 
pressure, the following guidance should be followed on intranasal dosing days:
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
102
Status: Approved, Date: 6 July 2016

If subsequent to fulfilling inclusion and exclusion criteria on Day 1 (ie, applicable for all 
other treatment session days after Day 1), a subject’s pre-dose systolic blood pressure (SBP)
is ˃140 mmHg and/or diastolic blood pressure (DBP) is ˃90 mm Hg, it is recommended to 
repeat the blood pressure measurement after subject rests in sitting or recumbent position. If 
after rest and repeated measurements pre-dose SBP is ˃140 mmHg and/or DBP is
˃90 mm Hg, then dosing should be postponed and the subject scheduled to return on the 
following day or within the given visit window. If the blood pressure elevation still persists 
on the next visit, the subject will be scheduled for a consultation by cardiologist, other 
specialist or primary care physician (PCP) prior to further dosing.

If at any post-dose time point on the dosing day the SBP is 180 mmHg but <200 mmHg 
and/or the DBP is 110 mmHg but <120 mmHg, further intranasal dosing should be 
interrupted and cardiologist, other specialist, or primary care physician for a follow-up
assessment.
-
After the assessment by cardiologist, other specialist or primary care physician, if 
recommended by the referring doctor and considered appropriate according to the clinical 
judgment for the subject to continue in the study, the subject may continue with 
intranasal dosing provided the pre-dose blood pressure at the next scheduled visit is 
within the acceptable range (see bullet above).

If at any post-dose time point on the dosing day the SBP is 200 mmHg and/or the DBP is 
120 mmHg, the subject must discontinue from further dosing and be referred for 
cardiologist, other specialist or primary care physician for a follow up assessment.
During the open-label induction phase, at 1.5 hours postdose, if the SBP is 160 mmHg and/or 
the DBP 100 mmHg, assessments should continue every 30 minutes until:

the blood pressure is <160 mmHg SBP and <100 mmHg DBP, or  

in the investigator’s clinical judgment, the subject is clinically stable and can be discharged 
from the study site, or

the subject is referred for appropriate medical care if clinically indicated.

If the blood pressure remains ≥180 mmHg SBP and/or ≥110 mmHg DBP, 2 hours after 
dosing, the subject should be referred for immediate medical treatment.
Guidance for Blood Pressure Monitoring on Intranasal Treatment Session Days 
(Subjects ≥65 years of age)
Given the potential for treatment emergent transient elevation in systolic and diastolic blood 
pressure, the following guidance should be followed on intranasal dosing days:

Prior to any dose escalation, subjects must have had a post-dose blood pressure, on the prior 
intranasal dosing day, of <180 mmHg systolic and <100 mm Hg diastolic blood pressure.

If subsequent to fulfilling the inclusion and exclusion criteria on Day 1 (ie, applicable for all 
other intranasal treatment session days after Day 1), a subjects pre-dose SBP is ˃150 mmHg 
and/or DBP is ˃90 mmHg, it is recommended to repeat the blood pressure measurement 
after subject rests in sitting or recumbent position. If after rest and repeated measurements, 
pre-dose SBP is ˃150 mmHg and/or DBP is ˃90 mmHg, then dosing should be postponed 
and the subject scheduled to return on the following day or within the given visit window. If 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
103
Status: Approved, Date: 6 July 2016
the blood pressure elevation still persists on the next visit, the subject will be scheduled for a 
consultation by cardiologist, other specialist, or a primary care physician, prior to further 
dosing.

If at any postdose time point on the dosing day the SBP is 180 mmHg but <190 mmHg 
and/or the DBP is 100 mmHg but <110 mmHg, further intranasal dosing should be
interrupted and the subject should be referred to a cardiologist, other specialist, or primary 
care physician for a follow-up assessment.
After the assessment by a cardiologist, other specialist, or primary care physician, if 
recommended by the referring doctor and considered appropriate according to the clinical 
judgment for the subject to continue in the study, the subject may continue with intranasal dosing 
if the pre-dose blood pressure at the next scheduled visit is within the acceptable range (see 
bullet above).

If at any postdose time point on the dosing day the SBP is 190 mmHg and/or the DBP is 
110 mmHg, the subject must discontinue from further dosing and be referred to a 
cardiologist, other specialist, or primary care physician for a follow-up assessment.
During the open-label induction phase, at 1.5 hours postdose, if the SBP is 160 mmHg 
and/or the DBP 100 mmHg, assessments should continue every 30 minutes until:

the blood pressure is <160 mmHg SBP and <100 mmHg DBP, or 

in the investigator’s clinical judgment, the subject is clinically stable and can be discharged 
from the study site, or

the subject is referred for appropriate medical care, if clinically indicated.

If the blood pressure remains ≥180 mmHg SBP and/or ≥110 mmHg DBP, 2 hours after 
dosing, the subject should be referred for immediate medical treatment.
6.1.1.
Open-label Induction Phase
This phase is only for direct-entry and transferred-entry non-responder subjects. All subjects will 
self-administer open-label intranasal esketamine twice a week for 4 weeks as a flexible dose 
regimen at the study site. 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
104
Status: Approved, Date: 6 July 2016
For direct-entry subjects <65 years, the dose titration of intranasal esketamine is described in 
Table 3:
Table 3:
Open-label Induction Phase Dose Titration of Intranasal Esketamine for Direct-entry Subjects 
<65 Years
Day 
Dose
Dose Titration Guidance
Day 1
56 mg
Day 4
56 or 84 mg
The dose may be increased to 84 mg or remain at 56 mg, as 
determined by the investigator based on efficacy and tolerability
Day 8
56 or 84 mg
The dose may be increased to 84 mg (if Day 4 dose was 56 mg), 
remain the same as Day 4, or be reduced to 56 mg (if Day 4 dose 
was 84 mg), as determined by the investigator based on efficacy 
and tolerability
Day 11
56 or 84 mg
The dose may be increased to 84 mg (if Day 8 dose was 56 mg), 
remain the same as on Day 8, or be reduced to 56 mg (if Day 8 
dose was 84 mg), as determined by the investigator based on 
efficacy and tolerability.
Day 15
56 or 84 mg
A dose reduction from 84 mg to 56 mg is permitted, if required 
for tolerability. If the dose is 56 mg on Day 11, no dose increase 
is permitted on Day 15.
Day 18, 22, 25
56 or 84 mg
No dose increase from 56 mg is permitted beyond Day 15. If 
needed for tolerability, one additional dose down-titration from 
84 mg to 56 mg is permitted from Day 15 until Day 25.
For direct-entry subjects <65 years, the intranasal treatment will be administered as described 
in Table 4. 
Table 4:
Open-Label Induction Phase Intranasal Treatment Sessions for Subjects <65 Years
Intranasal Treatment
Time of Administrationa
0a
5 minutes
10 minutes
Intranasal Deviceb
First
Second
Third
Esketamine 56 mg
1 spray of esketamine
to each nostril
1 spray of esketamine
to each nostril
No device required.
Esketamine 84 mg
1 spray of esketamine
to each nostril
1 spray of esketamine
to each nostril
1 spray of esketamine
to each nostril
a
Time 0 is defined as the time of administration of the first intranasal spray to one nostril from the first intranasal 
device. 
b
One device will be used at each time point. Each intranasal device contains 2 sprays. The intranasal devices 
containing esketamine deliver 14 mg per spray, for a total of 28 mg per individual device (ie, 2 sprays).
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
105
Status: Approved, Date: 6 July 2016
For direct-entry and transferred-entry non-responder subjects 65 years, the dose titration 
of intranasal esketamine is described in Table 5.
Table 5:
Open-Label Induction Phase Dose Titration of Intranasal Esketamine for Direct-entry and 
Transferred-entry Non-responder Subjects ≥65 Years
Day 
Dose
Dose Titration Guidance*
Day 1
28 mg
Day 4
28 or 56 mg
The dose may remain at 28mg or be increased to 56mg , as 
determined by the investigator based on efficacy and tolerability
Day 8, 11, 15
28, 56 or 84 mg
The dose may be maintained, or increased or reduced by 28mg 
from the previous dosing session, as determined by the 
investigator based on efficacy and tolerability. .
Days 18, 22 and 25
28, 56 or 84 mg 
No dose increase is permitted beyond Day 15. If needed for 
tolerability, a dose reduction by 28 mg from the previous dose is 
permitted on Days 18, 22, and 25.
*
Dose changes are determined by the investigator based on efficacy and tolerability and in accordance with blood 
pressure guidelines.
From Day 8 to Day 15, inclusive, for subjects who have had a prior down titration from a higher 
dose, a dose increase by 28 mg is allowed based on clinical judgment. Instructions for intranasal 
dosing for subjects ≥65 years:

Prior to intranasal dosing, subjects must have a blood pressure ≤150/90 mm Hg

Prior to any dose escalation, subjects ≥65 years must have had a post-dose blood pressure, 
on the prior intranasal dosing day, of <180 mmHg systolic and <100 mm Hg diastolic blood 
pressure.
For direct-entry and transferred-entry non-responder subjects 65 years, the intranasal 
treatment sessions will be administered as described in Table 6.
Table 6:
Open-Label Induction Phase Intranasal Treatment Sessions for Subjects ≥65 Years
Intranasal Treatment
Time of Intranasal Device Administration
0a
5 minutes
10 minutes
Intranasal Deviceb
First
Second
Third 
Esketamine 28 mg
1 spray of esketamine to 
each nostril
No device required
No device required
Esketamine 56 mg
1 spray of esketamine to 
each nostril
1 spray of esketamine to 
each nostril
No device required
Esketamine 84 mg
1 spray of esketamine to 
each nostril
1 spray of esketamine to 
each nostril
1 spray of esketamine to 
each nostril
a
Time 0 is defined as the time of administration of the first intranasal spray to one nostril from the first intranasal 
device. 
b
One device will be used at each time point. Each individual intranasal device contains 2 sprays. The intranasal 
devices containing esketamine deliver 14 mg per spray, for a total of 28 mg per individual device (ie, 2 sprays).
6.1.2.
Optimization/Maintenance Phase
Subjects who meet the response criteria at the end of the 4-week open-label induction phase of 
ESKETINTRD3004 study will participate in the optimization/maintenance phase. Subjects will 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
106
Status: Approved, Date: 6 July 2016
receive weekly treatment sessions
of intranasal esketamine for the first 4 weeks of 
optimization/maintenance phase at the same dose from the open-label induction phase.
Subjects entering the optimization/maintenance phase following the open-label induction phase 
may have the dose down titrated during this phase for tolerability.
Eligible transferred-entry responder subjects from ESKETINTRD3005 study will join the study 
at this phase. The first intranasal treatment session for these subjects will begin on Study Day 32 
of the optimization/maintenance phase. For the first 4 weeks of optimization/maintenance phase, 
these subjects will receive weekly treatment sessions with open-label intranasal esketamine as 
described in Table 7 below: 
Table 7:
Optimization/Maintenance Phase Dose Titration of Intranasal Esketamine for 
Transferred-entry Responder Subjects
Week 
Dose
Dose Titration Guidance
Week 5 
28 mg
Week 6 
28 or 56 mg
The dose may remain at 28mg or increased to 
56mg as determined by the investigator based 
on efficacy and tolerability
Week 7, 8 
28, 56 or 84 mg
The dose maybe maintained, increased or 
reduced by 28mg from the previous dosing 
session
For those who have had a prior down titration 
from a higher dose, a dose increase by 28 mg 
is allowed based on clinical judgment. 
Week 9 through end of phase
28, 56 or 84 mg
No dose increase is permitted after week 8. If 
needed for tolerability, a dose reduction by 
28mg from the previous dose is permitted 
from Week 9 through the end of the phase.
Instructions for intranasal dosing for subjects ≥65 years:

After week 5 all dosing decisions are to be determined by the investigator based on efficacy 
and tolerability.

Prior to intranasal dosing, subjects must have a blood pressure ≤150/90 mm Hg

Prior to any dose escalation, subjects ≥65 years must have had a post-dose blood pressure, 
on the prior intranasal dosing day, of <180 mmHg systolic and <100 mm Hg diastolic blood 
pressure.
Intranasal Treatment Session Frequency
As described above, for all subjects, the frequency of intranasal treatment sessions will be 
reduced from the twice-weekly frequency used in the induction phase to weekly for the first 
4 weeks of the optimization/maintenance phase (Week 5 to Week 8). 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
107
Status: Approved, Date: 6 July 2016
During the optimization/maintenance phase, the MADRS will be performed weekly for all 
subjects either at the clinic visit (prior to intranasal treatment session) or remotely during a 
telephone contact visit (if no intranasal treatment session planned that week). After the first 
4 weeks of this phase (ie, starting from Week 8), the intranasal treatment session frequency will 
be adjusted (if applicable) at fixed, 4-week intervals (starting at Week 8, and subsequently at 
Weeks. 12, 16, 20, 24, 28, 32, 36, 40, 44, 48), based on the guidance below.
Week 8:

If the MADRS total score is 12:
The esketamine treatment session frequency will be changed to every other week. (ie, the next 
intranasal treatment session after Week 8 will be at Week 10).

If the MADRS total score is >12:
There will be no change in esketamine treatment session frequency.

If the MADRS assessment at Week 8 is missed, the last MADRS total score available prior 
to Week 8 will be used to determine if a change in treatment session frequency is indicated 
at Week 8. In this case:
If the MADRS total score is ≤12, the subject will reduce the frequency to receive intranasal 
treatment sessions every other week for the next 4 weeks (ie, next treatment sessions will be at 
Weeks 10 and 12).
If the MADRS total score is >12, the subject will continue to receive weekly intranasal treatment 
sessions and no further change to the treatment session frequency is permitted for the next 
4 weeks.
From Week 12 onwards and at subsequent visits every 4 weeks:

If the MADRS total score is 12:
If esketamine treatment session frequency is weekly, the frequency will be changed to every 
other week. (.e.g. If this is Week 12, the next intranasal treatment session after Week 12 will be 
at Week 14).
If esketamine treatment session frequency is every other week, there will be no change in 
frequency.

If the MADRS total score is >12:
If esketamine treatment session frequency is weekly, there will be no change in frequency.
If esketamine treatment session frequency is every other week, the frequency will be changed to 
weekly.

If the MADRS is missed at that week, the last MADRS total score available prior to that 
week will be used to determine if a change in treatment session frequency is indicated at that 
week:
If the MADRS total score is 12:
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
108
Status: Approved, Date: 6 July 2016
o
If esketamine treatment session frequency is weekly, the frequency will be changed 
to every other week. (eg, If this is Week 12, the next intranasal treatment session 
after Week 12 will be at Week 14).
o
If esketamine treatment session frequency is every other week, there will be no 
change in frequency.
If the MADRS total score is >12:
o
If esketamine treatment session frequency is weekly, there will be no change in 
frequency.
o
If esketamine treatment session frequency is every other week, the frequency will 
be changed to weekly.
A maximum of 3 changes in intranasal treatment session frequency from weekly to every other 
week is permitted during the optimization/maintenance phase. After this time, if a given subject 
is unable to sustain improvement on every other week treatment sessions, they will remain on a 
weekly frequency for the remainder of the study.
Table 8
describes the administration of intranasal study drug from Week 6 of the 
optimization/maintenance phase for all subjects.
Table 8:
Intranasal Esketamine Treatment Sessions: Optimization/Maintenance Phase
Time of Administration
0a
5 minutes
10 minutes
Intranasal Deviceb
First
Second
Third
Esketamine 28 mgc
1 spray of esketamine to 
each nostril
No device required
No device required
Esketamine 56 mg
1 spray of esketamine
to each nostril
1 spray of esketamine
to each nostril
No device required.
Esketamine 84 mg
1 spray of esketamine
to each nostril
1 spray of esketamine
to each nostril
1 spray of esketamine
to each nostril
a
Time 0 is defined as the time of administration of the first intranasal spray to one nostril from the first intranasal 
device.
b
One device will be used at each designated time point. Each intranasal device contains 2 sprays. The intranasal 
devices containing esketamine deliver 14 mg per spray, for a total of 28 mg per individual device (ie, 2 sprays).
c
28 mg dose will be administered only for transferred-entry responder subjects, at Week 5.
If a subject misses >4 consecutive intranasal treatment sessions and/or ≥4 MADRS consecutive 
assessments in the optimization/maintenance phase, the subject will be discontinued from the 
study, complete the early withdrawal visit, and proceed to the follow-up phase.
If a subject misses a study visit (clinic or telephone visit) in the optimization/maintenance phase 
without notifying the site of the reason, the site personnel will attempt to contact the subject to 
confirm if the subject is still interested in participating in the study and if so, to schedule their 
next visit. During this contact the information on adverse events and concomitant medication 
will be collected.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
109
Status: Approved, Date: 6 July 2016
6.1.3.
Follow-up Phase
No intranasal study medication will be administered during this phase, but to facilitate 
maintenance of clinical benefit the oral antidepressant medication should continue if clinically 
indicated.  
6.2.
Oral Antidepressants
Study-site personnel will instruct subjects on how to take/use and store the oral antidepressants 
supplied during this study for at-home use. A subject diary to capture oral antidepressant study 
medication use will be provided.
If the oral antidepressant is taken in the morning on a dosing day, intranasal dosing may proceed 
provided acceptable blood pressure based on pre-dose blood pressure guidance.
On intranasal treatment sessions days, it is recommended that oral antidepressant treatment not 
be taken until at least 3 hours after the intranasal treatment session.
6.2.1.
Screening Phase for Direct-entry Subjects
Subjects will be eligible for screening regardless of whether or not they are currently taking oral 
antidepressant medication(s) at screening visit. Subjects taking oral antidepressant medication(s) 
at screening will discontinue their current antidepressant mediations(s) prior to the start of the 
induction phase. If clinically indicated, the antidepressant medication(s) can be either tapered 
and discontinued during the screening period, or discontinued and switched directly to the new 
oral antidepressant on Day 1 of the open-label induction phase, per clinical judgment. 
Subjects currently not taking any oral antidepressant medication(s) at screening will start 1 of the 
4 oral antidepressant medication(s) on Day 1of the induction phase.
6.2.2.
Open-label Induction and Optimization/Maintenance Phases
Direct-entry subjects: Starting on Study Day 1 of the open-label induction phase, a new, open-
label oral antidepressant treatment will be initiated and will be continued during the induction 
and optimization/maintenance phases of this study. The oral antidepressant will be 1 of 4 oral 
antidepressant medications (duloxetine, escitalopram, sertraline, or venlafaxine XR). The 
antidepressant medication will be assigned by the investigator and will be one that the subject 
has not previously had a nonresponse to in the current episode (per MGH-ATRQ), has not been 
previously intolerant to (lifetime), and that is available in the participating country.
Dosing of the new oral antidepressant will begin on Day 1 and will follow the local prescribing 
information for the respective product, with a forced titration to the maximally tolerated dose. A 
protocol-specified titration schedule is provided in Attachment 3 of the protocol. As subjects 
may not be able to tolerate the higher doses of the oral antidepressant during the induction phase, 
a down titration of the dose is permitted based on clinician’s judgment.
Transferred-entry subjects (responder and non-responder subjects): These subjects will
continue taking the same oral antidepressant medication(s) (duloxetine, escitalopram, sertraline, 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
110
Status: Approved, Date: 6 July 2016
or venlafaxine XR) which they were taking at the end of the double-blind induction phase of 
ESKETINTRD3005
study, 
at 
the 
same 
dose, 
during 
their 
participation 
in 
the 
optimization/maintenance phase of this ESKETINTRD3004 study.
6.2.3.
Follow-up Phase
At the start of the follow-up phase, further clinical/standard of care for the treatment of 
depression will be arranged by the study investigator and/or the subject’s treating physician. 
No intranasal esketamine will be administered during this phase. 
All subjects will be provided with an additional 4-week supply of the oral antidepressant 
medication at the last clinic visit prior to entering the follow-up phase, to ensure there is no 
interruption of antidepressant therapy during the transition to further clinical/standard of care. 
The decision to continue the oral antidepressant in this phase will be at the discretion of the 
investigator, however, in order to better assess potential withdrawal symptoms from intranasal 
study drug and to facilitate maintenance of clinical benefit, it is strongly recommended that the 
oral antidepressant be continued for the duration of the follow-up phase unless determined as not 
clinically appropriate.
7.
TREATMENT COMPLIANCE
All doses of intranasal study drug will be self-administered by the subjects at the investigative 
site under the direct supervision of the investigator or designee, and will be recorded.
Subjects will receive instructions on compliance with the oral antidepressant treatment. During 
the course of the study, the investigator or designated study-site personnel will be responsible for 
providing additional instruction to re-educate any subject to ensure compliance with taking the 
oral antidepressant. A subject diary will be provided to capture oral antidepressant study 
medication use. 
The investigator or designated study-site personnel will maintain a log of all intranasal study 
drug and oral antidepressant medication dispensed and returned. Drug supplies for each subject 
will be inventoried and accounted for throughout the study (see Section 14.5 Drug 
Accountability).
Antidepressant treatment compliance will be assessed by performing pill counts (ie, compliance 
check) and drug accountability.
8.
PRESTUDY AND CONCOMITANT THERAPY
Prestudy non-antidepressants therapies administered up to 30 days before the start of the 
screening phase must be recorded at the start of this phase.
All antidepressant treatment(s), including adjunctive treatment for MDD, taken during the 
current depressive episode (ie, including those taken more than 30 days prior to the start of the 
screening phase) will be recorded at the start of the screening phase. In addition, information will 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
111
Status: Approved, Date: 6 July 2016
also be obtained regarding any history of intolerance to any of the 4 antidepressant choices (ie,
duloxetine, venlafaxine XR, escitalopram, sertraline). Antidepressant treatments which are not 
listed on the MGH-ATRQ, but were used, or are currently being used as antidepressant treatment 
in the current depressive episode, must be recorded under ‘Concomitant Medication’ in the 
eCRF.
Concomitant therapies must be recorded throughout the study beginning with signing of the 
informed consent and continuing up to the last visit. Information on concomitant therapies 
should also be obtained beyond this time only in conjunction with new or worsening adverse 
events until resolution of the event. 
Subjects should continue to take their permitted concomitant medications (eg, antihypertensive 
medications) at their regular schedule; however, restrictions as outlined in Section 4.3 and 
Attachment 1 should be taken into account. Of note, if a subject routinely takes his/her oral 
antihypertensive medications in the morning on dosing days, the morning dose should be taken 
prior to intranasal esketamine on intranasal dosing.
Subjects receiving psychotherapy (including cognitive behavioral therapy; CBT), can continue 
receiving psychotherapy. New psychotherapy is allowed during the study. Any change in 
existing therapy or new therapy must be documented on the concomitant therapies form.
All therapies (prescription or over-the-counter medications, including vaccines, vitamins, herbal
supplements; non-pharmacologic therapies such as psychotherapy electrical stimulation, 
acupuncture, special diets, and exercise regimens) different from the study drug must be recorded 
in the eCRF. Modification of an effective preexisting therapy should not be made for the explicit 
purpose of entering a subject into the study, unless permitted by protocol (eg, adjustment of 
blood pressure medications).
Rescue Medications
Rescue medications will not be supplied by the sponsor. In case of treatment-emergent adverse 
events that cannot be resolved by stopping further administration of intranasal esketamine, the 
following rescue medications may be considered:

For agitation or anxiety: As required, midazolam (maximum dose 2.5 mg orally or IM) or 
short acting benzodiazepine

For nausea: As required, ondansetron 8 mg sublingually, metoclopramide (10 mg orally or 
IV or IM) or dimenhydrinate (25 to 50 mg, IV or IM)

Unless clinically indicated, it is recommended that transient increases in blood pressure not 
be treated, as the blood pressure typically returns to predose values in 2 hours. The effect of 
any treatment may result in hypotension.
Prohibited Medications
A list of prohibited medications is provided in Attachment 1 as general guidance for the 
investigator (but is not all inclusive).
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
112
Status: Approved, Date: 6 July 2016
The sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapies are administered.
9.
STUDY EVALUATIONS
9.1.
Study Procedures
9.1.1.
Overview
The Time and Events Schedules summarize the frequency and timing of efficacy, biomarker, 
pharmacogenomic, health economic, medical resource utilization and safety measurements 
applicable to this study.
With the exception of postdose assessments, visit-specific subject-reported outcomes
assessments should be conducted/completed before any tests, procedures, or other consultations 
for that visit to prevent influencing subject perceptions. A recommended order of study 
procedures will be provided to sites as a separate document.
Actual dates and times of assessments will be recorded in the source documentation and eCRF.
The approximate total blood volume to be collected from each subject will depend on whether a 
subject is a direct-entry subject, or transferred-entry responder or transferred-entry 
non-responder subject, from a short-term study (ESKETINTRD3005), and on sex/gender (since 
women will have pregnancy tests). Approximate calculations indicate that the maximum amount 
of blood drawn from each subject in this study during a full year of study participation will be 
approximately 139 mL (Table 9) and will not exceed the amount of blood donated by a volunteer 
for a single charitable blood donation in 1 day (about 500 mL). Repeat or unscheduled samples 
may be taken for safety reasons or for technical issues with the samples.
Additional serum or urine pregnancy tests may be performed, as determined necessary by the 
investigator or required by local regulation, to establish the absence of pregnancy at any time 
during the subject's participation in the study.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
113
Status: Approved, Date: 6 July 2016
Table 9:
Volume of Blood to be Collected From Each Subject 
Phase
Type of Sample
Volume per 
Sample(s), mL
Number of Samples 
per Subject
Total Volume of 
Blood (mL)a
Screening Phase
TSH, 
3.5
1
3.5
HbA1C
2
1
2
Hematology 
2
1
2
Serum chemistryb
5
1
5
Biomarkers (protein)c
10
1
10
Biomarker (DNA)
6
1
6
Tricyclic Antidepressant Blood leveld
Free thyroxine (FT4)e
6
3.5
1
1
6
3.5
Open-label Induction Phase
Hematology 
2
2
4
Serum Chemistry
2.5
2
5
Biomarkers: Protein (v 2.1, v 2.3, v 2.9)
10
3
30
Biomarkers: DNA
6
1
6
Optimization/Maintenance Phase
Hematology 
2
7
14
Serum Chemistry
2.5
7
17.5
Biomarkers: Protein (v 3.4)
10
1
10
Follow-up Phase
Hematology
2
1
2
Serum Chemistry
2.5
1
2.5
Biomarkers: Protein
10
1
10
Approximate volume of blood collected during the study
139 mL
Abbreviations: DNA= deoxyribonucleic acid; TSH=thyroid-stimulating hormone, EW-O/M=early withdrawal –
optimization/stabilization phase
a
Calculated as number of samples multiplied by amount of blood per sample.
b 
Serum chemistry includes serum -hCG pregnancy tests (for women of childbearing potential), and lipid panel.
d
For specific tricyclic antidepressants which are being taken at a dose below the MGH-ATRQ minimum 
therapeutic dose, a blood level that is within the therapeutic (antidepressant) range, is acceptable to establish 
the adequacy of the antidepressant treatment.
e
For any subject (regardless of thyroid history), if the TSH value is out of normal range, a free thyroxine (FT4) 
will be conducted.
Note: 10 mL of blood for protein biomarkers represents the volume of several tubes combined
Note: An indwelling IV cannula may be used for blood sample collection.
Note: Repeat or unscheduled samples may be taken for safety reasons or technical issues with the samples.
9.1.2.
Screening Phase
This phase is for direct-entry subjects only.
Prior to conducting any study procedure, the investigator (or designated study personnel) will 
review and explain the written ICF to each direct-entry subject. After signing the ICF, subjects 
who are 18 years of age (or older if the minimum legal age of consent in the country in which the 
study is taking place is >18 years) will begin to be screened to determine eligibility for study 
participation (please refer to the study entry criteria listed in Section 4). 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
114
Status: Approved, Date: 6 July 2016
Subjects must meet DSM-5 diagnostic criteria for single (if a single episode, duration of episode 
must be 2 years) or recurrent MDD, without psychotic features, based upon clinical assessment 
and confirmed by the MINI. 
At the start of this phase, subjects must have had nonresponse to 2 oral antidepressant 
treatments in the current episode of depression, as assessed by the MGH-ATRQ and confirmed 
by documented records (eg, medical/pharmacy/prescription records or a letter from a treating 
physician, etc,). 
Subjects will be screened regardless of whether or not they are currently taking oral 
antidepressant medication(s). Subjects taking antidepressant medication(s) during screening 
phase will discontinue their current antidepressant medication(s) prior to the start of the 
induction phase.
Benzodiazepines or nonbenzodiazepine sleep medications will be allowed to continue but will 
have specific restrictions regarding the administration time relative to the intranasal treatment 
sessions (see Attachment 1). 
Since all eligible subjects will be starting a new oral antidepressant during the open-label 
induction phase, no washout or drug-free period is required after discontinuing the current 
antidepressant treatment; however, if clinically indicated, the antidepressant treatment can be 
tapered and discontinued during the screening phase.
All other subjects who do not participate in the open-label induction phase will end study 
participation at this time. No further study visits or follow-up is required.
9.1.3.
Open-label Induction Phase
This phase is for direct-entry and transferred-entry non-responder subjects.
Transferred-entry non-responder subjects will join this study starting from Day 1 of the induction 
phase. Prior to conducting any study procedure for ESKETINTRD3004, the investigator (or 
designated study personnel) will review and explain the written ICF to each transferred-entry 
non-responder subject. The ICF will be signed at the start of this phase (after completion of 
Day 28 study procedures of the double-blind induction phase for ESKETINTRD3005). After 
signing the ICF, transferred-entry subjects will be evaluated to determine eligibility for study 
participation. 
During this phase, all subjects will self-administer open-label treatment with intranasal 
esketamine treatment twice a week for 4 weeks as a flexible dose regimen. Direct-entry subjects 
will initiate a new, open-label oral antidepressant. Transferred-entry subjects will continue the 
same oral antidepressant as they received in the induction phase of ESKETINTRD3005. Refer to 
Section 6, Dosage and Administration for details regarding intranasal and oral study medication.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
115
Status: Approved, Date: 6 July 2016
At the end of the open-label induction phase of ESKETINTRD3004, responder subjects (defined 
as ≥50% reduction in the MADRS total score from baseline [Day 1]) will enter the 
optimization/maintenance phase. 
Refer to Section 9.1.6 for information regarding early withdrawal subjects and subjects that are 
currently in this phase at the time the study is terminated. For direct-entry and transferred-entry 
non-responder subjects, results for all assessments performed on Day 28 of the induction phase 
(Visit 2.9 of ESKETINTRD3005 study) will serve as the baseline values for the 
optimization/maintenance phase and will not be repeated as part of Visit 3.1 in the current study.
9.1.4.
Optimization/Maintenance Phase
Transferred-entry responder subjects may participate in this study only if it is clinically 
appropriate in the opinion of the investigator. 
Prior to conducting any study procedure for ESKETINTRD3004, the investigator (or designated 
study personnel) will review and explain the written ICF to each transferred-entry responder 
subject. The ICF will be signed at the start of this phase (after completion of Day 28 study 
procedures of the double-blind induction phase for ESKETINTRD3005). After signing the ICF, 
transferred-entry subjects will be evaluated to determine eligibility for study participation.
The intranasal treatment session frequency will be reduced from that in the induction phase 
(twice weekly) to weekly for the first 4 weeks of the optimization/maintenance phase. After the 
first 4 weeks, the frequency of intranasal treatment sessions will be individualized to once 
weekly or once every other week based on the severity of depression, as assessed by the 
MADRS total score. All subjects will continue taking the same oral antidepressant treatment that 
was initiated in their respective induction phases (for direct-entry subjects, the oral 
antidepressant initiated in the open-label induction phase of the ESKETINTRD3004 study; and 
for transferred entry responder and non-responder subjects, the oral antidepressant initiated in the 
double-blind induction phase of ESKETINTRD3005 study, unless poorly tolerated, in which 
case the oral antidepressant may be discontinued after review with sponsor). Refer to Section 6
Dosing and Administration for further details regarding intranasal and oral antidepressant study 
medication.
Refer to Section 9.1.6 for information regarding early withdrawal subjects and subjects that are 
currently in this phase at the time the study is terminated.
If a subject misses a study visit (clinic or telephone contact) in the optimization/maintenance 
phase without notifying the site of the reason, the site personnel will attempt to contact the 
subject to confirm if the subject is still interested in participating in the study and if so, to 
schedule their next visit. During this contact the information on adverse events and concomitant 
medication will be collected.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
116
Status: Approved, Date: 6 July 2016
9.1.5.
Follow-up Phase
This phase will include all subjects who have received at least 1 dose of intranasal study 
medication in this study. Follow-up visits will be performed at 1, 2 and 4 weeks after the last 
dose of intranasal study drug.
At the start of the follow-up phase, further clinical/standard of care for the treatment of 
depression will be arranged by the study investigator and/or the subject’s treating physician.
Refer to the Time and Events Schedule for a list of study evaluations that will be performed 
during the follow-up phase. 
No intranasal study medication will be administered during this phase. Subjects will be provided 
with an additional 4-week supply of their oral antidepressant medication, to ensure there is no 
interruption of oral antidepressant therapy during the transition to further clinical/standard of 
care. The decision to continue the oral antidepressant in this phase will be at the discretion of the 
investigator, however, in order to better assess potential withdrawal symptoms from intranasal 
study drug and to facilitate maintenance of clinical benefit, it is strongly recommended that the 
oral antidepressant be continued for the duration of the follow-up phase, unless determined as 
not clinically appropriate.
An open-label safety extension study, 54135419TRD3008, may be available (pending country 
and site approval) for eligible subjects participating in the ESKETINTRD3001 study. Please 
refer to the 54135419TRD3008 protocol for full details when available.
If information is obtained via telephone contact, written documentation of the communication 
must be available for review in the source documents. 
Investigators may contact the subject after study completion to obtain long-term follow-up 
information to determine the subject's safety or survival status (refer to Section 16.2.3, Informed 
Consent).
Any clinically significant abnormalities persisting at the end of the study will be followed by the 
investigator until resolution or until a clinically stable endpoint is reached. All adverse events 
and special reporting situations, whether serious or non-serious, will be reported until completion 
of the subject's last study-related procedure.
9.1.6.
Early Withdrawal or End of Optimization/Maintenance Phase Visit
Early Withdrawal
If a subject withdraws before the end of the open-label induction or optimization/maintenance 
phase for reasons other than withdrawal of consent, an early withdrawal visit should be 
conducted, followed by the follow-up phase. 
Subjects in the induction phase at the time of study termination, will be permitted to complete 
the phase, will have an early withdrawal visit conducted, followed by the follow up phase. 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
117
Status: Approved, Date: 6 July 2016
If the early withdrawal visit occurs on the same day as a scheduled visit, the early withdrawal 
visit can be performed on the same day and duplicate assessments are not required.
End of Optimization/Maintenance Phase
Subjects in the optimization/maintenance phase at the time of study termination, will have an 
End of Optimization/Maintenance Phase visit conducted, followed by the follow up phase. If the 
End of Optimization/Maintenance Phase visit occurs on the same day as a scheduled visit, the 
End of Optimization/Maintenance Phase visit can be performed on the same day and duplicate 
assessments are not required.
Further clinical/standard of care for the treatment of depression will be arranged by the study 
investigator and/or the subject’s treating physician. The study investigator and/or treating 
physician will determine whether or not the current oral antidepressant will continue.
Subjects will receive additional oral antidepressant medication, if applicable, and it will be 
recommended that they continue taking the oral antidepressant medication for the duration of the 
follow-up phase, unless determined as not clinically appropriate.
If a subject discontinues the follow-up phase prior to completion of all visits, an early withdrawal 
visit is not required.
9.2.
Safety 
9.2.1.
Safety Evaluations
Details regarding the Independent Data Monitoring Committee (IDMC) are provided in 
section 11.8.
Any clinically relevant changes occurring during the study must be recorded on the Adverse 
Event section of the eCRF.
Any clinically significant abnormalities persisting at the end of the study/early withdrawal will 
be followed by the investigator until resolution or until a clinically stable endpoint is reached. 
The study will include the following evaluations of safety and tolerability according to the time 
points provided in the Time and Events Schedules:
There may be instances where a subject has started a scheduled clinic visit in which an intranasal 
treatment session is planned, but due to predose vital sign measurements (eg, blood pressure 
value), a decision has been made to postpone/delay the intranasal treatment session within the 
visit window permitted per protocol. In such cases, all time points (including predose) of the 
following assessments must be repeated on the actual intranasal treatment session day: vital sign 
(ie, blood pressure, pulse, respiratory rate, and temperature), 12-lead ECG, C-SSRS (since last 
visit), MOAA/S, pulse oximetry, BPRS+, and CADSS.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
118
Status: Approved, Date: 6 July 2016
Adverse Events
Treatment-emergent adverse events (TEAE) will be assessed.
TEAEs of special interest will be examined separately grouped in the following categories: drug 
abuse, dependence and withdrawal (SMQ), increased blood pressure, increased heart rate, 
transient dizziness/vertigo; impaired cognition; anxiety and cystitis.
Adverse events will be reported by the subject (or, when appropriate, by a caregiver, surrogate, 
or the subject's legally acceptable representative) for the duration of the study. Adverse events 
will be followed by the investigator as specified in Section 12, Adverse Event Reporting.
Clinical Laboratory Tests
Blood samples for serum chemistry and hematology and urine samples for urinalysis will be 
collected. The investigator must review the laboratory report, document this review, and record 
any clinically relevant changes occurring during the study in the adverse event section of the 
eCRF. The laboratory reports must be filed with the source documents.
The use of local laboratories is allowed in cases where initiation of treatment or safety follow-up 
is time-critical and the central laboratory results are not expected to be available before the need 
to begin dosing or if actions need to be taken for safety reasons.
The following tests will be performed by the central laboratory, unless noted otherwise:

Hematology panel:
- hemoglobin
- white blood cell count with differential
- hematocrit
- platelet count
- red blood cell count

Serum chemistry panel:
- sodium
- gamma-glutamyltransferase
- potassium
- total bilirubin
- chloride
- alkaline phosphatase
- bicarbonate
- creatine phosphokinase 
- blood urea nitrogen 
- calcium
- creatinine
- phosphate
- glucose (only done if subject is fasted)
- albumin
- aspartate aminotransferase 
- total protein
- alanine aminotransferase 
- fasting lipid panel
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
119
Status: Approved, Date: 6 July 2016

Urinalysis:
Dipstick:
Sediment (if dipstick result is abnormal):
- specific gravity
- red blood cells
- pH
- white blood cells
- glucose
- epithelial cells
- protein
- crystals
- blood
- casts
- ketones
- bacteria
- bilirubin
- urobilinogen
- nitrite
- leukocyte esterase
If dipstick result is abnormal, flow cytometry or microscopy will be used to measure 
sediment. In case of discordance between the dipstick results and the flow cytometric
results, the sediment will be examined microscopically.
The following tests will be done at time points specified in the Time and Events Schedule:

Lipid panel: total cholesterol, low-density lipoprotein (LDL)-cholesterol, high-density 
lipoprotein (HDL)-cholesterol, and triglycerides

Serum and urine pregnancy testing (for women of childbearing potential only)

Urine drug screen: barbiturates, methadone, opiates, cocaine, cannabinoids (cannabinoids 
are only tested at Day 1 predose), phencyclidine, and amphetamine/methamphetamine

Alcohol breath test 

Thyroid-stimulating hormone (TSH)

Free thyroxine (FT4) if applicable (TSH is out of normal range)

Calculation of creatinine clearance

HbA1c

A serum follicle stimulating hormone (FSH) level test, only if required for documentation 
that a female subject is not of childbearing potential (refer to Inclusion Criteria No.8)
Single, 12-Lead Electrocardiogram (ECG)
During the collection of ECGs, subjects should be in a quiet setting without distractions (eg, 
television, cell phones). Subjects should rest in a supine position for at least 5 minutes before 
ECG collection and should refrain from talking or moving arms or legs. 
All ECG tracings will be sent to a central ECG laboratory. The ECGs will be read at the 
scheduled time points and summarized by a central ECG laboratory. The central ECG laboratory 
will send the sponsor an electronic copy of the data for inclusion in the clinical database. In 
addition, the investigator or sub-investigator is required to review all ECGs at the study visit to 
assess for any potential safety concerns or evidence of exclusionary conditions prior to dosing.
The subject must be discontinued at any time point after baseline (Day 1, predose), if:
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
120
Status: Approved, Date: 6 July 2016

QTcF change from baseline is ≥ 60 msec and QTcF > 480 msec, or 

QTCF > 500 msec.
Vital Signs (blood pressure, pulse/heart rate, temperature, and respiratory rate)
Blood pressure and pulse/heart rate measurements will be assessed supine with a completely 
automated device. Manual techniques will be used only if an automated device is not available.
Blood pressure and pulse/heart rate measurements should be preceded by at least 5 minutes of 
rest in a quiet setting without distractions (eg, television, cell phones).
For further details regarding blood pressure, please see Guidance for Blood Pressure Monitoring 
on Intranasal Dosing Days (Section 6.1).
Tympanic temperature is recommended.
An automated device will be used for measurement of respiratory rate.
Pulse Oximetry
Pulse oximetry will be used to measure arterial oxygen saturation. 
On each dosing day, the device will be attached to the finger, toe, or ear before the first nasal 
spray and then, after the first spray it will be monitored and documented at prespecified time
points. Any arterial oxygen saturation (SpO2) <93% should be confirmed by an additional 
measurement on another part of the body. 
On intranasal treatment session days, pulse oximetry will be recorded every 15 minutes from 
predose to t=1.5 hours postdose. If oxygen saturation levels are <93% at any time during the
1.5 hour postdose interval, pulse oximetry will be recorded every 5 minutes until levels return to 
93% or until the subject is referred for appropriate medical care, if clinically indicated.
Physical Examination, Height, Body Weight and Neck Circumference
Physical examinations, height, and body weight, will be performed/measured as per the Time 
and Events Schedule.
In addition body mass index (BMI) will be calculated and neck circumference measured as part 
of the information required for the STOP-Bang questionnaire, at screening.
Nasal Examinations 
Nasal examinations (including the upper respiratory tract/throat) will be conducted by a qualified 
healthcare practitioner. The objective of the examination at screening is to rule out any subjects 
with anatomical or medical conditions that may impede drug delivery or absorption. 
Subsequent examinations will consist of a visual inspection of the nostrils, nasal mucosa, and 
throat for nasal erythema, rhinorrhea, rhinitis, capillary/blood vessel disruption, and epistaxis, 
and will be graded as follows: absent, mild, moderate, or severe. 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
121
Status: Approved, Date: 6 July 2016
Nasal Symptom Questionnaire
Subjects will complete a nasal symptom questionnaire. The nasal symptom questionnaire was 
developed by the Sponsor to assess nasal tolerability following intranasal administration of study 
drug. The questionnaire asks about nasal symptoms, which are rated by the subject as none, mild, 
moderate, or severe, based on how he or she feels at the time of the assessment.
Columbia Suicide Severity Rating Scale (C-SSRS)
The C-SSRS will be used to assess potential suicidal ideation and behavior. 
The C-SSRS is a low-burden measure of the spectrum of suicidal ideation and behavior that was 
developed in the National Institute of Mental Health Treatment of Adolescent Suicide 
Attempters Study to assess severity and track suicidal events through any treatment.70 It is a 
clinical interview providing a summary of both suicidal ideation and behavior that can be 
administered during any evaluation or risk assessment to identify the level and type of suicidality 
present. The C-SSRS can also be used during treatment to monitor for clinical worsening.
Two versions of the C-SSRS will be used in this study, the Baseline/Screening version, and the 
Since Last Visit version. The Baseline/Screening version of the C-SSRS will be used in the 
screening phase. In this version, suicidal ideation will be assessed at 2 time points: “lifetime” and 
“in the past 6 months,” and suicidal behavior will be assessed at 2 time points: “lifetime” and “in 
the past year.” All subsequent C-SSRS assessments in this study will use the Since Last Visit 
version, which will assess suicidal ideation and behavior since the subject’s last visit.
Clinician Administered Dissociative States Scale (CADSS)
The CADSS is an instrument for the measurement of present-state dissociative symptoms,5 and 
will be administered to assess treatment-emergent dissociative symptoms.
The CADSS consists of 23 subjective items, divided into 3 components: depersonalization 
(Items 3 to 7, 20, and 23), derealization (Items 1, 2, 8 to 13, 16 to 19, and 21) and amnesia (Items 
14 and 15, and 22). Participant’s responses are coded on a 5-point scale (0=not at all through to 
4=extremely). CADSS has excellent inter-rater reliability and internal consistency. 
Positive-symptom Subscale of the Brief Psychiatric Rating Scale (BPRS+)
Four items of the BPRS will be administered to assess potential treatment-emergent psychotic 
symptoms. 
The BPRS is an 18-item rating scale that is used to assess a range of psychotic and affective 
symptoms, rated from both observation of the subject and the subject's own report.64,65 It 
reportedly provides a rapid and efficient evaluation of treatment response in clinic drug studies 
and in clinical settings.73
Only the 4-item positive symptom subscale BPRS+ (ie, suspiciousness, hallucinations, unusual 
thought content, and conceptual disorganization) will be used in this study. It is highly sensitive 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
122
Status: Approved, Date: 6 July 2016
to change, and excellent inter-rater reliability can be achieved with training and a standard 
interview procedure. 
Modified Observer's Assessment of Alertness/Sedation (MOAA/S)
The MOAA/S will be used to measure treatment-emergent sedation, with correlation to levels of 
sedation defined by the American Society of Anesthesiologists continuum.
The MOAA/S scores range from 0=no response to painful stimulus (corresponds to ASA 
continuum for general anesthesia) to 5=readily responds to name spoken in normal tone (awake; 
corresponds to ASA continuum for minimal sedation).
On each intranasal dosing day, the MOAA/S will be performed every 15 minutes from predose 
to t=+1.5 hours postdose.

If the score is 3 at any time during the 1.5 hour postdose interval, the MOAA/S will be 
performed every 5 minutes until a score of 4 is reached (at which point a frequency of every 
15 minutes can be resumed until t=+1.5 hours post dose). 

If a subject does not have a score of at least 5 at t=+1.5 hours postdose, they should continue 
to be monitored. For subjects with a score of 4, the assessment should be repeated every 
15 minutes. And for subjects with a score of 3, the assessment should be repeated every 
5 minutes until the score returns to 5 or the subject is referred for appropriate medical care, 
if clinically indicated.
Clinical Global Assessment of Discharge Readiness (CGADR)
The CGADR will be used to measure the subject’s current clinical status and is the clinician’s 
assessment of the readiness to be discharged from the study site. 
The clinician will answer “Yes” or “No” to the question “Is the subject considered ready to be 
discharged based on their overall clinical status (eg, sedation, blood pressure, and other adverse 
events)?”
On each intranasal dosing day, the CGADR will be performed at 1 hour and 1.5 hours postdose; 
if the response is not “Yes” at 1.5 hours postdose, the assessment will be repeated every 
15 minutes until a “Yes” response is achieved or until the subject is referred for appropriate 
medical care, if clinically indicated. 
A subject should not be discharged prior to the 1.5 hour time point.
On all intranasal treatment session days, subjects must remain at the clinical site until study 
procedures have been completed and the subject is ready for discharge.
Physician Withdrawal Checklist, 20-item (PWC-20)
The PWC-20 will be administered to assess potential withdrawal symptoms following cessation 
of intranasal esketamine treatment. An assessment will be performed pre-dose on Day 25 to 
establish a baseline prior to discontinuation of intranasal esketamine treatment. In order to better 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
123
Status: Approved, Date: 6 July 2016
assess potential withdrawal symptoms from the intranasal medication it is recommended that the 
oral antidepressant medication be continued for the duration of the follow up phase unless 
determined as not clinically appropriate.
The PWC-20 is a 20-item simple and accurate method to assess potential development of 
discontinuation symptoms after stopping of study drug. The PWC-20 is a reliable and sensitive 
instrument for the assessment of discontinuation symptoms.72 Discontinuation symptoms occur 
early and disappear rather swiftly, depending upon speed of taper, daily medication dose, and 
drug elimination half-life. 
Bladder Pain/Interstitial Cystitis Symptom Score (BPIC-SS)
The BPIC-SS will be used to monitor subjects for potential symptoms of cystitis, bladder pain, 
and interstitial cystitis.
The BPIC-SS is a patient-reported outcome measure that was developed to identify an 
appropriate bladder pain syndrome/interstitial cystitis population for clinical studies to evaluate
new treatments for bladder pain syndrome.39
The BPIC-SS contains 8 questions with a recall period of the past 7 days, and addresses key 
symptoms identified by subjects with BPS including symptom concepts of pain and/or pressure 
of the bladder and urinary frequency. Subjects respond to items using a 5-point scale (0=never, 
1=rarely, 2=sometimes, 3=most of the time, 4=always for frequency-based questions, and 0=not 
at all, 1=a little, 2=somewhat, 3=moderately, and 4=a great deal for items related to bother 
associated with symptoms). Question 8 records the worst bladder pain in the last 7 days using a 
0-10 numerical rating scale. A total score is calculated by adding up the numbers beside the 
response options chosen by the subject. The range of scores for the scale is 0 to 28.
A total score of 19 or more has demonstrated good sensitivity/specificity and is considered a 
relevant cut-off to distinguish those with significant bladder symptoms or cystitis.39
If any items are missing, a total score cannot be calculated.
If a subject has a score greater than18 on the BPIC-SS scale and urinalysis and microscopy 
indicate no evidence of urinary tract infection then the subject will be referred to a specialist for 
further evaluation. If a subject is diagnosed with ulcerative cystitis, the subject must be 
discontinued from the study and followed up with appropriate medical care. As such, in addition 
to urinalysis, a urine culture should also be obtained if the BPIC-SS score on an applicable study 
day is greater than 18.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
124
Status: Approved, Date: 6 July 2016
Cognition Testing
Computerized Cognitive Battery 
The computerized cognitive battery provides assessment of multiple cognitive domains, 
including attention, visual learning and memory, and executive function. The tests use culture-
neutral stimuli, enabling use in multilingual/multicultural settings. The computerized battery 
includes:

Simple and choice reaction time tests; scored for speed of response (mean of the 
log 10-transformed reaction times for correct responses)

Visual episodic memory; visual recall test scored using arcsine transformation of the 
proportion of correct responses

Working memory (n back); scored for speed of correct response (mean of the 
log 10-transformed reaction times for correct responses)

Executive function; maze/sequencing test, scored for total number of errors
All measures have been validated against traditional neuropsychological tests and are sensitive to 
the effects of various drugs on cognitive performance, including alcohol and benzodiazepines. 
Completing the cognitive battery requires approximately 25 minutes.
Hopkins Verbal Learning Test-Revised (HVLT-R)
The HVLT-R, a measure of verbal learning and memory, is a 12-item word list recall test. 
Administration includes 3 learning trials, a 24-word recognition list (including 12 target and 
12 foil words), and a delayed recall trial (20-minute).3 The test administrator reads instructions 
and word lists aloud, and records words recalled/recognized by the subject. Scores include 
learning, delayed recall, and recognition. The HVLT-R is a well-validated and widely used 
measure of verbal episodic memory. 
The tests will be administered in the following order: HVLT-R, computerized cognitive test 
battery, and HVLT-R Delayed.
All subjects will complete a practice session for the computerized cognitive battery during the 
screening phase. There is no practice session for the HVLT-R.
9.2.2.
Safety Endpoints 
Safety endpoints will include:

Monitoring of TEAEs, including TEAEs of special interest

Clinical laboratory tests, including hematology, serum chemistry, and urinalysis

Physical examination, and body weight measurements

Serum and urine pregnancy testing (for women of childbearing potential)

Urine drug screen

Alcohol breath test
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
125
Status: Approved, Date: 6 July 2016
Safety evaluations to assess short-term effects following intranasal esketamine dosing will 
include:

12-lead electrocardiogram

Vital signs

Pulse oximetry

Clinician Administered Dissociative States Scale (CADSS), to assess treatment-emergent 
dissociative symptoms

Four-item positive symptom subscale of the BPRS+, to assess treatment-emergent psychotic 
symptoms

Modified Observer’s Assessment of Alertness/Sedation, to measure treatment-emergent 
sedation

Clinical Global Assessment of Discharge Readiness (CGADR), to document the subject’s 
current clinical status based on the clinician's assessment of the readiness to be discharged 
from the study site
Safety evaluations will also include assessment of any long-term adverse events, with special 
attention to:

Nasal examination and nasal symptom questionnaire to local assess nasal tolerability 

Columbia Suicide Severity Rating Scale (C-SSRS), to assess suicidal ideation and behavior

Bladder Pain/ Interstitial Cystitis Symptom Score (BPIC-SS), to monitor for symptoms of 
cystitis, bladder pain, and interstitial cystitis

Physician Withdrawal Checklist (PWC-20) to assess potential withdrawal symptoms 
following cessation of intranasal esketamine treatment

Computerized cognitive battery and HVLT-R, to assess the effect of intranasal esketamine 
on cognition
9.3.
Efficacy 
9.3.1.
Efficacy Evaluations
Every effort should be made to ensure that all clinician-administered efficacy assessments are 
completed by the same individual who made the initial baseline determinations.
9.3.1.1.
Montgomery-Asberg Depression Rating Scale (MADRS)
The MADRS is a clinician-rated scale designed to measure depression severity and detects 
changes due to antidepressant treatment.53 The scale consists of 10 items, each of which is scored 
from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a 
total possible score of 60. Higher scores represent a more severe condition. The MADRS 
evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, 
lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts. The test 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
126
Status: Approved, Date: 6 July 2016
exhibits high inter-rater reliability. The structured interview guide for the MADRS (SIGMA) 
will be used for each administration.
The typical recall period for the MADRS is 7 days. 
The MADRS will be used to measure the secondary objectives of effects on depressive 
symptoms.
9.3.1.2.
Clinical Global Impression - Severity (CGI-S)
The CGI-S provides an overall clinician-determined summary measure of the severity of the 
subject’s illness that takes into account all available information, including knowledge of the 
subject’s history, psychosocial circumstances, symptoms, behavior, and the impact of the 
symptoms on the subject’s ability to function.34 The CGI-S evaluates the severity of 
psychopathology on a scale of 0 to 7. Considering total clinical experience, a subject is assessed 
on severity of mental illness at the time of rating according to: 0=not assessed; 1=normal (not at 
all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 
7=among the most extremely ill patients. The CGI-S permits a global evaluation of the subject’s 
condition at a given time.
9.3.1.3.
Patient Health Questionnaire, 9-Item (PHQ-9)
The PHQ-9 is a 9-item, patient-reported outcome measure to assess depressive symptoms.88 The 
scale scores each of the 9 symptom domains of the DSM-5 MDD criteria and it has been used 
both as a screening tool and a measure of response to treatment for depression. Each item is rated 
on a 4-point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every 
day). The subject’s item responses are summed to provide a total score (range of 0 to 27) with 
higher scores indicating greater severity of depressive symptoms. The recall period is 2 weeks. 
9.3.1.4.
Generalized Anxiety Disorder, 7-item (GAD-7)
The 7-item subject-reported GAD-7 will be used to measure the secondary objective of 
symptoms of anxiety. The GAD-7 is a brief and validated measure of overall anxiety. Each item 
is rated on a 4-point scale (0 = not at all; 1 = several days; 2 = more than half the days; and 
3 = nearly every day).87 Item responses are summed to yield a total score with range of 0 to 21, 
where higher scores indicate more anxiety. The recall period is 2 weeks.
9.3.1.5.
European Quality of Life (EuroQol) Group, 5-Dimension, 5-Level (EQ 
5D-5L)
The EQ-5D-5L is a standardized instrument for use as a measure of health outcome, primarily 
designed for self-completion by respondents. It consists of the EQ-5D-5L descriptive system and 
the EQ visual analogue scale (EQ VAS). The EQ-5D-5L descriptive system comprises the 
following 
5 
dimensions: 
mobility, 
self-care, 
usual 
activities, 
pain/discomfort 
and 
anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems 
(Level 1 indicating no problem, Level 2 indicating slight problems, Level 3 indicating moderate 
problems, Level 4 indicating severe problems, and Level 5 indicating extreme problems).29,30
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
127
Status: Approved, Date: 6 July 2016
The subject selects an answer for each of the 5 dimensions considering the response that best 
matches his or her health “today.” The descriptive system can be represented as a health state. 
The EQ VAS self-rating records the respondent’s own assessment of his or her overall health 
status at the time of completion, on a scale of 0 to 100. 
The time taken to complete the questionnaire varies with age, health status, and setting but is 
likely to be around 1 minute.
9.3.1.6.
Sheehan Disability Scale (SDS)
The Sheehan Disability Scale will be used to assess the secondary objective of functional impact 
and associated disability. The SDS, a patient-reported outcome measure, is a 5 item 
questionnaire which has been widely used and accepted for assessment of functional impairment 
and associated disability.48,82 The first three items assess disruption of (1) work/school, (2) social 
life, and (3) family life/home responsibilities using a 0-10 rating scale. The score for the first 
three items are summed to create a total score of 0-30 where a higher score indicates greater 
impairment. It also has one item on days lost from school or work and one item on days when 
underproductive. The recall period for this study is 7 days.
9.3.2.
Efficacy Endpoints 
Efficacy endpoints include the mean total score over time, individual scores over time as well as 
change from baseline in the total score and individual scores for the following rating scales:

Depressive symptoms, using the MADRS and the self-reported PHQ-9 

Overall severity of illness, using the CGI-S

Symptoms of anxiety, using the GAD-7 scale

Health-related quality of life and health status, using the EQ-5D-5L questionnaire

Functioning and associated disability, using the SDS

Long-term efficacy will also be assessed by:
Response rate over time, defined as:
o
percentage of subjects with 50% reduction from baseline (induction phase) in the 
MADRS total score, 
o
percentage of subjects with 50% reduction from baseline (induction phase) in the 
PHQ-9 total score 
Remission rate over time, defined as: 
o
percentage of subjects with MADRS total score 12, 
o
percentage of subjects with PHQ-9 total score 5
9.4.
Biomarker and Pharmacogenomic Evaluations
During the study, blood will be collected for the assessment of biomarkers (protein and 
metabolite) at the time points indicated in the Time and Events schedule. The biomarker blood 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
128
Status: Approved, Date: 6 July 2016
samples should be collected prior to dosing. It is preferred that subjects adhere to a low fat diet 
on the day of sample collection. 
In blood, biomarkers (protein, and metabolites) related to (but not limited to) the immune system 
activity, hypothalamus pituitary adrenal (HPA) axis activation, neurotrophic factors and 
metabolic factors will be investigated. Biomarkers may be added or deleted based on scientific 
information or technical innovations under the condition that the total volume of blood collected 
will not be increased. 
The biomarker data obtained from this study may also be included in an ongoing cross-study 
analysis to investigate the relationship between depression severity and phenotypes and 
biomarkers.
Pharmacogenomics
Blood samples for DNA analyses will be collected at the time points indicated in the Time and 
Events Schedule for the assessment of genetic and epigenetic variation in genes in pathways 
relevant to depression (eg, HPA axis, inflammation, growth factors, monoamine transporters, ion 
channels, and circadian rhythm etc). 
Genotyping will be conducted only on the screening/baseline sample; pharmacogenomic and 
epigenetic evaluations may be performed on any/all collected samples.
DNA samples will be used for research related to esketamine, oral antidepressants, TRD, or 
MDD. They may also be used to develop tests/assays related to esketamine, oral antidepressants, 
TRD, or MDD. Pharmacogenomic research may consist of the analysis of 1 or more candidate 
genes or of the analysis of genetic markers throughout the genome (as appropriate) in relation to 
esketamine, oral antidepressants, TRD, or MDD clinical endpoints.
Further information regarding handling, shipment, and labeling of biological samples will be 
provided in a separate laboratory manual.
9.5.
Medical Resource Utilization 
Medical resource utilization data, associated with healthcare encounters, will be collected using 
the HRUQ during the optimization/maintenance and follow up phases of the study. Protocol-
mandated procedures, tests, and encounters are excluded. The data collected may be used to 
conduct exploratory economic analyses and will include:

Number, duration and type of healthcare encounters (inpatient and outpatient).

Duration of hospitalization (total days length of stay, including duration by wards)
9.6.
Other Evaluations
Menstrual Cycle Tracking
Menstrual cycle tracking (start date of last menstrual period) will be documented for female 
subjects with a menstrual cycle at the study visits specified in the Time and Events Schedule.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
129
Status: Approved, Date: 6 July 2016
MINI
The MINI is a brief, structured diagnostic interview to confirm the diagnosis of MDD and to 
determine if there are other psychiatric conditions present. 
Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire 
(MGH-ATRQ)
The MGH-ATRQ is used to determine treatment resistance in MDD.20
The MGH-ATRQ evaluates the adequacy of duration and dose of all antidepressant medications 
used for the current major depressive episode. In addition, the MGH-ATRQ assesses the degree 
of improvement on a scale from 0% (not improved at all) to 100% (completely improved). The 
MGH-ATRQ will be completed by the clinician in collaboration with the subject.
Snoring, Tiredness, Observed Apnea, High Blood Pressure, Body Mass Index, Age, Neck 
Size, Gender (STOP-Bang) Questionnaire 
The STOP-Bang Questionnaire is a concise, easy-to-use, validated, and sensitive screening tool 
for obstructive sleep apnea (OSA). This questionnaire has 8 items which address key risk factors 
for obstructive sleep apnea: snoring, tiredness, observed breathing interruption during sleep, high 
blood pressure, body mass index, age, neck size, and gender. The STOP-Bang questions do not 
specify a recall period. Subjects will answer yes or no to questions about snoring, tiredness, 
observed breathing interruption, and high blood pressure (these are the “STOP” items in the 
STOP-BANG acronym); this takes approximately 1 minute.7
Study site staff will answer yes or no to questions about body mass index (more than 35 kg/m²?), 
age (older than 50 years?), neck circumference (larger than 17 inches [43 cm] in men, or larger 
than 16 inches [41 cm] in women?), and gender (male?). 
The total STOP-BANG score is calculated by summing the number of positive responses, 
yielding a score range of 0 to 8. A score of 5 on the STOP-Bang indicates a moderate to severe 
risk for Obstructive Sleep Apnea (apnea hypopnea index of >30).7
MMSE
The MMSE is a validated, brief examination that rates subjects on orientation (total score, 10), 
registration (total score, 3), attention and calculation (total score, 5), recall (total score, 3), and 
language (total score, 9).31 The MMSE is effective as a screening tool for cognitive impairment 
with older community dwelling, hospitalized and institutionalized adults. The maximum score is 
30. The MMSE will be completed at screening only. A total score <25 will be used in the current 
study in order to exclude subjects with potential neurodegenerative disorder.
Patient Stated-choice Preference Survey
Stated-choice conjoint analysis is a method specifically designed to provide information about an 
individual’s willingness to accept tradeoffs between treatments with multiple outcomes 43, 46, 75, 76
Preference studies have been performed with patients with depression and other mental illnesses.
49, 95 The Patient Stated-choice Preference Surveys will be used as an exploratory tool to assess 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
130
Status: Approved, Date: 6 July 2016
the manner and degree to which subjects’s value or weigh the benefit and harm clinical outcomes 
associated with esketamine. 
The intent is to have the subject complete the survey after having some experience with 
esketamine. The survey will be administered once and only at sites in the United States, United 
Kingdom and Australia and only for English speakers. Subjects at any other site, regardless of 
whether they speak English, will not be surveyed. It is expected that subjects will require 20 to 
25 minutes to complete the survey. Since subjects may be in different stages of the trial when the 
survey becomes available, trial sites should have subjects complete the survey as noted in the
T&E schedule. Specifically, the survey should be completed during or shortly after Visit 2.9, or 
if the subject completed this visit prior to when the survey becomes available, trial sites should 
have the subject complete the survey at the earliest possible opportunity. Note, for 
transferred-entry responder subjects from the ESKETINTRD3005 study who enter directly to the 
optimization/maintenance phase, the survey should be completed during or shortly after 
Visit 3.5, or if the subject completed this visit prior to when the survey becomes available, the 
subject should complete the survey at the earliest possible opportunity. Subjects who completed 
the Patient Stated-choice preference survey while enrolled in ESKETINTRD3005 should not be 
issued the survey. The survey should be administered predose (if/when performed on intranasal 
dosing days). 
If the patient indicates a desire to discontinue the study, the patient should be asked to complete 
the survey by his or her last visit if, in the study coordinator’s judgment, the patient will give the 
survey the required time and attention. If the study coordinator believes a patient will not give 
the survey the required time and attention on this last visit, the survey should not be 
administered. 
The survey will be administered on a table-based computer during a site visit prior to 
administration of study drug if dosing is scheduled to occur on that day.  
9.7.
Sample Collection and Handling
The actual dates and times of sample collection must be recorded in the eCRF or laboratory 
requisition form.
If blood samples are collected via an indwelling cannula, an appropriate amount (1 mL) of 
serosanguineous fluid slightly greater than the dead space volume of the lock will be removed 
from the cannula and discarded before each blood sample is taken. After blood sample 
collection, the cannula will be flushed with 0.9% sodium chloride, United States Pharmacopeia 
(USP) (or equivalent) and charged with a volume equal to the dead space volume of the lock.
Refer to the Time and Events Schedule for the timing and frequency of all sample collections.
Instructions for the collection, handling, storage, and shipment of samples are found in the 
laboratory manual that will be provided. Collection, handling, storage, and shipment of samples 
must be under the specified, and where applicable, controlled temperature conditions as indicated 
in the laboratory manual.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
131
Status: Approved, Date: 6 July 2016
10.
SUBJECT COMPLETION/WITHDRAWAL
10.1.
Criteria for Completion
A subject will be considered to have completed the study if he or she has completed safety 
assessments at Week 52 of the optimization/maintenance phase.
Subjects in the induction phase of the study at the time of study completion will be allowed to 
complete the phase, will complete an early withdrawal visit, and continue into the follow-up 
phase but will not be considered completers.
Subjects in the optimization/maintenance phase of the study at the time of study completion will 
complete an End of Optimization/Maintenance visit, and continue into the follow-up phase but 
will not be considered completers.
An open label safety extension study, 54135419TRD3008, may be available (pending country 
and site approval) for eligible subjects participating in the ESKETINTRD3004 study. Please 
refer to the 54135419TRD3008 protocol for full details, when available.
10.2.
Criteria for Withdrawal from the Study
During any phase of the study, a subject will be withdrawn from the study for any of the 
following reasons:

The investigator believes that for safety reasons (eg, an adverse event) it is in the best 
interest of the subject to stop treatment.
See Section 6.1 for discontinuation criteria related to blood pressure

The subject does not meet response criteria for continuing into the optimization/maintenance
phase at the end of the open-label induction phase (direct-entry subjects and transferred-
entry non-responder subjects only).

The subject must be discontinued at any time point after baseline (Day 1, predose), if:
- QTcF change from baseline is ≥ 60 msec and QTcF > 480 msec, or 
- QTCF > 500 msec.

Lack of efficacy, as determined by the investigator

Violation of protocol procedures (determined on a case-by-case basis)

The subject becomes pregnant

The subject is lost to follow-up

Death

The sponsor terminates the study.

Withdrawal of consent (Note: See “Withdrawal of Consent” section below: this should only 
be selected as a reason for withdrawal if the subject does not agree to any further study 
assessments or procedures. If the subject is agreeable to participating in the Early 
Withdrawal visit and the follow-up phase, another reason for withdrawal should be selected)
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
132
Status: Approved, Date: 6 July 2016

The subject misses ≥4 consecutive MADRS assessments or >4 consecutive intranasal 
treatment sessions in the optimization/maintenance phase
Refer to Section 9.1.6 for further information on the Early Withdrawal or End of 
Optimization/Maintenance Phase Visit.
If a subject misses a study visit (clinic or telephone visit) in the optimization/maintenance phase 
without notifying the site of the reason, the site personnel will attempt to contact the subject to 
confirm if the subject is still interested in participating in the study and if so, to schedule their 
next visit. During this contact the information on adverse events and concomitant medication 
will be collected. These contacts will be repeated weekly until successful scheduling of the next 
dosing session or otherwise until discontinuation from the study (up to 4 contacts will be made).
If the subject withdraws from the study before the end of the open-label induction phase or 
optimization/maintenance phase, an Early Withdrawal visit is to be performed.
If a subject is lost to follow-up, every reasonable effort must be made by the study site personnel 
to contact the subject and determine the reason for discontinuation/withdrawal. This should 
include at least 3 telephone calls, certified letters, email requests, etc. To ensure access to follow-
up subjects, the study site personnel should attempt to obtain both primary and secondary 
telephone contact numbers (eg, home, work, and mobile phone numbers), as well as other 
contact information (eg, email addresses) from subjects. In addition, the study site should 
emphasize the importance of follow-up information to the subject before initiation of the open-
label induction phase. The measures taken to follow up must be documented.
When a subject withdraws, the reason for withdrawal is to be documented in the eCRF and in the 
source document. Subjects who withdraw will not be replaced. Study drug assigned to the 
withdrawn subject may not be assigned to another subject.
Withdrawal of Consent
Every effort will be made in the study to ensure “withdrawal of consent” is not selected as a 
reason for discontinuation when in fact the subject withdrew for an identifiable reason (eg, due to 
adverse event or withdrew due to lack of efficacy).
Subjects who wish to withdraw from the study should be asked if they are agreeable to be 
contacted to collect follow-up information. Subjects who are not agreeable to follow-up contact 
will be withdrawn from the study as “withdrawal of consent.” Subjects who no longer wish to 
take study drug but agree to provide follow-up information will be withdrawn from the open-
label induction phase or the optimization/maintenance phase with the reason noted as “Other” 
and will specify the reason why.
For a subject who “withdraws consent”, it is recommended that the subject withdraw consent in 
writing; if the subject refuses or is physically unavailable, the study site should document and 
sign the reason for the subject’s failure to withdraw consent in writing and maintain it with the 
subjects source records.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
133
Status: Approved, Date: 6 July 2016

The investigator will be responsible for making all required notifications to the 
Institutional Review Board (IRB) or Independent Ethics Committee (IEC).
10.3.
Withdrawal from the Use of Samples in Future Research
The subject may withdraw consent for use of samples for research (refer to Section 16.2.5, 
Long-Term Retention of Samples for Additional Future Research). In such a case, samples will 
be destroyed after they are no longer needed for the clinical study. Details of the sample 
retention for research are presented in the main ICF.
11.
STATISTICAL METHODS
Statistical analysis will be done by the sponsor or under the authority of the sponsor. A general 
description of the statistical methods to be used to analyze the efficacy and safety data is outlined 
below. Specific details will be provided in the Statistical Analysis Plan (SAP).
11.1.
Subject Information
The following analysis sets will be used to summarize efficacy and safety data.

Full Analysis Set for open-label induction phase: will be defined as all subjects who 
receive at least 1 dose of intranasal esketamine or 1 dose of oral antidepressant during 
this phase.

Full Analysis Set for Optimization/Maintenance phase: will be defined as all subjects 
who receive at least 1 dose of intranasal esketamine or 1 dose of oral antidepressant 
during this phase. 
11.2.
Sample Size Determination
No formal sample size calculation was performed for the study. The projected sample size of 
750 direct entry subjects plus transferred entry subjects is considered adequate to obtain at least 
300 subjects who have received treatment with esketamine for 6 months and at least 100 subjects 
for 12 months (Note: the total number of subjects will be based on subjects from this study and 
subjects from other intranasal esketamine Phase 3 studies). The number of transferred entry 
subjects is based on predictions related to discontinuation rate and efficacy, and therefore may 
vary.
The sample size will include at least 100 older subjects (who are either direct entry subjects or
transferred entry subjects from the ESKETINTRD3005 study) aged 65 years.
11.3.
Safety Analyses
Safety data for the open-label induction phase, the optimization/maintenance phase and 
follow-up phase will be analyzed separately for each phase as well as for the entire treatment 
period (induction and optimization/maintenance phase). The baseline for safety assessments will 
be defined in the Statistical Analysis Plan.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
134
Status: Approved, Date: 6 July 2016
Cognitive Function

Computerized cognitive test battery and HVLT-R: Descriptive statistics of each of the 
cognitive domain scores and changes from baseline will be summarized at each scheduled 
time point.

Reversibility of any potential changes from baseline to end of treatment visit in cognitive 
test battery and HVLT-R will be assessed at follow-up phase.
Treatment-emergent lower urinary tract symptoms

BPIC-SS+: Descriptive statistics of scores and their changes from predose or baseline will 
be summarized at each scheduled time point.

Adverse events related to lower urinary tract symptoms will be summarized descriptively. 
Reversibility of any changes from baseline to end of treatment visit in BPIC-SS, and 
reversibility of any ongoing adverse events related to LUTS will be assessed during the 
follow-up phase.
Withdrawal and/or rebound symptoms

PWC-20: Descriptive statistics of scores and their changes from predose on the last day of 
dosing will be summarized at each scheduled time point during the follow-up phase.

Adverse events related to withdrawal and/or rebound symptoms will be summarized 
descriptively. Reversibility of any ongoing adverse events related to withdrawal and/or 
rebound symptoms will be assessed during the follow-up phase.
Adverse Events
The verbatim terms used in the eCRF by investigators to identify adverse events will be coded 
using the Medical Dictionary for Regulatory Activities (MedDRA). Treatment-emergent adverse 
events are adverse events with onset during the treatment phase or that are a consequence of a 
pre-existing condition that has worsened since baseline. All reported adverse events with onset 
during the treatment phase (ie, TEAEs, and adverse events that have worsened since baseline) 
will be included in the analysis. For each adverse event, the percentage of subjects who 
experience at least 1 occurrence of the given event will be summarized.
TEAEs of special interest will be examined separately grouped in the following categories: drug 
abuse, dependence and withdrawal (SMQ), increased blood pressure, increased heart rate, 
transient dizziness/vertigo; impaired cognition; anxiety and lower urinary tract symptoms SMQ 
including cystitis.
Adverse events occurring during the follow-up phase will be summarized separately. For 
transferred-entry subjects, adverse events ongoing at the time of entry into the study will be 
summarized separately.
Summaries, listings, datasets, or subject narratives may be provided, as appropriate, for those
subjects who die, who discontinue treatment due to an adverse event, or who experience a severe 
or a serious adverse event.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
135
Status: Approved, Date: 6 July 2016
Clinical Laboratory Tests
Laboratory data will be summarized by type of laboratory test. Reference ranges and markedly 
abnormal results (specified in the SAP) will be used in the summary of laboratory data. 
Descriptive statistics will be calculated for each laboratory analyte at baseline and at each 
scheduled time point in each phase of the study. Changes from baseline results will be provided. 
Frequency tabulations of the abnormalities will be provided. Listings of subjects with laboratory 
results outside the reference ranges and markedly abnormal laboratory results will be provided.
Electrocardiogram (ECG)
The effects on cardiovascular variables will be evaluated by means of descriptive statistics and 
frequency tabulations. These tables will include observed values and changes from baseline 
values.
Electrocardiogram data will be summarized by ECG parameter. Descriptive statistics will be 
calculated at baseline and for observed values and changes from baseline at each scheduled time 
point. Frequency tabulations of the abnormalities will be made.
The ECG variables that will be analyzed are heart rate, PR interval, QRS interval, QT interval, 
and QT interval corrected (QTc) according to Bazett's formula (QTcB) and Fridericia's formula 
(QTcF).2,78
Descriptive statistics of QTc intervals and changes from baseline will be summarized at each 
scheduled time point. The percentage of subjects with QTc interval >450 msec, >480 msec, or 
>500 msec will be summarized, as will the percentage of subjects with QTc interval increases 
from baseline <30 msec, 30 to 60 msec, or >60 msec.
All important abnormalities in ECG waveform that are changes from the baseline readings will 
be reported (eg, changes in T-wave morphology or the occurrence of U-waves).
Vital Signs
Descriptive statistics of body weight, temperature, pulse/heart rate, respiratory rate, pulse 
oximetry and supine blood pressure (systolic and diastolic) values and changes from baseline 
will be summarized at each scheduled time point. Any treatment-emergent abnormalities will be 
listed.
Nasal Examination and Nasal Symptom Questionnaire
Changes in findings from the baseline nasal examination (including the upper respiratory 
tract/throat) will be listed. Examinations will provide ratings (none, mild, moderate, or severe) 
that are based on a visual inspection of the nostrils, nasal mucosa, and throat for nasal erythema, 
rhinorrhea, rhinitis, capillary/blood vessel disruption and epistaxis. A shift table for changes 
from baseline in ratings for each examination will be presented. Percentage of subjects having 
findings in the nasal exam and tolerability questionnaire will be assessed over time.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
136
Status: Approved, Date: 6 July 2016
In addition, scoring from the nasal symptom questionnaire will be summarized descriptively for 
each scheduled time point.
Other Safety and Tolerability Questionnaires and Assessments

C-SSRS: Suicide-related thoughts and behaviors based on the C-SSRS will be summarized 
in incidence and shift tables. Separate endpoints for suicidal ideation and suicidal behavior 
will be defined and summarized descriptively. Missing scores will not be imputed.

CADSS, CGDAR, BPRS+ and MOAA/S: Descriptive statistics of scores and their changes 
(and/or percent changes) from predose or baseline will be summarized at each scheduled 
time point.
11.4.
Efficacy Analyses
Depression symptoms using the MADRS as well as a patient reported outcome (PHQ-9), global 
change in severity (CGI-S), social, occupational and family functioning related disability (SDS), 
anxiety (GAD-7), and health status (EQ-5D-5L) will be summarized descriptively at each 
scheduled visit for each phase, using both last observation carried forward and observed data.
The proportion of subjects who responded and remitted based on the MADRS total score as well 
as PHQ-9 total score will be provided over time for each phase. 
11.5.
Biomarker and Pharmacogenomic Analysis
Baseline biomarker values and changes from baseline biomarker values to the time points 
specified in the Time and Events Schedule will be summarized. Exploratory analyses may 
include correlation of biomarker values at baseline and change from baseline in biomarker values 
with the efficacy parameters and other measures. Additional exploratory analyses may also 
include relationship of baseline and change from baseline in biomarker measures to clinical 
response, maintenance/stabilization of response and non-response. 
Pharmacogenomic analyses may include candidate gene analyses or genome-wide association 
analyses in relation to treatment response, maintenance/stabilization of response, non-response 
and MDD/TRD.
Details of the analysis plan and summary of results from both biomarker and pharmacogenomics 
analyses will be reported separately.
11.6.
Medical Resource Utilization Analysis
Medical resource utilization data (including HRUQ results) will be descriptively summarized.
11.7.
Patient Stated-choice Preference Survey
The conjoint analysis based patient stated-choice preference survey will be used as an 
exploratory tool to assess the outcomes with esketamine.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
137
Status: Approved, Date: 6 July 2016
The patient stated-choice preference survey, generate data that can be used to estimate relative 
preference weights for specified levels of treatment-related benefits and harms. A regression 
model described in a SAP will be used to estimate a distribution of preferences around each 
model parameter. All estimates will be reported with 95% confidence intervals. A key result will 
be the maximum acceptable risk for each harm, defined as the largest increase in probability or 
severity of that harm that a patient is willing to accept for a given degree of benefit. Reporting of 
the survey results may be conducted separately from this study. 
11.8.
Independent Data Monitoring Committee 
An IDMC will be established to monitor data on an ongoing basis to ensure the continuing safety 
of the subjects enrolled in this study. The committee will meet every 6 months to review safety 
data. After the reviews, the IDMC will make recommendations regarding the continuation of the 
study. The details will be provided in a separate IDMC charter.
The IDMC will consist of at least 1 medical expert in the relevant therapeutic area and at least 
1 statistician. The IDMC responsibilities, authorities, and procedures will be documented in its 
charter.
12.
ADVERSE EVENT REPORTING
Timely, accurate, and complete reporting and analysis of safety information from clinical studies 
are crucial for the protection of subjects, investigators, and the sponsor, and are mandated by 
regulatory agencies worldwide. The sponsor has established Standard Operating Procedures in 
conformity with regulatory requirements worldwide to ensure appropriate reporting of safety
information; all clinical studies conducted by the sponsor or its affiliates will be conducted in 
accordance with those procedures.
12.1.
Definitions
12.1.1.
Adverse Event Definitions and Classifications
Adverse Event
An adverse event is any untoward medical occurrence in a clinical study subject administered a 
medicinal (investigational or non-investigational) product. An adverse event does not necessarily 
have a causal relationship with the treatment. An adverse event can therefore be any unfavorable 
and unintended sign (including an abnormal finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational or non-investigational) product, whether or not 
related to that medicinal (investigational or non-investigational) product. (Definition per 
International Conference on Harmonisation [ICH])
This includes any occurrence that is new in onset or aggravated in severity or frequency from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory test 
abnormalities.
Note: The sponsor collects adverse events starting with the signing of the ICF (refer to 
Section 12.3.1, All Adverse Events, for time of last adverse event recording).
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
138
Status: Approved, Date: 6 July 2016
Serious Adverse Event
A serious adverse event based on ICH and European Union Guidelines on Pharmacovigilance for 
Medicinal Products for Human Use is any untoward medical occurrence that at any dose:

Results in death

Is life-threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that 
hypothetically might have caused death if it were more severe.)

Requires inpatient hospitalization or prolongation of existing hospitalization

Results in persistent or significant disability/incapacity

Is a congenital anomaly/birth defect

Is a suspected transmission of any infectious agent via a medicinal product

Is Medically Important*
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
also appropriate in other situations, such as important medical events that may not be 
immediately life threatening or result in death or hospitalization but may jeopardize the subject 
or may require intervention to prevent one of the other outcomes listed in the definition above. 
These should usually be considered serious.
If a serious and unexpected adverse event occurs for which there is evidence suggesting a causal 
relationship between the study drug and the event (eg, death from anaphylaxis), the event must 
be reported as a serious and unexpected suspected adverse reaction even if it is a component of 
the study endpoint (eg, all-cause mortality).
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An adverse event is considered unlisted if the nature or severity is not consistent with the 
applicable product reference safety information. For, intranasal esketamine expectedness of an 
adverse event will be determined by whether or not it is listed in the Reference Safety 
Information Section of the Investigator’s Brochure. 
For oral antidepressants with marketing authorizations (duloxetine, escitalopram, sertraline, and 
venlafaxine XR), the expectedness of an adverse event will be determined by whether or not it is 
listed in the SmPC or USPI.
Adverse Event Associated With the Use of the Drug
An adverse event is considered associated with the use of the drug if the attribution is possible, 
probable, or very likely by the definitions listed in Section 12.1.2
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
139
Status: Approved, Date: 6 July 2016
12.1.2.
Attribution Definitions
Not Related
An adverse event that is not related to the use of the drug.
Doubtful
An adverse event for which an alternative explanation is more likely, eg, concomitant drug(s), 
concomitant disease(s), or the relationship in time suggests that a causal relationship is unlikely.
Possible
An adverse event that might be due to the use of the drug. An alternative explanation, 
eg, concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; therefore, the causal relationship cannot be excluded.
Probable
An adverse event that might be due to the use of the drug. The relationship in time is suggestive 
(eg, confirmed by dechallenge). An alternative explanation is less likely, eg, concomitant 
drug(s), concomitant disease(s).
Very Likely
An adverse event that is listed as a possible adverse reaction and cannot be reasonably explained 
by an alternative explanation, eg, concomitant drug(s), concomitant disease(s). The relationship 
in time is very suggestive (eg, it is confirmed by dechallenge and rechallenge).
12.1.3.
Severity Criteria 
An assessment of severity grade will be made using the following general categorical 
descriptors:
Mild: Awareness of symptoms that are easily tolerated, causing minimal discomfort and not 
interfering with everyday activities.
Moderate: Sufficient discomfort is present to cause interference with normal activity.
Severe: Extreme distress, causing significant impairment of functioning or incapacitation. 
Prevents normal everyday activities.
The investigator should use clinical judgment in assessing the severity of events not directly 
experienced by the subject (eg, laboratory abnormalities).
12.2.
Special Reporting Situations
Safety events of interest on a sponsor study drug that may require expedited reporting and/or 
safety evaluation include, but are not limited to:

Overdose of a sponsor study drug
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
140
Status: Approved, Date: 6 July 2016

Suspected abuse/misuse of a sponsor study drug

Inadvertent or accidental exposure to a sponsor study drug

Medication error involving a sponsor product (with or without subject/patient exposure to 
the sponsor study drug, eg, name confusion)
Special reporting situations should be recorded in the eCRF. Any special reporting situation that 
meets the criteria of a serious adverse event should be recorded on the serious adverse event page 
of the eCRF.
12.3.
Procedures
12.3.1.
All Adverse Events
All adverse events and special reporting situations, whether serious or non-serious, will be 
reported from the time a signed and dated ICF is obtained until completion of the subject's last 
study-related procedure (which may include contact for follow-up of safety), with the exception 
of pregnancy which will be reported up to 6 weeks after the last dose of study medication 
(females) or 90 days after the last dose of study medication (partners of male participants). 
Serious adverse events, including those spontaneously reported to the investigator must be 
reported using the Serious Adverse Event Form. The sponsor will evaluate any safety 
information that is spontaneously reported by an investigator beyond the time frame specified in 
the protocol.
All events that meet the definition of a serious adverse event will be reported as serious adverse 
events, regardless of whether they are protocol-specific assessments. Anticipated events will be 
recorded and reported as described in Attachment 4.
All adverse events, regardless of seriousness, severity, or presumed relationship to study drug, 
must be recorded using medical terminology in the source document and the eCRF. Whenever 
possible, diagnoses should be given when signs and symptoms are due to a common etiology 
(eg, cough, runny nose, sneezing, sore throat, and head congestion should be reported as "upper 
respiratory infection"). Investigators must record in the eCRF their opinion concerning the 
relationship of the adverse event to study therapy. All measures required for adverse event 
management must be recorded in the source document and reported according to sponsor 
instructions.
The sponsor assumes responsibility for appropriate reporting of adverse events to the regulatory 
authorities. The sponsor will also report to the investigator (and the head of the investigational 
institute where required) all suspected unexpected serious adverse reactions (SUSARs). The 
investigator (or sponsor where required) must report SUSARs to the appropriate Independent 
Ethics Committee/Institutional Review Board (IEC/IRB) that approved the protocol unless 
otherwise required and documented by the IEC/IRB.
For all studies with an outpatient phase, including open-label studies, the subject must be 
provided with a "wallet (study) card" and instructed to carry this card with them for the duration 
of the study indicating the following: 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
141
Status: Approved, Date: 6 July 2016

Study number

Statement, in the local language(s), that the subject is participating in a clinical study

Investigator's name and 24-hour contact telephone number

Local sponsor's name and 24-hour contact telephone number (for medical staff only)

Site number

Subject number
12.3.2.
Serious Adverse Events
All serious adverse events occurring during the study must be reported to the appropriate sponsor 
contact person by study-site personnel within 24 hours of their knowledge of the event.
Information regarding serious adverse events will be transmitted to the sponsor using the Serious 
Adverse Event Form, which must be completed and signed by a physician from the study site, 
and transmitted to the sponsor within 24 hours. The initial and follow-up reports of a serious 
adverse event should be made by facsimile (fax).
All serious adverse events that have not resolved by the end of the study, or that have not 
resolved upon discontinuation of the subject's participation in the study, must be followed until 
any of the following occurs:

The event resolves

The event stabilizes

The event returns to baseline, if a baseline value/status is available

The event can be attributed to agents other than the study drug or to factors unrelated to 
study conduct

It becomes unlikely that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow-up after demonstration 
of due diligence with follow-up efforts)
Suspected transmission of an infectious agent by a medicinal product will be reported as a 
serious adverse event. Any event requiring hospitalization (or prolongation of hospitalization) 
that occurs during the course of a subject's participation in a study must be reported as a serious 
adverse event, except hospitalizations for the following:

Hospitalizations not intended to treat an acute illness or adverse event (eg, social reasons 
such as pending placement in long-term care facility)

Surgery or procedure planned before entry into the study (must be documented in the 
eCRF). Note: Hospitalizations that were planned before the signing of the ICF, and where 
the underlying condition for which the hospitalization was planned has not worsened, will 
not be considered serious adverse events. Any adverse event that results in a prolongation of 
the originally planned hospitalization is to be reported as a new serious adverse event.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
142
Status: Approved, Date: 6 July 2016

For convenience the investigator may choose to hospitalize the subject for some part of the 
duration of the treatment period.
The cause of death of a subject in a study, whether or not the event is expected or associated with 
the study drug, is considered a serious adverse event.
12.3.3.
Pregnancy
All initial reports of pregnancy must be reported to the sponsor by the study-site personnel 
within 24 hours of their knowledge of the event using the appropriate pregnancy notification 
form. Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered serious adverse events and must be reported using 
the Serious Adverse Event Form. Any subject who becomes pregnant during the study must be 
promptly withdrawn from the study and discontinue further study treatment.
Because the effect of the study drug on sperm is unknown, pregnancies in partners of male subjects 
included in the study will be reported by the study-site personnel within 24 hours of their 
knowledge of the event using the appropriate pregnancy notification form.
Follow-up information regarding the outcome of the pregnancy and any postnatal sequelae in the 
infant will be required.
12.4.
Contacting Sponsor Regarding Safety
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding safety issues or questions regarding the study are listed on the Contact Information 
page(s), which will be provided as a separate document.
13.
PRODUCT QUALITY COMPLAINT HANDLING
A product quality complaint (PQC) is defined as any suspicion of a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity, quality, 
durability, or reliability of a product, including its labeling or package integrity. A PQC may have 
an impact on the safety and efficacy of the product. Timely, accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protection of subjects, investigators, 
and the sponsor, and are mandated by regulatory agencies worldwide. The sponsor has 
established procedures in conformity with regulatory requirements worldwide to ensure 
appropriate reporting of PQC information; all studies conducted by the sponsor or its affiliates 
will be conducted in accordance with those procedures.
13.1.
Procedures
All initial PQCs must be reported to the sponsor by the study-site personnel within 1 business 
day after being made aware of the event.
If the defect is combined with a serious adverse event, the study-site personnel must report the 
PQC to the sponsor according to the serious adverse event reporting timelines (refer to 
Section 12.3.2, Serious Adverse Events). A sample of the suspected product should be 
maintained for further investigation if requested by the sponsor.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
143
Status: Approved, Date: 6 July 2016
13.2.
Contacting Sponsor Regarding Product Quality
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding product quality issues are listed on the Contact Information page(s), which will be 
provided as a separate document.
14.
STUDY DRUG INFORMATION
14.1.
Physical Description of Study Drugs
14.1.1.
Intranasal Study Drug
Esketamine will be supplied as a clear, colorless intranasal solution of esketamine hydrochloride 
(16.14% weight/volume [w/v]; equivalent to 14% w/v of esketamine base) in a nasal spray 
pump. The solution will consist of 161.4 mg/mL esketamine hydrochloride (equivalent to 
140 mg of esketamine base) formulated in 0.12 mg/mL ethylenediaminetetraacetic acid (EDTA) 
and 1.5 mg/mL citric acid at a pH of 4.5 in water for injection. It is provided in a nasal spray 
pump, which delivers 16.14 mg esketamine hydrochloride (14 mg esketamine base) per 100 mcl 
spray. Each individual nasal spray pump (device) contains a total of 28 mg (ie, 2 sprays). 
Esketamine will be manufactured and provided under the responsibility of the sponsor. Please 
refer to the Investigator’s Brochure for a list of excipients.
14.1.2.
Oral Antidepressant Medications
Duloxetine
Duloxetine 30 mg will be obtained from commercial stock and provided under the responsibility 
of the sponsor. Refer to the SmPC/USPI for the physical description and a list of excipients.22,23
Escitalopram
Escitalopram 10 mg will be obtained from commercial stock and provided under the 
responsibility of the sponsor. Refer to the SmPC/USPI for the physical description and a list of 
excipients.27,28
Sertraline
Sertraline 25 mg and 50 mg (as applicable) will be obtained from commercial stock and provided 
under the responsibility of the sponsor. Refer to the SmPC/USPI for the physical description and 
a list of excipients.80,81
Venlafaxine XR
Venlafaxine 37.5 mg and 75 mg (as applicable) will be obtained from commercial stock and 
provided under the responsibility of the sponsor. Refer to the SmPC/USPI for the physical 
description and a list of excipients.89,90
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
144
Status: Approved, Date: 6 July 2016
14.2.
Packaging
Intranasal Study Drug
Study drug (ie, intranasal esketamine) will be supplied by the sponsor in a bi-dose nasal spray 
device. The devices will contain 230 µL (of which ~30µL is the residual volume). Each device 
delivers 16.14 mg esketamine hydrochloride (14 mg esketamine base) or 0.1 µg of denatonium 
benzoate per 100 µL spray. 
Each nasal spray device will be individually packaged in a blister tray and subsequently put into a 
carton box. Each carton box constitutes one non-child-resistant subject kit, labeled with a unique 
medication kit number. 
Device for Practicing Intranasal Study Drug Administration (Direct-entry subjects only)
The demonstration intranasal device will also be supplied by the sponsor and will contain placebo 
solution. Subjects will practice spraying (into the air, not intranasal).
Oral Antidepressant Medication
Oral antidepressant tablets or capsules will remain in their commercial packaging. 
Each will be packaged into a child-resistant dose pack to constitute a subject kit, labeled with a 
unique medication kit number. These will be labeled according to applicable regulatory 
requirements.
14.3.
Labeling
Study drug labels will contain information to meet the applicable regulatory requirements.
14.4.
Preparation, Handling, and Storage 
Study drugs will be stored at the study site in a secure area with restricted access until dispensed to 
the subjects. 
All study drugs must be stored at controlled temperatures as indicated on the product-specific 
labeling.
Refer to the pharmacy manual/study site investigational product manual for additional guidance on 
study drug preparation, handling, and storage.
14.5.
Drug Accountability
The investigator is responsible for ensuring that all study drug received at the site is inventoried 
and accounted for throughout the study.
The dispensing of study drug to the subject, and the return of study drug from the subject (if 
applicable), must be documented on the drug accountability form. Subjects must be instructed to 
return all original containers, whether empty or containing study drug.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
145
Status: Approved, Date: 6 July 2016
The study drug administered to the subject must be documented on the drug accountability form. 
All study drugs will be stored and disposed of according to the sponsor's instructions. Study-site 
personnel must not combine contents of the study drug containers.
Study drug must be handled in strict accordance with the protocol and the container label, and 
must be stored at the study site in a limited-access area or in a locked cabinet under appropriate 
environmental conditions. Unused study drug, and study drug returned by the subject, must be 
available for verification by the sponsor's study site monitor during on-site monitoring visits. The 
return to the sponsor of unused study drug, or used returned study drug for destruction, will be 
documented on the investigational product destruction form. When the study site is an authorized 
destruction unit and study drug supplies are destroyed on-site, this must also be documented on 
the investigational product destruction form.
Potentially hazardous materials such as used ampules, needles, syringes and vials containing 
hazardous liquids, should be disposed of immediately in a safe manner and therefore will not be 
retained for drug accountability purposes. 
Study drug should be dispensed under the supervision of the investigator or a qualified member 
of the study-site personnel, or by a hospital/clinic pharmacist. Study drug will be supplied only 
to subjects participating in the study. Returned study drug must not be dispensed again, even to 
the same subject. Whenever a subject brings his or her study drug to the study site for pill count, 
this is not seen as a return of supplies. Study drug may not be relabeled or reassigned for use by 
other subjects. The investigator agrees neither to dispense the study drug from, nor store it at, 
any site other than the study sites agreed upon with the sponsor.
15.
STUDY-SPECIFIC MATERIALS
The investigator will be provided with the following supplies:

Practice intranasal devices 

Investigator’s Brochure for esketamine

SmPC/USPI and local prescribing information for oral antidepressant study medications: 
duloxetine, escitalopram, sertraline, and venlafaxine XR.

Investigational Product (IP) Binder, including the IP Procedures investigational product 
procedures manual 

Laboratory manual and materials

Clinician-administered and subject-completed/patient-reported outcomes assessments 
o
Paper versions, as applicable
o
Electronic devices and associated materials

IWRS Manual

ECG equipment and associated materials (eg, manual)
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
146
Status: Approved, Date: 6 July 2016

Instructions for Use documents (subject and healthcare provider versions) for intranasal 
study medication

Subject diary

Computerized cognitive battery and HVLT-R, and all associated equipment and materials

Device to measure respiratory rate

Guidance on recommended order of study procedures

Guidance document for the use of the MGH-ATRQ.

Web-based Patient Stated-choice Preference Survey.
16.
ETHICAL ASPECTS
16.1.
Study-Specific Design Considerations
Clinical Study in Treatment-resistant Major Depression
Major depressive disorder is a common, severe, chronic and often life-threatening illness. It is 
now the leading cause of disability worldwide. There is a clear need to develop novel and 
improved therapeutics for treatment-resistant major depression.
Studies with esketamine have shown robust antidepressant effects in several clinical studies and 
it has been well tolerated in these clinical studies.
Selection of Subjects
The primary aim of the study is to evaluate long-term safety and tolerability of intranasal 
esketamine plus an oral antidepressant in subjects with TRD. Thus, the study cannot be 
conducted in healthy subjects. 
Potential subjects will be fully informed of the risks and requirements of the study and, during the 
study, subjects will be given any new information that may affect their decision to continue 
participation.
As part of study entry criteria, at screening subjects must have a history of TRD inadequate 
response to at least 2 antidepressants at adequate doses and for adequate duration of time). 
Transferred-entry non-responder subjects from ESKETINTRD3005 will join this study starting 
from Day 1 of the induction phase and transferred-entry responder subjects will join this study on 
the first day of the optimization/maintenance phase.
The blind for transferred entry subjects will not be broken. This results in 4 cohorts:
1) Subjects who are non-responders to placebo have the potential of receiving esketamine in 
this study,
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
147
Status: Approved, Date: 6 July 2016
2) Subjects who are non-responders to esketamine in the ESKETINTRD3005 study who 
decide to participate in this study may not benefit from additional treatment with 
esketamine. However, the time to response to oral antidepressants in elderly takes typically 
longer than 4 weeks. The benefit of additional treatment with esketamine remains 
unknown. In case of no perceived benefit of esketamine to the subjects after 2-3 dosing 
sessions they may choose to discontinue from this study,
3) Subjects who are responders to esketamine are expected to benefit from longer term 
treatment to maintain their treatment response,
4) Subjects who are responders to the oral antidepressant. These subjects were documented to 
be treatment-resistant prior to the study, and the probability of responding to a new oral 
antidepressant is very limited. In case of no additional benefit over that achieved during the 
induction phase in this study after 2-3 dosing session, subjects may choose to discontinue 
from this study.
Direct entry subjects will receive 4 weeks of treatment in the open-label induction phase; those 
who are responders will be eligible to participate in the optimization/maintenance phase.
Subjects will be told that their consent to participate in the study is voluntary and may be 
withdrawn at any time with no reason given and without penalty or loss of benefits to which they 
would otherwise be entitled. Only subjects who are fully able to understand the risks, benefits, 
and potential adverse events of the study, and provide their consent voluntarily will be enrolled. 
At any time during the study, subjects may discontinue and proceed to the 4 week follow-up 
phase; they will be provided with an additional 4 week supply of oral antidepressant and 
appropriate follow-up care will be arranged.
Precautions to Ensure Subject Safety in the Study
Subjects may participate in the study only if they have adequate capacity to give consent and 
after fully understanding the potential risks and giving an informed consent. Determination of 
capacity will be made by the study investigator. Subjects may discontinue the study at any time. 
Potential disadvantages and adverse events of participating in the study and alternative treatment 
options will be discussed. For subjects who do not meet predefined response criteria during the 
study, clinical care will be arranged between the subject and the study investigator and/or the 
subject's physician.
Compensation for any procedure will be fair per local standards and approved by the 
participating site's IRB, in order to avoid offering any undue incentive to participate in the study.
Subjects will be carefully monitored during the study and subjects who are unable to tolerate 
study drugs will be discontinued from the study. If the investigator judges it to be necessary to 
immediately stop study drug, he or she has the option to do so. Specific guidance is provided 
regarding blood pressure monitoring on dosing days (see Section 6.1).
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
148
Status: Approved, Date: 6 July 2016
Only subjects who had non-response to their current or previous oral antidepressant treatment, 
where a clinician would consider changing it in the future due to lack of response, will be 
enrolled (direct entry).
The total blood volume to be collected is considered to be within the normal range allowed for 
this subject population over this time frame. The total blood volume to be collected during a full 
year of study participation is approximately 148 mL, which will be less than a Red Cross blood 
donation.
16.2.
Regulatory Ethics Compliance
16.2.1.
Investigator Responsibilities
The investigator is responsible for ensuring that the study is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory and 
country-specific requirements.
Good Clinical Practice is an international ethical and scientific quality standard for designing, 
conducting, recording, and reporting studies that involve the participation of human subjects. 
Compliance with this standard provides public assurance that the rights, safety, and well-being of 
study subjects are protected, consistent with the principles that originated in the Declaration of 
Helsinki, and that the study data are credible.
16.2.2.
Independent Ethics Committee or Institutional Review Board
Before the start of the study, the investigator (or sponsor where required) will provide the 
IEC/IRB with current and complete copies of the following documents (as required by local 
regulations):

Final protocol and, if applicable, amendments

Sponsor-approved ICF (and any other written materials to be provided to the subjects)

Investigator's Brochure (or equivalent information) and amendments/addenda

Sponsor-approved subject recruiting materials

Sponsor-approved training and informational materials.

Information on compensation for study-related injuries or payment to subjects for 
participation in the study, if applicable

Investigator's curriculum vitae or equivalent information (unless not required, as 
documented by the IEC/IRB)

Information regarding funding, name of the sponsor, institutional affiliations, other potential 
conflicts of interest, and incentives for subjects

Any other documents that the IEC/IRB requests to fulfill its obligation
This study will be undertaken only after the IEC/IRB has given full approval of the final 
protocol, amendments (if any, excluding the ones that are purely administrative, with no 
consequences for subjects, data or study conduct), the ICF, applicable recruiting materials, and 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
149
Status: Approved, Date: 6 July 2016
subject compensation programs, and the sponsor has received a copy of this approval. This 
approval letter must be dated and must clearly identify the IEC/IRB and the documents being 
approved.
During the study the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:

Protocol amendments (excluding the ones that are purely administrative, with no 
consequences for subjects, data or study conduct)

Revision(s) to ICF and any other written materials to be provided to subjects

If applicable, new or revised subject recruiting materials approved by the sponsor

Revisions to compensation for study-related injuries or payment to subjects for participation 
in the study, if applicable

New edition(s) of the Investigator's Brochure and amendments/addenda

Summaries of the status of the study at intervals stipulated in guidelines of the IEC/IRB (at 
least annually)

Reports of adverse events that are serious, unlisted/unexpected, and associated with the 
study drug

New information that may adversely affect the safety of the subjects or the conduct of the 
study

Deviations from or changes to the protocol to eliminate immediate hazards to the subjects

Report of deaths of subjects under the investigator's care

Notification if a new investigator is responsible for the study at the site

Development Safety Update Report and Line Listings, where applicable

Any other requirements of the IEC/IRB
For all protocol amendments (excluding the ones that are purely administrative, with no 
consequences for subjects, data or study conduct), the amendment and applicable ICF revisions 
must be submitted promptly to the IEC/IRB for review and approval before implementation of 
the change(s).
At least once a year, the IEC/IRB will be asked to review and reapprove this study. The 
reapproval should be documented in writing (excluding the ones that are purely administrative, 
with no consequences for subjects, data, or study conduct).
At the end of the study, the investigator (or sponsor where required) will notify the IEC/IRB 
about the study completion.
16.2.3.
Informed Consent
Each subject must give written consent according to local requirements after the nature of the 
study has been fully explained. The ICF(s) must be signed before performance of any study-
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
150
Status: Approved, Date: 6 July 2016
related activity. The ICF(s) that is/are used must be approved by both the sponsor and by the 
reviewing IEC/IRB and be in a language that the subject can read and understand. The informed 
consent should be in accordance with principles that originated in the Declaration of Helsinki, 
current ICH and GCP guidelines, applicable regulatory requirements, and sponsor policy.
Before enrollment in the study, the investigator or an authorized member of the study-site 
personnel must explain to potential subjects the aims, methods, reasonably anticipated benefits, 
and potential hazards of the study, and any discomfort participation in the study may entail. 
Subjects will be informed that their participation is voluntary and that they may withdraw 
consent to participate at any time. They will be informed that choosing not to participate will not 
affect the care the subject will receive for the treatment of his or her disease. Subjects will be told 
that alternative treatments are available if they refuse to take part and that such refusal will not 
prejudice future treatment. Finally, they will be told that the investigator will maintain a subject 
identification register for the purposes of long-term follow up if needed and that their records 
may be accessed by health authorities and authorized sponsor personnel without violating the 
confidentiality of the subject, to the extent permitted by the applicable law(s) or regulations. By 
signing the ICF the subject is authorizing such access, and agrees to allow his or her study 
physician to recontact the subject for the purpose of obtaining consent for additional safety 
evaluations, if needed.
The subject will be given sufficient time to read the ICF and the opportunity to ask questions. 
After this explanation and before entry into the study, consent should be appropriately recorded 
by means of the subject's personally dated signature. After having obtained the consent, a copy of 
the ICF must be given to the subject.
Where local regulations require, a separate ICF may be used for the required DNA component of 
the study.
16.2.4.
Privacy of Personal Data
The collection and processing of personal data from subjects enrolled in this study will be 
limited to those data that are necessary to fulfill the objectives of the study.
These data must be collected and processed with adequate precautions to ensure confidentiality 
and compliance with applicable data privacy protection laws and regulations. Appropriate 
technical and organizational measures to protect the personal data against unauthorized 
disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be 
put in place. Sponsor personnel whose responsibilities require access to personal data agree to 
keep the identity of subjects confidential.
The informed consent obtained from the subject includes explicit consent for the processing of 
personal data and for the investigator/institution to allow direct access to his or her original 
medical records (source data/documents) for study-related monitoring, audit, IEC/IRB review, 
and regulatory inspection. This consent also addresses the transfer of the data to other entities 
and to other countries.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
151
Status: Approved, Date: 6 July 2016
The subject has the right to request through the investigator access to his or her personal data and 
the right to request rectification of any data that are not correct or complete. Reasonable steps 
will be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study, and the applicable laws and regulations.
Exploratory DNA and biomarker research is not conducted under standards appropriate for the 
return of data to subjects. In addition, the sponsor cannot make decisions as to the significance of 
any findings resulting from exploratory research. Therefore, exploratory research data will not be 
returned to subjects or investigators, unless required by law or local regulations. Privacy and 
confidentiality of data generated in the future on stored samples will be protected by the same 
standards applicable to all other clinical data.
16.2.5.
Long-Term Retention of Samples for Additional Future Research 
Samples collected in this study may be stored for up to 15 years (or according to local 
regulations) for additional research. Samples will only be used to understand esketamine, oral 
antidepressants, to understand depression, to understand differential drug responders, and to 
develop tests/assays related to esketamine, oral antidepressants, and depression. The research 
may begin at any time during the study or the post-study storage period.
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be 
stored for research (refer to Section 10.2 Criteria for Withdrawal From the Study).
16.2.6.
Country Selection
This study will only be conducted in those countries where the intent is to launch or otherwise 
help ensure access to the developed product, unless explicitly addressed as a specific ethical 
consideration in Section 16.1, Study-Specific Design Considerations.
17.
ADMINISTRATIVE REQUIREMENTS
17.1.
Protocol Amendments
Neither the investigator nor the sponsor will modify this protocol without a formal amendment 
by the sponsor. All protocol amendments must be issued by the sponsor, and signed and dated by 
the investigator. Protocol amendments must not be implemented without prior IEC/IRB 
approval, or when the relevant competent authority has raised any grounds for non-acceptance, 
except when necessary to eliminate immediate hazards to the subjects, in which case the 
amendment must be promptly submitted to the IEC/IRB and relevant competent authority. 
Documentation of amendment approval by the investigator and IEC/IRB must be provided to the 
sponsor. When the change(s) involves only logistic or administrative aspects of the study, the 
IRB (and IEC where required) only needs to be notified.
During the course of the study, in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact the appropriate sponsor 
representative (see Contact Information page(s) provided separately). Except in emergency 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
152
Status: Approved, Date: 6 July 2016
situations, this contact should be made before implementing any departure from the protocol. In 
all cases, contact with the sponsor must be made as soon as possible to discuss the situation and 
agree on an appropriate course of action. The data recorded in the eCRF and source documents 
will reflect any departure from the protocol, and the source documents will describe this 
departure and the circumstances requiring it.
17.2.
Regulatory Documentation
17.2.1.
Regulatory Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory authorities 
in each respective country, if applicable. A study may not be initiated until all local regulatory 
requirements are met.
17.2.2.
Required Prestudy Documentation
The following documents must be provided to the sponsor before shipment of study drug to the 
study site:

Protocol and amendment(s), if any, signed and dated by the principal investigator

A copy of the dated and signed (or sealed, where appropriate per local regulations), written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approval must clearly identify the specific 
protocol by title and number and must be signed (or sealed, where appropriate per local 
regulations) by the chairman or authorized designee.

Name and address of the IEC/IRB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a letter of explanation, or equivalent, 
from the IEC/IRB, a general statement may be substituted for this list. If an investigator or a 
member of the study-site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the 
vote/opinion of the study.

Regulatory authority approval or notification, if applicable

Signed and dated statement of investigator (eg, Form FDA 1572), if applicable

Documentation of investigator qualifications (eg, curriculum vitae)

Completed investigator financial disclosure form from the principal investigator, where 
required

Signed and dated clinical trial agreement, which includes the financial agreement

Any other documentation required by local regulations
The following documents must be provided to the sponsor before enrollment of the first subject:

Completed investigator financial disclosure forms from all subinvestigators

Documentation of subinvestigator qualifications (eg, curriculum vitae)
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
153
Status: Approved, Date: 6 July 2016

Name and address of any local laboratory conducting tests for the study, and a dated copy of 
current laboratory normal ranges for these tests, if applicable

Local 
laboratory 
documentation 
demonstrating 
competence 
and 
test 
reliability 
(eg, accreditation/license), if applicable
17.3.
Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study. This document will be reviewed by the 
sponsor study-site contact for completeness.
The subject identification and enrollment log will be treated as confidential and will be filed by 
the investigator in the study file. To ensure subject confidentiality, no copy will be made. All 
reports and communications relating to the study will identify subjects by subject identification
and date of birth. In cases where the subject is not randomized into the study, the date seen and 
date of birth will be used.
The investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibility for inclusion in the study.
17.4.
Source Documentation
At a minimum, source documentation consistent in the type and level of detail with that 
commonly recorded at the study site as a basis for standard medical care must be available for 
the following to confirm data collected in the eCRF: subject identification, eligibility, and study 
identification; study discussion and date of signed informed consent; dates of visits; results of 
safety and efficacy parameters as required by the protocol; record of all adverse events and 
follow-up of adverse events; concomitant medication; drug receipt/dispensing/return records; 
study drug administration information; and date of study completion and reason for early 
discontinuation of study drug or withdrawal from the study, if applicable.
The author of an entry in the source documents should be identifiable.
Specific details required as source data for the study and source data collection methods will be 
reviewed with the investigator before the study and will be described in the monitoring 
guidelines (or other equivalent document).
Some subject-completed and clinician-completed scales and assessments designated by the 
sponsor) will be recorded directly into an electronic device and will be considered source data.
The minimum source documentation requirements for Section 4.1, Inclusion Criteria and 
Section 4.2, Exclusion Criteria that specify a need for documented medical history are as 
follows:

Referral letter from treating physician or

Complete history of medical notes at the site

Discharge summaries
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
154
Status: Approved, Date: 6 July 2016

Antidepressant treatment in the current episode of depression
Inclusion and exclusion criteria not requiring documented medical history must be verified at a 
minimum by subject interview or other protocol required assessment (eg, physical examination, 
laboratory assessment) and documented in the source documents.
17.5.
Case Report Form Completion
Case report forms are provided for each subject in electronic format. All CRF entries, 
corrections, and alterations must be made by the investigator or authorized study-site personnel. 
The investigator must verify that all data entries in the CRF are accurate and correct.
Electronic Data Capture (eDC) will be used for this study. The study data will be transcribed by 
study-site personnel from the source documents onto an eCRF, and transmitted in a secure 
manner to the sponsor within the timeframe agreed upon between the sponsor and the study site. 
The electronic file will be considered to be the eCRF.
Worksheets may be used for the capture of some data to facilitate completion of the eCRF. Any 
such worksheets will become part of the subject's source documents. All data relating to the 
study must be recorded in eCRFs prepared by the sponsor. Data must be entered into eCRFs in 
English. Study site personnel must complete the eCRF as soon as possible after a subject visit, 
and the forms should be available for review at the next scheduled monitoring visit.
The investigator must verify that all data entries in the eCRFs are accurate and correct.
All subject measurements (eg, clinician reported questionnaires) will be completed by the same 
individual who made the initial baseline determinations whenever possible.
All eCRF entries, corrections, and alterations must be made by the investigator or other 
authorized study-site personnel. If necessary, queries will be generated in the eDC tool. The 
investigator or study-site personnel must adjust the eCRF (if applicable) and complete the query.
If corrections to an eCRF are needed after the initial entry into the eCRF, this can be done in 
either of the following ways:

Investigator and study site personnel can make corrections in the eDC tool at their own 
initiative or as a response to an auto query (generated by the eDC tool).

Sponsor or sponsor delegate can generate a query for resolution by the study-site personnel.
17.6.
Data Quality Assurance/Quality Control
Steps to be taken to ensure the accuracy and reliability of data include the selection of qualified 
investigators and appropriate study sites, review of protocol procedures with the investigator and 
study-site personnel before the study, periodic monitoring visits by the sponsor, and uploading 
data transfers from external service providers into the sponsor’s database. Written instructions 
will be provided for collection, handling, storage, and shipment of samples.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
155
Status: Approved, Date: 6 July 2016
Guidelines for eCRF completion will be provided and reviewed with study-site personnel before 
the start of the study.
The sponsor will review eCRFs for accuracy and completeness during on-site monitoring visits 
and after transmission to the sponsor; any discrepancies will be resolved with the investigator or 
designee, as appropriate. After upload of the data into the study database they will be verified for 
accuracy and consistency with the data sources.
17.7.
Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRFs 
and all source documents that support the data collected from each subject, as well as all study 
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
Clinical Trial, and all study documents as specified by the applicable regulatory requirement(s). 
The investigator/institution will take measures to prevent accidental or premature destruction of 
these documents.
Essential documents must be retained until at least 2 years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or until at least 2 years have elapsed since the formal
discontinuation of clinical development of the investigational product. These documents will be 
retained for a longer period if required by the applicable regulatory requirements or by an 
agreement with the sponsor. It is the responsibility of the sponsor
to inform the 
investigator/institution as to when these documents no longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility of keeping the study records, custody must be transferred to a person who will 
accept the responsibility. The sponsor must be notified in writing of the name and address of the 
new custodian. Under no circumstance shall the investigator relocate or dispose of any study 
documents before having obtained written approval from the sponsor.
If it becomes necessary for the sponsor or the appropriate regulatory authority to review any 
documentation relating to this study, the investigator/institution must permit access to such 
reports.
17.8.
Monitoring
The sponsor will perform on-site monitoring visits as frequently as necessary. The monitor will 
record dates of the visits in a study site visit log that will be kept at the study site. The first post-
initiation visit will be made as soon as possible after enrollment has begun. At these visits, the 
monitor will compare the data entered into the eCRFs with the hospital or clinic records (source 
documents); a sample will be reviewed. The nature and location of all source documents will be 
identified to ensure that all sources of original data required to complete the eCRF are known to 
the sponsor and study-site personnel and are accessible for verification by the sponsor study-site 
contact. If electronic records are maintained at the study site, the method of verification must be 
discussed with the study-site personnel. 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
156
Status: Approved, Date: 6 July 2016
Direct access to source documentation (medical records) must be allowed for the purpose of 
verifying that the data recorded in the eCRF are consistent with the original source data. Findings 
from this review of eCRFs and source documents will be discussed with the study-site personnel. 
The sponsor expects that, during monitoring visits, the relevant study-site personnel will be 
available, the source documentation will be accessible, and a suitable environment will be 
provided for review of study-related documents. The monitor will meet with the investigator on a 
regular basis during the study to provide feedback on the study conduct.
In addition to on-site monitoring visits, the monitor may contact the site by telephone for an 
update on study progress. It is expected that study -site personnel will be available to provide an 
update on the progress of the study at the site.
17.9.
Study Completion/Termination
17.9.1.
Study Completion
The end of the study will occur when at least 300 subjects have received treatment with 
intranasal esketamine for 6 months and at least 100 subjects for 12 months (Note: the total 
number of subjects will be based on subjects from this study and subjects from other intranasal 
esketamine Phase 3 studies). 
The study is considered completed with the last study assessment for the last subject 
participating in the study. The final data from the study site will be sent to the sponsor (or 
designee) after completion of the final subject assessment at that study site, in the time frame 
specified in the Clinical Trial Agreement.
17.9.2.
Study Termination
The sponsor reserves the right to close the study site or terminate the study at any time for any 
reason at the sole discretion of the sponsor. Study sites will be closed upon study completion. A
study site is considered closed when all required documents and study supplies have been 
collected and a study-site closure visit has been performed.
The investigator may initiate study-site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the early closure of a study site by the sponsor or investigator may include but are 
not limited to:

Failure of the investigator to comply with the protocol, the requirements of the IEC/IRB or 
local health authorities, the sponsor's procedures, or GCP guidelines

Inadequate recruitment of subjects by the investigator

Discontinuation of further study drug development
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
157
Status: Approved, Date: 6 July 2016
17.10. On-Site Audits
Representatives of the sponsor's clinical quality assurance department may visit the study site at 
any time during or after completion of the study to conduct an audit of the study in compliance 
with regulatory guidelines and company policy. These audits will require access to all study 
records, including source documents, for inspection and comparison with the eCRFs. Subject 
privacy must, however, be respected. The investigator and study-site personnel are responsible 
for being present and available for consultation during routinely scheduled study-site audit visits 
conducted by the sponsor or its designees. 
Similar auditing procedures may also be conducted by agents of any regulatory body, either as 
part of a national GCP compliance program or to review the results of this study in support of a 
regulatory submission. The investigator should immediately notify the sponsor if he or she has
been contacted by a regulatory agency concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regarding esketamine or the sponsor's 
operations (eg, patent application, formulas, manufacturing processes, basic scientific data, prior 
clinical data, formulation information) supplied by the sponsor to the investigator and not 
previously published, and any data, including pharmacogenomic or exploratory biomarker 
research data, generated as a result of this study, are considered confidential and remain the sole 
property of the sponsor. The investigator agrees to maintain this information in confidence and 
use this information only to accomplish this study, and will not use it for other purposes without 
the sponsor's prior written consent.
The investigator understands that the information developed in the study will be used by the 
sponsor in connection with the continued development of esketamine, and thus may be disclosed 
as required to other clinical investigators or regulatory agencies. To permit the information 
derived from the clinical studies to be used, the investigator is obligated to provide the sponsor 
with all data obtained in the study.
The results of the study will be reported in a Clinical Study Report generated by the sponsor and 
will contain eCRF data from all study sites that participated in the study and will represent 
uploaded data transfers from external service providers into the sponsor’s database. Recruitment 
performance or specific expertise related to the nature and the key assessment parameters of the 
study will be used to determine a coordinating investigator. Results of pharmacogenomic or 
exploratory biomarker analyses performed after the Clinical Study Report has been issued will 
be reported in a separate report and will not require a revision of the Clinical Study Report. 
Study subject identifiers will not be used in publication of results. Any work created in 
connection with performance of the study and contained in the data that can benefit from 
copyright protection (except any publication by the investigator as provided for below) shall be 
the property of the sponsor as author and owner of copyright in such work.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
158
Status: Approved, Date: 6 July 2016
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, the sponsor shall have the right to publish such primary (multicenter) data 
and information without approval from the investigator. The investigator has the right to publish 
study site-specific data after the primary data are published. If an investigator wishes to publish 
information from the study, a copy of the manuscript must be provided to the sponsor for review 
at least 60 days before submission for publication or presentation. Expedited reviews will be 
arranged for abstracts, poster presentations, or other materials. If requested by the sponsor in 
writing, the investigator will withhold such publication for up to an additional 60 days to allow 
for filing of a patent application. In the event that issues arise regarding scientific integrity or 
regulatory compliance, the sponsor will review these issues with the investigator. The sponsor 
will not mandate modifications to scientific content and does not have the right to suppress 
information. For multicenter study designs and substudy approaches, secondary results generally 
should not be published before the primary endpoints of a study have been published. Similarly, 
investigators will recognize the integrity of a multicenter study by not submitting for publication 
data derived from the individual study site until the combined results from the completed study
have been submitted for publication, within 12 months of the availability of the final data (tables, 
listings, graphs), or the sponsor confirms there will be no multicenter study publication. 
Authorship of publications resulting from this study will be based on the guidelines on 
authorship, such as those described in the Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals, which state that the named authors must have made a significant 
contribution to the design of the study or analysis and interpretation of the data, provided critical 
review of the paper, and given final approval of the final version.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and/or disclose the existence of and the results of clinical studies as 
required by law.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
159
Status: Approved, Date: 6 July 2016
REFERENCES
1.
aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for 
treatment-resistant depression. Biol Psychiatry. 2010;67(2):139-145.
2.
Bazett HC. An analysis of the time-relationship of electrocardiograms. Heart. 1920;7:353-380.
3.
Benedict RHB, Schretlen D, Groninger L, Brandt J. Hopkins Verbal Learning Test-Revised: normative data 
and analysis of inter-form and test-retest reliability. Clin. Neuropsychologist. 1998;12:43-55.
4.
Blier P, Zigman D, Blier J. On the safety and benefits of repeated intravenous injections of ketamine for 
depression. Biol Psychiatry. 2012;72:e11-e12.
5.
Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM. Measurement of 
dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress. 
1998;11(1):125-136.
6.
Chang T, Savory A, Albin M, Goulet R, Glasko AJ. Metabolic disposition of tritium-labelled ketamine 
(Ketalar®, CI-581) in normal human subjects. Clin Res. 1970;18:597.
7.
Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen patients for obstructive sleep 
apnea. Anesthesiology. 2008;108:812-821.
8.
Clinical Study Protocol ESKETINTRD2003. A double-blind, doubly-randomized, placebo-controlled study of 
intranasal esketamine in an adaptive treatment protocol to assess safety and efficacy in treatment-resistant 
depression (SYNAPSE). Document ID No. EDMS-ERI-71950055 (28 Apr 2014). 
9.
Clinical Study Protocol ESKETINTRD3005. A Randomized, Double-blind, Multicenter, Active-controlled 
Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant 
in Elderly Subjects with Treatment-resistant Depression. Janssen Research & Development (10 March 2015). 
Document No. EDMS-ERI-93094734:1.0.
10.
Clinical Study Protocol ESKETINTRD1012. An Open-Label, Single-Dose Study to Assess the 
Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Elderly (75 Years of 
Age) and Healthy Younger Adult Subjects (18 to 55 Years of Age, Inclusive). Document No. 
EDMS-ERI-92316094 (03 December 2014).
11.
Clinical Study Report ESKETINTRD1001. An open-label Phase 1 study to evaluate the pharmacokinetics of 
intranasal esketamine administered with and without a nasal guide on the intranasal device. Document No. 
EDMS-ERI-73676925 (21 Aug 2014).
12.
Clinical Study Report ESKETINTRD1002. An open-label, single-dose study to assess the pharmacokinetics, 
safety, and tolerability of intranasally administered esketamine in healthy Japanese and Caucasian subjects. 
Document No. EDMS-ERI-74234860 (21 Aug 2014).
13.
Clinical Study Report ESKETINTRD1003. An open-label, single-dose study to assess the pharmacokinetics, 
safety, and tolerability of intranasally administered esketamine in healthy elderly and adult subjects. Document 
No. EDMS-ERI-81854053 (30 Dec 2014).
14.
Clinical Study Report ESKETIVTRD2001. A double-blind, double-randomization, placebo-controlled study of 
the efficacy of intravenous esketamine in adult subjects with treatment-resistant depression. Document No. 
EDMS-ERI-63623355 (01 May 2014).
15.
Clinical Study Report KETIVTRD2002. A double-blind, randomized, placebo-controlled, parallel group, dose 
frequency study of ketamine in subjects with treatment-resistant depression. Document No. 
EDMS-ERI-63976766 (5 Sep 2014).
16.
ClinicalTrials.gov Registry Entry NCT01557712. Estimate the efficiency of the association of an injection of 
ketamine and the venlafaxine in the severe major depressive disorder for six weeks (KETADEP). Sponsor: 
University Hospital, Grenoble. http://clinicaltrials.gov/ct2/show/NCT01557712. Last updated 16 Mar 2012. 
Accessed 16 Dec 2014.
17.
ClinicalTrials.gov Registry Entry NCT01880593. Ketamine plus lithium in treatment-resistant depression. 
Sponsor: Mount Sinai School of Medicine. https://clinicaltrials.gov/ct2/show/NCT01880593. Last updated 
6 Dec 2014. Accessed 16 Dec 2014.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
160
Status: Approved, Date: 6 July 2016
18.
Critchlow DG. A case of ketamine dependence with discontinuation symptoms. Addiction. 
2006;101(8):1212-1213.
19.
Curran HV, Morgan C. Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on 
the night of drug use and 3 days later. Addiction. 2000;95(4):575-590.
20.
Desseilles M, Witte J, Chang TE, Iovieno N, Dording CM, Ashih H, Nyer M, Freeman MP, Fava M, 
Mischoulon D. Assessing the adequacy of past antidepressant trials: a clinician's guide to the antidepressant 
treatment response questionnaire. J Clin Psychiatry. 2011;72(8):1152-1154. 
21.
DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Iosifescu DV. The promise of ketamine for treatment-
resistant depression: current evidence and future directions. Ann N Y Acad Sci. 2015 Feb 3. (17)
22.
Duloxetine (Cymbalta®): US Prescribing Information. Lilly USA, LLC, Indianapolis, Indiana, USA; December 
2014. http://pi.lilly.com/us/cymbalta-pi.pdf (accessed 9 February 2015). 
23.
Duloxetine (Cymbalta®): Summary of Product Characteristics. Eli Lilly Nederland, Houten, The Netherlands; 
August 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000572/WC500036781.pdf (accessed 6 March 2015).
24.
Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012 
Oct 5;338(6103):68-72.
25.
Ebert B, Mikkelsen S, Thorkildsen C, Borgbjerg FM. Norketamine, the main metabolite of ketamine, is a 
non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol. 1997;333:99-104.
26.
Endou M, Hattori Y, Nakaya H, Gotoh Y, Kanno M. Electrophysiologic mechanisms responsible for inotropic 
responses to ketamine in guinea pig and rat myocardium. Anesthesiology. 1992;76:409-418.
27.
Escitalopram (Cipralex®): US Prescribing Information. Lundbeck Canada Inc., Quebec, Canada; 12 November 
2014. http://www.lundbeck.com/upload/ca/en/files/pdf/product_pi/Cipralex_November_2013/Cipralex.pdf 
(accessed 9 February 2015).
28.
Escitalopram: Summary of Product Characteristics. Actavis Group PTC ehf., Iceland; July 2014. 
http://www.medicines.org.uk/emc/medicine/28956 (accessed 6 March 2015).
29.
EuroQol Group. About EQ-5D. http://www.euroqol.org/about-eq-5d.html (accessed 18 June 2014).
30.
EuroQol Group. EQ-5D-5L User Guide: basic information on how to use the EQ-5D-5L instrument. Version 
2.0; October 2013. 
http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/UserGuide_EQ-5D-
5L_v2.0_October_2013.pdf (accessed 6 August 2014).
31.
Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003 Apr 15;53(8):649-659. 
Review. 
32.
Fond G, Loundou A, Rabu C et al. Ketamine administration in depressive disorders: a systematic review and 
meta-analysis. Psychopharmacology (Berl). 2014:231(18):3663-3676
33.
Geisslinger G, Hering W, Thomann P, Knoll R, Kamp H-D, Brune K. Pharmacokinetics and 
pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method. Br J 
Anaesth. 1993;70:666-671. 
34.
Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: U.S. Department of Health, 
Education, and Welfare; 1976.
35.
Haas DA, Harper DG. Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia. 
Anesth Prog. 1992;39(3):61-68. 
36.
Hagelberg NM, Peltoniemi MA, Saari TI, et al. Clarithromycin, a potent inhibitor of CYP3A, greatly increases 
exposure to oral S-ketamine. Eur J Pain. 2010;14:625-629. 
37.
Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of 
ketamine in human liver microsomes. Drug Metab Dispos. 2002; 30: 853-858.  
38.
Holtman JR, Crooks PA, Johnson-Hardy JK, Hojomat M, Kleven M, Wala EP. Effects of norketamine 
enantiomers in rodent models of persistent pain. Pharmacol Biochem Behav. 2008; 90: 676-685.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
161
Status: Approved, Date: 6 July 2016
39.
Humphrey L, Arbuckle R, Moldwin R, et al. The Bladder Pain/Interstitial Cystitis Symptom Score: 
development, validation, and identification of a cut score. Eur Urology. 2012;61:271-279. 
40.
Hurt PH, Ritchie EC. A case of ketamine dependence. Am J Psychiatry. 1994 May;151(5):779. 
41.
Investigator’s Brochure, JNJ-54135419-AAC (esketamine hydrochloride),. Document ID: EDMS-ERI-
49489196.
42.
Jansen KL. Ketamine--can chronic use impair memory? Int J Addict. 1990 Feb;25(2):133-9.
43.
Johnson FR, Hauber B, Özdemir S, Siegel CA, Hass S, Sands BE. Are gastroenterologists less tolerant of 
treatment risks than patients? Benefit-risk preferences in Crohn's disease management. J Manag Care Pharm. 
2010; 16: 616-628.
44.
Ketamine HCl Injection: US Prescribing Information; March 2012. JHP Pharmaceuticals, LLC. Rochester, 
Minnesota, USA. http://www.drugs.com/pro/ketalar.html (accessed 25 February 2015). 
45.
Ketanest-S®: Summary of Product Characteristics. Ankeveen, The Netherlands: Eurocept BV; 2011.
46.
Kinter ET, Schmeding A, Rudolph I, dosReis S, Bridges JF. Identifying patient-relevant endpoints among 
individuals with schizophrenia: an application of patient-centered health technology assessment. Int J Technol 
Assess Health Care. 2009; 25: 35-41. 
47.
Lapidus KA, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major 
depressive disorder. Biol Psychiatry. 2014;76(12):970-6.
48.
Leon AC, Olfson M, Portera L, Farber L, Sheehan DV. Assessing psychiatric impairment in primary care with 
the Sheehan Disability Scale. Int J Psychiatry Med. 1997; 27(2):93-105. 
49.
Levitan B, Markowitz M, Mohamed AF, Johnson FR, Alphs L, Citrome L, Bridges JF. Patients' Preferences 
Related to Benefits, Risks, and Formulations of Schizophrenia Treatment. Psychiatr Serv. 2015; 66(7):719-726. 
50.
Lim DK. Ketamine associated psychedelic effects and dependence. Singapore Med J. 2003;44(1):31-34.
51.
McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta-analysis of 
randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive 
episodes. Psychol Med. 2015 Mar;45(4):693-704. 
52.
Monteggia LM, Zarate C Jr. Antidepressant actions of ketamine: from molecular mechanisms to clinical 
practice. Curr Opin Neurobiol. 2015 Feb;30C:139-143.
53.
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 
1979;134:382-389. 
54.
Montgomery SA. Clinically relevant effect sizes in depression. Eur Neuropsychopharmacology. 1994;(4)283-284. 
55.
Moore NN, Bostwick JM. Ketamine dependence in anesthesia providers. Psychosomatics. 1999 
Jul-Aug;40(4):356-9. 
56.
Morgan CJ, Curran HV. Acute and chronic effects of ketamine upon human memory: a review. 
Psychopharmacology. 2006;188:408-424. 
57.
Morgan CJ, Muetzelfeldt L, Curran HV. Ketamine use, cognition and psychological wellbeing: a comparison 
of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction. 2009;104:77-87.
58.
Morgan CJ, Curran HV; Independent Scientific Committee on Drugs. Ketamine use: a review. Addiction. 2012 
Jan;107(1):27-38. 
59.
Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon 
neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction. 2010 
Jan;105(1):121-33. 
60.
Muetzelfeldt L, Kamboj SK, Rees H, Taylor J, Morgan CJ, Curran HV. Journey through the K-hole: 
phenomenological aspects of ketamine use. Drug Alcohol Depend. 2008 Jun 1; 95(3):219-29.
61.
Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine 
infusions in treatment-resistant major depression. Biol Psychiatry. 2013; 74:250-256. 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
162
Status: Approved, Date: 6 July 2016
62.
Narendran R, Frankle WG, Keefe R, et al. Altered prefrontal dopaminergic function in chronic recreational 
ketamine users. Am J Psychiatry. 2005 Dec; 162(12):2352-9. 
63.
Opler LA, Opler MG, Arnsten AF. Ameliorating treatment-refractory depression with intranasal ketamine: 
potential NMDA receptor actions in the pain circuitry representing mental anguish. CNS Spectr. 
2015 Jan 26:1-11. 
64.
Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment 
and scaling. Psychopharmacol Bull. 1988;24:97-99.
65.
Overall JE; Gorham D R. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812. 
66.
Pal HR, Berry N, Kumar R, Ray R. Ketamine dependence. Anaesth Intensive Care. 2002 Jun;30(3):382-4. 
67.
Persson J. Wherefore ketamine? Curr Opin Anaesthesiol. 2010 Aug;23(4):455-60. 
68.
Pharmacokinetic Report KET-PK-007. A randomized, open label, single center, single-dose, cross-over study 
to determine the absolute bioavailability and the nasopharyngeal absorption of PMI-150 (intranasal ketamine) 
in healthy adult volunteers. Javelin Pharmaceuticals, Inc. Document No. EDMS-ERI-44757121 (31 Oct 2008). 
69.
Portmann S, Kwan HY, Theurillat R, Schmitz A, Mevissen M, Thormann W. Enantioselective capillary 
electrophoresis for identification and characterization of human cytochrome P450 enzymes which metabolize 
ketamine and norketamine in vitro. J Chromatogr A. 2010;1217:7942-7948.
70.
Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide 
Assessment (C-CASA): classification of suicidal events in the FDA’s pediatric suicidal risk analysis of 
antidepressants. Am J Psychiatry. 2007;164:1035-1043. 
71.
Reich DL, Silvay G. Ketamine: An update on the first twenty-five years of clinical experience. Can J Anaesth. 
1989;36(2):186-197. 
72.
Rickels K, Garcia-Espana F, Mandos L, Case GW. Physician Withdrawal Checklist (PWC-20). J Clin 
Psychopharmacol. 2008;28(4):447–451.
73.
Rugani F, Bacciardi S, Rovai L, et al. Symptomatological Features of patients with and without ecstasy use 
during their first psychotic episode. Int. J. Environ. Res. Public Health. 2012;9(7):2283-2292. 
74.
Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients 
requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 Nov;163(11):1905-17. 
75.
Ryan M, Hughes J. Using conjoint analysis to assess women's preferences for miscarriage management. Health 
Econ. 1997; 6(3): 261-273.
76.
Ryan M, Gerard K. Using discrete choice experiments to value health care programmes: current practice and 
future research reflections. Appl Health Econ Health Policy. 2003; 2(1): 55-64.  
77.
Safety Report (Interim) ESKETINTRD2003. A double-blind, doubly-randomized, placebo-controlled study of 
intranasal esketamine in an adaptive treatment protocol to assess safety and efficacy in treatment-resistant 
depression (SYNAPSE). Document ID No. EDMS-ERI-97270375 (6 February 2015). 
78.
Sagie A, Larson MG, Goldberg RJ, Bengston JR, Levy D. An improved method for adjusting the QT interval 
for heart rate (the Framingham Heart Study). Am J Cardiol. 1992;70:797-801. 
79.
Saveanu R, Etkin A, Duchemin AM, et al. The International Study to Predict Optimized Treatment in 
Depression (iSPOT-D): Outcomes from the acute phase of antidepressant treatment. J Psychiatr Res. 2015 
Feb;61:1-12
80.
Sertraline (Zoloft®): US Prescribing Information. Pfizer, Inc., New York, New York, USA; August 2014. 
http://labeling.pfizer.com/ShowLabeling.aspx?id=517 (accessed 9 February 2015). 
81.
Sertraline: Summary of Product Characteristics. Sandoz Limited, Surrey, United Kingdom; September 2012. 
http://www.medicines.org.uk/emc/medicine/28749/SPC (accessed 6 March 2015).
82.
Shahani R, Streutker C, Dickson B, Stewart RJ. Ketamine-associated ulcerative cystitis: a new clinical entity. 
Urology. 2007;69(5):810-2.
83.
Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996 
Jun;11 Suppl 3:89-95. Review. 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
163
Status: Approved, Date: 6 July 2016
84.
Shiroma PR, Johns B, Kuskowski M, et al. Augmentation of response and remission to serial intravenous 
subanesthetic ketamine in treatment resistant depression. J Affect Disord. 2014; 155: 123-129. 
85.
Shram MJ, Sellers EM, Romach MK. Oral ketamine as a positive control in human abuse potential studies. 
Drug Alcohol Depend. 2011 Apr 1;114(2-3):185-93. 
86.
Sinner B, Graf BM. Ketamine. In: Schüttler J, Schwilden H, eds. Modern Anesthetics: Handbook of 
Experimental Pharmacology. Berlin: Springer-Verlag; 2008; 182: 313-333.
87.
Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the 
GAD-7. Arch Intern Med. 2006;166(10):1092-1097. 
88.
Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ 
primary care study. JAMA. 1999; 282:1737-1744. 
89.
Venlafaxine Extended-release: US Prescribing Information. Pfizer, Inc., New York, New York, USA; August 
2014. http://labeling.pfizer.com/ShowLabeling.aspx?id=612 (accessed 9 February 2015). 
90.
Venlafaxine: Summary of Product Characteristics. Actavis Group PTC ehf, Iceland; May 2012. 
http://www.medicines.org.uk/emc/medicine/24329 (accessed 6 March 2015)
91.
Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases 
and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 
2012 Dec 15;380(9859):2163-96. 
92.
Walker E, McGee R, Druss B. Mortality in Mental Disorders and Global Disease Burden Implications: A 
Systematic Review and Meta-analysis. JAMA Psychiatry. 2015. (new ref for the first sent)
93.
Whitmyer VG, Dunner DL, Kornstein SG, et al. A comparison of initial duloxetine dosing strategies in patients 
with major depressive disorder. J Clin Psychiatry. 2007 Dec; 68(12):1921-30. 
94.
Wieber J, Gugler R, Hengstmann JH, Dengler HJ. Pharmacokinetics of ketamine in man. Anaesthesist. 
1975 Jun;24(6):260-3. 
95.
Wittink MN, Cary M, Tenhave T, Baron J, Gallo JJ. Towards patient-centered care for depression: conjoint 
methods to tailor treatment based on preferences. Patient. 2010; 3(3): 145-157.
96.
Woolf TF, Adams JD. Biotransformation of ketamine, (Z)-6-hydroxyketamine, and (E)-6-hydroxyketamine by 
rat, rabbit, and human liver microsomal preparations. Xenobiotica. 1987; 17: 839-847. 
97.
World Health Organization. Depression (fact sheet). October 2012. 
http://www.who.int/mediacentre/factsheets/fs369/en/ (accessed 5 February 2015). 
98.
Yanagihara Y, Kariya S, Ohtani M, et al. Involvement of CYP2B6 in N demethylation of ketamine in human 
liver microsomes. Drug Metab Dispos. 2001; 29: 887-890.
99.
Zarate CA Jr, Quiroz JA, Singh JB, et al. An open-label trial of the glutamate-modulating agent riluzole in 
combination with lithium for the treatment of bipolar depression. Biol Psychiatry. 2005; 57: 430-432.
100. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in 
treatment-resistant major depression. Arch Gen Psychiatry. 2006; 63: 856-864. 
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
164
Status: Approved, Date: 6 July 2016
ATTACHMENTS
Attachment 1: Prohibited Concomitant Medications with Intranasal Study Medication 
(Esketamine)
This list of medications is not all-inclusive; if necessary, please contact the medical monitor for any 
questions regarding a medication(s).
Please refer to the local prescribing information of the subject’s oral antidepressant treatment for 
information regarding prohibited concomitant medications. 
Except where specifically noted, the prohibited medications listed in this table are prohibited from 1 week 
(or 5 half-lives, whichever is longer) prior to the first dose of intranasal study medication until at least 
1 day (24 hours) after the last dose of intranasal study medication. Of note, other than for MAOIs (see 
table below), for all antidepressants being taken at the start of or during the screening phase, no washout 
or drug-free period is required after discontinuing the antidepressant treatment; however, if clinically 
indicated, the antidepressant treatment can be tapered and discontinued during the screening phase.
N = Prohibited, Y = Permitted (see Comments column for additional guidance)
Drug Class
Episodic Use 
(as needed)
Continuous 
Use
Comments
Reason for 
Prohibition
Amantadine
N
N
PD interaction
Anorexiants 
(eg, phentermine, 
phendimetrazine)
N
N
Safety
Anticholinesterase 
inhibitors
N
N
Subject 
population is 
excluded
Anticonvulsants
N
N
Subjects with seizures are excluded. 
Use as adjunctive treatment for major 
depressive disorder (MDD) is 
prohibited. 
-
Note: Anticonvulsants used for 
indications other than seizures 
may be allowed (eg, valproate for 
migraine, pregabalin)
Safety and PD 
interaction
Antidepressants 
(other than the specific 
antidepressant started in 
the induction phase of 
the study)
N
N
-
Only 1 of the 4 predefined oral 
antidepressant treatment options 
are permitted
-
If a subject is taking a monoamine 
oxidase inhibitor (MAOI) during 
the screening phase, there must be 
a minimum washout interval of 
2 weeks prior to the first dose of 
intranasal study medication.
-
Even if used primarily for sleep,
trazodone use is not permitted 
during the treatment phase.
Safety and PD 
interaction
Antipsychotics
N
N
PD interaction
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
165
Status: Approved, Date: 6 July 2016
Drug Class
Episodic Use 
(as needed)
Continuous 
Use
Comments
Reason for 
Prohibition
Benzodiazepines (at 
dosages equal to or less 
than the equivalent of 
6 mg/day of lorazepam)
and non-benzodiazepine 
sleeping medication
(including: zolpidem, 
zaleplon, eszopiclone, 
and ramelteon)
Y
Y
Prohibited within 12 hours prior to 
the start of each intranasal treatment 
session or cognition testing
Safety and PD 
interaction
Benztropine
Y
N
Prohibited if use is continuous and 
prohibited within 12 hours prior to 
the start of cognition testing
Safety and PD 
interaction. 
Chloral hydrate, 
melatonin, valerian
N
N
Safety and PD 
interaction
Clonidine
N
N
Safety and PD 
interaction
Corticosteriods 
(systemic)
Y
N
Inhaled, intranasal, topical, and 
ophthalmic steroids are not 
prohibited.
Intermittent IM/IV corticosteroids are 
permitted (chronic use prohibited)
PD interaction
Cough/cold 
preparations/nasal 
solutions containing 
vasoconstrictors, 
decongestants
Y
Y
Intranasally-administered 
decongestants (vasoconstrictors) 
should not be used from 1 hour prior 
to each intranasal study medication 
administration.
Pseudoephedrine- containing oral
products should not be used within 
12 hours prior to an intranasal 
treatment session.
Safety and PD 
interaction
CYP3A4 inducers -
Potent
N
N
Subjects may not take a known potent 
inducer of hepatic CYP3A activity 
within 2 weeks of the first 
administration of intranasal study 
medication until at least 24 hours 
after the last intranasal dose of study 
medication.
Examples (not all-inclusive): 
Efavirenz, nevirapine, barbiturates, 
carbamazepine, glucocorticoids, 
modafinil, oxcarbazepine, 
phenobarbital, phenytoin, rifabutin, 
rifampin, and St. John's wort
PK
Dextromethorphan
N
N
PD interaction
Diphenhydramine
Y
N
Prohibited within 12 hours prior to 
the start of each intranasal treatment 
session
Safety
Ketanserin
N
N
Safety
Lithium
N
N
PD interaction
Memantine
N
N
PD interaction
Methyldopa
N
N
Safety and PD 
Interaction
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
166
Status: Approved, Date: 6 July 2016
Drug Class
Episodic Use 
(as needed)
Continuous 
Use
Comments
Reason for 
Prohibition
Metyrosine
N
N
Safety and PD 
interaction
Non-vitamin K 
antagonist oral 
anticoagulation agents 
(eg, dabigatran, 
rivaroxaban, apixaban)
N
N
Safety
Opioids
N
N
PD interaction
Psychostimulants 
(eg, amphetamines, 
methylphenidate, and 
modafinil, armodafinil)
N
Y
Prescribed psychostimulants taken for 
indications other than MDD can be 
continued but must not be taken 
within 12 hours prior to the intranasal 
treatment session or for 2 hours after 
the intranasal treatment session.
Cardiovascular 
safety
ADHD medications (eg, 
atomoxetine, guanfacine)
N
Y
Can be continued but must not be 
taken within 12 hours prior to the 
intranasal treatment session or for 2 
hours after the intranasal treatment 
session.
Safety
Reserpine
N
N
PD interaction
Scopolamine
N
N
PD interaction
St. John’s Wort
N
N
PD interaction 
and PK
Thyroid hormone 
supplement for treatment 
of thyroid condition only 
(not for depression)
N
Y
Safety
Thyroxine/ 
triiodothyronine (T3), 
thyroid hormone 
prescribed for depression
N
N
PD interaction
Warfarin
N
N
Primary 
condition 
where used is 
excluded
Abbreviations: IM, intramuscular; IV, intravenous; N, Prohibited; PD, pharmacodynamics; PK, pharmacokinetics; 
Y, Permitted, with restrictions 
(please refer to the column labeled “Comments” for additional guidance).
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
167
Status: Approved, Date: 6 July 2016
Attachment 2: New York Heart Association Classification of Cardiac Disease
Category
Description
Functional Capacity
Class I
Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical 
activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.
Class II
Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at 
rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III
Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable 
at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain.
Class IV
Patients with cardiac disease resulting in inability to carry on any physical activity without 
discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any 
physical activity is undertaken, discomfort is increased.
Objective Assessment
A
No objective evidence of cardiovascular disease.
B
Objective evidence of minimal cardiovascular disease.
C
Objective evidence of moderately severe cardiovascular disease.
D
Objective evidence of severe cardiovascular disease.
Source: Criteria Committee of the New York Heart Association. Functional capacity and objective assessment. In: 
Dolgin M, ed. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th ed. Boston, 
MA: Little, Brown & Co; 1994, 253-255.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
168
Status: Approved, Date: 6 July 2016
Attachment 3: Oral Antidepressant Titration Schedules for Open-label Induction Phase
Below is the titration schedule for the 4 oral antidepressants to be used in the current study. 
Adjustments to the titration schedule may be required in other countries in order to conform to 
local prescribing information.
Titration schedule for subjects <65 years (except for Taiwan, South Korea and Malaysia)
Oral Antidepressant
(Active Comparator)
Titration Schedule
Week 1
(Starting Day 1)
Week 2
(Starting Day 8)
Week 3
(Starting Day 15)
Week 4
(Starting Day 22)
Duloxetine
60 mga
60 mg
60 mg
60 mg
Escitalopram
10 mg
20 mg
20 mg
20 mg
Sertraline
50 mg
100 mg
150 mg
150 mg
Venlafaxine XR
75 mg
150 mg
225 mg
225 mg
Titration schedule for subjects <65 years in Taiwan and South Korea 
Oral Antidepressant
(Active Comparator)
Titration Schedule
Week 1
(Starting Day 1)
Week 2
(Starting Day 8)
Week 3
(Starting Day 15)
Week 4
(Starting Day 22)
Duloxetine
30 mg
60 mg
60 mg
60 mg
Escitalopram
10 mg
20 mg
20 mg
20 mg
Sertraline
50 mg
100 mg
150 mg
150 mg
Venlafaxine XR
37.5 mg
75 mg
150 mg
225 mg
Titration schedule for subjects <65 years in Malaysia
Oral Antidepressant
(Active Comparator)
Titration Schedule
Week 1
(Starting Day 1)
Week 2
(Starting Day 8)
Week 3
(Starting Day 15)
Week 4
(Starting Day 22)
Duloxetine
60 mga
60 mg
60 mg
60 mg
Escitalopram
10 mg
20 mg
20 mg
20 mg
Sertraline
50 mg
100 mg
150 mg
150 mg
Venlafaxine XR
37.5 mg
75mg
150 mg
225 mg
Titration schedule for subjects’ 65 years old – all countries
Oral Antidepressant
(Active Comparator)
Titration Schedule
Week 1
(Starting Day 1)
Week 2
(Starting Day 8)
Week 3
(Starting Day 15)
Week 4
(Starting Day 22)
Duloxetine
30 mg
60 mg
60 mg
60 mg
Escitalopram
10 mg
10 mg
10 mg
10 mg
Sertraline
25 mg
50 mg
100 mg
150 mg
Venlafaxine XR
37.5 mg
75 mg
150 mg
150 mg
aDuloxetine: Subjects should be initiated with 60 mg/day. Subjects that have in the past shown increased 
sensitivity towards serotonin reuptake inhibitors (SSRI) and norepinephrine reuptake inhibitors (SNRI), 
can, at the discretion of the treating physician, be started on a 30 mg dose and up-titrated into the 
therapeutic range of 60 mg by the start of Week 2.
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
169
Status: Approved, Date: 6 July 2016
Attachment 4: Anticipated Events
An anticipated event is an adverse event (serious or non-serious) that commonly occurs as a consequence 
of the underlying disease or condition under investigation (disease related) or background regimen. For 
the purposes of this study the following events will be considered anticipated events.22,23,27,28,41,80,81,89,90  
For esketamine and major depressive disorder (MDD) (including treatment-resistant depression [TRD]; 
based on DSM-5):

Suicidal thinking, ideation, and behavior

Sleep changes, difficulty sleeping, reduced sleep, abnormal sleep, abnormal sleep, tiredness, fatigue, 
and reduced energy

Difficulty in sexual desire, performance or satisfaction

Reduced appetite and weight changes (loss or increase)

Activation or hypomania/ mania

Excessive happiness

Irritability, anger, and impulsive behavior

Agitation, feeling anxious/anxiety, tension, panic attacks, and phobia
For esketamine, regarding events related to concomitant therapy with oral antidepressants (from the 
product’s reference safety information/US prescribing information):

Duloxetine

Most commonly observed adverse reactions from pooled studies of all indications (incidence of 
at least 5% and at least twice the incidence in placebo subjects) were nausea, dry mouth, 
somnolence, fatigue, constipation, decreased appetite, and hyperhidrosis (sweating). Duloxetine 
treatment worsens glycemic control in some subjects with diabetes.

Increased the risk compared to placebo of suicidal thinking and behavior; serotonin syndrome; 
hepatotoxicity; hepatic failure; orthostatic hypotension, syncope; abnormal bleeding; severe skin 
reactions, including erythema multiforme and Stevens-Johnson Syndrome (SJS); activation of 
mania or hypomania; hyponatremia.

Venlafaxine XR

According to the US prescribing information, adverse events in short-term studies occurring in at 
least 5% of subjects receiving venlafaxine XR and at a rate twice the incidence in placebo 
subjects: abnormal ejaculation, gastrointestinal complaints (nausea, dry mouth, and anorexia), 
central nervous system complaints (dizziness, somnolence, and abnormal dreams), and sweating. 
Sustained hypertension is noted within Warnings and Precautions section.

Increased the risk compared to placebo of suicidal thinking and behavior, treatment-emergent 
insomnia and nervousness, activation of mania/hypomania, hyponatremia, mydriasis, abnormal 
bleeding, sustained hypertension, and serotonin syndrome.

Escitalopram

Most commonly observed adverse reactions (incidence of approximately 5% or greater and 
approximately twice the incidence in placebo subjects) were insomnia, ejaculation disorder 
(primarily ejaculatory delay), nausea, sweating increased, fatigue, and somnolence.

Increased the risk compared to placebo of suicidal thinking and behavior, serotonin syndrome, 
activation of mania/hypomania, hyponatremia and abnormal bleeding
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
170
Status: Approved, Date: 6 July 2016

Sertraline

Most common treatment-emergent AEs associated with sertraline (incidence of at least 5% for 
sertraline or at least twice the incidence in placebo subjects) were ejaculation failure, dry mouth, 
increased sweating, somnolence, tremor, dizziness, fatigue, pain, malaise, abdominal pain, 
anorexia, constipation, diarrhea/loose stools, dyspepsia, nausea, agitation, insomnia, and 
decreased libido, and serotonin syndrome. 

Increased the risk compared to placebo of suicidal thinking and behavior, activation/mania; 
bleeding events related to SSRI use (have ranged from ecchymosis, hematomas, epistaxis, and 
petechiae to life-threatening hemorrhages), hyponatremia (appears to be the result of the 
syndrome of inappropriate antidiuretic hormone secretion [SIADH]); serotonin syndrome
Reporting of Anticipated Events
These events will be captured on the CRF and in the database, and will be reported to the sponsor as 
described in Section 12.3.1, All Adverse Events. Any event that meets serious adverse event criteria will 
be reported to the sponsor within the appropriate timeline as described in Section 12.3.2, Serious Adverse 
Events. These anticipated events are exempt from expedited reporting as individual single cases to Health 
Authorities. However, if based on an aggregate review, it is determined that an anticipated event is 
possibly related to study drug, the sponsor will report these events in an expedited manner.
Anticipated Event Review Committee (ARC)
An Anticipated Event Review Committee (ARC) will be established to perform reviews of pre-specified 
anticipated events at an aggregate level. The ARC is a safety committee within the sponsor’s organization 
that is independent of the sponsor’s study team. The ARC will meet to aid in the recommendation to the 
sponsor’s study team as to whether there is a reasonable possibility that an anticipated event is related to 
the study drug. 
Statistical Analysis
Details of statistical analysis of anticipated events, including the frequency of review and threshold to 
trigger an aggregate analysis of anticipated events will be provided in a separate Anticipated Events 
Safety Monitoring Plan (ASMP).
NCT02497287


JNJ-54135419-AAC (esketamine)
Clinical Protocol ESKETINTRD3004 Amendment 4
171
Status: Approved, Date: 6 July 2016
INVESTIGATOR AGREEMENT
NCT02497287

SAP_001.pdf: 
1
Approved, Date: 10 November 2017
Janssen Research & Development *
Statistical Analysis Plan
An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in 
Treatment-resistant Depression
Safety and Sustenance of Esketamine Treatment Response With Repeated Doses at Intervals 
Determined by Symptom Severity (SUSTAIN-2)
Protocol ESKETINTRD3004; Phase 3
JNJ-54135419 (esketamine)
Status:
Approved
Date:
10 November 2017
Prepared by:
Janssen Research & Development, LLC  
Document No.: EDMS-ERI-131851138, 1.0
Compliance: The study described in this report was performed according to the principles of Good Clinical Practice (GCP). 
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and may 
not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by 
them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as privileged or 
confidential.
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
2
Approved, Date: 10 November 2017
TABLE OF CONTENTS
TABLE OF CONTENTS ............................................................................................................................... 2
LIST OF IN-TEXT TABLES.......................................................................................................................... 4
LIST OF IN-TEXT FIGURES ........................................................................................................................ 4
ABBREVIATIONS ........................................................................................................................................ 5
1.
INTRODUCTION.................................................................................................................................. 6
1.1.
Trial Objectives ................................................................................................................................ 6
1.2.
Trial Design ...................................................................................................................................... 7
1.3.
Statistical Hypotheses for Trial Objectives..................................................................................... 11
1.4.
Sample Size Justification ............................................................................................................... 11
1.5.
Randomization and Blinding .......................................................................................................... 12
2.
GENERAL ANALYSIS DEFINITIONS .............................................................................................. 12
2.1.
Analysis Phases............................................................................................................................. 12
2.1.1.
Study Reference Start and End Dates ....................................................................................... 12
2.1.2.
Analysis Phase Start and End Dates.......................................................................................... 12
2.1.3.
Study Day and Relative Day....................................................................................................... 13
2.2.
Baseline and End Point.................................................................................................................. 14
2.3.
Visit Windows................................................................................................................................. 15
2.4.
Analysis Sets.................................................................................................................................. 23
2.4.1.
All Enrolled Analysis Set............................................................................................................. 23
2.4.2.
Full Analysis Sets ....................................................................................................................... 24
2.4.3.
Follow-up Analysis Set ............................................................................................................... 24
2.5.
Definition of Subgroups.................................................................................................................. 24
2.6.
Imputation Rules for Missing AE Dates ......................................................................................... 24
2.7.
Imputation Rules for Missing Concomitant Medication Dates ....................................................... 26
3.
DATA MONITORING COMMITTEE REVIEW................................................................................... 27
4.
SUBJECT INFORMATION................................................................................................................ 28
4.1.
Demographics and Baseline Characteristics ................................................................................. 28
4.2.
Disposition Information................................................................................................................... 29
4.3.
Extent of Exposure......................................................................................................................... 29
4.4.
Protocol Deviations ........................................................................................................................ 30
4.5.
Prior and Concomitant Medications ............................................................................................... 30
5.
EFFICACY ......................................................................................................................................... 31
5.1.1.
Data Handling Rules................................................................................................................... 31
5.1.2.
Imputation Methods for Missing Items........................................................................................ 31
5.2.
Efficacy Endpoint(s) ....................................................................................................................... 31
5.2.1.
MADRS....................................................................................................................................... 31
5.2.1.1.
Definition.................................................................................................................................. 31
5.2.1.2.
Analysis Methods .................................................................................................................... 32
5.2.2.
PHQ-9......................................................................................................................................... 32
5.2.2.1.
Definition.................................................................................................................................. 32
5.2.2.2.
Analysis Methods .................................................................................................................... 32
5.2.3.
CGI-S.......................................................................................................................................... 32
5.2.3.1.
Definition.................................................................................................................................. 32
5.2.3.2.
Analysis Methods .................................................................................................................... 33
5.2.4.
GAD-7......................................................................................................................................... 33
5.2.4.1.
Definition.................................................................................................................................. 33
5.2.4.2.
Analysis Methods .................................................................................................................... 33
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
3
Approved, Date: 10 November 2017
5.2.5.
Sheehan Disability Scale (SDS) ................................................................................................. 33
5.2.5.1.
Definition.................................................................................................................................. 33
5.2.5.2.
Analysis Methods .................................................................................................................... 34
5.2.6.
EuroQol Group; 5 Dimension; 5 Level (EQ-5D-5L) .................................................................... 34
5.2.6.1.
Definition.................................................................................................................................. 34
5.2.6.2.
Analysis Methods .................................................................................................................... 35
6.
SAFETY............................................................................................................................................. 35
6.1.
Adverse Events .............................................................................................................................. 35
6.2.
Clinical Laboratory ......................................................................................................................... 37
6.3.
Vital Signs, Weight, and BMI ......................................................................................................... 38
6.4.
Electrocardiogram.......................................................................................................................... 38
6.5.
Nasal Examination ......................................................................................................................... 40
6.5.1.
Nasal Symptom Questionnaire................................................................................................... 40
6.6.
Other Safety Parameters ............................................................................................................... 40
6.6.1.
Columbia Suicide Severity Rating Scale (C-SSRS) ................................................................... 40
6.6.2.
Clinician Administered Dissociative States Scale (CADSS)....................................................... 41
6.6.3.
Brief Psychiatric Rating Scale (BPRS+) ..................................................................................... 42
6.6.4.
Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) .......................................... 42
6.6.5.
Clinical Global Assessment of Discharge Readiness (CGADR) ................................................ 43
6.6.6.
Physician Withdrawal Checklist (PWC-20)................................................................................. 43
6.6.7.
Computerized Cognitive Battery and Hopkins Verbal Learning Test-Revised (HVLT-R) .......... 44
7.
HEALTH ECONOMICS ..................................................................................................................... 44
7.1.
Healthcare Resource Use Questionnaire (HRUQ) ........................................................................ 44
REFERENCES............................................................................................................................................ 45
ATTACHMENTS......................................................................................................................................... 46
Attachment 1:
Criteria of Markedly Abnormal Laboratory Values ..................................................... 46
Attachment 2:
Statistical Analysis Plan for COGSTATE ................................................................... 47
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
4
Approved, Date: 10 November 2017
LIST OF IN-TEXT TABLES
Table 1:
Analysis Visits ........................................................................................................................... 16
Table 2:
Demographic Variables and Baseline Characteristics.............................................................. 28
Table 3:
Psychiatric History at Baseline Variables ................................................................................. 29
Table 4:
Treatment-Emergent Abnormality Categories for Vital Signs................................................... 38
Table 5:
Limits for HR, PR, QRS and QT Interval Abnormality .............................................................. 39
Table 6:
Criteria for Abnormal QTc Values and Changes From Baseline.............................................. 39
Table 7: 
CADSS Scoring ........................................................................................................................ 42
LIST OF IN-TEXT FIGURES
Figure 1:
Schematic Overview of the Study............................................................................................. 11
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
5
Approved, Date: 10 November 2017
ABBREVIATIONS
AD
antidepressant
AE
adverse event
BMI
body mass index
BP
Blood Pressure
BPIC-SS
Bladder Pain / Interstitial Cystitis Symptom Score 
BPRS+
Four-item positive symptom subscale of the brief psychiatric rating scale
CADSS
Clinician Administered Dissociative States Scale
CGADR
Clinical Global Assessment of Discharge Readiness
CGI-S
Clinical Global Impression – Severity
CRF
case report form
C-SSRS
Columbia-Suicide Severity Rating Scale
DB
Double-blind
D/C
Discontinued
DSM-IV
Diagnostic and Statistical Manual of Mental Disorders (4th edition)
ECG
Electrocardiogram
eCRF
electronic case report form
EQ-5D-5L
EuroQol Group; 5 dimension; 5 level
EQ-VAS
EuroQol Group: visual analogue scale
EU
European Union
FDA
Food and Drug Administration
FU
Follow-Up
GAD-7
Generalized Anxiety Disorder 7-item scale
HVLT-R
Hopkins Verbal Learning Test-Revised
IDMC
Independent Data Monitoring Committee
ICH
International Conference on Harmonization
IDS-C30
Inventory of Depressive Symptoms-Clinician rated, 30 item
LOCF
last observation carried forward
MADRS
Montgomery-Asberg Depression Rating Scale
MDD
major depressive disorder
MedDRA
Medical Dictionary for Regulatory Activities
MINI
Mini International Neuropsychiatric Interview
MGH-ATRQ
Massachusetts General Hospital Antidepressant Treatment History
MOAA/S
Modified observer’s assessment of alertness/sedation
OL
Open-label
PHQ-9
Patient health questionnaire – 9
PWC-20
Physician Withdrawal Checklist; 20 item
SAE
serious adverse event
SAP
Statistical Analysis Plan
SD
standard deviation
SDS
Sheehan Disability Scale
SE
Standard error
SOC
System Organ Class
SNRI
Serotonin and Norepinephrine Reuptake Inhibitors
SSRI
Selective Serotonin Reuptake Inhibitors
TEAEs
Treatment-emergent adverse events
TEMA
treatment-emergent markedly abnormal
TRD
Treatment Resistant Depression
XR
Extended release
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
6
Approved, Date: 10 November 2017
1.
INTRODUCTION
This statistical analysis plan (SAP) contains definitions of analysis sets, derived variables, and
statistical methods for all planned analyses for study JNJ54135419-ESKETINTRD3004.
1.1.
Trial Objectives
Primary Objective
The primary objective of this study is to assess the long-term safety and tolerability of intranasal 
esketamine plus a newly initiated oral antidepressant in subjects with TRD, with special attention 
to the following:

Potential effects on cognitive function

Potential treatment-emergent symptoms of cystitis and/or lower urinary tract symptoms

Potential withdrawal and/or rebound symptoms following cessation of intranasal esketamine 
treatment 
Secondary Objectives
To assess the effect of intranasal esketamine plus a newly initiated oral antidepressant in subjects 
with TRD on

Safety and tolerability with special attention to the following:
Treatment-emergent adverse events (TEAEs), including TEAEs of special interest
Local nasal tolerability 
Effects on heart rate, blood pressure, respiratory rate and blood oxygen saturation
Effects on alertness and sedation 
Potential psychosis-like effects
Dissociative symptoms 
Potential effects on suicidal ideation/behavior. 

Long-term efficacy, including effects on:
Depressive symptoms (clinician and self-reported), overall severity of depressive illness, 
functional impairment and associated disability, anxiety symptoms, and health-related 
quality of life and health status

Response rate over time, defined as:
o
percentage of subjects with 50% reduction from baseline (induction phase) in the 
Montgomery-Asberg Depression Rating Scale (MADRS) total score, 
o
percentage of subjects with 50% reduction from baseline (induction phase) in the 
Patient Health Questionnaire, 9-item (PHQ-9) total score 
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
7
Approved, Date: 10 November 2017

Remission rate over time, defined as: 
o
percentage of subjects with MADRS total score 12, 
o
percentage of subjects with PHQ-9 total score 5
Exploratory Objectives

To assess the potential relationship of biomarkers with response/non-response to intranasal 
esketamine plus an oral antidepressant in subjects with TRD

To assess medical resource utilization

To assess subject tradeoff preferences for key benefit and harm outcomes associated with 
TRD treatment, using a stated-choice conjoint analysis survey. Reporting of these survey 
results may be conducted separately from this study.
1.2.
Trial Design
This is an open-label, multicenter, long-term study to evaluate the safety and efficacy of 
intranasal esketamine plus a newly initiated oral antidepressant in subjects with TRD. Subjects 
will enter the study either directly (referred to as ‘direct-entry subjects’) or after completing the 
double-blind induction phase of ESKETINTRD3005, a short-term efficacy study in elderly 
subjects with TRD (referred to as ‘transferred-entry subjects’). Approximately 750 direct entry 
subjects will be enrolled in this study, plus transferred-entry subjects from study 
ESKETINTRD3005. A total of at least 100 subjects 65 years or older (who are either direct entry 
subjects or transferred entry subjects from the ESKETINTRD3005 study) will be enrolled.
ESKETINTRD3005 is a randomized, double-blind, active-controlled, 4-week study in male and 
female elderly subjects (65 years) with TRD to assess the efficacy, safety, and tolerability of 
flexibly dosed intranasal esketamine (28 mg, 56 mg or 84 mg) plus a newly initiated oral 
antidepressant, compared with a newly initiated oral antidepressant (active comparator) plus 
intranasal placebo. 
Transferred-entry subjects who are non-responders (defined as <50% reduction in the MADRS 
total score from baseline [Day 1] at the end of the 4-week double-blind induction phase of 
ESKETINTRD3005 study) will be referred to as ‘transferred-entry non-responder subjects’ in 
the subsequent sections of the SAP. Transferred-entry subjects who are responders (defined as 
≥50% reduction in the MADRS total score from baseline [Day 1]) at the end of the 4-week 
double-blind induction phase of ESKETINTRD3005 study) will be referred to as 
‘transferred-entry responder subjects’ in the subsequent sections of the SAP. 
An Independent Data Monitoring Committee (IDMC) will be commissioned for this study to 
review safety data periodically.
This study (ESKETINTRD3004) has 4 phases:

Up to 4-week screening phase (direct-entry subjects only)
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
8
Approved, Date: 10 November 2017

A 4-week open-label induction phase (direct-entry subjects and transferred-entry 
non-responder subjects)

A 48-week open-label optimization/maintenance phase (all responder subjects from the 
open-label induction phase of the current study, and transferred-entry responder 
subjects).

A 4-week follow-up phase (for all subjects treated with intranasal esketamine)
The maximum duration of the subject’s participation in ESKETINTRD3004 study will be 
60 weeks for direct-entry subjects; 56 weeks for transferred-entry non-responder subjects, and 
52 weeks for transferred-entry responder subjects. The end of the study will occur when at least 
300 subjects have received treatment with intranasal esketamine for 6 months and at least 
100 subjects for 12 months (Note: the total number of subjects will be based on subjects from 
this study and subjects from other intranasal esketamine Phase 3 studies). 
A description of the study phases is provided below.
Screening Phase
After giving informed consent, direct-entry subjects with TRD who are 18 years of age (or 
older if the minimum legal age of consent in the country in which the study is taking place is >18 
years), will be screened to determine eligibility for study participation. Transferred-entry 
subjects from ESKETINTRD3005 study will not participate in this 4-week screening phase. 
Direct-entry subjects will be eligible for screening regardless of whether or not they are currently 
taking oral antidepressant treatments. At screening, subjects must have had a nonresponse to 
2 different oral antidepressant treatments in the current episode of depression, as assessed by 
the Massachusetts General Hospital-Antidepressant Treatment Response Questionnaire (MGH-
ATRQ), and confirmed by documented records (eg, medical/pharmacy/prescription records or a 
letter from treating physician etc,), in their current episode of depression. 
Eligible subjects taking antidepressant medication(s) at the start of the screening phase must 
discontinue all of their current oral antidepressant medication(s), being used for depression 
treatment, including adjunctive/augmentation therapies, prior to the start of the induction phase. 
Of note, subjects taking benzodiazepines (at dosages equal to or less than the equivalent of 
6 mg/day of lorazepam) and/or permitted non-benzodiazepine sleep medications (eg, zolpidem, 
zaleplon) during the screening phase can continue these medications. No dose increases beyond 
the equivalent of 6 mg/day of lorazepam, or new benzodiazepine medications are permitted. If 
clinically indicated, the antidepressant treatments may either be tapered and discontinued during 
the screening phase, or, discontinued and switched directly to 1 of the 4 new oral antidepressant 
medication(s) on Day 1 of the open-label induction phase, per clinical judgment. 
Subjects not currently taking oral antidepressant medication(s) at screening will start 1 of the 
4 new oral antidepressant medication (duloxetine, escitalopram, sertraline, or venlafaxine 
extended release [XR]) on Day 1 of the open-label induction phase. 
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
9
Approved, Date: 10 November 2017
Subjects meeting the inclusion/exclusion criteria are eligible to proceed to the open-label 
induction phase. 
Open-label Induction Phase (4 weeks)
Direct-entry subjects and transferred-entry non-responder subjects will participate in this phase.
Direct-entry subjects: Intranasal esketamine treatment will be self-administered at scheduled 
treatment sessions in the clinic/study site, twice weekly for 4 weeks. Subjects who are <65 years 
old will start intranasal esketamine with an initial dose of 56 mg on Day 1, with the dose 
adjusted based on efficacy and tolerability in the subsequent visits of the induction phase 
(flexible dose: 56 mg or 84 mg). Subjects who are 65 years old will start intranasal esketamine 
with an initial dose of 28 mg on Day 1, with the dose adjusted based on efficacy and tolerability 
(28, 56 or 84 mg) in the subsequent visits of the induction phase. In addition, all direct-entry 
subjects will initiate a new, open-label oral antidepressant on Day 1, which should be taken daily 
during the study. 
The assigned oral antidepressant will be 1 of 4 oral antidepressant medications (duloxetine, 
escitalopram, sertraline, or venlafaxine extended release [XR]), that the subject has not 
previously had a nonresponse to in the current depressive episode, has not been previously 
intolerant to (lifetime), and is available in the participating country.
Transferred-entry non-responder subjects from ESKETINTRD3005 study (all will be ≥65 years 
old) will join this study at the start of the open-label induction phase. These subjects will start 
intranasal esketamine with an initial dose of 28 mg on Day 1, with the dose adjusted based on 
efficacy and tolerability (28, 56 or 84 mg) in the subsequent visits of the induction phase. These 
subjects should continue taking the same oral antidepressant (at the same dose) during the study, 
as taken in the last week of the double-blind induction phase of ESKETINTRD3005 study.
Transferred-entry subjects’ may participate in this study only if it is clinically appropriate in the 
opinion of the investigator. 
For transferred-entry non-responder subjects, results of all assessments performed on Day 28 of 
the induction phase of that study (Visit 2.9 of ESKETINTRD3005 study) will not be repeated as 
part of Visit 2.1 of the current study. For these subjects, the Day 28 visit of the 
ESKETINTRD3005 study will coincide with Day 1 (Visit 2.1) for the current study. There is no 
gap allowed between studies.
Optimization/Maintenance Phase: 
Responder subjects at the end of the induction phase (≥50% reduction in MADRS from baseline 
[Day 1] to end of induction phase) of the ESKETINTRD3004 study, will be eligible to proceed 
to the optimization/maintenance phase; and continue receiving open-label intranasal esketamine 
treatment (at the same dose; 28 mg, 56 mg, or 84 mg) and should continue to take the same oral 
antidepressant (at the same dose) as taken in the last week of the induction phase of 
ESKETINTRD3004 study, unless poorly tolerated, in which case the oral antidepressant may be 
discontinued after review with sponsor.
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
10
Approved, Date: 10 November 2017
Non-responders at the end of the induction phase of the current study will complete an early 
withdrawal visit and proceed to the follow-up phase.
Eligible transferred-entry responder subjects from the ESKETINTRD3005 study (all will be 
≥65 years old) will join the current study starting from the optimization/maintenance phase. 
Transferred-entry subjects may participate in this study only if, it is clinically appropriate in the 
opinion of the investigator. These subjects will start intranasal esketamine with an initial dose of 
28 mg (Week 5; Study Day 32) and have their dose adjusted over the following 3 weeks of the 
optimization/maintenance phase. Subjects should continue to take the same oral antidepressant 
(at the same dose) during the study, as taken in the last week of the double-blind induction phase 
of ESKETINTRD3005 study, unless poorly tolerated, in which case the oral antidepressant may 
be discontinued after review with sponsor.
For transferred-entry responder subjects, results of all assessments performed on Day 28 of the 
induction phase (Visit 2.9 of ESKETINTRD3005 study) will not be repeated as part of Visit 3.1 
of the current study. The Day 28 visit of the ESKETINTRD3005 study will coincide with Day 
28 (Visit 3.1) for the current study. There is no gap allowed between studies.
For all subjects, the intranasal treatment session frequency will be reduced from that in the 
induction phase (twice weekly) to weekly for the first 4 weeks of optimization/maintenance 
phase (ie, Week 5 to Week 8). After the first 4 weeks, the frequency of intranasal treatment 
sessions will be adjusted to either once weekly or once every other week based on the severity of 
depressive symptoms, as assessed by the MADRS total score. A maximum of 3 changes in 
intranasal treatment session frequency from weekly to every other week is permitted during the 
optimization/maintenance phase. 
Follow-up Phase: 
This phase will include all subjects who have received at least 1 dose of intranasal study 
medication in this study. Follow-up visits will be performed at 1, 2 and 4 weeks after the last 
dose of intranasal study drug.
At the start of the follow-up phase, further clinical/standard of care for the treatment of 
depression will be arranged by the study investigator and/or the subject’s treating physician. 
There will be no intranasal esketamine administered during this phase. Subject will be provided 
with an additional 4 week supply of the oral antidepressant medication, to ensure that there is no 
interruption of oral antidepressant therapy during the transition to further clinical/standard of 
care. 
The decision to continue the oral antidepressant in this phase will be at the discretion of the 
investigator. However, in order to better assess potential withdrawal symptoms from intranasal 
study drug and facilitate maintenance of clinical benefit, the oral antidepressant medication 
should be continued for the duration of the follow-up phase unless determined as not clinically 
appropriate.
A diagram of the study design is provided in Figure 1.
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
11
Approved, Date: 10 November 2017
Figure 1:
Schematic Overview of the Study
* Intranasal esketamine 28 mg dose is the only option for subjects ≥65 years.
Note: At entry to the ESKETINTRD3004, transferred entry non-responder subjects will continue to receive the same 
oral antidepressant initiated in the ESKETINTRD3005 study. The new oral AD is for direct entry subjects only
AD, antidepressant; MDD, major depressive disorder; OL, open-label; 
An additional open-label safety extension study, 54135419TRD3008, may be available (pending 
country and site approval) for eligible subjects participating in the ESKETINTRD3004 study. 
Refer to the 54135419TRD3008 protocol for full details.
1.3.
Statistical Hypotheses for Trial Objectives
There is no formal hypothesis for this safety study.
1.4.
Sample Size Justification
No formal sample size calculation was performed for the study. The projected sample size of 
750 direct entry subjects plus transferred entry subjects is considered adequate to obtain at least 
300 subjects who have received treatment with esketamine for 6 months and at least 100 subjects 
for 12 months (Note: the total number of subjects will be based on subjects from this study and 
subjects from other intranasal esketamine Phase 3 studies). The number of transferred entry 
subjects is based on predictions related to discontinuation rate and efficacy, and therefore may 
vary.
The sample size will include at least 100 older subjects (who are either direct entry subjects or 
transferred entry subjects from the ESKETINTRD3005 study) aged 65 years.
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
12
Approved, Date: 10 November 2017
1.5.
Randomization and Blinding
This is an open label study. Randomization and blinding procedures will not be applicable for 
this study. All the subjects will self-administer intranasal esketamine and an oral antidepressant 
in an open label manner. 
However, the blind of intranasal treatment from ESKETINTRD3005 study will not be broken for 
transferred-entry subjects. Since there may be responders to intranasal placebo and oral 
antidepressant who did not receive intranasal esketamine prior to ESKETINTRD3004 study, all 
transferred-entry responder subjects will start at a dose of 28 mg of intranasal esketamine. 
2.
GENERAL ANALYSIS DEFINITIONS
2.1.
Analysis Phases
This study will have 3 analysis phases:

A 4-week open-label induction phase (direct-entry subjects and transferred-entry non-
responders)

A 48-week open-label optimization/maintenance phase (all responder subjects from the 
open label induction phase of the current study and transferred-entry responder 
subjects)

A 4-week follow-up phase (post-treatment phase)

Each analysis phase has its own analysis phase start and end dates.
2.1.1.
Study Reference Start and End Dates
For direct-entry and transferred-entry non-responder subjects, the reference start date for the 
study is defined as the earlier date of the first dose of intranasal study drug or the oral 
antidepressant (the date is missing for screened subjects who did take not any intranasal study 
drug or oral antidepressant). For transferred-entry responder subjects, the reference start date is 
the date of first dose of oral antidepressant medication in the optimization/maintenance phase.
The reference end date for subjects who have completed/discontinued from the study is the 
maximum of the date of last visit and trial completion/discontinuation.
2.1.2.
Analysis Phase Start and End Dates
Screening Phase 
The start date of the screening phase is the informed consent date. For subjects who continue to 
the open-label induction phase, the screening phase end date is the open-label induction phase 
start date. 
The start and end dates for the screening phase are defined for direct entry subjects only.
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
13
Approved, Date: 10 November 2017
Open-Label Induction Phase (direct-entry and transferred-entry non-responder subjects)
The start date of the open-label induction phase (referred to as, ‘IND start date’) is the earlier of 
date of the first dose of intranasal study medication or oral antidepressant in the open-label 
induction phase. For subjects who enter the optimization/maintenance phase, the open-label 
induction phase end date (referred to as, ‘IND end date’) is the date of first dose of oral 
antidepressant taken in the optimization/maintenance phase or the date of the last visit in the 
open-label induction phase if date of the first oral medication is missing. For subjects who 
discontinue in the open-label induction phase, IND end date is the maximum of date of the last 
visit in the open-label induction phase or date of early termination from the induction phase.
The start date/time of the open-label induction phase (referred to as, ‘IND start date/time’) is the 
IND start date and the time of the first dose of intranasal study medication in this phase. If no 
intranasal study medication is administered or it is administered after the start of oral 
antidepressant, then the time will be left blank.
The start and end dates for the open-label induction phase are defined for direct entry subjects
and transferred-entry non-responders only.
Optimization/Maintenance Phase
The start date of the optimization/maintenance phase (referred to as, ‘OP/MA start date’) is the 
date of the first dose of oral antidepressant medication in the optimization/maintenance phase.
For subjects who complete/discontinue from the optimization/maintenance phase, the phase end 
date (referred to as, ‘OP/MA end date’) is the maximum of date of last visit in the 
optimization/maintenance 
phase 
or 
the 
date 
of 
completion/withdrawal 
from 
the 
optimization/maintenance phase.
Follow-Up Phase 
The start date of the follow-up (post-treatment) phase (referred to as, ‘F/U start date’) is the day 
after the end date of the last treatment phase in which the subject participated. For subjects who 
complete/discontinue from the follow-up phase, the follow-up phase end date (referred to as, 
‘F/U end date’) is the maximum of the last follow-up visit date or end of trial date.
2.1.3.
Study Day and Relative Day
Study day is calculated relative to the reference start date for the study. Relative day is calculated 
relative to the analysis phase start date of the analysis phase in which the data are captured. A 
minus (-) sign indicates days prior to the start of study or prior to the start of the analysis phase.
Study day for an event on or after the start of the study is calculated as:
event date- reference start date+1.
Study day for an event prior to the start of the study is calculated as:
event date-reference start date 
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
14
Approved, Date: 10 November 2017
Relative day for an event on or after the analysis phase start date is calculated as:
event date – analysis phase start date + 1.
Relative day for an event prior to the analysis phase start date is calculated as:
event date – analysis phase start date.
There is no study day 0 or relative day 0.
2.2.
Baseline and End Point
Baseline is defined for each parameter/assessment.

Open-label Induction phase:
–
For direct-entry and transferred-entry non-responder subjects: The last observation prior 
to or on the start date of open-label induction phase is denoted as, ‘Baseline (IND)’. For 
transfer-entry responder subjects: Baseline (IND) is from study 3005. Baseline (IND) will 
be copied from the 3005 study into the 3004 study.

Baseline for the ECG measurements is defined as the average of all non-missing 
assessments on or before the date of the first dose of study medication for direct-entry 
and transferred-entry responders. Baseline for transferred-entry non-responders is the last 
observation prior to or on the start date of the open-label induction phase.  The ‘Average 
Predose’ is computed in the database for study 3005 and will be copied into study 3004.

Optimization/Maintenance phase: The last observation prior to or on the start date of the 
optimization/maintenance phase is denoted as ‘Baseline (OP/MA)’. For most subjects this 
pertains to assessments performed on Day 28 of the open-label induction phase for direct-
entry and transferred-entry non-responder subjects (Visit 2.9), and Day 28 of the double-
blind induction phase for transferred-entry responder subjects (Visit 2.10 of study 
ESKETINTRD3005) and is denoted as ‘Baseline (OP/MA)’.
For each variable measured over time, the ‘End Point (IND)’ value is defined as the last 
postbaseline assessment value during the open-label induction phase for direct-entry subjects and 
transfer-entry non-responder subjects. This value will be the same as the Baseline (OP/MA) 
value for subjects who continue into the optimization/maintenance phase from the open-label 
induction phase of 3004.
The ‘End Point (OP/MA)’ value is defined as the last postbaseline assessment value during the 
optimization/maintenance phase.
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
15
Approved, Date: 10 November 2017
2.3.
Visit Windows
As subjects do not always adhere to the protocol visit schedule, the following rules are applied to 
assign actual visits to protocol visits. Listed below are the visit windows and the target days for 
each visit. The reference day is Study Day 1 (which is the first day that any study drug was taken 
in the open-label induction phase for direct-entry subject and transferred-entry non-responders, 
and the first day any study drug was taken in the optimization/maintenance phase for responders 
from induction phase and transferred-entry responders). 
If a subject has 2 or more scheduled or unscheduled visits in one visit window, the visit closest to 
the target day will be used as the protocol visit for that visit window. If 2 actual visits are 
equidistant from the target day within a visit window, the later visit is used. If a visit window has 
no scheduled visits but does have unscheduled visits, then the unscheduled visit closest to the 
scheduled visit will be used.
All assignments will be made in chronological order. Once a visit is assigned to a visit window, 
it will no longer be used for a later time point except for the end point. 
Listed below are the visit windows and the target days (if applicable) for each visit defined in the 
protocol for all phases (Table 1).
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
16
Approved, Date: 10 November 2017
Table 1:
Analysis Visits
Parameter
Analysis 
Phase
Scheduled Day
Time Interval
(label on output)
Time Intervala
(Day)
Target Time 
Point from 
start of each 
phase
(Day)
MADRS
Screening
Within 4 Weeks 
of Day 1
Screening 
IND
1
Baseline (IND)
<= 1
1
8
Day 8 (IND)
2-11
8
15
Day 15 (IND)
12-18
15
22
Day 22 (IND)
19-24
22
28
Day 28 (IND)
25 to end of IND
28
IND final visit
End Point (IND)
2 to end of IND
OP/MA 
Weekly 
x=1, 2, 3, ... , 
46
28
Baseline (OP/MA)
1
1
32
Week 1 (OP/MA)
2-8
5
32 + x*7
Week (x+1) (OP/MA)
2 + x*7 to
8 + x*7
5 + x*7
361
Week 48 (OP/MA)
331 to end of OP/MA
334
OP/MA final 
visit
End Point (OP/MA)
2 to end of OP/MA
F/U
F/U Day 7 (Last 
dose +7 days)
F/U Week 1
1 to 10
7
F/U Day 14 
(Last dose +14 
days)
F/U Week 2
11 to 21
14
F/U Day 28 
(Last dose +28 
days)
F/U Week 4
22 to
end of F/U
28
F/U final visit
End Point (F/U)
1 to end of F/U
PHQ-9 and 
EQ-5D-5L
EQ-VAS and 
Health Status 
Index
Screening
Screening
IND
1
Baseline (IND)
<= 1
1
15
Day 15 (IND)
2-21
15
28
Day 28 (IND)
22 to end of IND
28
IND final visit
End Point (IND)
2 to end of IND
OP/MA Every 
Two Weeks 
x=1, 2, 3, … , 
21
28
Baseline (OP/MA)
1
1
32
Week 1 (OP/MA)
2-12
5
46
Week 3 (OP/MA)
13-26
19
46 + x*14
Week (3 + x*2)  
(OP/MA)
13 + x*14 to
26 + x*14
19 + x*14
354
Week 47 (OP/MA)
321 to end of OP/MA
327
OP/MA final 
visit
End Point (OP/MA)
2 to end of OP/MA
F/U
F/U Day 14 
(Last dose +14 
days)
F/U Week 2
1 to 21
14
F/U Day 28 
(Last dose +28 
days)
F/U Week 4
22 to
end of F/U
28
F/U final visit
End Point (F/U)
1 to end of F/U
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
17
Approved, Date: 10 November 2017
Table 1:
Analysis Visits
Parameter
Analysis 
Phase
Scheduled Day
Time Interval
(label on output)
Time Intervala
(Day)
Target Time 
Point from 
start of each 
phase
(Day)
CGI-S
Screening
Screening
IND
1
Baseline (IND)
<=1
1
4
Day 4 (IND)
2-6
4
8
Day 8 (IND)
7-9
8
11
Day 11 (IND)
10-13
11
15
Day 15 (IND)
14-18
15
22
Day 22 (IND)
19-24
22
28
Day 28 (IND)
25 to end of IND
28
IND final visit
End Point (IND)
2 to end of IND
OP/MA 
Weekly x=1, 
2, 3, ... , 46
28
Baseline (OP/MA)
1
1
32
Week 1 (OP/MA)
2-8
5
32 + x*7
Week (x+1) (OP/MA)
2 + x*7 to
8 + x*7
5 + x*7
361
Week 48 (OP/MA)
331 to end of OP/MA
334
OP/MA final 
visit
End Point (OP/MA)
2 to end of OP/MA
F/U
F/U Day 14 
(Last dose 
+14 days)
F/U Week 2
1 to 21
14
F/U Day 28 
(Last dose 
+28 days)
F/U Week 4
22 to
end of F/U
28
F/U final visit
End Point (F/U)
1 to end of F/U
GAD-7
Screening
Screening
IND
1
Baseline (IND)
<= 1
1
28
Day 28 (IND)
2 to end of IND
28
IND final visit
End Point (IND)
2 to end of IND
OP/MA
Every 4 weeks
x=1, 2, 3, … , 
10
28
Baseline (OP/MA)
1
1
53
Week 4 (OP/MA)
2-40
26
53 + x*28
Week (4 + x*4) 
(OP/MA)
13 + x*28 to
40 + x*28
26 + x*28
361
Week 48 (OP/MA)
321 to end of OP/MA
334
OP/MA final
visit
End Point (OP/MA)
2 to end of OP/MA
F/U
F/U Day 28 
(Last dose 
+28 days)
F/U Week 4
1 to
end of F/U
28
F/U final visit
End Point (F/U)
1 to end of F/U
SDS
Screening
Screening
IND
1
Baseline (IND)
<= 1
1
15
Day 15 (IND)
2-21
15
28
Day 28 (IND)
22 to end of IND
28
IND final visit
End Point (IND)
2 to end of IND
OP/MA
Every 4 weeks
x=1, 2, 3, … , 
10
28
Baseline (OP/MA)
1
1
53
Week 4 (OP/MA)
2-40
26
53 + x*28
Week (4 + x*4) 
(OP/MA)
13 + x*28 to
40 + x*28
26 + x*28
361
Week 48 (OP/MA)
321 to end of OP/MA
334
OP/MA final 
visit
End Point (OP/MA)
2 to end of OP/MA
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
18
Approved, Date: 10 November 2017
Table 1:
Analysis Visits
Parameter
Analysis 
Phase
Scheduled Day
Time Interval
(label on output)
Time Intervala
(Day)
Target Time 
Point from 
start of each 
phase
(Day)
F/U
F/U Day 28 
(Last dose +28 
days)
F/U Week 4
1 to
end of F/U
28
F/U final visit
End Point (F/U)
1 to end of F/U
Hematology, 
Chemistry, 
Urinalysis
from LAB
Screeningb
Screening
IND
1
Baseline (IND)
<= 1
1
28
Day 28 (IND)
2 to end of IND 
28
IND final visit
End Point (IND)
2 to end of IND
OP/MA Every 
8 weeks
x=1, 2, 3
28
Baseline (OP/MA)
<=1
1
53
Week 4 (OP/MA)
2-40
26
109
Week 12 (OP/MA)
41-110
82
109+56*x
Week (12+8*x) 
(OP/MA)
55+56*x to 
110+56*x
82+56*x
333
Week 44(OP/MA)
279-320
306
361
Week 48(OP/MA)
321 to end of OP/MA
334
OP/MA final 
visit
End Point (OP/MA)
2 to end of OP/MA
F/U
F/U Day 28 
(Last dose 
+28 days)
F/U Week 4
1 to
end of F/U
28
Urinalysis
IND
1
Baseline (IND)
<=1
1
15
Day 15 (IND)
2-21
15
28
Day 28 (IND)
22 to end of IND
28
IND final visit
End Point (IND)
2 to end of IND
OP/MA Every 
8 weeks
x=1,2,3
28
Baseline (OP/MA)
<=1 
1
53
Week 4 (OP/MA)
2-40
26
109
Week 12 (OP/MA)
41-110
82
109+56*x
Week (12+8*x) 
(OP/MA)
55+56*x to 
110+56*x
82+56*x
333
Week 44 (OP/MA)
279-320
306
361
Week 48(OP/MA)
321 to end of OP/MA
334
OP/MA final 
visit
End Point (OP/MA)
2 to end of OP/MA
F/U
F/U Day 14 
(Last dose 
+14 days)
F/U Week 2
1-21
14
F/U Day 14 
(Last dose 
+28 days)
F/U Week 4
22 to end of F/U
28
F/U final visit
End Point(F/U)
1 to end of F/U
Vital Signs:
(TEMP 
[predose at 
each visit], 
BPc, Pulse, 
RR (at each 
visit, predose, 
40M, 1H, 
1.5H)
IND 
1
Baseline(IND)g
Day 1 (IND): 40M
Day 1 (IND): 1H
Day 1 (IND): 1H30M
<=1/predose
1
4
Day 4 (IND): Predose
Day 4 (IND): 40M
Day 4 (IND): 1H
Day 4 (IND): 1H30M
2-6
4
8
Day 8 (IND): Predose
7-9
8
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
19
Approved, Date: 10 November 2017
Table 1:
Analysis Visits
Parameter
Analysis 
Phase
Scheduled Day
Time Interval
(label on output)
Time Intervala
(Day)
Target Time 
Point from 
start of each 
phase
(Day)
Day 8 (IND): 40M
Day 8 (IND): 1H
Day 8 (IND): 1H30M
11
Day 11 (IND): 
Predose
Day 11 (IND): 40M
Day 11 (IND): 1H
Day 11 (IND): 
1H30M
10-13
11
15
Day 15 (IND): 
Predose
Day 15 (IND): 40M
Day 15 (IND): 1H
Day 15 (IND): 
1H30M
14-16
15
18
Day 18 (IND): 
Predose
Day 18: 40M
Day 18: 1H
Day 18: 1H30M
17-20
18
22
Day 22 (IND): 
Predose 
Day 22 (IND): 40M
Day 22 (IND): 1H
Day 22 (IND): 
1H30M
21- 23
22
25
Day 25 (IND): 
Predose 
Day 25 (IND): 40M
Day 25 (IND): 1H
Day 25 (IND): 
1H30M
24 to end of IND
25
IND final visit
End Point (IND)
Day 1: 40M to end of 
IND
OP/MA 
Weekly x=1, 
2, 3, ... , 46
25
Baseline (OP/MA)
<=1
1
32
Week 1 (OP/MA): 
Predose
Week 1 (OP/MA): 
40M
Week 1 (OP/MA): 
1H
Week 1 (OP/MA): 
1H30M
1-8
5
32 + x*7
Week (x+1) 
(OP/MA): Predose
Week (x+1) 
(OP/MA): 40M
Week (x+1) 
(OP/MA): 1H
Week (x+1) 
2 + x*7  to
8 + x*7
5 +  x*7
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
20
Approved, Date: 10 November 2017
Table 1:
Analysis Visits
Parameter
Analysis 
Phase
Scheduled Day
Time Interval
(label on output)
Time Intervala
(Day)
Target Time 
Point from 
start of each 
phase
(Day)
(OP/MA): 1H30M
361
Week 48 (OP/MA): 
Predose
Week 48 (OP/MA): 
40M
Week 48 (OP/MA): 
1H
Week 48 (OP/MA): 
1H30M
331 to end of OP/MA
334
OP/MA final 
visit
End Point (OP/MA)
Day 1: 40M to end of 
OP/MA
F/U 
F/U Day 14 
(Last dose 
+14 days)
F/U Week 2
1 to 21
14
F/U Day 28 
(Last dose 
+28 days)
F/U Week 4
22 to
end of F/U
28
F/U final visit
End Point (F/U)
1 to end of F/U
Weight, BMI, 
Nasal 
Examination
Screening
Screening
IND
1
Day 1
<= 1/predose
1
28
Day 28 (IND)
2 to end of IND
28
IND final visit
End Point (IND)
2 to end of IND
OP/MA
Every 4 weeks
x=1, 2, 3, … , 
10
28
Baseline (OP/MA)
<=1
1
53
Week 4 (OP/MA)
2-40
26
53 + x*28
Week (4 + x*4) 
(OP/MA)
13 + x*28 to
40 + x*28
26 + x*28
361
Week 48 (OP/MA)
321 to end of OP/MA
334
OP/MA final 
visit
End Point (OP/MA)
2 to end of OP/MA
F/U (not for 
Weight)
F/U Day 28 
(Last dose 
+28 days)
F/U Week 4
1 to
end of F/U
28
F/U final visit
End Point (F/U)
1 to end of F/U
12-lead ECG
IND
Screening, 1
Baseline (IND)
<=1/predose
1
1
Day 1 (IND): 1H
1
1
8
Day 8 (IND): 1H
2-11
8
15
Day 15 (IND): 1H
12-20
15
25
Day 25 (IND): 1H
21 to end of IND
25
IND final visit
End Point (IND)
Day 1: 1H to end of 
IND
OP/MA
Every 4 weeks
x=1, 2, 3, … , 
10
25
Baseline (OP/MA)
<=1
1
32
Week 1 (OP/MA): 
Predose
2-8
5
32
Week 1 (OP/MA): 
1H
2-8
5
39
Week 2 (OP/MA): 
1H
9-19
12
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
21
Approved, Date: 10 November 2017
Table 1:
Analysis Visits
Parameter
Analysis 
Phase
Scheduled Day
Time Interval
(label on output)
Time Intervala
(Day)
Target Time 
Point from 
start of each 
phase
(Day)
53
Week 4 (OP/MA): 
1H
20-40
26
53 + x*28
Week (4 + x*4) 
(OP/MA): 1H
13 + x*28 to
40 + x*28
26 + x*28
361
Week 48 (OP/MA): 
1H
321 to end of OP/MA
334
OP/MA final 
visit
End Point (OP/MA)
2 to end of OP/MA
F/U
F/U Day 28 
(Last dose 
+28 days)
F/U Week 4)
1 to
end of F/U
28
Nasal 
Symptom 
Questionnaire 
(Predose and 
1H postdose)
IND 
1
Day 1 (IND)
<=1
1
4
Day 4 (IND)
2-7
4
11
Day 11 (IND)
8-14
11
18
Day 18 (IND)
15-21
18
25
Day 25 (IND)
22 to end of IND 
25
IND final visit
End Point (IND)
2 to end of IND
OP/MA
Every 4 weeks
x=1, 2, 3, … , 
10
32
Week 1 (OP/MA)
1-15
5
53
Week 4 (OP/MA)
16-40
26
53 + x*28
Week (4 + x*4) 
(OP/MA)
13 + x*28 to
40 + x*28
26 + x*28
361
Week 48 (OP/MA)
321 to end of OP/MA
334
OP/MA final 
visit
End Point (OP/MA)
2 to end of OP/MA
C-SSRS
(BL/SC 
version and 
since last visit 
version)
Screening
Screening
<=1
IND 
1
Baseline (IND)
<=1
1
4
Day 4 (IND)
2-6
4
8
Day 8 (IND)
7-9
8
11
Day 11 (IND)
10-13
11
15
Day 15 (IND)
14-16
15
18
Day 18 (IND)
17-20
18
22
Day 22 (IND)
21- 23
22
25
Day 25 (IND)
24-26
25
28
Day 28 (IND)
27 to end of IND
28
IND final visit
End Point (IND)
2 to end of IND
OP/MA 
Weekly x=1, 
2, 3, ... , 46
28
Baseline (OP/MA)
<=1
1
32
Week 1 (OP/MA)
2-8
5
32 + x*7
Week (x+1) (OP/MA)
2 + x*7  to
8 + x*7
5 + x*7
361
Week 48 (OP/MA)
331 to end of OP/MA
334
OP/MA final 
visit
End Point (OP/MA)
2 to end of OP/MA
F/U
F/U Day 14 
(Last dose 
+14 days)
F/U Week 2
1 to 21
14
F/U Day 28 
(Last dose 
+28 days)
F/U Week 4
22 to
end of F/U
28
F/U final visit
End Point (F/U)
1 to end of F/U
MOAA/Sd,
IND 
1
Baseline (IND): only 
<=1
1
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
22
Approved, Date: 10 November 2017
Table 1:
Analysis Visits
Parameter
Analysis 
Phase
Scheduled Day
Time Interval
(label on output)
Time Intervala
(Day)
Target Time 
Point from 
start of each 
phase
(Day)
Pulse 
Oximetrye
(predose and 
every 15 
minutes to 
1.5H),
BPRS+ and
CADSS 
(predose, 
40M, 1.5H) 
CGADRf,
(1H, 1.5H)
for Pulse Oximetry
1
Day 1 (IND)
<=1
1
4
Day 4 (IND)
2-6
4
8
Day 8 (IND)
7-9
8
11
Day 11 (IND)
10-13
11
15
Day 15 (IND)
14-16
15
18
Day 18 (IND)
17-20
18
22
Day 22 (IND)
21- 23
22
25
Day 25 (IND)
24 to end of IND
25
OP/MA 
Weekly x=1, 
2, 3, ... , 46
32
Week 1 (OP/MA)
1-8
5
32 + x*7
Week (x+1) (OP/MA)
2 + x*7 to
8 + x*7
5 + x*7
361
Week 48 (OP/MA)
331 to end of OP/MA
334
BPIC-SS
IND
1
Baseline (IND)
<= 1
1
15
Day 15 (IND)
2-21
15
28
Day 28 (IND)
22 to end of IND
28
IND final visit
End Point (IND)
2 to end of IND
OP/MA
Every 4 weeks
x=1, 2, 3, … , 
10
28
Baseline (OP/MA)
1
1
53
Week 4 (OP/MA)
2-40
26
53 + x*28
Week (4 + x*4) 
(OP/MA)
13 + x*28 to
40 + x*28
26 + x*28
361
Week 48 (OP/MA)
321 to end of OP/MA
334
OP/MA final 
visit
End Point (OP/MA)
2 to end of OP/MA
F/U
F/U Day 14 
(Last dose 
+14 days)
F/U Week 2
1 to 21
14
F/U Day 28 
(Last dose 
+28 days)
F/U Week 4
22 to
end of F/U
28
PWC-20
IND
IND final visit
End Point (IND)
2 to end of IND
OP/MA
OP/MA final 
visit
End Point (OP/MA)
1 to end of OP/MA
F/U
F/U Day 7 (Last 
dose +7 days)
F/U Week 1
1 to 10
7
F/U Day 14 
(Last dose 
+14 days)
F/U Week 2
11 to 21
14
F/U Day 28 
(Last dose 
+28 days)
F/U Week 4
22 to
end of F/U
28
F/U final visit
End Point (F/U)
1 to end of F/U
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
23
Approved, Date: 10 November 2017
Table 1:
Analysis Visits
Parameter
Analysis 
Phase
Scheduled Day
Time Interval
(label on output)
Time Intervala
(Day)
Target Time 
Point from 
start of each 
phase
(Day)
HRUQ
OP/MA Every 
Two Weeks 
x=1, 2, 3, … , 
20
42
Week 6 (OP/MA)
1-49
42
56
Week 8 (OP/MA)
50-63
56
56 + x*14
Week (8 + x*2) 
(OP/MA)
50 + x*14 to
63 + x*14
56 + x*14
361
Week 48 (OP/MA)
321 to end of OP/MA
334
OP/MA final 
visit
End Point (OP/MA)
2 to end of OP/MA
F/U
F/U Day 14 
(Last dose 
+14 days)
F/U Week 2
1 to 21
14
F/U Day 28 
(Last dose 
+28 days)
F/U Week 4
22 to
end of F/U
28
F/U final visit
End Point (F/U)
1 to end of F/U
a
For each phase, the time interval is relative to the first day of that phase.
b
TSH, HbA1c and Lipid panel (fasting) are only recorded at screening. Summarize the statistics of these 
variables at screening phase. 
c
During each phase, at 1.5 hours postdose, if the SBP is ≥160 mm Hg and/or the DBP ≥100 mm Hg, assessments 
should continue every 30 minutes until the blood pressure is <160 mm Hg SBP and <100 mm Hg DBP or until 
the subject is referred for appropriate medical care if clinically indicated.
d
If the MOAA/S score is ≤ 3 at any time during the 1.5 hour postdose interval, the MOAA/S will be performed 
every 5 minutes until a score of 4 is reached (at which point a frequency of every 15 minutes can be resumed 
until t=+1.5 hours post dose).). If a subject does not have a score of at least 5 at t=+1.5 hours postdose, they 
should continue to be monitored. For subjects with a score of 4, the assessment should be repeated every 15 
minutes. And for subjects with a score of 3, the assessment should be repeated every 5 minutes until the score
returns to 5 or the subject is referred for appropriate medical care, if clinically indicated.
e
If pulse oximetry is <93% at any time during the 1.5 hour postdose interval, pulse oximetry will be performed 
every 5 minutes until oxygen saturation returns to ≥93% or until the subject is referred for appropriate medical 
care, if clinically indicated.
f
If the response is not “Yes” at 1.5 hour postdose, the assessment will be repeated every 15 minutes until a “Yes” 
response is achieved or until the subject is referred for appropriate medical care if clinically indicated.
g
This would be labeled as Day 1(IND): Predose for changes from Predose summaries.
2.4.
Analysis Sets
Subjects will be classified into the following analysis sets: all enrolled, full analysis sets and 
follow-up analysis set. Due to Good Clinical Practice (GCP) issues, Dr. 
 will not 
be included in any analysis sets.  However, data for this site will be presented in listings. 
Analyses of change from baseline will include only those subjects who have both baseline and at 
least 1 post-baseline observation in that phase.
2.4.1.
All Enrolled Analysis Set
This analysis set will include all transferred-entry and direct-entry subjects who are not screen 
failures and received at least one dose of intranasal study medication or 1 dose of oral 
antidepressant.
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
24
Approved, Date: 10 November 2017
2.4.2.
Full Analysis Sets
The following analysis sets will be used to summarize efficacy and safety data and are defined 
for each phase.
Full (IND) analysis set: All subjects who receive at least 1 dose of intranasal study medication or 
1 dose of oral antidepressant in the open-label induction phase (for direct-entry and transferred-
entry non-responder subjects). 
Full (OP/MA) analysis set: All subjects who receive at least 1 dose of intranasal study 
medication or 1 dose of oral antidepressant in the optimization/maintenance phase.
2.4.3.
Follow-up Analysis Set
The Follow-up analysis set includes all subjects who enter the follow-up phase. This analysis set 
will be used to summarize all efficacy and safety evaluations during the follow-up phase.
2.5.
Definition of Subgroups
Descriptive statistics will be provided for the change from baseline in MADRS total score, using 
the following subgroups.

Sex

Race (White, Black, Other)

Age Group (18-44 years, 45-64 years, 65-74 years, ≥75 years)

Region (North America, Europe, Asia, Other)

Country (Brazil, Belgium, France, Poland, Spain, United States, Italy, United Kingdom, 
Sweden, Mexico, Germany, Bulgaria, Malaysia, Romania, Taiwan, South Africa, Argentina, 
Austria, Australia, Turkey, Republic of South Korea, Lithuania, Finland)

Number of Previous Treatment Failures in Current Episode (based on ATRQ)

Functional Impairment based on Baseline (IND) SDS Total Score: not impaired (0-3), mild 
(4-11), moderate (12-19), marked (20-26) or extreme (27-30) 

Baseline (IND) MADRS total score (≤/> median)

Class of antidepressant study medication (SNRI or SSRI)
2.6.
Imputation Rules for Missing AE Dates 
Treatment-emergent adverse events (AEs):

For direct-entry and transfer-entry non-responder subjects, treatment-emergent AEs are 
those events with an onset date/time on or after the start of IND phase study medication, and 
occurred on or before the end of the optimization/maintenance phase. A conservative 
approach will be used to handle the missing dates for AEs

For transferred-entry responder subjects, treatment-emergent AEs are those events with an 
onset date/time on or after the start of optimization/maintenance phase study medication, 
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
25
Approved, Date: 10 November 2017
and occurred on or before the end of the optimization/maintenance phase. A conservative 
approach will be used to handle the missing dates for AEs
Onset Date
AEs for each phase are those events with an onset date/time on or after the start of that particular 
phase, and occurred before the end of that phase. The rules for estimating incomplete AE onset 
dates will be as follows:
Direct-entry and transferred-entry non-responder subjects:
If the onset date of an adverse event is missing the day only, it will be set to:
i)
First day of the month that the AE occurred, if month/year of the onset of AE is different 
than the month/year of IND start date
ii)
The day of IND start date, if the month/year of the onset of AE is the same as month/year 
of the IND start date and month/year of the AE resolution date is different
iii) The day of IND start date or day of AE resolution date, whichever is earliest, if 
month/year of the onset of AE and month/year of the IND start date and month/year of 
the AE resolution date are the same.
If the onset date of an adverse event is missing both day and month, it will be set to the earliest 
of:
i)
January 1 of the year of onset, as long as this date is after the IND start date
ii)
One day after the IND start date, if this date is the same year that the AE occurred. 
A completely missing onset date of an adverse event will be set to the IND start date. 
Transferred-entry responder subjects:
If the onset date of an adverse event is missing day only, it will be set to:
i)
First day of the month that the AE occurred, if month/year of the onset of AE is different 
than the month/year of OP/MA start date
ii)
The day of OP/MA start date, if the month/year of the onset of AE is the same as 
month/year of the OP/MA start date and month/year of the AE resolution date is different
iii) The day of OP/MA start date or day of AE resolution date, whichever is earliest, if 
month/year of the onset of AE and month/year of the OP/MA start date and month/year 
of the AE resolution date are the same.
If the onset date of an adverse event is missing both day and month, it will be set to the earliest 
of:
i)
January 1 of the year of onset, as long as this date is after the OP/MA start date
ii)
One day after the OP/MA start date, if this date is the same year that the AE occurred. 
A completely missing onset date of an adverse event will be set to the OP/MA start date. 
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
26
Approved, Date: 10 November 2017
Resolution Date
The missing day of resolution of an adverse event will be set to the last day of the month of 
resolution.
If the resolution date of an adverse event is missing both day and month, it will be set to 
December 31 of the year.
A completely missing resolution date of an adverse event that is not recorded as ongoing will be 
set to the date of withdrawal or study completion.
Direct-entry and transferred-entry non-responder subjects:
If the time of onset is missing, it will be imputed as follows:
(i)
00:00 if the date of onset is after IND start date
(ii) 00:00 if the date is the same as IND start date, but the intranasal study medication in the 
open-label induction phase was started after the oral antidepressant medication in this 
phase
(iii) The time of intranasal medication start in the open-label induction phase if the intranasal 
medication was started on or before the oral antidepressant medication in this phase
Transferred-entry responder subjects:
If the time of onset is missing, it will be imputed as follows:
(i)
00:00 if the date of onset is after OP/MA start date 
(ii) 00:00 if the date is the same as OP/MA transferred-entry responder subjects, start date, 
but the intranasal study medication in the optimization/maintenance phase was started 
after the oral antidepressant medication in this phase 
(iii) The time of intranasal medication start in the optimization/maintenance phase if the 
intranasal medication was started on or before the oral antidepressant medication in this 
phase
If a missing time is associated with a partial or missing date, the date will be imputed first prior 
to imputing the time.
2.7.
Imputation Rules for Missing Concomitant Medication Dates
If a partial date is reported, it is assumed the medication (or therapy) was taken in all phases that 
overlap with the partial date. If both start and end dates are missing but this concomitant 
medication was taken both prior to the study entry and still ongoing at study end, it is assumed 
medication was taken in all phases.
The rules for estimating an incomplete concomitant medication start date are as follows:
Direct-entry and transferred-entry non-responder subjects: If the month of the 
concomitant medication start date is equal to the month of the start of the induction phase, 
then the estimated start date is the IND start date; 
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
27
Approved, Date: 10 November 2017
If the month of the concomitant medication start date is greater than the month of the start of 
the induction phase and earlier than the study end date, then the estimated start date of the 
concomitant medication is the first day of the month; 
If the month of the concomitant medication start date is greater than the month of the study 
end date, then no imputation will be done;
If the month and year of the concomitant medication start date are known and the IND start 
date is after the month of the concomitant medication start date, then no imputation will be 
done;
If either the month or year of the concomitant medication start date is missing, no 
imputation is to be performed.
Transferred-entry responder subjects: 
If the month of the concomitant medication start date is equal to the month of the start of the 
optimization/maintenance phase, then the estimated start date is the OP/MA start date; 
If the month of the concomitant medication start date is greater than the month of the start of 
the optimization/maintenance phase and earlier than the study end date, then the estimated 
start date of the concomitant medication is the first day of the month; 
If the month of the concomitant medication start date is greater than the month of the study 
end date, then no imputation will be done;
If the month and year of the concomitant medication start date are known and the OP/MA
start date is after the month of the concomitant medication start date, then no imputation will 
be done;
If either the month or year of the concomitant medication start date is missing, no 
imputation is to be performed.
3.
DATA MONITORING COMMITTEE REVIEW
An IDMC will be established to monitor data on an ongoing basis to ensure the continuing safety of 
the subjects enrolled in this study. The committee will meet every 6 months to review safety data.
After the reviews, the IDMC will make recommendations regarding the continuation of the study.
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
28
Approved, Date: 10 November 2017
4.
SUBJECT INFORMATION
4.1.
Demographics and Baseline Characteristics
Demographic and baseline characteristics (Table 2) and psychiatric history at baseline (Table 3) 
will be summarized for the All Enrolled analysis set (described in Section 2.4.1). Continuous 
variables will be summarized using descriptive statistics (N, mean, standard deviation [SD], 
median, minimum, and maximum). Categorical variables will be summarized using a frequency 
distribution with the number and percentage of subjects in each category. Baseline (IND) values 
will be used for these summaries.
Table 2:
Demographic Variables and Baseline Characteristics
Continuous Variables:

Age (years) (informed consent date (for transfer entry subjects use 3004 informed 
consent date) – date of birth + 1) / 365.25

Baseline weight (kg)

Baseline height (cm)

Baseline BMI (kg/m2) calculated as Weight (kg)/[Height (m)]2
Categorical Variables:

Age in years (18-44, 45-64, 65-74, ≥75)

Sex (male, female)

Racea (White, Black or African American, Asian, American Indian or Alaskan native, 
Native Hawaiian or other Pacific islander, other)

Ethnicity (Hispanic or Latino, not Hispanic or Latino)

Baseline BMI (underweight <18.5kg/m2; normal: 18.5 to <25 kg/m2, overweight: 
25 kg/m2 to <30 kg/m2, obese:30 to <40 kg/m2; morbidly obese: 40 kg/m2)

Employment Status 

Hypertension status

Class of antidepressant (SSRI/SNRI)

Oral antidepressant

Country

Region (North America, Europe, Other)
a If multiple race categories are indicated, then Race is recorded as “Multiple”.
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
29
Approved, Date: 10 November 2017
Table 3:
Psychiatric History at Baseline Variables
Continuous Variables:

Baseline MADRS total score

Baseline CGI-S score

Baseline PHQ-9 total score

Age (years) when diagnosed with MDD

Duration of current episode
Categorical Variables:

Baseline CGI-S category

Screening C-SSRS category lifetime (no event, suicidal ideation, suicidal behavior)

Screening C-SSRS category past 6 or 12 months (no event, suicidal ideation [past 6 
months], suicidal behavior [past 12 months])

Antidepressant treatment history (number of medications with non-response taken for at 
least 2 weeks during the current episode as obtained in the MGH-ATRQ) 

Family history of
-
Depression
-
Anxiety Disorder
-
Bipolar Disorder
-
Schizophrenia
-
Alcohol Abuse
-
Substance Abuse
4.2.
Disposition Information
The number of subjects who enrolled from study ESKETINTRD3005 by responder status and 
direct-entry into ESKETINTRD3004 will be provided. 
The following disposition summaries will be provided for each phase separately. These 
summaries will be provided for each of the full analysis sets described in Section 2.4. 

The number of subjects who entered a specific treatment phase 

The number of subjects who discontinued a specific treatment phase prematurely and 
their reasons for discontinuation

The number of subjects who are ongoing in each phase at the time the sponsor
terminated the study.
Subjects who terminated the trial and the reasons for ending study participation throughout the 
study will also be summarized. This will be summarized for All Enrolled analysis sets described 
in Section 2.4.
4.3.
Extent of Exposure
Extent of exposure in terms of total duration of exposure and number of dosing sessions of 
intranasal study medication will be summarized by phase for the full analysis sets described in 
Section 2.4.
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
30
Approved, Date: 10 November 2017
Extent of exposure in terms of total duration of exposure and number of dosing sessions of 
intranasal study medication will be summarized by phase for Full (IND) and Full (OP/MA) 
analysis sets, and across both phases for the All Enrolled described in Section 2.4
The total duration of exposure for the intranasal study drug and for each type of oral 
antidepressant (AD) during each phase is defined as the time between the first and the last dose 
of each type of study medication in that specific phase (last day of study medication-first day of 
study medication +1). If a subject only receives a partial dose it is considered as a day of dosing.
Modal dose for a subject is defined as the most frequently taken dose by a subject during that 
phase. Mean dose of a subject is calculated as the sum of doses during the phase divided by the 
total number of days exposed. The final dose is the last non-zero dose received during that phase. 
The calculation of mean, modal and final dose will exclude days off study drug.
Descriptive statistics (N, mean, SD, median, minimum and maximum) of modal dose, mean dose 
and final dose will be presented for the induction phase and for the optimization/maintenance 
phase for intranasal study drug.
Doses of oral AD will be summarized using descriptive statistics of the mean dose (days on 
drug), final dose and mode dose (days on drug), by each type of oral AD during the induction 
phase and during the optimization/maintenance phase.  The doses will also be presented for 
direct entry subjects during the induction phase.
At the end of the induction phase and the optimization/maintenance phase, the number and 
percentage of subjects at each dose (28 mg, 56 mg and 84 mg) will be provided.
A frequency distribution of subjects with 6 months (≥180 days) of exposure and 12 months 
(≥350 days) of exposure will be provided.
During the optimization/maintenance phase, the number and percentage of subjects at each 
dosing frequency (weekly or every other week) and the number of subjects who changed their 
frequency (weekly to every other week and every other week to weekly) will be summarized 
every 4 weeks starting at Week 8.
4.4.
Protocol Deviations
Deviations that occurred during the study will be tabulated for the All Enrolled analysis set.
Major deviations will be tabulated for the following categories: subject not withdrawn as per 
protocol, selection criteria not met, excluded concomitant treatment, treatment deviation, non-
compliance, regulatory requirement. More categories may be included depending on the nature 
of the protocol deviation.
4.5.
Prior and Concomitant Medications
The number and percent of subjects receiving prior antidepressant medications/therapies will be 
summarized for the direct-entry subjects using Full (IND) analysis set described in Section 2.4. 
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
31
Approved, Date: 10 November 2017
The number and percent of subjects who receive concomitant therapies will be summarized by 
phase using the generic term of the medication for the Full (IND, OP/MA) analysis sets and the 
Follow-up analysis set described in Section 2.4.
5.
EFFICACY
Efficacy measures will be summarized descriptively at each scheduled visit for each phase, using 
both last observation carried forward and observed data.
5.1.1.
Data Handling Rules
For the efficacy scales MADRS, CGI-S, PHQ-9, GAD-7, and SDS, both observed case and last 
observation carried forward (LOCF) values will be determined for the induction and
optimization/maintenance phases. The last post baseline observation during the phase will be 
carried forward as the “End Point” for that phase. Besides the observed cases and the end point 
assessment, the LOCF values will be created for intermediate postbaseline time points as well. 
These imputed time points will be labeled ‘DAY X LOCF’ or ‘WEEK X LOCF’.
5.1.2.
Imputation Methods for Missing Items
Imputation of missing individual item scores will apply to MADRS and is described in 
Section 5.2.1. For all other scales where multiple items are summed to create a total, if any item 
of the scale is missing at a visit, the total score for that scale at that visit will be considered 
missing.
5.2.
Efficacy Endpoint(s)
Efficacy analyses during the induction phase and the optimization/maintenance phase will be 
provided for the Full analysis sets defined in Section 2.4.2 and for the follow-up phase will be 
provided for the Follow-up analysis set defined in Section 2.4.3. 
5.2.1.
MADRS
5.2.1.1.
Definition
The Montgomery-Asberg Depression Rating Scale (MADRS)6 is a clinician-rated scale designed 
to measure depression severity and to detect changes due to antidepressant treatment. The scale 
consists of 10 items, each of which is scored from 0 (item is not present or is normal) to 6 
(severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores 
represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, 
inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and 
suicidal thoughts. The test exhibits high inter-rater reliability.
If 2 or more items are missing, no imputation will be performed and the total score will be left 
missing. Otherwise, the total score will be calculated as sum of the non-missing items multiplied 
by the ratio of the maximum number of items (i.e., 10) to the number of non-missing items.
A subject is defined a responder at a given time point if the percent improvement in MADRS 
total score is ≥50%. 
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
32
Approved, Date: 10 November 2017
A subject is defined as a remitter at a given time point if the MADRS total score of ≤12 at that 
time point.
5.2.1.2.
Analysis Methods
Descriptive statistics of the total score and change from baseline (of the respective phase) will be
provided for each visit during all phases, including the follow-up phase. Graphical presentations 
will be provided. In addition, the proportion of subjects who responded and remitted based on 
the MADRS total score will be provided over time for each phase. Summaries of both observed 
and LOCF data will be presented. 
5.2.2.
PHQ-9
5.2.2.1.
Definition
The PHQ-9 is a 9-item, self-report scale assessing depressive symptoms. Each item is rated on a 
4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every 
day), with a total score range of 0-27. A higher score indicates greater severity of depression. 
The recall period is 2 weeks. The scale scores each of the nine symptom domains of the DSM 
MDD criteria and it has been used both as a screening tool and a measure of response to 
treatment for depression. The severity of the PHQ-9 is categorized as follows: None-minimal (0-
4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19) and Severe (20-27).
A subject is defined a responder at a given time point if the percent improvement from Baseline 
(IND) in PHQ-9 total score is ≥50%. 
A subject is defined as a remitter at a given time point if the PHQ-9 total score is ≤5 at that time 
point.
5.2.2.2.
Analysis Methods
Descriptive statistics of the total score and change from baseline (of the respective phase) will be 
provided for each visit during during all phases, including the follow-up phase Graphical 
presentations will be provided. Summaries of both observed and LOCF data will be presented.
In addition, a frequency distribution by severity will be provided for each assessment visit for all 
phases, including the follow-up phase. In addition, the proportion of subjects who responded and 
remitted based on the PHQ-9 total score will be provided over time for each phase. Summaries 
of both observed and LOCF data will be presented. 
5.2.3.
CGI-S
5.2.3.1.
Definition
The Clinical Global Impression of Severity (CGI-S)4 provides an overall clinician-determined 
summary measure of the severity of the subject’s illness that takes into account all available 
information, including knowledge of the subject’s history, psychosocial circumstances, 
symptoms, behavior, and the impact of the symptoms on the subject’s ability to function. The 
CGI-S evaluates the severity of psychopathology on a scale of 0 to 7. Considering total clinical 
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
33
Approved, Date: 10 November 2017
experience, a subject is assessed on severity of mental illness at the time of rating according to: 
0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately 
ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. The CGI-S permits a 
global evaluation of the subject’s condition at a given time.
5.2.3.2.
Analysis Methods
Descriptive statistics of the total score and change from baseline (of the respective phase) will be 
provided for each visit during all phases, including the follow-up phase. Summaries of both 
observed and LOCF data will be presented.
In addition, a frequency distribution by severity will be provided for each visit for all phases, 
including the follow-up phase. Summaries of both observed and LOCF data will be presented. 
5.2.4.
GAD-7
5.2.4.1.
Definition
The GAD-7 (Generalized Anxiety Disorder - 7 Items) 9 is a brief and validated 7-item self-report 
assessment of overall anxiety. Subjects respond to each item using a 4 point scale with response 
categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. 
Item responses are summed to yield a total score with a range of 0 to 21, where higher scores 
indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as 
follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21).
5.2.4.2.
Analysis Methods
Descriptive statistics of the actual values and change from baseline (of the respective phase) will 
be provided for each visit during all phases, including the follow-up phase. Graphical 
presentations will be provided. Summaries of both observed case data and LOCF will be 
presented. 
In addition, a frequency distribution of GAD-7 severity categories will be provided for each 
assessment visit for all phases, including follow-up phase. Summaries of both observed and 
LOCF data will be presented.
5.2.5.
Sheehan Disability Scale (SDS)
5.2.5.1.
Definition
The SDS is a subject-reported outcome measure and is a 5-item questionnaire which has been 
widely used and accepted for assessment of functional impairment and associated disability. The 
first three items assess disruption of (1) work/school, (2) social life, and (3) family life/home 
responsibilities using a 0-10 rating scale. The score for the first three items are summed to create 
a total score of 0-30 where a higher score indicates greater impairment. It also has one item on 
days lost from school or work and one item on days when underproductive. The recall period for 
this study is 7 days. Scores ≤4 for each item and ≤12 for the total score are considered response. 
Scores ≤2 for each item and ≤6 for the total score are considered remission. If any of the first 
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
34
Approved, Date: 10 November 2017
three items are missing, the total score will be set to missing as well as response and remission 
status.
5.2.5.2.
Analysis Methods
Descriptive statistics of the actual values and change from baseline (of the respective phase) will 
be provided for each visit during all phases, including the follow-up phase. Graphical 
presentations will be provided. Summaries of both observed and LOCF data will be presented. 
The total score as well as the individual item scores will be summarized.
In addition, the 
proportion of subjects who achieve response and remission will be summarized at
each time point.
5.2.6.
EuroQol Group; 5 Dimension; 5 Level (EQ-5D-5L)
5.2.6.1.
Definition
The EQ-5D-5L (EuroQol Group - 5 Dimension - 5 Level) 2,3 is a standardized 2-part instrument 
for use as a measure of health outcome, primarily designed for self-completion by respondents. It 
essentially consists of the EQ-5D-5L descriptive system and the EQ visual analogue scale 
(EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, 
self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is 
divided into 5 levels of perceived problems (Level 1 indicating no problem, Level 2 indicating 
slight problems, Level 3 indicating moderate problems, Level 4 indicating severe problems, and 
Level 5 indicating extreme problems).
The subject selects an answer for each of the 5 dimensions considering the response that best 
matches his or her health “today.” The descriptive system can be represented as a health state. 
The EQ VAS self-rating records the respondent’s own assessment of his or her overall health 
status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the 
best health you can imagine). 
The time taken to complete the questionnaire varies with age, health status, and setting but is 
likely to be around 1 minute.
Individual scores from the 5 dimensions will be used to obtain a weighted health status index as 
shown below: 
(i)
Scores from each dimension will be combined to obtain a 5L profile score or health state: 
eg, a score of 1 for each dimension will give a 5L profile score of 11111. Dimension 
scores will be combined in the following order: Mobility, Self-Care, Usual Activities, 
Pain/Discomfort, Anxiety/Depression
(ii) The value set of the Health Status Index for various values of 5L profile scores is 
published for Canada in the following website: 
https://www.ncbi.nlm.nih.gov/pubmed/26492214
(iii) The Canadian value set will be used to get the HSI values for all the countries 
participating in the study. 
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
35
Approved, Date: 10 November 2017
In addition, a sum score will be derived as follows: The scores of the five dimensions (values 1-5) 
will be added (sums between 5 and 25). From this score, subtract 5 (range 0-20) and multiply by 
5 (range 0-100).
5.2.6.2.
Analysis Methods
Descriptive statistics of actual values and changes from baseline for the weighted EQ-5D health 
status index, the EQ-VAS, and the sum score will be summarized for each visit for all phases 
including the follow-up phase. In addition, individual dimension responses using a frequency 
distribution will also be summarized for each visit for all phases, including the follow-up phase.
Summaries of observed data will be presented. 
6.
SAFETY
Safety data for the open-label induction phase, the optimization/maintenance phase and 
follow-up phase will be summarized separately for each phase. Summaries will be based on Full 
analysis sets and the Follow-up analysis set described in Section 2.4. In addition, adverse event
and cognition data, and most severe postbaseline C-SSRS, treatment-emergent abnormal vital 
signs, ECG, laboratory, and MOAS/S data will be summarized for the entire treatment period
combining the induction and optimization/maintenance phase. All enrolled analysis set will be 
used for summarizing the combined treatment phases.
6.1.
Adverse Events
The Medical Dictionary for Regulatory Activities (MedDRA) (version 18.1 or above) will be 
used to classify AEs by system organ class and preferred term. Treatment-emergent adverse 
events (TEAEs) that occurred in each study phase will be summarized by system organ class and 
preferred term. 
The number (%) of subjects with TEAEs, serious TEAEs (SAEs), and TEAEs that led to study 
drug discontinuation will be summarized by system organ class and preferred term. Data listings 
will be generated for deaths, other SAEs, and discontinuations due to AEs.
For transferred-entry subjects, the number (%) of adverse events ongoing at the time of entry into 
the ESKETINTRD3004 study will be listed separately.
A TEAE is an event that is new in onset or increased in severity following treatment initiation. 
An event that starts prior to, and ends after the initiation of study medication will be considered 
treatment-emergent only if the severity increases after the start of medication.
TEAEs are defined as follows for each study phase:

TEAEs in the induction phase: 
a.
If AE onset time is not missing: 
i. If subjects continue to OP/MA phase: IND phase start date/time <= AE onset date 
and time < IND phase end date
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
36
Approved, Date: 10 November 2017
ii. If subjects discontinue in the IND phase: IND phase start date/time <= AE onset date 
and time <= IND phase end date
b.
If AE onset time is missing:
i. If subjects continue to OP/MA phase: IND phase start date <= AE onset date < IND 
phase end date
ii. If subjects discontinue in the IND phase: IND phase start date <= AE onset date <= 
IND phase end date

TEAEs in the optimization/maintenance phase: 
a.
If AE onset time is not missing: OP/MA phase start date ≤ AE onset date ≤OP/MA
phase end date
b.
If AE onset time is missing: OP/MA phase start date ≤ AE onset date ≤ OP/MA phase
end date

AEs in follow-up phase: F/U start date ≤ AE onset date ≤ F/U end date 

For the AEs that have both day and month missing, treatment emergent flag is be assigned 
based on the rules presented in Section 2.6.
In addition, TEAEs will be summarized by severity and relationship to study medication using 
the preferred term. For the summaries of AEs by severity/relationship to study medication, the 
observation with the most severe occurrence/closest relationship to study medication will be 
chosen if there is more than one incident of an adverse event reported during the analysis phase 
by the subject. AE duration for transient dizziness/vertigo and anxiety will also be summarized.
Adverse Events of Special Interest
Clinically relevant TEAEs of special interest will be examined separately grouped in the 
following categories: 

drug abuse, dependence and withdrawal (Aggression, Confusional state, Decreased activity, 
Dependence, Disorientation, Dissociation, Dissociative disorder, Dizziness, Drug use 
disorder, Drug abuse, Drug abuser, Drug dependence, Drug detoxification, Drug diversion, 
Drug rehabilitation, Drug tolerance, Drug tolerance increased, Drug withdrawal convulsions, 
Drug withdrawal headache, Drug withdrawal syndrome, Euphoric mood, Feeling abnormal,  
Feeling drunk, Feeling of relaxation, Hallucination, Hallucination, auditory, Hallucination, 
gustatory, Hallucination, olfactory, Hallucination, synaesthetic, Hallucination, tactile, 
Hallucination, visual, Hallucinations, mixed, Inappropriate affect, Mental impairment, 
Product tampering, Psychomotor hyperactivity, Psychotic disorder, Rebound effect, Somatic 
hallucination, Somnolence, Substance abuser, Substance dependence, Substance use, 
Substance use disorder, Substance-induced mood disorder, Substance-induced psychotic 
disorder, Thinking abnormal, Withdrawal arrhythmia, Withdrawal syndrome);

increased blood pressure (Blood pressure increased, Blood pressure diastolic increased, 
Blood pressure systolic increased, Hypertensive crisis, Hypertensive emergency, 
Hypertension);

increased heart rate (Heart rate increased, Tachycardia);
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
37
Approved, Date: 10 November 2017

transient dizziness/vertigo (Dizziness, Dizziness exertional, Dizziness postural, Procedural
dizziness, Vertigo, Vertigo labyrinthine, Vertigo positional, Vertigo CNS origin);

impaired cognition (Cognitive disorder); 

cystitis (Allergic cystitis, Chemical cystitis, Cystitis, Cystitis erosive, Cystitis haemorrhagic, 
Cystitis interstitial, Cystitis noninfective, Cystitis ulcerative, Cystitis-like symptom); 

anxiety (Anticipatory anxiety, Anxiety, Anxiety disorder).
The number and percentage of subjects taking concomitant medication for dissociation events 
(preferred term of Dissociation) at any time during each treatment phase will be provided.
Summary statistics for the duration of all episodes of TEAEs associated with discharge readiness
(Dissociation, Dizziness, Feeling abnormal, Feeling drunk, Nausea, Somnolence, Vertigo, and 
Vomiting) with an onset on the day of intranasal study drug administration is summarized for 
each treatment phase. These summaries are presented for each dosing session during both the 
induction phase and for the optimization/maintenance phase. In addition, the number of 
occurrences of TEAEs associated with discharge readiness and the number of occurrences of 
TEAEs associated with substance dependence is presented by dosing session for each treatment 
phase.
6.2.
Clinical Laboratory
Descriptive statistics (N, mean, median, minimum, and maximum and range) for values and
changes from baseline will be provided for clinical laboratory tests (hematology, chemistry and 
urinalysis) at each scheduled time point for all phases, including the follow-up phase. Baseline 
(IND) will be used for change summaries and to determine abnormal values during all treatment 
phases and during the follow-up phase.
Clinical laboratory tests that meet the criteria for markedly abnormal will be listed by subject for 
each phase. The incidence of treatment emergent markedly abnormal (TEMA) laboratory values 
that occurred at any time during each treatment phase will be presented. Clinical laboratory test 
values will be considered “TEMA using the criteria defined by the Sponsor (Janssen Research & 
Development, LLC)” listed in Attachment 1. The identification of TEMA laboratory values is 
based on the postbaseline value being out of range while the baseline value (Baseline (IND)) is 
either missing or within the range given in Attachment 1. If post-baseline laboratory results are 
above the upper limit and the baseline value is below the lower limit, then the post-baseline 
abnormality will also be considered TEMA. The same applies to the postbaseline value being 
below the lower limit with the baseline value being above the upper limit. Baseline (IND) will 
be used.
In addition, incidence of subjects with ALT values >3*upper normal limit (ULN) will be 
presented for each study phase. Additionally, incidence of hepatic toxicity (Hy’s Law)10 defined 
as ALT values >3*ULN and total bilirubin values >2*ULN will be presented for each study 
phase. Similar to the markedly abnormal analysis, only subjects with Baseline (IND) ALT values 
≤3*ULN (and baseline (IND) total bilirubin values ≤2*ULN for hepatic toxicity) (or if the 
baseline (IND) value is missing) will be eligible for these analyses.
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
38
Approved, Date: 10 November 2017
6.3.
Vital Signs, Weight, and BMI
Descriptive statistics for values and changes from Baseline (IND) at each scheduled time-point 
during the open-label induction phase, the optimization/maintenance phase, the follow-up phase 
will be presented for temperature, systolic blood pressure, diastolic blood pressure, pulse rate,
respiratory rate, oxygen saturation, weight, and BMI. Baseline (IND) will be used for change 
summaries and to determine abnormal values during all treatment phases and during the follow-
up phase.  Graphical presentations will be provided.
Vital sign mean and mean changes from Baseline (IND) at each scheduled time point during 
each phase will also be provided by sex and dose level and by age group (<65 years; ≥65 years) 
and dose level.
In addition, descriptive statistics of pulse rate and blood pressure (systolic and diastolic) values 
and changes and percent changes from predose will be provided for each intranasal dosing day.
The proportion of subjects who have a treatment-emergent abnormality, as defined in Table 4
below, during each treatment phase will be presented. A listing of subjects meeting any of the 
criteria will also be provided.
Table 4:
Treatment-Emergent Abnormality Categories for Vital Signs
Vital Parameter
Post-baseline value outside of normal limit if:
Abnormally low
Abnormally high
Pulse (bpm)
A decrease from baseline of 15 to a 
value 50
An increase from baseline of 15 to a 
value 100
Systolic BP (mmHg)
A decrease from baseline of 20 to a 
value 90
An increase from baseline of 20 to a 
value 180
Diastolic BP (mmHg)
A decrease from baseline of 15 to a 
value 50
An increase from baseline of 15 to a 
value 105
BP = blood pressure
The proportion of subjects who experienced treatment-emergent acute hypertension (systolic 
BP≥180 or diastolic BP≥110) at any time during each treatment phase will be summarized by 
hypertension status.
Mean (+/-SE) values for systolic BP, diastolic BP and heart rate will be summarized by 
hypertension status and presented graphically for each treatment phase.
In addition, for subjects 
with hypertension who receive antihypertensive medication, the same tables and graphs will be 
summarized by medication type (beta-blockers, all other agents)
A listing of subjects with oxygen saturation less than 93% will be provided.
6.4.
Electrocardiogram
ECG variables that will be analyzed include heart rate, RR, PR interval, QRS interval, QT
interval and QTc intervals. The corrected QT (QTc) intervals will include QTcB (Bazett) and 
QTcF (Fridericia).
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
39
Approved, Date: 10 November 2017
Baseline ECG is defined as the average of all ECG results collected up to and including the day 
of first dose of study medication (either intranasal or oral AD) for direct entry and transferred-
entry responders. Baseline is the last observation prior to or on the start date of the open-label 
induction phase for transferred-entry nonresponders. 
The maximum post-baseline value during each treatment phase (open-label induction phase, and 
optimization/maintenance phase) will be presented separately and will be computed for each 
ECG parameter using data from both scheduled and unscheduled visits.
Summary tables for observed values and changes from baseline will be presented at each 
scheduled time
point during both treatment phases
(open-label induction phase
and 
optimization/maintenance phase), and during the follow-up phase.
The frequency of treatment-emergent abnormalities will be tabulated and presented for all 
treatment phases. The identification of treatment-emergent abnormal ECG values is based on the 
post-baseline value (a value occurring after the start of the phase) being out of range while the 
baseline value is either missing or within the limits given in Table 5. If post-baseline ECG results 
are above the upper limits (abnormally high) and the baseline value is below the lower limits 
(abnormally low), then the post-baseline abnormality will also be considered treatment-
emergent. The same applies to the post-baseline value being below the lower limits (abnormally 
low) with the baseline value being above the upper limits (abnormally high). Abnormal ranges 
for the HR, PR, QRS and QT intervals are given in Table 5.
Table 5:
Limits for HR, PR, QRS and QT Interval Abnormality
ECG parameter
Abnormally Low
Abnormally High
HR (bpm)
50
100
PR interval (msec)
--
210
QRS interval (msec)
50
120
QT interval (msec)
200
500
Based on the maximum QTc value for each subject during a given phase (separate for each QTc 
correction QTcB and QTcF) the incidence of abnormal QTc values and changes from baseline
will be summarized. Criteria for abnormal corrected QT intervals and changes from baseline are 
given in Table 6 and are derived from the ICH E14 Guidance5 (the same criteria apply to all QT 
corrections).
Table 6:
Criteria for Abnormal QTc Values and Changes From Baseline
Parameter
Classification
Criteria
Clinically Significant QTc Value
No
500
Yes
>500
QTc change from baselinea
No concern
30
Concern
>30 – 60
Clear concern
>60
QTc value
Normal
450
>450 – 480
>450 - 480 
>480 – 500
>480 – 500
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
40
Approved, Date: 10 November 2017
>500
>500
These criteria are based on ICH E14 Guideline
a 
Baseline is defined as the average pre-dose.
The proportion of subjects with treatment emergent abnormalities will be presented for both
treatment phases. A listing of subjects with abnormalities will also be provided.
6.5.
Nasal Examination
Targeted nasal examinations (including the upper respiratory tract/throat) will be conducted by a 
qualified healthcare practitioner. The objective of the examination at Screening is to rule out any 
subjects with anatomical or medical conditions that may impede drug delivery or absorption.
Subsequent examinations will consist of a visual inspection of the nostrils, nasal mucosa, and 
throat for nasal erythema, rhinorrhea, rhinitis, capillary/blood vessel disruption and epistaxis and 
graded as follows: absent, mild, moderate, or severe. 
Changes in findings from baseline for each examination (including the upper respiratory 
tract/throat) will be listed for each treatment phase. Baseline (IND) will be used as baseline for 
change summaries.
6.5.1.
Nasal Symptom Questionnaire
Subjects will complete a nasal symptom questionnaire on every dosing day at predose and again 
at 1 hour postdose. The questionnaire was developed to assess nasal tolerability following 
intranasal administration of study drug. Subjects will rate nasal symptoms as none, mild, 
moderate, or severe for the following items: stuffy nose, blocked nose, runny nose, itching nose, 
crusting discharge in or on nose, dryness of nose, burning sensation in the nose, discomfort of 
nose, bleeding from the nose, postnasal drip, cough, sore throat, taste disturbance and sneezing.
Frequency distributions will be provided for each of the items at each time point during each 
treatment phase. Shift from pre-dose to post-dose questionnaires during each time point 
throughout the study will be provided to see if there is any change after repeated administrations 
of study drug. Frequency of subjects who report moderate/severe symptoms at any postdose 
timepoint will be presented for each treatment phase. In addition, a listing of severe symptoms 
will also be presented.
6.6.
Other Safety Parameters
6.6.1.
Columbia Suicide Severity Rating Scale (C-SSRS)
The Columbia Suicide Severity Rating Scale (C-SSRS)7 is a low-burden measure of the 
spectrum of suicidal ideation and behavior that was developed in the National Institute of Mental 
Health Treatment of Adolescent Suicide Attempters Study to assess severity and track suicidal 
events through any treatment. It is a semi structured clinician-administered questionnaire 
designed to solicit the occurrence, severity, and frequency of suicide-related ideation and 
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
41
Approved, Date: 10 November 2017
behaviors during the assessment period. Using the C-SSRS, potentially suicide-related events 
will be categorized using the following scores:
Suicidal Ideation (1-5)
1: Wish to be Dead
2: Non-specific Active Suicidal Thoughts
3: Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act
4: Active Suicidal Ideation with Some Intent to Act, without Specific Plan
5: Active Suicidal Ideation with Specific Plan and Intent
Suicidal Behavior (6-10)
6: Preparatory Acts or Behavior
7: Aborted Attempt
8: Interrupted Attempt
9: Actual Attempt (non-fatal)
10: Completed Suicide
If no events qualify for a score of 1 to 10, a score of 0 will be assigned (0=“no event that can be 
assessed on the basis of C-SSRS”). Higher scores indicate greater severity. Missing scores will 
not be imputed.
The summaries of the C-SSRS outcomes will be based on the Full analysis set for subjects who 
have at least 1 post-baseline C-SSRS measurement and a pre-treatment C-SSRS assessment.
A frequency distribution at each scheduled time point will be provided. Shifts from the Baseline 
(IND) value to the most severe/maximum score during each phase, will be summarized.
The maximum score assigned for each subject will also be summarized into one of three broad 
categories: No suicidal ideation or behavior (0), Suicidal ideation (1-5), Suicidal behavior (6-10). 
Shifts from the Baseline (IND) value to the maximum category during each phase will be 
summarized.
6.6.2.
Clinician Administered Dissociative States Scale (CADSS)
The CADSS (Clinician Administered Dissociative States Scale) 1 is an instrument for the 
measurement of present-state dissociative symptoms, and is administered to assess treatment-
emergent dissociative symptoms. The CADSS comprises 23 subjective items and participant’s 
responses are coded on a 5-point scale (0 = “Not at all”, 1 = “Mild”, 2 = “Moderate”, 3 = 
‘Severe” and 4 = “Extreme”). The CADSS is divided into 3 components using the scoring 
method shown in Table 7.
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
42
Approved, Date: 10 November 2017
Table 7: 
CADSS Scoring
Component
Questions
Range
Depersonalization
Sum of 3, 4, 5, 6, 7, 20, 23
0-28
Derealization
Sum of 1, 2, 8, 9, 10, 11, 12, 13, 16, 17, 18, 19, 21
0-52
Amnesia
Sum of 14, 15, 22
0-12
Total Score
Sum of 1 through 23
0-92
For the total score and each component, a higher score represents a more severe condition. If any 
of the response is missing, then the total score is set to missing. The CADSS is measured prior to 
each dose, at 40 minutes, and at 1.5 hours postdose.
Descriptive statistics (N, mean, SD, median, minimum, and maximum) of the total scores and 
component scores at each time point and visit, changes from pre-dose and proportion of subjects 
with an increase in CADSS total score from the pre-dose value at any time during the study will 
be summarized. Mean change in CADSS from pre-dose value will be presented graphically for 
each intranasal dose day.
6.6.3.
Brief Psychiatric Rating Scale (BPRS+)
The Brief Psychiatric Rating Scale (BPRS+) is an 18 item rating scale which is used to assess 
potential treatment-emergent psychotic symptoms. The BPRS assesses a range of psychotic and 
affective symptoms rated from both observation of the subject and the subject's own report. Only 
the four-item positive symptom subscale (BPRS+) will be used in the study to assess treatment-
emergent psychotic symptoms. The BPRS+ consists of: suspiciousness, hallucinations, unusual 
thought content and conceptual disorganization. Each symptom is rated on a scale of 0 to 6 as
follows: 0: not present, not evident or absent; 1: very mild; 2: mild; 3: moderate; 4: moderate
severe; 5: severe; or 6: extreme. A total score will be derived by summing the individual items,
with a range of 0 to 24 with a higher score representing a more severe condition.
The BPRS+ is measured prior to each dose, at 40 minutes, and at 1.5 hours post dose during each 
of the dosing phase.
Descriptive statistics (N, mean, SD, median, minimum, and maximum) of the total scores at each 
time point, change from the pre-dose time point within each visit, and the proportion of subjects 
with an increase in BPRS+ from the pre-dose value at any time during the study will be provided
for each treatment phase. The proportion of subjects with a total score of 3 or more at any time 
during the study will also be provided. Mean (SE) BPRS+ values from pre-dose value will be 
presented graphically for each intranasal dosing day.
6.6.4.
Modified Observer’s Assessment of Alertness/Sedation (MOAA/S)
The MOAA/S (Modified Observer’s Assessment of Alertness/Sedation) will be used to measure 
treatment-emergent sedation with correlation to levels of sedation defined by the American 
Society of Anesthesiologists (ASA) continuum. The MOAA/S scores range from 0 [No response 
to painful stimulus; corresponds to ASA continuum for general anesthesia] to 5 [Readily 
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
43
Approved, Date: 10 November 2017
responds to name spoken in normal tone (awake); corresponds to ASA continuum for minimal 
sedation].
The MOAA/S is measured on each dosing day every 15 minutes from pre-dose to 1.5 hours post 
dose or longer, if necessary, until the subject has a score of 5.

If the score is ≤3 at any time during the 1.5 hour postdose interval, the MOAA/S will be 
performed every 5 minutes until a score of 4 is reached (at which point a frequency of every 
15 minutes can be resumed until t=+1.5 hours post dose). 

If a subject does not have a score of 5 at t=+1.5 hours postdose, they should continue to be 
monitored. For subjects with a score of 4, the assessment should be repeated every 
15 minutes. And for subjects with a score of ≤3, the assessment should be repeated every 
5 minutes until the score returns to 5 or the subject is referred for appropriate medical care, 
if clinically indicated.
Descriptive statistics of the MOAA/S score and changes from predose will be summarized at 
each scheduled time point. Additionally, the proportion of subjects experiencing sedation (score 
less than or equal to 3) will be summarized at each scheduled time point.
MOAA/S score will be presented graphically for each intranasal dosing day.
6.6.5.
Clinical Global Assessment of Discharge Readiness (CGADR)
The Clinical Global Assessment of Discharge Readiness (CGADR) will be used to measure a
subject’s current clinical status and is the clinician’s assessment of the readiness to be discharged
from the study site. 
The clinician will answer “Yes” or “No” to the question “Is the subject considered ready to be 
discharged based on their overall clinical status (e.g., sedation, blood pressure, and other adverse 
events)?”
On each intranasal dosing day, the CGADR will be performed at 1 hour and 1.5 hours postdose, 
repeated every 15 minutes if necessary until the response is ‘Yes’. A subject should not be 
discharged prior to the 1.5-hour time point.
The proportion of subjects with a response of ‘No’ at each time point will be presented during 
each treatment phase.
6.6.6.
Physician Withdrawal Checklist (PWC-20)
The PWC-20 is a 20-item simple and accurate method to assess potential withdrawal symptoms 
following cessation of intranasal esketamine treatment. The PWC-20 will be performed for all 
subjects on Day 25 to establish a baseline prior to discontinuation of esketamine treatment –
although only relevant for those subjects not continuing to the next phase. For those subjects who 
proceed to the optimization/maintenance phase, the PWC-20 is conducted at the End of Study 
Visit. If subjects withdraw early from the study during any phase, the PWC-20 will be conducted 
at the Early Withdrawal Visit.
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
44
Approved, Date: 10 November 2017
The proportion of subjects with withdrawal symptoms at the end of each treatment phase (IND, 
OP/MA) and during the follow-up phase will be presented. In addition, symptoms at follow-up 
will be compared to the last assessment in the relevant treatment phase (IND, OP/MA) for 
subjects who discontinue during that treatment phase and will be summarized using the 
following categories: new or worsened symptoms, symptoms present and unchanged, no 
symptoms, and improved.
6.6.7.
Computerized Cognitive Battery and Hopkins Verbal Learning 
Test-Revised (HVLT-R)
The effect of intranasal esketamine on cognition will be assessed using the computerized 
cognitive battery and Hopkins Verbal Learning Test-Revised (HVLT-R). 
The computerized cognitive battery provides assessment of multiple cognitive domains, 
including attention, visual learning and memory, and executive function. The tests use culture-
neutral stimuli, enabling use in multilingual/multicultural settings. The HVLT-R is a measure of 
verbal learning and memory and is a 12-item word list recall test. The total number of correct 
responses are captured for 4 trials as well as the number of true-positive responses and false-
positive errors in Trial 4 (Delayed Recall). The Total Recall will be derived as the sum of trials 
1, 2 and 3. Retention % will be derived as (the number of correct responses in Trial 4)/(higher 
score of Trials 2 and 3) X 100. Recognition Discrimination Index will be derived as the total 
number of true-positives – the total number of false-positives.
The computerized cognitive battery and HVLT-R will be assessed at Day 1 predose, Day 28/ET 
of the open-label induction phase, Week 16 of the optimization phase, and every 12 weeks 
during the maintenance phase. It will also be assessed again at week 4 post-treatment during the 
follow-up phase.
See Attachment 2 for details of this analysis.
7.
HEALTH ECONOMICS
7.1.
Healthcare Resource Use Questionnaire (HRUQ)
Medical resource utilization data, associated with medical encounters, will be collected using the 
Healthcare Resource Use Questionnaire (HRUQ) during the optimization/maintenance phase and 
follow-up phase bi-weekly.
The number and percentage of subjects who visited at least one healthcare professional or had a 
hospital emergency room visit because of their depression in the 2 weeks preceding each time 
point will be summarized for each type of healthcare professional. The total number of visits to 
each type of healthcare professional, total number of visits to any healthcare professional, and 
the total number of hospital emergency room visits related to depression in the 2 weeks 
preceding each time point will be summarized at each time point with descriptive statistics.
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
45
Approved, Date: 10 November 2017
REFERENCES
1.
Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM. Measurement of 
dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress. 
1998;11(1):125-136.
2.
EuroQol Group. About EQ-5D. http://www.euroqol.org/about-eq-5d.html (accessed 18 June 2014).
3.
EuroQol Group. EQ-5D-5L User Guide: basic information on how to use the EQ-5D-5L instrument. Version 
2.0; October 2013. 
http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/UserGuide_EQ-5D-
5L_v2.0_October_2013.pdf (accessed 6 August 2014)
4.
Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: U.S. Department of Health, 
Education, and Welfare; 1976.
5.
International Conference on Harmonization (ICH) Tripartite Guideline E14. London: s.n., 2005. pp. The 
clinical evaluation of QT/QTc interval prolongation and proarrhythmic for non-antiarrhythmic drugs.
6.
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 
1979;134:382-389.
7.
Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide 
Assessment (C-CASA): classification of suicidal events in the FDA’s pediatric suicidal risk analysis of 
antidepressants. Am J Psychiatry. 2007;164:1035-1043.
8.
Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ 
primary care study. JAMA. 1999; 282:1737-1744.
9.
Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the 
GAD-7. Arch Intern Med. 2006;166(10):1092-1097.
10.
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation 
and Research (CDER), Center for Biologics Evaluation and Research (CBER). [2009] Guidance for industry 
drug induced liver injury: premarketing clinical evaluation. Available: 
http://www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf.
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
46
Approved, Date: 10 November 2017
ATTACHMENTS
Attachment 1: Criteria of Markedly Abnormal Laboratory Values
Markedly Abnormal Limits
Laboratory Parameter
Low
High
Albumin [g/L]
24
60
Alkaline phosphatase [U/L]
N/A
250
Alanine transaminase (SGPT) [U/L]
N/A
200
Alanine transaminase (SGPT) [U/L]
N/A
>3X ULN
Aspartate transaminase (SGOT) [U/L]
N/A
250
Bicarbonate [mmol/L]
15.1
34.9
Blood urea nitrogen [mmol/L]
N/A
17.9
Calcium [mmol/L]
1.5
3
Chloride [mmol/L]
94
112
Creatine kinase (U/L)
N/A
990
Creatinine [mol/L]
N/A
265.2
Gamma glutamyl transferase [U/L]
N/A
300
Glucose [mmol/L]
2.2
16.7
Phosphate [mmol/L]
0.7
2.6
Potassium [mmol/L]
3.0
5.8
Sodium [mmol/L]
125
155
Bilirubin, total [mol/L]
N/A
51.3
Protein, total [g/L]
50
N/A
Urine pH
N/A
8.0
Hematocrit [fraction] - female
0.28
0.5
- male
0.24
0.55
Hemoglobin [g/L]
80
190
Neutrophils, segmented [%]
30
90
Monocytes [%]
N/A
20
Eosinophils [%]
N/A
10
Basophils [%]
N/A
6
Lymphocytes [%]
10
60
Platelet count [x109/L]
100
600
Erythrocytes (RBC) [x1012/L] -- female
3.0
5.5
                                                 -- male
3.0
6.4
Leukocyted (WBC) [x109/L]
2.5
15.0
Hy’s Law criteria:
Alanine transaminase (SGPT) [U/L]
>3X ULN
AND
Bilirubin, total [mol/L]
>2X ULN
Note: The same limits apply to both males and females unless gender is indicated; 
N/A = Not applicable.
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
47
Approved, Date: 10 November 2017
Attachment 2: Statistical Analysis Plan for COGSTATE
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
48
Approved, Date: 10 November 2017
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
49
Approved, Date: 10 November 2017
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
50
Approved, Date: 10 November 2017
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
51
Approved, Date: 10 November 2017
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
52
Approved, Date: 10 November 2017
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
53
Approved, Date: 10 November 2017
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
54
Approved, Date: 10 November 2017
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
55
Approved, Date: 10 November 2017
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
56
Approved, Date: 10 November 2017
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
57
Approved, Date: 10 November 2017
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
58
Approved, Date: 10 November 2017
NCT02497287


JNJ-54135419 (esketamine)
Statistical Analysis Plan ESKETINTRD3004
59
Approved, Date: 10 November 2017
NCT02497287